# ::snt Persistent Amyloidosis following Suppression of A Production in a Transgenic Model of Alzheimer Disease .
# ::tok Persistent Amyloidosis following Suppression of A Production in a Transgenic Model of Alzheimer Disease .
# ::alignments 9-14|0.1.4+0.1.3+0.1.2+0.1.1+0.1.0+0.1+0 6-7|0.0.1.0 3-4|0.0.1 2-3|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:30.547
(t / thing 
      :ARG1-of (f / follow-01 
            :ARG0 (p2 / persistent) 
            :ARG2 (s / suppression 
                  :poss (p / production))) 
      :name (n / name 
            :op1 "Transgenic" 
            :op2 "Model" 
            :op3 "of" 
            :op4 "Alzheimer" 
            :op5 "Disease"))

# ::snt The proteases ( secretases ) that cleave amyloid- ( A ) peptide from the amyloid precursor protein ( APP ) have been the focus of considerable investigation in the development of treatments for Alzheimer disease .
# ::tok The proteases ( secretases ) that cleave amyloid- ( A ) peptide from the amyloid precursor protein ( APP ) have been the focus of considerable investigation in the development of treatments for Alzheimer disease .
# ::alignments 34-35|0.0.0.2.1.0 33-34|0.0.0.2.1.0.0 31-32|0.0.0.2.1 29-30|0.0.0.2 26-27|0.0.0 25-26|0.0.0.1 23-24|0.0.0.0 18-19|0.0.0.0.0.0.0+0.0.0.0.0.0+0.0.0.0.0 16-17|0 15-16|0.0 14-15|0.1 6-7|0.0.0.2.2 3-4|0.0.0.2.0 1-2|0.0.0.2.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:32.003
(p / protein 
      :mod (p2 / precursor 
            :ARG1-of (i / investigate-01 
                  :ARG0-of (f / focus-01 
                        :ARG1 (o / organization 
                              :name (n / name 
                                    :op1 "APP"))) 
                  :manner (c / considerable) 
                  :topic (d2 / develop-02 
                        :ARG0 (s / secretas) 
                        :ARG1 (t / treat-03 
                              :ARG1 (d / disease 
                                    :mod (a / alzheim))) 
                        :ARG2 (c2 / cleave-01 
                              :ARG1 (p3 / proteas))))) 
      :mod (a2 / amyloid))

# ::snt The prediction has been that reducing A production in the brain , even after the onset of clinical symptoms and the development of associated pathology , will facilitate the repair of damaged tissue and removal of amyloid lesions .
# ::tok The prediction has been that reducing A production in the brain , even after the onset of clinical symptoms and the development of associated pathology , will facilitate the repair of damaged tissue and removal of amyloid lesions .
# ::alignments 37-38|0.2.0.1.0.0 36-37|0.2.0.1.0.0.0 34-35|0.2.0.1.0 33-34|0.2.0.1 32-33|0.2.0 31-32|0.2.0.1.0.1 29-30|0.2.0.0 27-28|0.2.0.0.1 24-25|0.2.1 23-24|0.2.1.0 21-22|0.2 19-20|0 18-19|0.1 17-18|0.1.0 15-16|0.0 13-14|0.0.0 12-13|0.0.0.0 10-11|0.2.0.0.0.0.1 7-8|0.2.0.0.0.0.0 5-6|0.2.0.0.0.0 1-2|0.2.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:33.698
(a4 / and 
      :op1 (o / onset 
            :op1-of (a5 / after 
                  :op1-of (e / even))) 
      :op2 (s / symptom 
            :mod (c / clinical)) 
      :op3 (d2 / develop-02 
            :ARG0 (t / tissue 
                  :ARG1-of (r2 / repair-01 
                        :ARG0 (p3 / predict-01 
                              :ARG0-of (r3 / reduce-01 
                                    :ARG1 (p2 / produce-01) 
                                    :location (b / brain))) 
                        :ARG1-of (f / facilitate-01)) 
                  :op1-of (a2 / and 
                        :op2 (r / remove-01 
                              :ARG1 (l / lesion 
                                    :mod (a / amyloid)) 
                              :ARG1-of (d / damage-01)))) 
            :ARG1 (p / pathology 
                  :ARG1-of (a3 / associate-01))))

# ::snt However , no long-term studies using animal models of amyloid pathology have yet been performed to test this hypothesis .
# ::tok However , no long-term studies using animal models of amyloid pathology have yet been performed to test this hypothesis .
# ::alignments 18-19|0.1.0.0.0.0 17-18|0.1.0.0.0.0.0 16-17|0.1.0.0.0 14-15|0.1.0.0.0.1 12-13|0.1.0.0.0.1.1 10-11|0 9-10|0.0 7-8|0.1 6-7|0.1.1 5-6|0.1.0 4-5|0.1.0.0 3-4|0.1.0.0.1 2-3|0.1.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:34.362
(p2 / pathology 
      :mod (a / amyloid) 
      :topic-of (m / model 
            :ARG1-of (u / use-01 
                  :ARG0 (s / study-01 
                        :ARG0-of (t2 / test-01 
                              :ARG1 (h / hypothesi 
                                    :mod (t / this)) 
                              :ARG1-of (p / perform-02 
                                    :polarity - 
                                    :time (y / yet))) 
                        :ARG1 (l / long-term))) 
            :mod (a2 / animal)))

# ::snt We have generated a transgenic mouse model that genetically mimics the arrest of A production expected from treatment with secretase inhibitors .
# ::tok We have generated a transgenic mouse model that genetically mimics the arrest of A production expected from treatment with secretase inhibitors .
# ::alignments 20-21|0.1.0 19-20|0.1.0.0 17-18|0.1 15-16|0 14-15|0.0 11-12|0.0.0 9-10|0.0.0.1 8-9|0.0.0.0 6-7|0.0.0.1.0.0.0 5-6|0.0.0.1.0.0.0.0 2-3|0.0.0.1.0.0 0-1|0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:34.799
(e / expect-01 
      :ARG1 (p / produce-01 
            :ARG1-of (a / arrest-01 
                  :ARG0 (g / genetics) 
                  :ARG1-of (m / mimic-01 
                        :ARG0 (w / we 
                              :ARG0-of (g2 / generate-01 
                                    :ARG1 (m2 / model 
                                          :mod (m3 / mouse))))))) 
      :source (t / treat-03 
            :ARG1 (i / inhibitor 
                  :mod (s / secretase))))

# ::snt These mice overexpress mutant APP from a vector that can be regulated by doxycycline .
# ::tok These mice overexpress mutant APP from a vector that can be regulated by doxycycline .
# ::alignments 13-14|0.0.0.0 11-12|0.0.0 9-10|0.0 7-8|0.0.0.1 4-5|0.2.1.0+0.2.1+0.2 3-4|0.2.0 1-2|0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:34.961
(m2 / mouse 
      :ARG0-of (p / possible-01 
            :ARG1 (r / regulate-01 
                  :ARG0 (d / doxycycline) 
                  :ARG1 (v / vector))) 
      :mod (t / this) 
      :poss-of (o / organization 
            :mod (m / mutant) 
            :name (n / name 
                  :op1 "APP")))

# ::snt Under normal conditions , high-level expression of APP quickly induces fulminant amyloid pathology .
# ::tok Under normal conditions , high-level expression of APP quickly induces fulminant amyloid pathology .
# ::alignments 12-13|0.0.0 11-12|0.0.0.0 10-11|0.0.0.0.0 9-10|0.0 8-9|0.0.1 7-8|0.1.0.0+0.1.0+0.1 5-6|0 4-5|0.2 2-3|0.0.2.0 1-2|0.0.2.0.0 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:35.208
(e / express-01 
      :ARG0-of (i / induce-01 
            :ARG1 (p / pathology 
                  :mod (a / amyloid 
                        :mod (f / fulminant))) 
            :ARG1-of (q / quick-02) 
            :time (u / under 
                  :op1 (c / condition 
                        :ARG1-of (n2 / normal-02)))) 
      :ARG1 (o / organization 
            :name (n / name 
                  :op1 "APP")) 
      :mod (h / high-level))

# ::snt We show that doxycycline administration inhibits transgenic APP expression by greater than 95 % and reduces A production to levels found in nontransgenic mice .
# ::tok We show that doxycycline administration inhibits transgenic APP expression by greater than 95 % and reduces A production to levels found in nontransgenic mice .
# ::alignments 23-24|0.1.1.2.2.2 22-23|0.1.1.2.2.2.0 20-21|0.1.1.2.2 19-20|0.1.1.2.2.1 17-18|0.1.1.2.1 15-16|0.1.1.2 14-15|0.1.1 13-14|0.1.1.1 12-13|0.1.1.1.0 10-11|0.1.0 8-9|0.1.1.0 7-8|0.1.1.0.0.0.0+0.1.1.0.0.0+0.1.1.0.0 5-6|0.1 4-5|0.1.1.2.0 3-4|0.1.1.2.2.0 1-2|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:36.492
(s / show-01 
      :ARG0 (w / we) 
      :ARG1 (i / inhibit-01 
            :ARG1 (g / great) 
            :op1-of (a / and 
                  :ARG1-of (e / express-01 
                        :ARG0 (o / organization 
                              :name (n2 / name 
                                    :op1 "APP"))) 
                  :op2 (p2 / percentage-entity 
                        :value 95) 
                  :op3 (r / reduce-01 
                        :ARG0 (a2 / administrate-01) 
                        :ARG1 (p / produce-01) 
                        :ARG2 (f / find-01 
                              :ARG0 (d / doxycycline) 
                              :ARG1 (l / level) 
                              :location (m / mouse 
                                    :mod (n / nontransgenic)))))))

# ::snt Suppression of transgenic A synthesis in this model abruptly halts the progression of amyloid pathology .
# ::tok Suppression of transgenic A synthesis in this model abruptly halts the progression of amyloid pathology .
# ::alignments 14-15|0.1.0 13-14|0.1.0.0 11-12|0.1 9-10|0 8-9|0.2 7-8|0.1.0.1 6-7|0.1.0.1.0 4-5|0.0.0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:36.557
(h / halt-01 
      :ARG0 (s2 / suppression 
            :mod (s / synthesi)) 
      :ARG1 (p2 / progress-01 
            :ARG1 (p / pathology 
                  :mod (a / amyloid) 
                  :poss (m / model 
                        :mod (t / this)))) 
      :manner (a2 / abrupt))

# ::snt However , formation and disaggregation of amyloid deposits appear to be in disequilibrium as the plaques require far longer to disperse than to assemble .
# ::tok However , formation and disaggregation of amyloid deposits appear to be in disequilibrium as the plaques require far longer to disperse than to assemble .
# ::alignments 23-24|0.0.1.0.0.0.1 20-21|0.0.1.0.0.0 18-19|0.0.1.0.0.0.2 17-18|0.0.0.0 16-17|0.0.1.0.0 15-16|0.0.1.0 12-13|0.0.1.0.0.0.1.0 8-9|0 7-8|0.1 6-7|0.0.1.0.0.0.0 4-5|0.0.1 3-4|0.0 2-3|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:37.087
(a2 / appear-02 
      :ARG0 (a4 / and 
            :op1 (f2 / form-01 
                  :ARG0 (f / far)) 
            :op2 (d4 / disaggregation 
                  :name-of (p / plaqu 
                        :ARG0-of (r / require-01 
                              :ARG1 (d / disperse-01 
                                    :ARG0 (a3 / amyloid) 
                                    :ARG1 (a / assemble-01 
                                          :ARG1 (d2 / disequilibrium)) 
                                    :ARG1-of (l / long-03)))))) 
      :ARG1 (d3 / deposit))

# ::snt Mice in which APP synthesis was suppressed for as long as 6 mo after the formation of A deposits retain a considerable amyloid load , with little sign of active clearance .
# ::tok Mice in which APP synthesis was suppressed for as long as 6 mo after the formation of A deposits retain a considerable amyloid load , with little sign of active clearance .
# ::alignments 30-31|0.0.2.0.0.0.0.0 29-30|0.0.2.0.0.0.0.0.2 27-28|0.0.2.0.0.0.0.0.3 26-27|0.0.2.0.0.0.0.0.3.0 23-24|0.0.2.0.0.0.0 22-23|0.0.2.0.0.0.0.2 21-22|0.0.2.0.0.0.0.1 19-20|0.0.2.0.0.0 18-19|0.0.2.0.0 15-16|0.0.2.0 13-14|0.0.2 12-13|0.0.1 11-12|0.0.2.0.0.0.0.0.0 9-10|0.0.2.0.0.0.0.0.1 6-7|0.0 4-5|0 3-4|0.1.0.0+0.1.0+0.1 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:37.516
(s3 / synthesi 
      :ARG1-of (s2 / suppress-01 
            :ARG0 (m2 / mouse) 
            :ARG2 (m / mo) 
            :time (a3 / after 
                  :op1 (f / form-01 
                        :ARG1 (d / deposit 
                              :ARG0-of (r / retain-01 
                                    :ARG1 (l2 / load 
                                          :location-of (c / clear-02 
                                                :ARG1 6 
                                                :ARG1-of (l3 / long-03) 
                                                :ARG1-of (a / activity-06) 
                                                :ARG1-of (s / sign-02 
                                                      :mod (l / little))) 
                                          :mod (c2 / considerable) 
                                          :mod (a2 / amyloid))))))) 
      :mod (o / organization 
            :name (n / name 
                  :op1 "APP")))

# ::snt This study demonstrates that amyloid lesions in transgenic mice are highly stable structures in vivo that are slow to disaggregate .
# ::tok This study demonstrates that amyloid lesions in transgenic mice are highly stable structures in vivo that are slow to disaggregate .
# ::alignments 19-20|0.0.0 17-18|0.0.0.0 14-15|0.1.2 12-13|0.1 11-12|0.1.0 10-11|0.1.0.1 8-9|0.1.0.0 5-6|0.1.1 4-5|0.1.1.0 2-3|0 1-2|0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:37.644
(d2 / demonstrate-01 
      :ARG0 (s4 / study-01 
            :ARG1 (d / disaggregate 
                  :prep-to-of (s / slow)) 
            :mod (t / this)) 
      :ARG1 (s2 / structure 
            :ARG1-of (s3 / stable-03 
                  :ARG0 (m / mouse) 
                  :degree (h / high)) 
            :domain (l / lesion 
                  :mod (a / amyloid)) 
            :location (v / vivo)))

# ::snt Our findings suggest that arresting A production in patients with Alzheimer disease should halt the progression of pathology , but that early treatment may be imperative , as it appears that amyloid deposits , once formed , will require additional intervention to clear .
# ::tok Our findings suggest that arresting A production in patients with Alzheimer disease should halt the progression of pathology , but that early treatment may be imperative , as it appears that amyloid deposits , once formed , will require additional intervention to clear .
# ::alignments 42-43|0.0.2 40-41|0.0.1 39-40|0.0.1.0 38-39|0.0 35-36|0.0.0.0 34-35|0.0.0.0.0 32-33|0.0.0 31-32|0.1.1.0 29-30|0 25-26|0.1 23-24|0.1.0 22-23|0.1.1 21-22|0.1.1.1 19-20|0.1.0.0 17-18|0.1.0.0.0.0.1.0 15-16|0.1.0.0.0.0.1 13-14|0.1.0.0.0.0 12-13|0.1.0.0.0 11-12|0.1.0.0.0.0.0.0.0.0.0 10-11|0.1.0.0.0.0.0.0.0.0.0.0 8-9|0.1.0.0.0.0.0.0.0.0.1+0.1.0.0.0.0.0.0.0.0+0.1.0.0.0.0.0.0.0 6-7|0.1.0.0.0.0.0.0 4-5|0.1.0.0.0.0.0 2-3|0.1.0.0.0.1 1-2|0.1.0.0.0.1.0.0+0.1.0.0.0.1.0 0-1|0.1.0.0.0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:40.026
(a3 / appear-02 
      :ARG1 (r / require-01 
            :ARG0 (d / deposit 
                  :ARG1-of (f / form-01 
                        :time (o / once))) 
            :ARG1 (i / intervene-01 
                  :mod (a / additional)) 
            :ARG2 (c / clear-06)) 
      :concession-of (i2 / imperative 
            :ARG1-of (p / possible-01 
                  :ARG2-of (c2 / contrast-01 
                        :ARG1 (r2 / recommend-01 
                              :ARG1 (h / halt-01 
                                    :ARG0 (a5 / arrest-01 
                                          :ARG1 (p6 / produce-01 
                                                :ARG1 (p4 / person 
                                                      :ARG0-of (h2 / have-rel-role-91 
                                                            :ARG1 (d2 / disease 
                                                                  :mod (a4 / alzheim)) 
                                                            :ARG2 (p5 / patient))))) 
                                    :ARG1 (p3 / progress-01 
                                          :ARG1 (p2 / pathology))) 
                              :ARG1-of (s / suggest-01 
                                    :ARG0 (t2 / thing 
                                          :ARG1-of (f2 / find-01 
                                                :ARG0 (w / we))))))) 
            :domain (t / treat-03 
                  :ARG1 (a2 / amyloid) 
                  :time (e / early))))

# ::snt Over a decade ago the amyloid cascade hypothesis predicted that increased levels of amyloid- ( A ) peptide lead to secondary pathologies that ultimately culminate in the onset of Alzheimer disease ( AD ) [ 1 ] .
# ::tok Over a decade ago the amyloid cascade hypothesis predicted that increased levels of amyloid- ( A ) peptide lead to secondary pathologies that ultimately culminate in the onset of Alzheimer disease ( AD ) [ 1 ] .
# ::alignments 35-36|0.0.1.1.1.0.1 32-33|0.0.1.1.0 30-31|0.0.1.1.1.1.0.0 29-30|0.0.1.1.1.1.0 27-28|0.0.1.1.1.1 24-25|0.0.1.1.1 23-24|0.0.1.1.1.2 21-22|0.0.1.1.2 20-21|0.0.1.0 18-19|0.0.1.1 17-18|0.0.1.1.3 11-12|0.0.0.0 10-11|0.0.0 8-9|0 7-8|0.0 6-7|0.0.1 5-6|0.0.2 2-3|0.0.1.1.1.0.2+0.0.1.1.1.0 0-1|0.0.1.1.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:41.022
(p3 / predict-01 
      :ARG0 (h / hypothesi 
            :ARG0-of (i / increase-01 
                  :ARG1 (l2 / level)) 
            :ARG1-of (c2 / cascade-01 
                  :ARG0 (s / secondary) 
                  :ARG1-of (l / lead-02 
                        :ARG0 "AD" 
                        :ARG1-of (c / culminate-01 
                              :ARG0 (t / temporal-quantity 
                                    :op1-of (o2 / over) 
                                    :quant 1 
                                    :unit (d2 / decade)) 
                              :ARG2 (o / onset 
                                    :mod (a / alzheim 
                                          :mod-of (d / disease))) 
                              :time (u / ultimate)) 
                        :ARG2 (p / pathologi) 
                        :mod (p2 / peptide))) 
            :mod (a2 / amyloid)))

# ::snt Early support for this hypothesis came from genetic studies linking early-onset AD to mutations in the amyloid precursor protein ( APP ) , from which A is derived , and presenilins 1 and 2 , which are interchangeable components of a endoprotease complex that releases A from APP ( for review see [ 2,3 ] ) .
# ::tok Early support for this hypothesis came from genetic studies linking early-onset AD to mutations in the amyloid precursor protein ( APP ) , from which A is derived , and presenilins 1 and 2 , which are interchangeable components of a endoprotease complex that releases A from APP ( for review see [ 2,3 ] ) .
# ::alignments 51-52|0.0 50-51|0.0.0 44-45|0.0.0.1 42-43|0.0.0.1.0 38-39|0.1.2.1 33-34|0.0.0.0 32-33|0 31-32|0.1.1.1.0 30-31|0.1.2.0 29-30|0.1.2 27-28|0.1.0.0 20-21|0.1.0.0.0.0.0+0.1.0.0.0.0+0.1.0.0.0 18-19|0.1.0 17-18|0.1.0.1 16-17|0.1.0.2 13-14|0.1 11-12|0.1.1.1.1.0 9-10|0.1.1.1.1 8-9|0.1.1.1 7-8|0.1.1.1.2 5-6|0.1.1 4-5|0.1.1.0.0 3-4|0.1.1.0.0.0 1-2|0.1.1.0 0-1|0.1.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:42.701
(a / and 
      :ARG1-of (s / see-01 
            :ARG0 (r / review-01 
                  :ARG1 2 
                  :ARG2-of (r2 / release-01 
                        :ARG0 (c / complex)))) 
      :op1 (m / mutate-01 
            :ARG1 (p2 / protein 
                  :ARG1-of (d / derive-01 
                        :ARG0 (o / organization 
                              :name (n / name 
                                    :op1 "APP"))) 
                  :mod (p3 / precursor) 
                  :mod (a3 / amyloid)) 
            :ARG4-of (c3 / come-01 
                  :ARG1 (s3 / support-01 
                        :ARG1 (h / hypothesi 
                              :mod (t / this)) 
                        :mod (e / early)) 
                  :ARG3 (s2 / study-01 
                        :ARG1 1 
                        :ARG3-of (l / link-01 
                              :ARG1 "AD") 
                        :mod (g / gene))) 
            :op1-of (a2 / and 
                  :op2 (p / presenilin) 
                  :op3 (c2 / component))))

# ::snt If , as predicted , overproduction of A initiates the cascade of events leading to disease , then therapeutic strategies that lower A levels should either arrest or reverse the progression from peptide to dementia .
# ::tok If , as predicted , overproduction of A initiates the cascade of events leading to disease , then therapeutic strategies that lower A levels should either arrest or reverse the progression from peptide to dementia .
# ::alignments 34-35|0.0.2.1.2 32-33|0.0.2.1.1.0 30-31|0.0.2.1 28-29|0.0.2 27-28|0.0 26-27|0.0.2.1.1 25-26|0.0.0 24-25|0 23-24|0.0.2.0.0.0 21-22|0.0.2.0.0 19-20|0.0.2.0 18-19|0.0.1 17-18|0.0.2.0.1 15-16|0.0.3.0.1.0.0 13-14|0.0.3.0.1.0 12-13|0.0.3.0.1 10-11|0.0.3.0 8-9|0.0.3 5-6|0.0.3.0.0 3-4|0.0.2.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:43.077
(r2 / recommend-01 
      :ARG1 (o / or 
            :mod (e / either) 
            :op1 (t / therapeutic) 
            :op2 (r / reverse-01 
                  :ARG0 (s / strategy 
                        :ARG0-of (l2 / low-04 
                              :ARG1 (l / level)) 
                        :time (t2 / then)) 
                  :ARG1 (p2 / progress-01 
                        :ARG1-of (p3 / predict-01) 
                        :ARG1-of (a / arrest-01 
                              :ARG2 (p / peptide)) 
                        :ARG2 (d / dementia))) 
            :time (i / initiate-01 
                  :ARG1 (c / cascade-01 
                        :ARG0 (o2 / overproduction) 
                        :ARG1 (e2 / event 
                              :ARG1-of (l3 / lead-01 
                                    :ARG4 (d2 / disease)))))))

# ::snt Early evidence from clinical trials of antibody-mediated clearance , one of the first A-lowering approaches tested in humans , suggested that treatments designed to reduce amyloid burden may indeed be beneficial .
# ::tok Early evidence from clinical trials of antibody-mediated clearance , one of the first A-lowering approaches tested in humans , suggested that treatments designed to reduce amyloid burden may indeed be beneficial .
# ::alignments 30-31|0.0 28-29|0.0.2 27-28|0.0.1 26-27|0.0.0.1.0.0 25-26|0.0.0.1.0.0.1 24-25|0.0.0.1.0 22-23|0.0.0.1 21-22|0.0.0 19-20|0 17-18|0.0.0.0.1 15-16|0.0.0.0 14-15|0.0.0.0.0 13-14|0.0.0.0.0.0 7-8|0.0.0.1.0.0.0.1 6-7|0.0.0.1.0.0.0.1.0 4-5|0.0.0.1.0.0.0 3-4|0.0.0.1.0.0.0.2 1-2|0.0.0.1.0.0.0.0 0-1|0.0.0.1.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:43.898
(s / suggest-01 
      :ARG1 (b / benefit-01 
            :ARG0 (t / treat-03 
                  :ARG0-of (t2 / test-01 
                        :ARG1 (a2 / approach-02 
                              :manner (a3 / a-lower)) 
                        :ARG2 (h / human)) 
                  :ARG1-of (d / design-01 
                        :ARG3 (r / reduce-01 
                              :ARG1 (b2 / burden-01 
                                    :ARG1 (t3 / trial-06 
                                          :ARG0-of (e / evidence-01 
                                                :mod (e2 / early)) 
                                          :ARG1 (c / clear-02 
                                                :mod (a4 / antibody-mediat)) 
                                          :mod (c2 / clinical)) 
                                    :mod (a / amyloid))))) 
            :ARG1-of (p / possible-01) 
            :mod (i / indeed)))

# ::snt Although the trials were halted because of adverse effects in a subset of volunteers [ 4,5 ] , further analysis of several patients found evidence that amyloid pathology , and to a lesser degree cognitive function , was improved in proportion to the patient 's titer of A-specific antibody [ 6,7 ] .
# ::tok Although the trials were halted because of adverse effects in a subset of volunteers [ 4,5 ] , further analysis of several patients found evidence that amyloid pathology , and to a lesser degree cognitive function , was improved in proportion to the patient 's titer of A-specific antibody [ 6,7 ] .
# ::alignments 48-49|0.1.1.0.3.0 47-48|0.1.1.0.3.1.0+0.1.1.0.3.1+0.1.1.0.3 45-46|0.1.1.0.2.0.0 43-44|0.1.1.0.2.1+0.1.1.0.2+0.1.1.0.2.0 40-41|0.1.1.1.0.1 38-39|0.1.1.1.0 35-36|0.1.1.1.0.0 34-35|0.1.1.1.0.0.0 33-34|0.1.1.0.1.0 32-33|0.1.1.1.0.0.1 29-30|0.1.1.1.0.2 27-28|0.1.0.0 24-25|0.1.1.1 23-24|0.1.1 22-23|0.1.1.0.0.1+0.1.1.0.0+0.1.1.0 21-22|0.1.1.0.4 19-20|0.1.1.0.1 18-19|0.1.1.0.1.1 13-14|0.1.1.0.0.0.0+0.1.1.0.0.0 11-12|0.1.1.0.0.0.1 8-9|0.0 7-8|0.0.0 5-6|0 4-5|0.1 2-3|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:45.430
(c3 / cause-01 
      :ARG0 (e2 / effect 
            :mod (a4 / adverse)) 
      :ARG1 (h3 / halt-01 
            :ARG1 (t2 / trial-06 
                  :ARG1 (p4 / pathology)) 
            :time-of (f2 / find-01 
                  :ARG0 (p5 / person 
                        :ARG0-of (h2 / have-rel-role-91 
                              :ARG1 (p7 / person 
                                    :ARG0-of (v / volunteer-01) 
                                    :poss-of (s2 / subset)) 
                              :ARG2 (p6 / patient)) 
                        :ARG1-of (a3 / analyze-01 
                              :ARG0 (d / degree) 
                              :mod (f3 / further)) 
                        :ARG1-of (h / have-rel-role-91 
                              :ARG0 (p / person 
                                    :poss-of (t / tit)) 
                              :ARG2 (p2 / patient)) 
                        :mod (c / country 
                              :mod-of (a / antibody) 
                              :name (n / name 
                                    :op1 "A-specific")) 
                        :quant (s / several)) 
                  :ARG1 (e / evidence-01 
                        :ARG0-of (i / improve-01 
                              :ARG1 (f / function-01 
                                    :ARG1 (c2 / cognitive) 
                                    :compared-to-of (l / less)) 
                              :location (p3 / proportion) 
                              :op1-of (a2 / and))))))

# ::snt While this approach is promising , constant exposure to antibodies that recognize an epitope highly enriched in the brain may have unexpected side effects that will limit its long-term use .
# ::tok While this approach is promising , constant exposure to antibodies that recognize an epitope highly enriched in the brain may have unexpected side effects that will limit its long-term use .
# ::alignments 29-30|0.0.0.0 28-29|0.0.0.0.1 26-27|0.0.0.0.0 23-24|0.0.0.0.0.0 22-23|0.0.0.0.0.0.2 21-22|0.0.0.0.0.0.1.0+0.0.0.0.0.0.1 19-20|0.0.0.0.0.0.0 18-19|0.1.0.1 15-16|0.1.0 14-15|0.1.0.0 13-14|0.1 11-12|0 9-10|0.0 7-8|0.0.0 6-7|0.0.0.1 4-5|0.0.0.0.0.0.0.0 2-3|0.0.0.0.0.0.0.0.0 1-2|0.0.0.0.0.0.0.0.0.0 0-1|0.0.0.0.0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:45.673
(r / recognize-02 
      :ARG0 (a / antibodi 
            :ARG2-of (e5 / expose-01 
                  :ARG1 (u / use-01 
                        :ARG1-of (l2 / limit-01 
                              :ARG0 (e / effect 
                                    :ARG1-of (p / possible-01 
                                          :condition (p2 / promise-01 
                                                :ARG0 (a2 / approach-02 
                                                      :mod (t / this)) 
                                                :ARG0-of (w / while-01))) 
                                    :mod (e2 / expect-01 
                                          :polarity -) 
                                    :mod (s / side))) 
                        :mod (l / long-term)) 
                  :mod (c / constant))) 
      :ARG1 (e4 / epitope 
            :ARG1-of (e3 / enrich-01 
                  :degree (h / high) 
                  :location (b / brain))))

# ::snt An alternative approach that is being actively pursued for future treatment of AD seeks to lower A levels by limiting its production from the precursor protein APP .
# ::tok An alternative approach that is being actively pursued for future treatment of AD seeks to lower A levels by limiting its production from the precursor protein APP .
# ::alignments 26-27|0.0.2.0+0.0.2+0.0 25-26|0 24-25|0.0.1 21-22|0.0.0 19-20|0.0.0.0 17-18|0.0.0.0.0.0 15-16|0.0.0.0.0 13-14|0.0.0.0.0.1 12-13|0.0.0.0.0.1.1.1.0 10-11|0.0.0.0.0.1.1.1 9-10|0.0.0.0.0.1.1.1.1 7-8|0.0.0.0.0.1.1 6-7|0.0.0.0.0.1.1.0 2-3|0.0.0.0.0.1.0 1-2|0.0.0.0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:45.817
(p / protein 
      :mod-of (o / organization 
            :ARG0-of (p3 / produce-01 
                  :ARG1-of (l / limit-01 
                        :manner-of (l3 / low-04 
                              :ARG1 (l2 / level) 
                              :ARG1-of (s / seek-01 
                                    :ARG0 (a2 / approach-02 
                                          :mod (a3 / alternative)) 
                                    :ARG1-of (p4 / pursue-01 
                                          :ARG1-of (a / activity-06) 
                                          :purpose (t / treat-03 
                                                :ARG1 "AD" 
                                                :time (f / future))))))) 
            :mod (p2 / precursor) 
            :name (n / name 
                  :op1 "APP")))

# ::snt Peptide A is released from APP by the action of two enzymes , the -APP cleaving enzyme 1 ( BACE1 ) and -secretase , which cleave the holoprotein at the N - and C-termini of A , respectively .
# ::tok Peptide A is released from APP by the action of two enzymes , the -APP cleaving enzyme 1 ( BACE1 ) and -secretase , which cleave the holoprotein at the N - and C-termini of A , respectively .
# ::alignments 37-38|0.0.0.0.1.0.2 32-33|0 30-31|0.0.1 27-28|0.0.0 25-26|0.0 21-22|0.0.0.0 19-20|0.0.0.0.1.0.3 17-18|0.0.0.0.1.0.4 16-17|0.0.0.0.0 15-16|0.0.0.0.0.0 14-15|0.0.0.0.0.0.0.0.0+0.0.0.0.0.0.0.0+0.0.0.0.0.0.0 11-12|0.0.0.0.0.0.1 10-11|0.0.0.0.0.0.1.0 8-9|0.0.0.0.1 5-6|0.0.0.0.1.0.1.0.0+0.0.0.0.1.0.1.0+0.0.0.0.1.0.1 3-4|0.0.0.0.1.0 0-2|0.0.0.0.1.0.0.0.1+0.0.0.0.1.0.0.0.0+0.0.0.0.1.0.0.0+0.0.0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:47.084
(a / and 
      :ARG0-of (c / cleave-01 
            :ARG1 (h / holoprotein 
                  :op2-of (a2 / and 
                        :op1 (e / enzyme 
                              :ARG1-of (c2 / cleave-01 
                                    :ARG0 (t / thing 
                                          :name (n2 / name 
                                                :op1 -APP)) 
                                    :location (e2 / enzym 
                                          :quant 2))) 
                        :time (a3 / action 
                              :ARG0-of (r2 / release-01 
                                    :ARG1 (t2 / thing 
                                          :name (n4 / name 
                                                :op1 (p / Peptide) 
                                                :op2 (a4 / A))) 
                                    :ARG2 (o / organization 
                                          :name (n3 / name 
                                                :op1 "APP")) 
                                    :op1-of (r / respective) 
                                    :op1-of (b / BACE1) 
                                    :op1-of 1)))) 
            :location (n / N)))

# ::snt Several inhibitors of -secretase have already been produced [ 8,9 ] , and small molecule inhibitors of -APP cleaving enzyme 1 are currently being developed [ 10,11 ] .
# ::tok Several inhibitors of -secretase have already been produced [ 8,9 ] , and small molecule inhibitors of -APP cleaving enzyme 1 are currently being developed [ 10,11 ] .
# ::alignments 24-25|0.1 22-23|0.1.1 20-21|0.0.0 19-20|0.1.0.0.0 18-19|0.1.0.0 15-16|0.1.0 14-15|0.1.0.2 13-14|0.1.0.1 12-13|0 7-8|0.0 5-6|0.0.2 1-2|0.0.1 0-1|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:47.628
(a / and 
      :op1 (p / produce-01 
            :ARG0 1 
            :ARG1 (i2 / inhibitor 
                  :quant (s2 / several)) 
            :time (a2 / already)) 
      :op2 (d / develop-02 
            :ARG1 (i / inhibitor 
                  :ARG0-of (c2 / cleave-01 
                        :ARG1 (e / enzyme)) 
                  :mod (s / small) 
                  :mod (m / molecule)) 
            :time (c / current)))

# ::snt The long-term effectiveness of this approach in either humans or model systems , however , has not been reported .
# ::tok The long-term effectiveness of this approach in either humans or model systems , however , has not been reported .
# ::alignments 18-19|0 16-17|0.0.0.0 11-12|0.0.1.0.1 10-11|0.0.1.0.1.0 9-10|0.0.1.0 8-9|0.0.1.0.0 7-8|0.0.1 5-6|0.0.0 4-5|0.0.0.1 2-3|0.0 1-2|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:47.828
(r / report-01 
      :ARG1 (e2 / effective-04 
            :ARG0 (a / approach-02 
                  :ARG1 - 
                  :mod (t / this)) 
            :ARG1 (e / either 
                  :mod-of (o / or 
                        :op1 (h / human) 
                        :op2 (s / system 
                              :mod (m / model)))) 
            :mod (l / long-term)))

# ::snt Although loss of -APP cleaving enzyme 1 function can prevent the development of plaques in transgenic mouse models for AD ( F. Laird , H. Cai , P. C. Wong , personal communication ) , it is not known whether the brain can clear pre-existing amyloid deposits once production of A has been suppressed .
# ::tok Although loss of -APP cleaving enzyme 1 function can prevent the development of plaques in transgenic mouse models for AD ( F. Laird , H. Cai , P. C. Wong , personal communication ) , it is not known whether the brain can clear pre-existing amyloid deposits once production of A has been suppressed .
# ::alignments 53-54|0.0.0.0.1.2.1.0.3.0 48-49|0.0.0.0.1.2.1.0.3.0.0 47-48|0.0.0.0.1.2.1.0.3 46-47|0.0.0.0.1.2.1.0.1 45-46|0.0.0.0.1.2.1.0.3.0.1.1.0 44-45|0.0.0.0.1.1.0 43-44|0.0.0.0.1.2.1.0 42-43|0.0.0.0.1.2.1 41-42|0.0.0.0.1.2.1.0.0 38-39|0.0.0.0.1.2 37-38|0.0.0.0.1.2.2 32-33|0.0.0.0.1.2.1.0.3.0.1 31-32|0.0.0.0.1.2.1.0.3.0.1.1 27-30|0.0.0.0.1.2.1.0.3.0.1.0.0.2+0.0.0.0.1.2.1.0.3.0.1.0.0.1+0.0.0.0.1.2.1.0.3.0.1.0.0.0+0.0.0.0.1.2.1.0.3.0.1.0.0+0.0.0.0.1.2.1.0.3.0.1.0 24-26|0.0.0.0.0.0.1+0.0.0.0.0.0.0+0.0.0.0.0.0+0.0.0.0.0 21-23|0.0.0.0.1.2.1.0.3.0.0.0.0.1+0.0.0.0.1.2.1.0.3.0.0.0.0.0+0.0.0.0.1.2.1.0.3.0.0.0.0+0.0.0.0.1.2.1.0.3.0.0.0 19-20|0.0.0.0.1.2.1.0.2 17-18|0.0.0.0.2 16-17|0.0.0.0.2.0 13-14|0.0.0 11-12|0.0.0.0 9-10|0.0.0.0.1 8-9|0.0.0.0.1.1 7-8|0.0 6-7|0.0.0.0.1.2.0 5-6|0.0.1 4-5|0 1-2|0.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:49.604
(c3 / cleave-01 
      :ARG1 (f / function-01 
            :ARG0 (p8 / plaqu 
                  :ARG1-of (d2 / develop-02 
                        :ARG0 (p6 / person 
                              :name (n2 / name 
                                    :op1 "H." 
                                    :op2 "Cai")) 
                        :ARG1-of (p9 / prevent-01 
                              :ARG0 (l / loss) 
                              :ARG1-of (p10 / possible-01 
                                    :ARG0 (p2 / pre-exist)) 
                              :purpose-of (k / know-02 
                                    :ARG0 1 
                                    :ARG1 (p3 / possible-01 
                                          :ARG1 (c / clear-06 
                                                :ARG1 (b / brain) 
                                                :ARG2 (d / deposit) 
                                                :purpose "AD" 
                                                :time (o / once 
                                                      :op1 (s / suppress-01 
                                                            :ARG1 (p / produce-01 
                                                                  :ARG1 (p7 / person 
                                                                        :name (n3 / name 
                                                                              :op1 "F." 
                                                                              :op2 "Laird"))) 
                                                            :ARG2 (c2 / communicate-01 
                                                                  :ARG0 (p5 / person 
                                                                        :name (n / name 
                                                                              :op1 "P." 
                                                                              :op2 "C." 
                                                                              :op3 "Wong")) 
                                                                  :ARG1-of (p4 / personal-02 
                                                                        :ARG0 (a / amyloid))))))) 
                                    :polarity -)) 
                        :location (m / model 
                              :mod (m2 / mouse)))) 
            :ARG1 (e / enzyme)))

# ::snt Clearly , the amyloid-lowering approach should be rigorously examined in animal models before these reagents are tested in patients .
# ::tok Clearly , the amyloid-lowering approach should be rigorously examined in animal models before these reagents are tested in patients .
# ::alignments 18-19|0.0.4.0.0.0.0+0.0.4.0.0.0+0.0.4.0.0 16-17|0.0.4.0 14-15|0.0.4.0.1 13-14|0.0.4.0.1.0 12-13|0.0.4 11-12|0.0.0 10-11|0.0.0.0 8-9|0.0 7-8|0.0.3 5-6|0 4-5|0.0.1 3-4|0.0.1.0 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:50.472
(r3 / recommend-01 
      :ARG1 (e / examine-01 
            :ARG0 (m / model 
                  :mod (a / animal)) 
            :ARG1 (a2 / approach-02 
                  :mod (a3 / amyloid-lower)) 
            :ARG1-of (c / clear-06) 
            :manner (r2 / rigorously) 
            :time (b / before 
                  :op1 (t / test-01 
                        :ARG0 (p / person 
                              :ARG0-of (h / have-rel-role-91 
                                    :ARG2 (p2 / patient))) 
                        :ARG1 (r / reagent 
                              :mod (t2 / this))))))

# ::snt However , the chemical secretase inhibitors most likely to reach human trials are still in development .
# ::tok However , the chemical secretase inhibitors most likely to reach human trials are still in development .
# ::alignments 15-16|0.1.2 13-14|0.1.2.0 11-12|0.1 10-11|0.1.1 9-10|0 7-8|0.2 6-7|0.0 5-6|0.1.0 4-5|0.1.0.0 3-4|0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:50.602
(r / reach-01 
      :ARG0 (m / most) 
      :ARG1 (t / trial-06 
            :ARG0 (i / inhibitor 
                  :mod (s2 / secretase 
                        :mod (c / chemical))) 
            :ARG1 (h / human) 
            :ARG1-of (d / develop-02 
                  :mod (s / still))) 
      :ARG1-of (l / likely-01))

# ::snt Therefore , we developed a mouse model of Alzheimer-type amyloid that expresses a controllable APP transgene .
# ::tok Therefore , we developed a mouse model of Alzheimer-type amyloid that expresses a controllable APP transgene .
# ::alignments 15-16|0.1.0.0 14-15|0.1.0.0.0.0.0+0.1.0.0.0.0+0.1.0.0.0 13-14|0.1.0.0.1 11-12|0.1.0 9-10|0.1.2 8-9|0.1.2.0.0.0+0.1.2.0.0+0.1.2.0 6-7|0.1 5-6|0.1.1 3-4|0 2-3|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:50.713
(d / develop-02 
      :ARG0 (w / we) 
      :ARG1 (m / model 
            :ARG0-of (e / express-01 
                  :ARG1 (t / transgene 
                        :mod (o / organization 
                              :name (n / name 
                                    :op1 "APP")) 
                        :mod (c / controllable))) 
            :mod (m2 / mouse) 
            :mod (a / amyloid 
                  :mod (c2 / country 
                        :name (n2 / name 
                              :op1 "Alzheimer-type")))))

# ::snt This system , commonly known as the tet-off system , can be regulated by analogs of tetracycline administered in food or water [ 12,13 ] .
# ::tok This system , commonly known as the tet-off system , can be regulated by analogs of tetracycline administered in food or water [ 12,13 ] .
# ::alignments 21-22|0.0.2.2 20-21|0.0.2 19-20|0.0.2.1 17-18|0.0.2.0 16-17|0.0.2.0.0 14-15|0.0.0 12-13|0.0 10-11|0 8-9|0.0.1.0.0 4-5|0.0.1.0 3-4|0.0.1.0.1 1-2|0.0.1 0-1|0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:51.244
(p / possible-01 
      :ARG1 (r / regulate-01 
            :ARG0 (a2 / analog) 
            :ARG1 (s2 / system 
                  :ARG1-of (k / know-02 
                        :ARG2 (s / system) 
                        :mod (c / common)) 
                  :mod (t2 / this)) 
            :op1-of (o / or 
                  :ARG2-of (a / administer-01 
                        :ARG1 (t / tetracycline)) 
                  :op2 (f / food) 
                  :op3 (w / water))))

# ::snt The strong expression levels produced with the tet-off vectors , combined with the ability to reduce this expression by several orders of magnitude with tetracycline [ 14 ] , allowed for a stringent test of how a highly effective pharmaceutical inhibitor of A production would impact the progression of amyloid pathology and whether reversal of these lesions might be possible following such treatment .
# ::tok The strong expression levels produced with the tet-off vectors , combined with the ability to reduce this expression by several orders of magnitude with tetracycline [ 14 ] , allowed for a stringent test of how a highly effective pharmaceutical inhibitor of A production would impact the progression of amyloid pathology and whether reversal of these lesions might be possible following such treatment .
# ::alignments 62-63|0.2.1.0.0.2.0.0.1 61-62|0.2.1.0.0.2.0.0.1.0 60-61|0.2.1.0.0.2.0.0 59-60|0.2.1.0.0.2 57-58|0.2.1.0.0.2.0 56-57|0.2.1.0.0.2.0.0.0.0 55-56|0.2.1.0.0.2.0.0.0.0.0 53-54|0.2.1.0.0.2.0.0.0 51-52|0.2.1.0.0.2.1 50-51|0.2.1.0.0.2.1.2.1.0 49-50|0.2.1.0.0.2.1.2.1.0.0 47-48|0.2.1.0.0.2.1.2.1 45-46|0.2.1.0.0.2.1.2 43-44|0.2.1.0.0.2.1.1 40-41|0.2.1.0.0.2.1.2.0 39-40|0.2.1.0.0.2.1.2.0.1 38-39|0.2.1.0.0.2.1.2.0.0 37-38|0.2.1.0.0.2.1.2.0.0.0 33-34|0.2.1.0.0.2.1.0 32-33|0.2.1.0.0.2.1.0.0 29-30|0.2.1.0.0.2.1.0.1 26-27|0.2.0 24-25|0.1 22-23|0.3 20-21|0.0 19-20|0.0.0 17-18|0 16-17|0.4 15-16|0.2 13-14|0.2.1 10-11|0.2.1.0 8-9|0.2.1.0.0.1 4-5|0.2.1.0.0 3-4|0.2.1.0.0.0 2-3|0.2.1.0.0.0.0 1-2|0.2.1.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:21:53.854
(e2 / express-01 
      :ARG0 (o / order 
            :quant (s3 / several)) 
      :ARG1 (t4 / tetracycline) 
      :ARG1-of (r2 / reduce-01 
            :ARG0 14 
            :purpose-of (a4 / ability 
                  :ARG2-of (c / combine-01 
                        :ARG1 (p7 / produce-01 
                              :ARG0 (l2 / level 
                                    :ARG1-of (e3 / express-01) 
                                    :ARG1-of (s4 / strong-02)) 
                              :ARG1 (v / vector) 
                              :ARG1-of (p / possible-01 
                                    :ARG1-of (p2 / possible-01 
                                          :condition (f / follow-01 
                                                :ARG1 (r / reverse-01 
                                                      :ARG1 (l / lesion 
                                                            :mod (t2 / this))) 
                                                :ARG2 (t / treat-03 
                                                      :mod (s / such)))) 
                                    :op3-of (a / and 
                                          :ARG0-of (t3 / test-01 
                                                :ARG1 (s2 / stringent) 
                                                :ARG1-of (a3 / allow-01)) 
                                          :op1 (p5 / produce-01) 
                                          :op2 (i / impact-01 
                                                :ARG0 (i2 / inhibitor 
                                                      :ARG0-of (e / effective-04 
                                                            :degree (h / high)) 
                                                      :mod (p6 / pharmacy)) 
                                                :ARG1 (p4 / progress-01 
                                                      :ARG1 (p3 / pathology 
                                                            :mod (a2 / amyloid)))))))))) 
      :location (m / magnitude) 
      :mod (t5 / this))

# ::snt We created a tetracycline-responsive chimeric mouse/human APP695Swedish/Indiana ( swe/ind ) vector by replacing the promoter region of the moPrP.XhoI vector ( also known as pPrPpE1/E2 ,3 sal [ 15 ] ) with the tetracycline-responsive promoter of pTetSplice ( Life Technologies , Rockville , Maryland , United States ) , and then ligating mouse APP with a humanized A domain ( mo/huAPP695 ) cDNA into the new vector .
# ::tok We created a tetracycline-responsive chimeric mouse/human APP695Swedish/Indiana ( swe/ind ) vector by replacing the promoter region of the moPrP.XhoI vector ( also known as pPrPpE1/E2 ,3 sal [ 15 ] ) with the tetracycline-responsive promoter of pTetSplice ( Life Technologies , Rockville , Maryland , United States ) , and then ligating mouse APP with a humanized A domain ( mo/huAPP695 ) cDNA into the new vector .
# ::alignments 66-67|0.0.2 65-66|0.0.2.0 62-63|0.2.2.2 58-59|0.2.1.2.0 56-57|0.2.1.2 53-54|0.2.2.1 52-53|0.2.2.1.0 51-52|0.2.2 50-51|0.2.2.3 49-50|0.2 45-47|0.0.1.2.1+0.0.1.2.0.1+0.0.1.2.0.0+0.0.1.2.0+0.0.1.2 43-44|0.0.1.1.1+0.0.1.1.0.0+0.0.1.1.0+0.0.1.1 39-40|0.2.1.0 38-39|0.2.0.1 36-37|0.2.1.1 34-35|0.2.1 28-29|0.2.2.0 22-23|0.0.1 21-22|0.0.1.3 19-20|0.0.1.0 15-16|0.0.0.1 14-15|0.0.0.0 12-13|0.0.0 10-11|0.1 6-7|0.2.0.0.0+0.2.0.0+0.2.0 4-5|0.0.0.0.0 1-2|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:00.875
(c4 / create-01 
      :ARG0 (w / we 
            :ARG0-of (r2 / replace-01 
                  :ARG1 (p3 / promote-01 
                        :ARG1 (c3 / chimeric)) 
                  :ARG2 (r / region)) 
            :ARG0-of (k / know-02 
                  :ARG1 (v2 / vector) 
                  :ARG2 (s / state 
                        :name (n3 / name 
                              :op1 "Maryland") 
                        :wiki "Maryland") 
                  :location (c2 / country 
                        :name (n2 / name 
                              :op1 "United" 
                              :op2 "States") 
                        :wiki "United_States") 
                  :mod (a3 / also)) 
            :poss-of (v / vector 
                  :mod (n / new))) 
      :ARG1 (v3 / vector) 
      :manner (a2 / and 
            :op1 (p4 / person 
                  :name (n4 / name 
                        :op1 "APP695Swedish/Indiana") 
                  :poss-of (l2 / life)) 
            :op2 (p2 / promote-01 
                  :ARG0 (t2 / technologi) 
                  :ARG1 (p / pTetSplice) 
                  :ARG2 (h / humanize-01 
                        :ARG1 (d / domain))) 
            :op3 (l / ligate-01 
                  :ARG0 15 
                  :ARG1 (a / APP 
                        :mod (m / mouse)) 
                  :ARG2 (c / cdna) 
                  :time (t / then))))

# ::snt We began by cloning the tetracycline-responsive promoter ( bp 6 -- 481 ) from pTetSplice by PCR using primers that added external BamHI and NotI sites to the 5  end and a BamHI site to the 3  end , while destroying XhoI and BamHI sites within the promoter ( forward : GCC GGA TCC GCG GCC GCC GTC GAG TTT ACC ACT CCC TAT C ; reverse : GCC GGA TCC ACT CTA GAA GAT CCC CGG GTA CCG ) .
# ::tok We began by cloning the tetracycline-responsive promoter ( bp 6 -- 481 ) from pTetSplice by PCR using primers that added external BamHI and NotI sites to the 5  end and a BamHI site to the 3  end , while destroying XhoI and BamHI sites within the promoter ( forward : GCC GGA TCC GCG GCC GCC GTC GAG TTT ACC ACT CCC TAT C ; reverse : GCC GGA TCC ACT CTA GAA GAT CCC CGG GTA CCG ) .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:00.897
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt We then isolated the moPrP.XhoI intron by amplification with primers that added an external BamHI site to the 5  end of exon 1 and ran through the Asp718 site of exon 2 ( forward : GCC GGA TCC GAT CAG CAG ACC GAT TCT GG ; reverse : GCC GGT ACC ACT AGG AAG GCA GAA TGC ) .
# ::tok We then isolated the moPrP.XhoI intron by amplification with primers that added an external BamHI site to the 5  end of exon 1 and ran through the Asp718 site of exon 2 ( forward : GCC GGA TCC GAT CAG CAG ACC GAT TCT GG ; reverse : GCC GGT ACC ACT AGG AAG GCA GAA TGC ) .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:00.919
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt This 2-kb intron fragment was cloned into a TA cloning vector ( Invitrogen , Carlsbad , California , United States ) , then excised by Asp718 digestion and ligated to the 6.8-kb Asp718 fragment of moPrP.XhoI containing exon 2 , exon 3 , the 3  UTR , and pBluescript to generate an intermediate vector with all three exons and a central intron but no promoter .
# ::tok This 2-kb intron fragment was cloned into a TA cloning vector ( Invitrogen , Carlsbad , California , United States ) , then excised by Asp718 digestion and ligated to the 6.8-kb Asp718 fragment of moPrP.XhoI containing exon 2 , exon 3 , the 3  UTR , and pBluescript to generate an intermediate vector with all three exons and a central intron but no promoter .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:00.950
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt This vector was then opened at the BamHI site introduced by the intron cloning primer , and ligated to the 0.5-kb BamHI-cut tetracycline promoter fragment .
# ::tok This vector was then opened at the BamHI site introduced by the intron cloning primer , and ligated to the 0.5-kb BamHI-cut tetracycline promoter fragment .
# ::alignments 24-25|0.1.0 23-24|0.1.0.0 22-23|0.1.0.0.0 21-22|0.1.0.1.0.0+0.1.0.1.0+0.1.0.1 17-18|0.1 16-17|0 14-15|0.0.1.0.0 13-14|0.0.1.0.0.0 12-13|0.0.1.0.0.0.0 9-10|0.0.1.0 8-9|0.0.1 7-8|0.0.1.1.0.0+0.0.1.1.0+0.0.1.1 4-5|0.0 3-4|0.0.2 1-2|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:01.560
(a / and 
      :op1 (o / open-01 
            :ARG1 (v / vector 
                  :mod (t5 / this)) 
            :location (s / site 
                  :ARG1-of (i2 / introduce-02 
                        :ARG0 (p2 / primer 
                              :ARG1-of (c / clone-01 
                                    :ARG0 (i / intron)))) 
                  :mod (t3 / thing 
                        :name (n2 / name 
                              :op1 "BamHI"))) 
            :time (t4 / then)) 
      :op2 (l / ligate-01 
            :ARG2 (f / fragment-01 
                  :ARG1 (p / promote-01 
                        :ARG1 (t / tetracycline)) 
                  :instrument (t2 / thing 
                        :name (n / name 
                              :op1 "BamHI-cut")))))

# ::snt This ligation generated a 9.3-kb vector encoding the tetracycline promoter from pTetSplice with two exons , one intron , and the original 3  UTR of the moPrP.XhoI vector , all carried in the pBluescript cloning vector .
# ::tok This ligation generated a 9.3-kb vector encoding the tetracycline promoter from pTetSplice with two exons , one intron , and the original 3  UTR of the moPrP.XhoI vector , all carried in the pBluescript cloning vector .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:01.577
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt We incorporated the Swedish ( KM570/571NL ) and Indiana ( V617F ) mutations into the mo/huAPP695 cDNA ( in BS-KS ) by PCR using a four-primer strategy : first , two partially overlapping products were generated in separate reactions using primers that encode the desired mutations ( Swedish forward : GGA GAT CTC TGA AGT GAA TCT GGA TGC AGA ATT CCG/Indiana reverse : GGG TGA TGA AAA TCA CGG TTG C ; Indiana forward : CAA CCG TGA TTT TCA TCA CCC TGG/M13 reverse ) .
# ::tok We incorporated the Swedish ( KM570/571NL ) and Indiana ( V617F ) mutations into the mo/huAPP695 cDNA ( in BS-KS ) by PCR using a four-primer strategy : first , two partially overlapping products were generated in separate reactions using primers that encode the desired mutations ( Swedish forward : GGA GAT CTC TGA AGT GAA TCT GGA TGC AGA ATT CCG/Indiana reverse : GGG TGA TGA AAA TCA CGG TTG C ; Indiana forward : CAA CCG TGA TTT TCA TCA CCC TGG/M13 reverse ) .
# ::alignments 84-85|0.1 81-83|0.1.2.0.1+0.1.2.0.0+0.1.2.0+0.1.2 79-81|0.1.1.0.1+0.1.1.0.0+0.1.1.0+0.1.1 77-79|0.1.1.0.0.0.0.1+0.1.1.0.0.0.0.0+0.1.1.0.0.0.0+0.1.1.0.0.0 76-77|0.1.0.0.0+0.1.0.0+0.1.0 74-75|0.0.0.0.0.0.1.0.0.0.0 72-73|0 71-72|0.0.0.0.0.0.1.0.0.0.1.0 69-71|0.0.0.0.0.0.1.0.0.0.1.0.0.0.1+0.0.0.0.0.0.1.0.0.0.1.0.0.0.0+0.0.0.0.0.0.1.0.0.0.1.0.0.0+0.0.0.0.0.0.1.0.0.0.1.0.0 67-69|0.0.0.0.0.0.1.0.0.0.1.1.1+0.0.0.0.0.0.1.0.0.0.1.1.0+0.0.0.0.0.0.1.0.0.0.1.1+0.0.0.0.0.0.1.0.0.0.1 65-67|0.0.0.0.0.0.1.0.0.1.0.1+0.0.0.0.0.0.1.0.0.1.0.0+0.0.0.0.0.0.1.0.0.1.0+0.0.0.0.0.0.1.0.0.1 62-63|0.0.0.0.0.0.1.0.0.0.2.0.0.0.2.0 59-61|0.0.0.0.0.0.1.0.0.0.2.0.0.0.2.0.1.0.1+0.0.0.0.0.0.1.0.0.0.2.0.0.0.2.0.1.0.0+0.0.0.0.0.0.1.0.0.0.2.0.0.0.2.0.1.0+0.0.0.0.0.0.1.0.0.0.2.0.0.0.2.0.1 57-59|0.0.0.0.0.0.1.0.0.0.2.0.0.1.0.0.1+0.0.0.0.0.0.1.0.0.0.2.0.0.1.0.0.0+0.0.0.0.0.0.1.0.0.0.2.0.0.1.0.0+0.0.0.0.0.0.1.0.0.0.2.0.0.1.0 55-57|0.0.0.0.0.0.1.0.0.0.2.0.0.0.3.0.1+0.0.0.0.0.0.1.0.0.0.2.0.0.0.3.0.0+0.0.0.0.0.0.1.0.0.0.2.0.0.0.3.0+0.0.0.0.0.0.1.0.0.0.2.0.0.0.3 53-55|0.0.0.0.0.0.1.0.0.0.2.0.0.1.1.0.0.0.1+0.0.0.0.0.0.1.0.0.0.2.0.0.1.1.0.0.0.0+0.0.0.0.0.0.1.0.0.0.2.0.0.1.1.0.0.0+0.0.0.0.0.0.1.0.0.0.2.0.0.1.1.0.0 51-53|0.0.0.0.0.0.1.0.0.0.2.0.0.0.1.0.1+0.0.0.0.0.0.1.0.0.0.2.0.0.0.1.0.0+0.0.0.0.0.0.1.0.0.0.2.0.0.0.1.0+0.0.0.0.0.0.1.0.0.0.2.0.0.0.1 50-51|0.0.0.0.0.0.1.0.0.0.2.0.0.0.2.0.0.0.0+0.0.0.0.0.0.1.0.0.0.2.0.0.0.2.0.0.0+0.0.0.0.0.0.1.0.0.0.2.0.0.0.2.0.0 48-49|0.0.0.0.0.0.1.0.0.0.2.0.0.0.0.0 47-48|0.0.0.0.0.0.1.0.0.0.2.0.0.0.0.2+0.0.0.0.0.0.1.0.0.0.2.0.0.0.0.1.0+0.0.0.0.0.0.1.0.0.0.2.0.0.0.0.1+0.0.0.0.0.0.1.0.0.0.2.0.0.0.0 45-46|0.0.0.0.0.0.1.0.0.0 44-45|0.0.0.0.0.0.1.0.0 42-43|0.0.0.0.0.0.1.0.0.0.2 40-41|0.0.0.0.0.0.1.0.0.0.2.0 39-40|0.0.0.0.0.0.1.0.0.0.2.0.0 38-39|0.0.0.0.0.0.1.0.0.0.2.0.0.0 37-38|0.0.0.0.0.0.1.0.0.0.2.0.0.0.2 35-36|0.0.0.0.0.0.1.0.0.0.2.0.0.1 33-34|0.0.0.0.0.0.1.0.0.0.2.0.0.1.1 32-33|0.0.0.0.0.0.1.0.0.0.2.0.0.1.1.0 31-32|0.0.0.0.0.0.1.0.0.0.2.0.0.1.1.0.1 30-31|0.0.0.0.0.0.1.0.0.0.2.0.0.1.1.1 26-27|0.0.1 25-26|0.0.1.0 23-24|0.0 19-20|0.0.0.0.0.0.1.0.1.0+0.0.0.0.0.0.1.0.1+0.0.0.0.0.0.1.0 16-17|0.0.0.0.0.0.1 12-13|0.0.0.0.0.0 8-9|0.0.0.0.0.0.2.0.0+0.0.0.0.0.0.2.0+0.0.0.0.0.0.2 7-8|0.0.0.0.0 5-6|0.0.0.0.0.0.0.0.0+0.0.0.0.0.0.0.0+0.0.0.0.0.0.0 3-4|0.0.0.0.1.1+0.0.0.0.1.0.0+0.0.0.0.1.0+0.0.0.0.1 1-2|0.0.0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:20.661
(a / and 
      :op1 (u2 / use-01 
            :ARG0 (w / we 
                  :ARG0-of (i / incorporate-01 
                        :ARG1 (a6 / and 
                              :op1 (m2 / mutate-01 
                                    :ARG0 (t23 / thing 
                                          :name (n17 / name 
                                                :op1 "KM570/571NL")) 
                                    :ARG1 (c8 / cdna 
                                          :location (c7 / country 
                                                :ARG0-of (d / desire-01 
                                                      :ARG1 (m / mutate-01 
                                                            :ARG0 (f / forward) 
                                                            :ARG1 (t10 / thing 
                                                                  :mod (c3 / C 
                                                                        :mod-of (t8 / thing 
                                                                              :name (n5 / name 
                                                                                    :op1 (c4 / CGG) 
                                                                                    :op2 (t9 / TTG)))) 
                                                                  :name (n6 / name 
                                                                        :op1 (a2 / AAA) 
                                                                        :op2 (t11 / TCA))) 
                                                            :ARG1-of (e / encode-01 
                                                                  :ARG0 (p / primer 
                                                                        :ARG1-of (u / use-01 
                                                                              :ARG0 (r3 / react-01 
                                                                                    :ARG0 (c6 / country 
                                                                                          :mod-of (f2 / forward) 
                                                                                          :name (n14 / name 
                                                                                                :op1 "Sweden") 
                                                                                          :wiki "Sweden") 
                                                                                    :ARG1 (t22 / thing 
                                                                                          :name (n12 / name 
                                                                                                :op1 (g3 / GAT) 
                                                                                                :op2 (c5 / CTC))) 
                                                                                    :ARG1-of (s / separate-02 
                                                                                          :ARG2 (r2 / reverse-01 
                                                                                                :ARG0 (o2 / organization 
                                                                                                      :name (n13 / name 
                                                                                                            :op1 "GGA")) 
                                                                                                :ARG1 (t15 / thing 
                                                                                                      :name (n8 / name 
                                                                                                            :op1 (a3 / AGA) 
                                                                                                            :op2 (a4 / ATT))))) 
                                                                                    :ARG2 (t18 / thing 
                                                                                          :name (n10 / name 
                                                                                                :op1 (g2 / GAA) 
                                                                                                :op2 (t19 / TCT)))) 
                                                                              :manner-of (g4 / generate-01 
                                                                                    :ARG0 (t16 / thing 
                                                                                          :name (n9 / name 
                                                                                                :op1 (g / GGA) 
                                                                                                :op2 (t17 / TGC))) 
                                                                                    :ARG1 (p2 / product 
                                                                                          :mod (o3 / overlap-01 
                                                                                                :ARG1 (t20 / thing 
                                                                                                      :name (n11 / name 
                                                                                                            :op1 (t21 / TGA) 
                                                                                                            :op2 (a5 / AGT))) 
                                                                                                :degree (p3 / partial)) 
                                                                                          :quant 2)))))) 
                                                      :ARG2 (t12 / thing 
                                                            :name (n7 / name 
                                                                  :op1 (t13 / TGA) 
                                                                  :op2 (t14 / TGA)))) 
                                                :name (n15 / name 
                                                      :op1 "BS-KS"))) 
                                    :mod (c9 / country 
                                          :name (n16 / name 
                                                :op1 "Indiana")))) 
                        :ARG2 (c10 / country 
                              :name (n18 / name 
                                    :op1 "Sweden") 
                              :wiki "Sweden"))) 
            :ARG1 (s2 / strategy 
                  :mod (f3 / four-prim))) 
      :op2 (r / reverse-01 
            :ARG0 (o / organization 
                  :name (n4 / name 
                        :op1 "CAA")) 
            :ARG1 (t3 / thing 
                  :name (n2 / name 
                        :op1 (t4 / TTT 
                              :mod (t6 / thing 
                                    :name (n3 / name 
                                          :op1 (c2 / CCG) 
                                          :op2 (t7 / TGA)))) 
                        :op2 (t5 / TCA))) 
            :ARG2 (t / thing 
                  :name (n / name 
                        :op1 (t2 / TCA) 
                        :op2 (c / CCC)))))

# ::snt The two PCR products were ligated , digested with BglII and ApaI and cloned back into the original mo/huAPP695-BS-KS vector .
# ::tok The two PCR products were ligated , digested with BglII and ApaI and cloned back into the original mo/huAPP695-BS-KS vector .
# ::alignments 19-20|0.1.1 18-19|0.1.1.1 17-18|0.1.1.0 14-15|0.1.2 13-14|0.1 12-13|0 11-12|0.0.0.1.0.0.0+0.0.0.1.0.0+0.0.0.1.0 10-11|0.0.0.1 9-10|0.0.0.0.0+0.0.0.0+0.0.0 7-8|0.0 5-6|0.1.0.0 3-4|0.1.0 1-2|0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:20.870
(a / and 
      :op1 (d / digest-01 
            :ARG1 (t / thing 
                  :name (n2 / name 
                        :op1 "BglII") 
                  :op1-of (a2 / and 
                        :op2 (c2 / country 
                              :name (n / name 
                                    :op1 "ApaI"))))) 
      :op2 (c / clone-01 
            :ARG1 (p / product 
                  :ARG1-of (l / ligate-01) 
                  :quant 2) 
            :ARG2 (v / vector 
                  :mod (o / original) 
                  :mod (m / mo/huapp695-bs-k)) 
            :direction (b / back)))

# ::snt Finally , the new APP695swe/ind was subcloned into the XhoI site of the moPrP-tetP vector from above to complete the construct .
# ::tok Finally , the new APP695swe/ind was subcloned into the XhoI site of the moPrP-tetP vector from above to complete the construct .
# ::alignments 20-21|0.0.0 18-19|0.0 16-17|0.0.0.0 14-15|0.0.0.1.0.0 10-11|0.0.0.1.0 9-10|0.0.0.1.1.0+0.0.0.1.1+0.0.0.1 4-5|0.2.0+0.2+0 3-4|0.1 0-1|0.0.0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:21.021
(t2 / thing 
      :ARG0-of (c2 / complete-01 
            :ARG1 (c / construct-01 
                  :ARG1 (a / above) 
                  :mod (t / thing 
                        :mod-of (s / site 
                              :consist-of (v / vector) 
                              :manner (f / final)) 
                        :name (n / name 
                              :op1 "XhoI")))) 
      :mod (n3 / new) 
      :name (n2 / name 
            :op1 "APP695swe/ind"))

# ::snt Pronuclear Injection , Screening of Founders , and Maintenance of the Lines .
# ::tok Pronuclear Injection , Screening of Founders , and Maintenance of the Lines .
# ::alignments 11-12|0.1.1.0.0.0+0.1.1.0.0+0.1.1.0 8-9|0.1.1 7-8|0.1 5-6|0.0 3-4|0 0-2|0.1.0.0.1+0.1.0.0.0+0.1.0.0+0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:21.080
(s / screen-01 
      :ARG1 (f / founder-01) 
      :op2-of (a / and 
            :op1 (c / country 
                  :name (n2 / name 
                        :op1 "Pronuclear" 
                        :op2 "Injection")) 
            :op3 (m / maintenance 
                  :poss (o / organization 
                        :name (n / name 
                              :op1 "Lines")))))

# ::snt The moPrP-tetP-mo/huAPP695swe/ind vector was linearized and the pBluescript domain excised by digestion with NotI .
# ::tok The moPrP-tetP-mo/huAPP695swe/ind vector was linearized and the pBluescript domain excised by digestion with NotI .
# ::alignments 11-12|0.1.0.0 9-10|0.1.0 8-9|0.1 7-8|0.1.1 5-6|0 4-5|0.0 2-3|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:21.133
(a / and 
      :op1 (l / linearize 
            :domain (v / vector)) 
      :op2 (d2 / domain 
            :ARG1-of (e / excise-01 
                  :ARG0 (d / digestion)) 
            :mod (p / pBluescript)))

# ::snt The purified vector was injected into the pronucleus of fertilized eggs from C57BL/6J  C3HeJ F1 matings .
# ::tok The purified vector was injected into the pronucleus of fertilized eggs from C57BL/6J  C3HeJ F1 matings .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:21.136
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Founder animals were screened for the presence of the transgene by three-way PCR using the S36 and PrP-S/PrP-AS primers described below .
# ::tok Founder animals were screened for the presence of the transgene by three-way PCR using the S36 and PrP-S/PrP-AS primers described below .
# ::alignments 20-21|0.1.0.0.1.0.0 19-20|0.1.0.0.1.0 18-19|0.1.0.0.0 17-18|0.1.0.0.1.2 16-17|0.1.0.0.1 15-16|0.1.0.0.1.1.0.0+0.1.0.0.1.1.0+0.1.0.0.1.1 13-14|0.1.0.0 11-12|0.1.0.0.1.2.0 9-10|0.1.0 6-7|0.1 3-4|0 1-2|0.0 0-1|0.1.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:21.604
(s / screen-01 
      :ARG1 (a2 / animal) 
      :purpose (p3 / presence 
            :poss (t3 / transgene 
                  :ARG0-of (u / use-01 
                        :ARG1 (p / primer 
                              :ARG1-of (f / founder-01)) 
                        :op1-of (a / and 
                              :ARG1-of (d / describe-01 
                                    :manner (b / below)) 
                              :op2 (t / thing 
                                    :name (n / name 
                                          :op1 "S36")) 
                              :op3 (p2 / prp-s/prp-a 
                                    :mod (t2 / three-way)))))))

# ::snt Transgene-positive founders were bred to animals expressing the tetracycline transactivator ( tTA ) under control of the calcium-calmodulin kinase II ( CaMKII ) promoter obtained from Jackson Laboratory [ 16 ] ( Bar Harbor , Maine , United States ; stock # 3010 ; B6 ; CBA-TgN [ Camk2a-tTA ] 1Mmay ) .
# ::tok Transgene-positive founders were bred to animals expressing the tetracycline transactivator ( tTA ) under control of the calcium-calmodulin kinase II ( CaMKII ) promoter obtained from Jackson Laboratory [ 16 ] ( Bar Harbor , Maine , United States ; stock # 3010 ; B6 ; CBA-TgN [ Camk2a-tTA ] 1Mmay ) .
# ::alignments 42-43|0.2.0.0+0.2.0 40-41|0.2 39-40|0 37-39|0.1.1+0.1.0.1+0.1.0.0+0.1.0+0.1 35-36|0.0.1.0.1+0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 32-34|0.0.1.2.0.1+0.0.1.2.0.0+0.0.1.2.0+0.0.1.2 29-30|0.0.1.1.0.1 26-28|0.0.0.0.0.1+0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 24-25|0.0 23-24|0.0.0 19-20|0.0.0.1.1+0.0.0.1.0.2+0.0.0.1.0.1+0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 18-19|0.0.1.1.0.0.1.0 14-15|0.0.1 9-10|0.0.1.1 8-9|0.0.1.1.1 6-7|0.0.1.1.0 5-6|0.0.1.1.0.0.1.1 3-4|0.0.1.1.0.0.1 1-2|0.0.1.1.0.0.0+0.0.1.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:23.214
(a / and 
      :ARG0-of (o / obtain-01 
            :ARG1 (p / promote-01 
                  :ARG1 (t / thing 
                        :name (n4 / name 
                              :op1 "Jackson" 
                              :op2 "Laboratory")) 
                  :mod (w / war 
                        :name (n5 / name 
                              :op1 "World" 
                              :op2 "War" 
                              :op3 "II") 
                        :wiki "World_War_II")) 
            :ARG2-of (c3 / control-01 
                  :ARG0 (s2 / state 
                        :name (n2 / name 
                              :op1 "Maine") 
                        :wiki "Maine") 
                  :ARG1 (t2 / transactivator 
                        :ARG1-of (e / express-01 
                              :ARG0 (p2 / person 
                                    :ARG0-of (f / found-01) 
                                    :ARG1-of (b / breed-01 
                                          :ARG0 (k / kinase) 
                                          :ARG2 (a2 / animal))) 
                              :ARG2 16) 
                        :mod (t3 / tetracycline)) 
                  :location (c2 / country 
                        :name (n3 / name 
                              :op1 "Bar" 
                              :op2 "Harbor")))) 
      :op1 (c / country 
            :name (n / name 
                  :op1 "United" 
                  :op2 "States") 
            :wiki "United_States") 
      :op2 (s / stock 
            :mod (d / date-entity 
                  :year 3010)))

# ::snt The colony was thereafter maintained by crossing single transgenic tTA and APP offspring for each of the four APP lines .
# ::tok The colony was thereafter maintained by crossing single transgenic tTA and APP offspring for each of the four APP lines .
# ::alignments 19-20|0.1.0.0.0.0.0 17-18|0.1.0.0.0.0.0.1 14-15|0.1.0.0.0.0.0.0 12-13|0.1.0.0 11-12|0.1.0.0.0.1.0+0.1.0.0.0.1+0.1.0.0.0 10-11|0.1.0 7-8|0.1.0.0.0.0 6-7|0.1 4-5|0 3-4|0.2 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:23.389
(m / maintain-01 
      :ARG1 (c2 / colony) 
      :ARG2 (c / cross-02 
            :ARG1 (a / and 
                  :op1 (o / offspr 
                        :mod (o2 / organization 
                              :ARG1-of (s / single-02 
                                    :ARG0 (l / line 
                                          :mod (e / each) 
                                          :quant 4)) 
                              :name (n / name 
                                    :op1 "APP"))))) 
      :manner (t / thereaft))

# ::snt All mice were provided fresh food and water ad libitum .
# ::tok All mice were provided fresh food and water ad libitum .
# ::alignments 9-10|0.1.1 8-9|0.1.1.0 7-8|0.1.0 6-7|0.1 5-6|0.2 4-5|0.2.0 3-4|0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:23.538
(p / provide-01 
      :ARG0 (m / mouse 
            :quant (a3 / all)) 
      :ARG1 (a2 / and 
            :op1 (w / water) 
            :op2 (l / libitum 
                  :mod (a / ad))) 
      :ARG2 (f / food 
            :ARG1-of (f2 / fresh-04)))

# ::snt Animal protocols were approved by both the Johns Hopkins University and the California Institute of Technology Institutional Animal Care and Use Committees .
# ::tok Animal protocols were approved by both the Johns Hopkins University and the California Institute of Technology Institutional Animal Care and Use Committees .
# ::alignments 20-22|0.0.2.1.0.1+0.0.2.1.0.0+0.0.2.1.0+0.0.2.1 19-20|0.0.2 12-19|0.0.2.0.0.6+0.0.2.0.0.5+0.0.2.0.0.4+0.0.2.0.0.3+0.0.2.0.0.2+0.0.2.0.0.1+0.0.2.0.0.0+0.0.2.0.0+0.0.2.0 10-11|0.0 7-10|0.0.1.0.2+0.0.1.0.1+0.0.1.0.0+0.0.1.0+0.0.1 5-6|0.0.0 3-4|0 1-2|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:23.882
(a3 / approve-01 
      :ARG0 (a2 / and 
            :mod (b / both) 
            :op1 (o3 / organization 
                  :name (n3 / name 
                        :op1 "Johns" 
                        :op2 "Hopkins" 
                        :op3 "University")) 
            :op2 (a / and 
                  :op1 (o2 / organization 
                        :name (n2 / name 
                              :op1 "California" 
                              :op2 "Institute" 
                              :op3 "of" 
                              :op4 "Technology" 
                              :op5 "Institutional" 
                              :op6 "Animal" 
                              :op7 "Care")) 
                  :op2 (o / organization 
                        :name (n / name 
                              :op1 "Use" 
                              :op2 "Committees")))) 
      :ARG1 (p / protocol 
            :mod (a4 / animal)))

# ::snt Doxycycline ( dox ) was administered through commercially available dox-containing chow ( BioServ , Frenchtown , New Jersey , United States ) .
# ::tok Doxycycline ( dox ) was administered through commercially available dox-containing chow ( BioServ , Frenchtown , New Jersey , United States ) .
# ::alignments 19-21|0.0.0.0.1.0.1+0.0.0.0.1.0.0.1+0.0.0.0.1.0.0.0+0.0.0.0.1.0.0+0.0.0.0.1.0 16-18|0.0.0.0.1.2.0.1+0.0.0.0.1.2.0.0+0.0.0.0.1.2.0+0.0.0.0.1.2 14-15|0.0.0.0.1.1.0.0+0.0.0.0.1.1.0+0.0.0.0.1.1 12-13|0.0.0.0.0.0.0+0.0.0.0.0.0+0.0.0.0.0 10-11|0.0.0 9-10|0.0.0.1 8-9|0.0 7-8|0.0.1 5-6|0.0.0.0 2-3|0 0-1|0.0.0.0.1.3.0+0.0.0.0.1.3+0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:24.297
(d2 / dox 
      :ARG1-of (a / available-02 
            :ARG2 (c4 / chow 
                  :ARG2-of (a2 / administer-01 
                        :ARG0 (o / organization 
                              :name (n4 / name 
                                    :op1 "BioServ")) 
                        :ARG1 (p / person 
                              :mod (c / country 
                                    :name (n / name 
                                          :op1 "United" 
                                          :op2 "States") 
                                    :wiki "United_States") 
                              :mod (c3 / country 
                                    :name (n3 / name 
                                          :op1 "Frenchtown")) 
                              :mod (c2 / country 
                                    :name (n2 / name 
                                          :op1 "New" 
                                          :op2 "Jersey")) 
                              :name (n5 / name 
                                    :op1 "Doxycycline"))) 
                  :mod (d / dox-contain)) 
            :manner (c5 / commercial)))

# ::snt The chow contained 200 mg/kg of antibiotic ; based on estimated consumption of 5 g per mouse per day , the expected dose to each animal was 1 mg dox per day .
# ::tok The chow contained 200 mg/kg of antibiotic ; based on estimated consumption of 5 g per mouse per day , the expected dose to each animal was 1 mg dox per day .
# ::alignments 31-32|0.2.0.1.2.1 29-30|0.2.1 28-29|0.2.1.1 27-28|0.2.0.1.2.0 25-26|0.2.1.0.0 24-25|0.2.1.0.0.0 22-23|0.2.1.0 21-22|0.2.1.0.1 18-19|0.1 16-17|0.2.1.0.2 14-15|0.2.0.1.1 13-14|0.2.0.0 11-12|0.2.0.1 10-11|0.2.0.1.2 8-9|0.2.0 7-8|0.2 6-7|0.2.0.2 3-4|0.2.0.1.0 2-3|0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:24.802
(c2 / contain-01 
      :ARG0 (c3 / chow) 
      :ARG2 (d4 / day) 
      :op1-of (a2 / and 
            :op2 (b / base-02 
                  :ARG0 5 
                  :ARG2 (c / consume-01 
                        :ARG0 200 
                        :ARG1 (g / g) 
                        :ARG1-of (e3 / estimate-01 
                              :ARG0 1 
                              :ARG2 (d / day))) 
                  :location (a3 / antibiotic)) 
            :op3 (d2 / dox 
                  :ARG2-of (d3 / dose-01 
                        :ARG1 (a / animal 
                              :mod (e / each)) 
                        :ARG1-of (e2 / expect-01) 
                        :op1-of (m2 / mouse)) 
                  :mod (m / mg))))

# ::snt The average 25-g animal therefore received 40 g of dox per gram body weight per day .
# ::tok The average 25-g animal therefore received 40 g of dox per gram body weight per day .
# ::alignments 15-16|0.2 13-14|0.1.0.0.1 12-13|0.1.0.0 11-12|0.1.0.0.0.0+0.1.0.0.0 9-10|0.1.0 7-8|0.1 6-7|0.1.1 5-6|0 3-4|0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:25.177
(r / receive-01 
      :ARG0 (a / animal 
            :ARG1-of (a2 / average-01)) 
      :ARG1 (g2 / g 
            :mod (d2 / dox 
                  :poss (b / body 
                        :mod (m / mass-quantity 
                              :unit (g / gram)) 
                        :part (w / weight))) 
            :quant 40) 
      :time (d / day))

# ::snt Chow was changed 1 -- 2 times per week to prevent breakdown of the antibiotic .
# ::tok Chow was changed 1 -- 2 times per week to prevent breakdown of the antibiotic .
# ::alignments 14-15|0.1.1.1 11-12|0.1.1 10-11|0.1 8-9|0.1.0 5-6|0.1.1.2 3-4|0.1.1.0 2-3|0 0-1|0.0.0.0+0.0.0+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:25.327
(c / change-01 
      :ARG1 (p2 / person 
            :name (n / name 
                  :op1 "Chow")) 
      :purpose (p / prevent-01 
            :ARG0 (w / week) 
            :ARG1 (b / break-down-12 
                  :ARG0 1 
                  :ARG1 (a / antibiotic) 
                  :ARG2 2)))

# ::snt Offspring were genotyped for the presence of each transgene by PCR amplification of genomic DNA extracted from a 5-mm tail biopsy .
# ::tok Offspring were genotyped for the presence of each transgene by PCR amplification of genomic DNA extracted from a 5-mm tail biopsy .
# ::alignments 20-21|0.0 19-20|0 15-16|0.0.0 14-15|0.0.0.1 11-12|0.0.0.0 8-9|0.0.0.1.0 7-8|0.0.0.1.0.0 5-6|0.0.0.1.0.1 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:25.461
(t / tail-01 
      :ARG0 (b / biopsy 
            :ARG2-of (e / extract-01 
                  :ARG0 (a / amplification) 
                  :ARG1 (d / DNA 
                        :location-of (t2 / transgene 
                              :mod (e2 / each) 
                              :poss-of (p / presence))))) 
      :ARG1 (o / offspr))

# ::snt Tails were heated to 95 C for 45 min in 250 l of 50 mM NaOH , vortexed , then neutralized with an equal volume of 0.5 M Tris-HCl ( pH 5.5 ) .
# ::tok Tails were heated to 95 C for 45 min in 250 l of 50 mM NaOH , vortexed , then neutralized with an equal volume of 0.5 M Tris-HCl ( pH 5.5 ) .
# ::alignments 31-32|0.1.0.1.2 30-31|0.1.0.1.4 27-29|0.1.1.0.1+0.1.1.0.0+0.1.1.0+0.1.1 26-27|0.1.0.1.3 24-25|0.1 23-24|0 20-21|0.1.0 19-20|0.1.0.2 15-16|0.1.0.1.0.1.0.0.0+0.1.0.1.0.1.0.0+0.1.0.1.0.1.0 14-15|0.1.0.1.0.1 13-14|0.1.0.1.0.1.0.1 11-12|0.0 10-11|0.1.0.1.0.0 8-9|0.1.0.1.1 7-8|0.1.0.1.1.0 5-6|0.2 4-5|0.1.0.0 2-3|0.1.0.1 0-1|0.1.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:26.063
(e / equal-01 
      :ARG0 (l / l) 
      :ARG1 (v / volume 
            :ARG2-of (n2 / neutralize-01 
                  :op1-of 95 
                  :purpose-of (h / heat-01 
                        :ARG1 (t5 / tail-01 
                              :ARG2 250 
                              :op1-of (m2 / mm 
                                    :mod-of (t4 / thing 
                                          :name (n3 / name 
                                                :op1 "NaOH") 
                                          :quant 50))) 
                        :ARG2 (m3 / min 
                              :quant 45) 
                        :op1-of 5.5 
                        :op1-of 0.5 
                        :op1-of (p / ph)) 
                  :time (t3 / then)) 
            :quant-of (t / thing 
                  :name (n / name 
                        :op1 (m / M) 
                        :op2 (t2 / Tris-HCl)))) 
      :ARG2 (c / C))

# ::snt Debris was sedimented by centrifugation , and 3 l of supernatant was used for amplification .
# ::tok Debris was sedimented by centrifugation , and 3 l of supernatant was used for amplification .
# ::alignments 14-15|0.1.2 12-13|0.1 10-11|0.1.1.0 8-9|0.1.1 7-8|0.1.1.1 6-7|0 4-5|0.0 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:26.152
(a2 / and 
      :op1 (c / centrifugation) 
      :op2 (u / use-01 
            :ARG0 (d / debri) 
            :ARG1 (l / l 
                  :mod (s / supernatant) 
                  :quant 3) 
            :ARG2 (a / amplification)))

# ::snt Genotyping for APP and tTA transgenes was performed in the same PCR reaction , using five separate primers .
# ::tok Genotyping for APP and tTA transgenes was performed in the same PCR reaction , using five separate primers .
# ::alignments 17-18|0.0.0.0.1.0 16-17|0.0.0.0.1.0.0 15-16|0.0.0.0.0.1.0 14-15|0.0.0.0.1 12-13|0.0.0.0.0 11-12|0.0.0.0.0.0 10-11|0.0.0.0.0.1 7-8|0.0.0.0 5-6|0.0 4-5|0 3-4|0.0.0 2-3|0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 0-1|0.0.0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:26.492
(t2 / tTA 
      :mod-of (t / transgen 
            :op2-of (a / and 
                  :ARG1-of (p3 / perform-02 
                        :manner (r / react-01 
                              :ARG1 (p2 / PCR) 
                              :ARG1-of (s2 / same-01 
                                    :ARG2 5)) 
                        :purpose (u / use-01 
                              :ARG1 (p / primer 
                                    :ARG1-of (s / separate-02)) 
                              :ARG2 (g / genotyp))) 
                  :op1 (o / organization 
                        :name (n / name 
                              :op1 "APP")))))

# ::snt APP was amplified using forward primer S36 located in the 3  end of the APP cDNA ( CCG AGA TCT CTG AAG TGA AGA TGG ATG ) and reverse primer PrP-AS-J located in the 3  UTR of the vector ( CCA AGC CTA GAC CAC GAG AAT GC ) .
# ::tok APP was amplified using forward primer S36 located in the 3  end of the APP cDNA ( CCG AGA TCT CTG AAG TGA AGA TGG ATG ) and reverse primer PrP-AS-J located in the 3  UTR of the vector ( CCA AGC CTA GAC CAC GAG AAT GC ) .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:26.494
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt The tTA transgene was detected using a primer set that amplified across its two subdomains with tet forward located within the Tn10 tetracycline repressor ( CGC TGT GGG GCA TTT TAC TTT AG ) and tet reverse within the HSV1 VP16 ( CAT GTC CAG ATC GAA ATC GTC ) .
# ::tok The tTA transgene was detected using a primer set that amplified across its two subdomains with tet forward located within the Tn10 tetracycline repressor ( CGC TGT GGG GCA TTT TAC TTT AG ) and tet reverse within the HSV1 VP16 ( CAT GTC CAG ATC GAA ATC GTC ) .
# ::alignments 47-49|0.2.0.1+0.2.0.0+0.2.0+0.2 45-47|0.2.0.1.0.0.1+0.2.0.1.0.0.0+0.2.0.1.0.0+0.2.0.1.0 43-45|0.0.0.1.1.0.1+0.0.0.1.1+0.0.0.1.1.0+0.0.0.1.1.0.0 42-43|0.0.0.1.3+0.0.0.1.2.0+0.0.0.1.2+0.0.0.1 39-41|0.1.0.0.1+0.1.0.0.0+0.1.0.0+0.1.0 36-37|0.1 35-36|0.1.1 34-35|0 31-33|0.0.0.0.0.0.1.0.1+0.0.0.0.0.0.1.0.0+0.0.0.0.0.0.1.0+0.0.0.0.0.0.1 29-31|0.0.0.0.0.0.1.0.0.0.0.1+0.0.0.0.0.0.1.0.0.0.0.0+0.0.0.0.0.0.1.0.0.0.0+0.0.0.0.0.0.1.0.0.0 27-29|0.0.0.0.0.0.0.0.2.0.1+0.0.0.0.0.0.0.0.2.0.0+0.0.0.0.0.0.0.0.2.0+0.0.0.0.0.0.0.0.2 25-27|0.0.0.0.0.0.0.0.1.0.0.1+0.0.0.0.0.0.0.0.1.0.0.0+0.0.0.0.0.0.0.0.1.0.0+0.0.0.0.0.0.0.0.1.0 23-24|0.0 22-23|0.0.1 21-22|0.0.0.1.0.0.0+0.0.0.1.0.0+0.0.0.1.0 18-19|0.0.0 17-18|0.0.0.2 16-17|0.0.0.0 14-15|0.0.0.3 13-14|0.0.0.3.0 11-12|0.0.0.0.0 10-11|0.0.0.0.0.0 8-9|0.0.0.0.0.0.0 7-8|0.0.0.0.0.0.0.1 5-6|0.0.0.0.0.0.0.0 4-5|0.0.0.0.0.0.0.0.1 2-3|0.0.0.0.0.0.0.0.0 1-2|0.0.0.0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:32.445
(a3 / and 
      :op1 (r2 / repressor 
            :location-of (l / locate-01 
                  :ARG1 (t15 / tet 
                        :op1-of (a5 / across 
                              :ARG1-of (a6 / amplify-01 
                                    :ARG0 (s2 / set 
                                          :ARG1-of (u / use-01 
                                                :ARG0 (t16 / transgene 
                                                      :mod (t17 / tTA)) 
                                                :ARG1-of (d / detect-01 
                                                      :ARG2 (t11 / thing 
                                                            :name (n9 / name 
                                                                  :op1 (c2 / CGC) 
                                                                  :op2 (t12 / TGT)))) 
                                                :ARG2 (t10 / thing 
                                                      :name (n8 / name 
                                                            :op1 (g4 / GGG) 
                                                            :op2 (g5 / GCA)))) 
                                          :mod (p3 / primer)) 
                                    :ARG2 (t5 / thing 
                                          :name (n6 / name 
                                                :op1 (t6 / TTT 
                                                      :mod (t7 / thing 
                                                            :name (n7 / name 
                                                                  :op1 (t8 / TTT) 
                                                                  :op2 (t9 / TAC)))) 
                                                :op2 (a4 / AG)))))) 
                  :ARG2 (p / product 
                        :domain-of (t14 / thing 
                              :name (n10 / name 
                                    :op1 "Tn10")) 
                        :mod-of (g3 / GTC 
                              :op1-of (n3 / name 
                                    :name-of (t3 / thing) 
                                    :op2 (c / CAG))) 
                        :name (n4 / name 
                              :op1 "CAT-5") 
                        :wiki "Category_5_cable") 
                  :mod (f / forward) 
                  :mod-of (s / subdomain 
                        :quant 2)) 
            :mod (t13 / tetracycline)) 
      :op2 (r / reverse-01 
            :ARG0 (p2 / person 
                  :name (n5 / name 
                        :op1 "HSV1" 
                        :op2 "VP16")) 
            :ARG1 (t4 / tet)) 
      :op3 (t / thing 
            :name (n / name 
                  :op1 (a / ATC) 
                  :op2 (g / GTC 
                        :mod (t2 / thing 
                              :name (n2 / name 
                                    :op1 (a2 / ATC) 
                                    :op2 (g2 / GAA)))))))

# ::snt All reactions , whether transgene-positive or not , amplified a segment of the endogenous prion protein gene as a control for DNA quality using a forward primer , PrP-S-J , specific to the mouse PrP open reading frame ( GGG ACT ATG TGG ACT GAT GTC GG ) and a reverse primer , PrP-AS-J , shared by the 3  UTR of the endogenous PrP gene and the transgene vector .
# ::tok All reactions , whether transgene-positive or not , amplified a segment of the endogenous prion protein gene as a control for DNA quality using a forward primer , PrP-S-J , specific to the mouse PrP open reading frame ( GGG ACT ATG TGG ACT GAT GTC GG ) and a reverse primer , PrP-AS-J , shared by the 3  UTR of the endogenous PrP gene and the transgene vector .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:32.452
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Amplification reactions were run for 37 cycles at 94 C for 30 s , 64 C for 1 min , and 72 C for 1 min .
# ::tok Amplification reactions were run for 37 cycles at 94 C for 30 s , 64 C for 1 min , and 72 C for 1 min .
# ::alignments 25-26|0.4 24-25|0.0.0.1.1 22-23|0.3 21-22|0.0.0.1.2 20-21|0 18-19|0.2 17-18|0.0.1.0 14-16|0.1.0.1+0.1.0.0+0.1.0+0.1 12-13|0.0.1.1 11-12|0.0.1.1.0 9-10|0.0.0.1.0 8-9|0.0.0.1 6-7|0.0.1 5-6|0.0.1.2 3-4|0.0 1-2|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:32.691
(a / and 
      :op1 (r / run-01 
            :ARG1 (r2 / react-01 
                  :ARG1 (a2 / amplification) 
                  :location (9 / 94 
                        :mod (c3 / C) 
                        :mod 1 
                        :poss 72)) 
            :purpose (c4 / cycle-02 
                  :ARG1 1 
                  :ARG2 (s / s 
                        :quant 30) 
                  :quant 37)) 
      :op2 (t / thing 
            :name (n / name 
                  :op1 64 
                  :op2 (c2 / C))) 
      :op3 (m2 / min) 
      :op4 (c / C) 
      :op5 (m / min))

# ::snt All samples , transgenic and wild-type , gave a 750-bp product from the endogenous PrP gene .
# ::tok All samples , transgenic and wild-type , gave a 750-bp product from the endogenous PrP gene .
# ::alignments 15-16|0.0.0.1 13-14|0.0.0.1.0 10-11|0.0.0.0 7-8|0.0.0 4-5|0.0.0.2 1-2|0+0.0 0-1|0.0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:32.979
(s / sample-01 
      :ARG1 (t / thing 
            :ARG0-of (g2 / give-01 
                  :ARG1 (p / product) 
                  :ARG2 (g / gene 
                        :mod (e / endogenou)) 
                  :manner (a / and 
                        :mod (a2 / all)))))

# ::snt The APP transgene yielded an additional band at 400 bp ; the tTA product fell in between at 480 bp .
# ::tok The APP transgene yielded an additional band at 400 bp ; the tTA product fell in between at 480 bp .
# ::alignments 18-19|0.0.0.0.1 14-15|0.0 13-14|0.0.1 12-13|0.0.1.0 10-11|0 8-9|0.0.2 6-7|0.0.0.0.0 5-6|0.0.0.0.0.0 3-4|0.0.0.0 2-3|0.0.0 1-2|0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:33.196
(a / and 
      :op1 (f / fall-01 
            :ARG0 (t2 / transgene 
                  :ARG0-of (y / yield-01 
                        :ARG1 (b / band 
                              :mod (a2 / additional)) 
                        :ARG2 480) 
                  :mod (o / organization 
                        :name (n / name 
                              :op1 "APP"))) 
            :ARG1 (p / product 
                  :mod (t / tTA)) 
            :ARG2 400))

# ::snt Frozen cortical or whole forebrain tissue was homogenized by sonication in five volumes of phosphate-buffered saline ( PBS ) with 5 mM EDTA and protease inhibitors ( Mammalian cell cocktail , Sigma , St. Louis , Missouri , United States ) , using a probe sonicator set to 50 % output ( TEKMAR , Cincinnati , Ohio , United States ) .
# ::tok Frozen cortical or whole forebrain tissue was homogenized by sonication in five volumes of phosphate-buffered saline ( PBS ) with 5 mM EDTA and protease inhibitors ( Mammalian cell cocktail , Sigma , St. Louis , Missouri , United States ) , using a probe sonicator set to 50 % output ( TEKMAR , Cincinnati , Ohio , United States ) .
# ::alignments 58-60|0.0.1.0.3.8.2+0.0.1.0.3.8.1.1+0.0.1.0.3.8.1.0+0.0.1.0.3.8.1+0.0.1.0.3.8 56-57|0.0.1.0.3.7.0.0+0.0.1.0.3.7.0+0.0.1.0.3.7 54-55|0.0.1.0.3.6.0.0+0.0.1.0.3.6.0+0.0.1.0.3.6 52-53|0.0.1.0.0.0.0+0.0.1.0.0.0+0.0.1.0.0 50-51|0.0.2.0.0 49-50|0.0.2.0 48-49|0.0.2 45-46|0.0.1.0.3.0.0 44-45|0.0.1.0.3.0.0.0 42-43|0.0.1.0.3.0 38-40|0.0.0.1+0.0.0.0.1+0.0.0.0.0+0.0.0.0+0.0.0 36-37|0.0.1.0.3.8.0.1+0.0.1.0.3.8.0.0.0+0.0.1.0.3.8.0.0+0.0.1.0.3.8.0 33-35|0.0.1.0.3.5.0.1+0.0.1.0.3.5.0.0+0.0.1.0.3.5.0+0.0.1.0.3.5 31-32|0.0.1.0.3.4 29-30|0.0.1.0.3.3 28-29|0.0.1.0.3.3.0 27-28|0.0.1.0.3.3.1 25-26|0.0.1.0.3.2 24-25|0.0.1.0.3.2.0 23-24|0.0.1.0.3 22-23|0.0.1.0.3.1.1.0+0.0.1.0.3.1.1+0.0.1.0.3.1 21-22|0.0.1.0.3.1.0 20-21|0.0.1.0.3.0.0.0.0 17-18|0 15-16|0.0.1.0.2 14-15|0.0.1.0.2.0 12-13|0.0.1.0.2.1 11-12|0.0.1.0.3.0.0.0.1 9-10|0.0.1.0.3.0.1 5-6|0.0.1.0.1 4-5|0.0.1.0.1.0 3-4|0.0.1.0.1.1 2-3|0.0.1.0 1-2|0.0.1 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:35.056
(p4 / pb 
      :ARG2-of (f2 / freeze-01 
            :ARG0 (c4 / country 
                  :name (n5 / name 
                        :op1 "United" 
                        :op2 "States") 
                  :wiki "United_States") 
            :ARG1 (c8 / cortical 
                  :op1-of (o4 / or 
                        :mod-of (o / organization 
                              :name (n4 / name 
                                    :op1 "TEKMAR")) 
                        :op2 (t / tissue 
                              :mod (f / forebrain) 
                              :mod (w / whole)) 
                        :op3 (s4 / saline 
                              :mod (p5 / phosphate-buffer) 
                              :quant (v / volume)) 
                        :op4 (a / and 
                              :ARG2-of (u / use-01 
                                    :ARG1 (s / sonicator 
                                          :ARG1-of (p2 / probe-01 
                                                :ARG0 5 
                                                :op1-of 5)) 
                                    :op1-of (s5 / sonication)) 
                              :op1 (o3 / organization 
                                    :mod (m2 / mm) 
                                    :name (n8 / name 
                                          :op1 "EDTA")) 
                              :op2 (i / inhibitor 
                                    :mod (p3 / protease)) 
                              :op3 (c6 / cocktail 
                                    :mod (c7 / cell) 
                                    :mod (m / mammalian)) 
                              :op4 (s3 / sigma) 
                              :op5 (c5 / country 
                                    :name (n7 / name 
                                          :op1 "St." 
                                          :op2 "Louis")) 
                              :op6 (c3 / country 
                                    :name (n3 / name 
                                          :op1 "Cincinnati")) 
                              :op7 (c2 / country 
                                    :name (n2 / name 
                                          :op1 "Ohio")) 
                              :op8 (c / country 
                                    :domain-of (s2 / state 
                                          :name (n6 / name 
                                                :op1 "Missouri") 
                                          :wiki "Missouri") 
                                    :name (n / name 
                                          :op1 "United" 
                                          :op2 "States") 
                                    :wiki "United_States")))) 
            :op1-of (5 / 50 
                  :value-of (p / percentage-entity 
                        :mod-of (o2 / output)))))

# ::snt After dilution with an equal volume of PBS/EDTA/protease inhibitor , the samples were centrifuged briefly and the supernatant used for analysis .
# ::tok After dilution with an equal volume of PBS/EDTA/protease inhibitor , the samples were centrifuged briefly and the supernatant used for analysis .
# ::alignments 20-21|0.1 18-19|0.1.1 17-18|0.1.1.1 15-16|0 14-15|0.0 11-12|0.1.0.0.0+0.1.0.0 8-9|0.1.0.1.0 5-6|0.1.0.1 4-5|0.1.0 1-2|0.1.1.0 0-1|0.1.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:35.260
(a2 / and 
      :op1 (b / briefly) 
      :op2 (a / analyze-01 
            :ARG1 (e / equal-01 
                  :ARG0 (t / thing 
                        :ARG1-of (s2 / sample-01)) 
                  :ARG1 (v / volume 
                        :mod-of (i / inhibitor))) 
            :ARG2-of (u / use-01 
                  :ARG0 (d / dilution 
                        :op1-of (a3 / after)) 
                  :ARG1 (s / supernatant))))

# ::snt Fifty micrograms ( 6E10 and CT15 ) or 5 g ( 22C11 ) of brain homogenate was loaded per lane onto 7.5 % , 10 % -- 20 % , or 4 % -- 20 % Tris-HCl PAGE gels ( Bio-Rad Laboratories , Hercules , California , United States ) and electrophoresed for several hours in 1  Tris-glycine -- sodium dodecyl sulfate ( 1  TG-SDS ) buffer ( 6E10 and 22C11 ; Amresco , Solon , Ohio , United States ) or 1  Tris-tricine-SDS buffer ( CT15 ; Invitrogen , Carlsbad , California , United States ) .
# ::tok Fifty micrograms ( 6E10 and CT15 ) or 5 g ( 22C11 ) of brain homogenate was loaded per lane onto 7.5 % , 10 % -- 20 % , or 4 % -- 20 % Tris-HCl PAGE gels ( Bio-Rad Laboratories , Hercules , California , United States ) and electrophoresed for several hours in 1  Tris-glycine -- sodium dodecyl sulfate ( 1  TG-SDS ) buffer ( 6E10 and 22C11 ; Amresco , Solon , Ohio , United States ) or 1  Tris-tricine-SDS buffer ( CT15 ; Invitrogen , Carlsbad , California , United States ) .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:35.267
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Proteins were transferred overnight to 0.45-m Optitran nitrocellulose ( Schleicher and Schuell , Keene , New Hampshire , United States ) in 1  TG buffer ( Amresco ) .
# ::tok Proteins were transferred overnight to 0.45-m Optitran nitrocellulose ( Schleicher and Schuell , Keene , New Hampshire , United States ) in 1  TG buffer ( Amresco ) .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:35.272
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Blots were blocked in PBS containing 5 % nonfat dry milk powder , and incubated for 3 h at room temperature in blocking solution with one of the following antibodies : mouse monoclonal 22C11 ( kind gift of Konrad Beyreuther and Andreas Weidemann ; [ 17 ] ) diluted 1:1,000 , mouse monoclonal 6E10 ( Signet Laboratories , Dedham , Massachusetts , United States ) diluted 1:2,500 , rabbit polyclonal anti-superoxide dismutase 1 ( m/hSOD1 ) [ 18 ] diluted 1:2,500 to 1:4,000 , or rabbit polyclonal CT15 ( kind gift of Ed Koo ; [ 19 ] ) diluted 1:1,000 .
# ::tok Blots were blocked in PBS containing 5 % nonfat dry milk powder , and incubated for 3 h at room temperature in blocking solution with one of the following antibodies : mouse monoclonal 22C11 ( kind gift of Konrad Beyreuther and Andreas Weidemann ; [ 17 ] ) diluted 1:1,000 , mouse monoclonal 6E10 ( Signet Laboratories , Dedham , Massachusetts , United States ) diluted 1:2,500 , rabbit polyclonal anti-superoxide dismutase 1 ( m/hSOD1 ) [ 18 ] diluted 1:2,500 to 1:4,000 , or rabbit polyclonal CT15 ( kind gift of Ed Koo ; [ 19 ] ) diluted 1:1,000 .
# ::alignments 99-100|0.6.4.1.1.1.1.0.1.1 96-97|0.6.4.1.1.1.1.0.2 92-94|0.6.4.2.2.1+0.6.4.2.2.0+0.6.4.2.2+0.6.4.2 90-91|0.6.4.2.0+0.6.4.2.0.0 89-90|0.6.4.2.0.0.0 87-88|0.6.4.1.1.1.1.0.1.0 85-86|0.6.4.1.1.1.1.0.1 84-85|0.6.4.0 79-80|0.6.4.1.1.1 77-78|0.6.4.1.1.0 72-73|0.6.4.1.1.1.1.0.1.1.0 71-72|0.6.4.1.1.1.1.0.0 69-70|0.6.4.1.1.1.1 68-69|0.6.4.1.1.1.1.0 65-66|0.6.4.1.1 62-64|0.6.1.1+0.6.1.0.1+0.6.1.0.0+0.6.1.0+0.6.1 60-61|0.6.4.1.0.1+0.6.4.1.0.0.0+0.6.4.1.0.0+0.6.4.1.0 58-59|0.6.4.2.1.0.0+0.6.4.2.1.0+0.6.4.2.1 55-57|0.6.4.1.1.1.0.0.1+0.6.4.1.1.1.0.0.0+0.6.4.1.1.1.0.0+0.6.4.1.1.1.0 52-53|0.7 51-52|0.7.0 48-49|0.6.4.1 45-46|0.2.0 43-44|0.6.4 41-43|0.6.3.0.0.1+0.6.3.0.0.0+0.6.3.0.0+0.6.3.0 40-41|0.6.3 38-40|0.6.2.1+0.6.2.0+0.6.2+0.6 36-37|0.6.0+0.6.0.0 35-36|0.6.0.0.0 32-33|0.5 31-32|0.4 29-30|0.5.0.0 28-29|0.5.0 23-24|0.0.0 22-23|0.0 20-21|0.3.1 19-20|0.3.1.0 17-18|0.3.0 16-17|0.1.0.0 14-15|0.3 13-14|0 11-12|0.2 10-11|0.2.1 9-10|0.2.1.0 7-8|0.1.1 6-7|0.1.1.0 5-6|0.1 4-5|0.1.0.1.0 2-3|0.1.0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:45.228
(a4 / and 
      :ARG0-of (b / block-01 
            :ARG1 (s2 / solution)) 
      :manner-of (c4 / contain-01 
            :ARG0 (b3 / blot-01 
                  :ARG1 3 
                  :ARG1-of (b2 / block-01 
                        :location (p7 / pb))) 
            :ARG1 (p6 / percentage-entity 
                  :value 5)) 
      :op1 (p5 / powder-01 
            :ARG0 17 
            :ARG1 (m5 / milk 
                  :ARG1-of (d6 / dry-08))) 
      :op2 (i / incubate-01 
            :ARG1 (h / h) 
            :ARG2 (t3 / temperature 
                  :consist-of (r3 / room))) 
      :op3 (m4 / mouse) 
      :op4 (m3 / monoclonal 
            :ARG0-of (f / follow-01 
                  :ARG1 (a3 / antibodi))) 
      :op5 (p4 / person 
            :ARG0-of (g2 / gift-01 
                  :ARG1 (t2 / thing 
                        :mod (k2 / kind))) 
            :mod (c2 / country 
                  :name (n2 / name 
                        :op1 "United" 
                        :op2 "States") 
                  :wiki "United_States") 
            :name (n7 / name 
                  :op1 "Konrad" 
                  :op2 "Beyreuther") 
            :op1-of (a2 / and 
                  :op2 (p3 / person 
                        :name (n6 / name 
                              :op1 "Andreas" 
                              :op2 "Weidemann"))) 
            :op1-of (a / and 
                  :op1-of (o / or) 
                  :op2 (d5 / dilute-01 
                        :ARG0 (s / state 
                              :name (n3 / name 
                                    :op1 "Massachusetts") 
                              :wiki "Massachusetts") 
                        :ARG2 (d4 / dilute-01 
                              :ARG0 18 
                              :purpose-of (d2 / dilute-01 
                                    :ARG0 (o2 / organization 
                                          :name (n5 / name 
                                                :op1 "Signet" 
                                                :op2 "Laboratories")) 
                                    :ARG1 (p2 / polyclonal 
                                          :mod (r2 / rabbit-01 
                                                :ARG1 (d3 / dismutase) 
                                                :ARG2 (r / rabbit-01 
                                                      :ARG1 (c / CT15) 
                                                      :ARG1-of (d / dilute-01 
                                                            :ARG0 1)) 
                                                :op1-of 19))))) 
                  :op3 (p / person 
                        :ARG0-of (g / gift-01 
                              :ARG1 (t / thing 
                                    :mod (k / kind))) 
                        :mod (c3 / country 
                              :name (n4 / name 
                                    :op1 "Dedham")) 
                        :name (n / name 
                              :op1 "Ed" 
                              :op2 "Koo")))) 
      :op6 (m / monoclonal 
            :mod (m2 / mouse)))

# ::snt Subsequently , the blots were washed with PBS containing 0.1 % Tween-20 , and then incubated with either goat anti-mouse -- or goat anti-rabbit -- HRP conjugated secondary antibody diluted 1:1,000 in blocking solution .
# ::tok Subsequently , the blots were washed with PBS containing 0.1 % Tween-20 , and then incubated with either goat anti-mouse -- or goat anti-rabbit -- HRP conjugated secondary antibody diluted 1:1,000 in blocking solution .
# ::alignments 33-34|0.1.1.0.1 32-33|0.1.1.0 29-30|0.1.1 28-29|0.1.1.1 27-28|0.1.0.1 26-27|0.1.1.1.0 22-23|0.0.0.1 21-22|0.0.1 18-19|0.0.0.0.0 17-18|0.1.0.0 15-16|0.1 14-15|0.1.2 13-14|0 10-11|0.1.1.0.0 9-10|0.1.1.0.0.0 8-9|0.0.0 7-8|0.0.0.0 5-6|0.0 3-4|0.1.0 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:45.749
(a2 / and 
      :op1 (w / wash-01 
            :ARG1 (c2 / contain-01 
                  :ARG0 (p2 / pb 
                        :mod (g2 / goat)) 
                  :ARG1 (g / goat)) 
            :op1-of (o / or) 
            :time (s3 / subsequent)) 
      :op2 (i / incubate-01 
            :ARG1 (b2 / blot-01 
                  :ARG0 (e / either) 
                  :ARG1 (s2 / secondary)) 
            :purpose (d / dilute-01 
                  :ARG0 (b / block-01 
                        :ARG0 (p / percentage-entity 
                              :value 0.1) 
                        :ARG1 (s / solution)) 
                  :ARG1 (a / antibody 
                        :ARG1-of (c / conjugate-01))) 
            :time (t / then)))

# ::snt After several additional rinses in PBS with 0.1 % Tween-20 , blots were developed with enhanced chemiluminescence reagent and imaged with the Bio-Rad Molecular Imager FX system .
# ::tok After several additional rinses in PBS with 0.1 % Tween-20 , blots were developed with enhanced chemiluminescence reagent and imaged with the Bio-Rad Molecular Imager FX system .
# ::alignments 26-27|0.0.0 24-26|0.0.0.0.0.1+0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 23-24|0.1.0.0 18-19|0 17-18|0.0.1.0.0 16-17|0.0.1.0.0.0 15-16|0.0.1.0 13-14|0.0 11-12|0.0.1 8-9|0.0.1.1.0 7-8|0.0.1.1 5-6|0.1.0.1 3-4|0.1.0 2-3|0.1.0.2 1-2|0.1.0.3 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:46.298
(a / and 
      :op1 (d / develop-02 
            :ARG0 (s / system 
                  :mod (t / thing 
                        :name (n / name 
                              :op1 (i / Imager) 
                              :op2 (f / FX)))) 
            :ARG1 (b / blot-01 
                  :ARG0-of (e / enhance-01 
                        :ARG1 (r / reagent 
                              :mod (c / chemiluminescence))) 
                  :ARG1 (0 / 0.1 
                        :value-of (p / percentage-entity)))) 
      :time (a3 / after 
            :op1 (r2 / rinse-01 
                  :ARG0 (m / molecular) 
                  :ARG1 (p2 / pb) 
                  :mod (a2 / additional) 
                  :quant (s2 / several))))

# ::snt Staining intensity within each lane was quantified using the Quantity One image analysis software ( Molecular Imager FX , Bio-Rad Laboratories ) .
# ::tok Staining intensity within each lane was quantified using the Quantity One image analysis software ( Molecular Imager FX , Bio-Rad Laboratories ) .
# ::alignments 19-21|0.0.0.0.1+0.0.0.0.0+0.0.0.0+0.0.0 16-18|0.0.1.0.1.0.0.1+0.0.1.0.1.0.0.0+0.0.1.0.1.0.0+0.0.1.0.1.0 13-14|0.0.1 12-13|0.0.1.0 11-12|0.0.1.0.0 10-11|0.0.1.2 9-10|0.0.1.1 7-8|0.0 6-7|0 4-5|0.0.1.0.1 3-4|0.0.1.0.1.1 1-2|0.0.2 0-1|0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:46.930
(q2 / quantify-01 
      :ARG1 (u / use-01 
            :ARG0 (o / organization 
                  :name (n / name 
                        :op1 "Bio-Rad" 
                        :op2 "Laboratories")) 
            :ARG1 (s / software 
                  :ARG0-of (a / analyze-01 
                        :ARG1 (i2 / image) 
                        :ARG1-of (l / lane-01 
                              :ARG0 (t / thing 
                                    :name (n2 / name 
                                          :op1 (i / Imager) 
                                          :op2 (f / FX))) 
                              :mod (e / each))) 
                  :mod (q / quantity) 
                  :quant 1) 
            :ARG2 (i3 / intensity 
                  :ARG1-of (s2 / stain-01))))

# ::snt Background was calculated from across the image and subtracted from the entire file .
# ::tok Background was calculated from across the image and subtracted from the entire file .
# ::alignments 12-13|0.1.0 11-12|0.1.0.0 8-9|0.1 7-8|0 6-7|0.2 4-5|0.0.1 2-3|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:47.028
(a / and 
      :op1 (c / calculate-01 
            :ARG1 (b / background) 
            :ARG2 (a2 / across)) 
      :op2 (s / subtract-01 
            :ARG2 (f / file 
                  :mod (e / entire))) 
      :poss-of (i / image))

# ::snt The signal intensity for each band ( corrected signal intensity  pixel number ) was then calculated using the Volume report tool .
# ::tok The signal intensity for each band ( corrected signal intensity  pixel number ) was then calculated using the Volume report tool .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:47.029
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Slot Blot mRNA Analysis .
# ::tok Slot Blot mRNA Analysis .
# ::alignments 2-4|0.1.1+0+0.1+0.1.0 0-2|0.0.0.1+0.0.0.0+0.0.0+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:47.052
(m / mRNA 
      :mod (c / country 
            :name (n2 / name 
                  :op1 "Slot" 
                  :op2 "Blot")) 
      :op1-of (n / name 
            :name-of (t / thing) 
            :op2 (a / Analysis)))

# ::snt Five micrograms per sample of total RNA extracted from fresh-frozen brain , liver , kidney , heart , lung , spleen , and skeletal muscle was vacuum-filtered through 0.45-m Optitran nitrocellulose .
# ::tok Five micrograms per sample of total RNA extracted from fresh-frozen brain , liver , kidney , heart , lung , spleen , and skeletal muscle was vacuum-filtered through 0.45-m Optitran nitrocellulose .
# ::alignments 30-31|0.0.0.0.0 24-25|0.5 23-24|0.5.0 22-23|0 20-21|0.4 18-19|0.3 16-17|0.2 14-15|0.0.0.1.0 12-13|0.1 10-11|0.0.1 7-8|0.0 6-7|0.0.0 5-6|0.0.0.1 3-4|0.0.0.0 1-2|0.5.1 0-1|0.5.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:47.457
(a / and 
      :ARG0-of (e / extract-01 
            :ARG1 (r / rna 
                  :ARG1-of (s3 / sample-01 
                        :ARG0 (n / nitrocellulose)) 
                  :ARG2-of (t / total-01 
                        :ARG0 (k / kidney))) 
            :ARG2 (b / brain)) 
      :op1 (l2 / liver) 
      :op2 (h / heart) 
      :op3 (l / lung) 
      :op4 (s2 / spleen) 
      :op5 (m / muscle-01 
            :mod (s / skeletal) 
            :op1-of (m2 / microgram) 
            :op1-of 5))

# ::snt After several washes through the manifold with 10  SSC , blots were UV-cross-linked and probed with a radiolabeled  350-bp BglII -- XhoI cDNA fragment of mo/huAPP695 cDNA .
# ::tok After several washes through the manifold with 10  SSC , blots were UV-cross-linked and probed with a radiolabeled  350-bp BglII -- XhoI cDNA fragment of mo/huAPP695 cDNA .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:47.459
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt After hybridizing overnight at 65 C in 1 % BSA/1 mM EDTA/0 .5 M sodium phosphate buffer ( pH 7.2 ) / 7 % SDS [ 20 ] , the blots were washed twice at 65 C for 30 min each in 0.1 % BSA/1 mM EDTA/40 mM sodium phosphate buffer ( pH 7.2 ) / 5 % SDS before two final 30-min washes at 65 C with 1 mM EDTA/40 mM sodium phosphate buffer ( pH 7.2 ) / 1 % SDS .
# ::tok After hybridizing overnight at 65 C in 1 % BSA/1 mM EDTA/0 .5 M sodium phosphate buffer ( pH 7.2 ) / 7 % SDS [ 20 ] , the blots were washed twice at 65 C for 30 min each in 0.1 % BSA/1 mM EDTA/40 mM sodium phosphate buffer ( pH 7.2 ) / 5 % SDS before two final 30-min washes at 65 C with 1 mM EDTA/40 mM sodium phosphate buffer ( pH 7.2 ) / 1 % SDS .
# ::alignments 81-82|0.0.1.3.0 80-81|0.0.1.3.0.0 79-80|0.0.1.3 76-77|0.0.1.1 74-75|0.0 73-74|0 72-73|0.1 68-69|0.0.1.4.0.1 66-67|0.0.0.1 65-66|0.0.0.0.0.4.2 63-64|0.0.0.0.0 61-62|0.0.0.0.0.1 60-61|0.0.0.0.0.5 59-60|0.0.0.0 57-58|0.0.0 56-57|0.0.0.2 55-56|0.0.1.2 52-53|0.0.2 50-51|0.0.1 49-50|0.0.1.0 48-49|0.0.1.0.0 46-47|0.0.1.4.0.0.0+0.0.1.4.0.0+0.0.1.4.0 43-44|0.0.0.0.0.0.0 42-43|0.0.0.0.0.0 40-41|0.0.0.0.0.2 39-40|0.0.0.0.0.4.0.2.1.0 38-39|0.0.0.0.0.4.0.2.1 36-37|0.0.0.0.0.4.1 35-36|0.0.0.0.0.3 32-33|0.0.0.0.0.4 30-31|0.0.0.0.0.4.0 26-27|0.0.0.0.0.4.0.2.0.0.3 24-25|0.0.0.0.0.4.0.2.0.0.2.0.0.0.0+0.0.0.0.0.4.0.2.0.0.2.0.0.0+0.0.0.0.0.4.0.2.0.0.2.0.0 23-24|0.0.0.0.0.4.0.2.0.0.2.0 22-23|0.0.0.0.0.4.0.2.0.0.2 21-22|0.0.1.4 18-19|0.0.0.0.0.4.3 16-17|0.0.0.0.0.4.0.2 15-16|0.0.0.0.0.4.0.2.0.0.1.0 14-15|0.0.0.0.0.4.0.2.0 13-14|0.0.0.0.0.4.0.2.0.1.1+0.0.0.0.0.4.0.2.0.1.0.0+0.0.0.0.0.4.0.2.0.1.0+0.0.0.0.0.4.0.2.0.1 10-11|0.0.0.0.0.4.4 8-9|0.0.0.0.0.4.0.0 7-8|0.0.0.0.0.4.0.0.0 5-6|0.0.0.0.0.4.0.2.0.0.0 4-5|0.0.0.0.0.4.0.1 2-3|0.0.0.0.0.4.0.2.0.0.4 1-2|0.0.0.0.0.4.0.2.0.0 0-1|0.0.0.0.0.4.0.2.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:50.659
(p3 / phosphate 
      :ARG1-of (b / buffer-01 
            :ARG0 (p4 / percentage-entity 
                  :ARG3-of (b2 / before 
                        :op1 (w / wash-01 
                              :ARG2 (0 / 0.1 
                                    :value-of (p7 / percentage-entity)) 
                              :mod (f / final) 
                              :op1-of (e / each) 
                              :op1-of 65 
                              :purpose (w2 / wash-01 
                                    :ARG1 (b4 / blot-01 
                                          :op1-of (p11 / percentage-entity 
                                                :value 1) 
                                          :op1-of 65 
                                          :purpose (b5 / buffer-01 
                                                :ARG1 (s6 / sodium 
                                                      :ARG0-of (h / hybridize-01 
                                                            :ARG1 (c3 / C) 
                                                            :op1-of (a / after 
                                                                  :time-of (p10 / phosphate)) 
                                                            :op1-of (7 / 7 
                                                                  :value-of (p8 / percentage-entity 
                                                                        :mod-of (o / organization 
                                                                              :name (n2 / name 
                                                                                    :op1 "SDS")))) 
                                                            :op1-of 20 
                                                            :time (o2 / overnight)) 
                                                      :mod (v / vehicle 
                                                            :name (n3 / name 
                                                                  :op1 "M1") 
                                                            :wiki "M1_Abrams")) 
                                                :op1-of (3 / 30 
                                                      :quant-of (m / min)))) 
                                    :ARG2 (c2 / C) 
                                    :op1-of 65 
                                    :op1-of (p9 / ph) 
                                    :op1-of (m2 / mm)) 
                              :quant 2)) 
                  :name-of (c / C) 
                  :quant 5) 
            :ARG2 (b3 / buffer-01 
                  :ARG1 (p6 / phosphate 
                        :mod (s4 / sodium)) 
                  :op1-of (p2 / ph) 
                  :op1-of (s3 / slash) 
                  :op1-of (s / slash 
                        :op2 (p / percentage-entity 
                              :value 1)) 
                  :op2-of (s5 / slash 
                        :op1 (t / thing 
                              :name (n / name 
                                    :op1 "EDTA/40") 
                              :quant 1))) 
            :op1-of (p5 / ph)) 
      :mod (s2 / sodium))

# ::snt Blots were wrapped wet and exposed to phosphorscreens overnight at room temperature .
# ::tok Blots were wrapped wet and exposed to phosphorscreens overnight at room temperature .
# ::alignments 11-12|0.1.0 10-11|0.1.0.0 8-9|0.0.0.0 7-8|0.1.1 5-6|0.1 4-5|0 3-4|0.0.0.1 2-3|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:50.737
(a / and 
      :op1 (w2 / wrap-01 
            :ARG1 (b / blot-01 
                  :ARG1 (o / overnight) 
                  :ARG1-of (w / wet-01))) 
      :op2 (e / expose-01 
            :ARG1 (t / temperature 
                  :consist-of (r / room)) 
            :ARG2 (p / phosphorscreen)))

# ::snt Mice were euthanized by ether inhalation and brains removed for immersion fixation in 4 % paraformaldehyde/1  PBS .
# ::tok Mice were euthanized by ether inhalation and brains removed for immersion fixation in 4 % paraformaldehyde/1  PBS .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:50.739
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt After 48 h in fixative at 4 C , brains were transferred to PBS , dehydrated in alcohols , treated with cedarwood oil and methylsalicylate , and embedded in paraffin for sectioning .
# ::tok After 48 h in fixative at 4 C , brains were transferred to PBS , dehydrated in alcohols , treated with cedarwood oil and methylsalicylate , and embedded in paraffin for sectioning .
# ::alignments 31-32|0.3.1 29-30|0.3.0 27-28|0.3 26-27|0 24-25|0.3.2.0 23-24|0.3.2 22-23|0.2 21-22|0.3.1.0 19-20|0.1 17-18|0.0.0 15-16|0.0 13-14|0.4.1.1 11-12|0.4.1 9-10|0.4.1.0 7-8|0.1.0.0 6-7|0.1.0 4-5|0.4.0.0 2-3|0.4.0 1-2|0.4.0.1 0-1|0.4 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:51.008
(a / and 
      :op1 (d / dehydrate-01 
            :ARG1 (a3 / alcohol)) 
      :op2 (t / treat-01 
            :ARG1 (4 / 4 
                  :era (c2 / C))) 
      :op3 (o / oil) 
      :op4 (e / embed-01 
            :ARG1 (p / paraffin) 
            :ARG2 (s / section-01 
                  :ARG1 (c / cedarwood)) 
            :op2-of (a2 / and 
                  :op1 (m / methylsalicylate))) 
      :time (a4 / after 
            :op1 (h / h 
                  :location (f / fixative) 
                  :quant 48) 
            :time-of (t2 / transfer-01 
                  :ARG1 (b / brain) 
                  :ARG2 (p2 / pb))))

# ::snt Silver impregnation histology was performed on 10-m paraffin-embedded sections by Hirano 's modification of the Bielschowsky method [ 21 ] .
# ::tok Silver impregnation histology was performed on 10-m paraffin-embedded sections by Hirano 's modification of the Bielschowsky method [ 21 ] .
# ::alignments 18-19|0.0 16-17|0.1.0.0.1 15-16|0.1.0.0.1.0.0.0+0.1.0.0.1.0.0+0.1.0.0.1.0 12-13|0.1.0.0 10-11|0.1.0.0.0.0.0+0.1.0.0.0.0+0.1.0.0.0 8-9|0.1.0.1 7-8|0.1.0.1.0 4-5|0.1.0 2-3|0.1 1-2|0.1.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:51.371
(s2 / silver-01 
      :ARG0 21 
      :ARG1 (h / histology 
            :ARG1-of (p3 / perform-02 
                  :ARG0 (m2 / modify-01 
                        :ARG0 (p / person 
                              :name (n2 / name 
                                    :op1 "Hirano")) 
                        :ARG1 (m / method 
                              :mod (t / thing 
                                    :name (n / name 
                                          :op1 "Bielschowsky")))) 
                  :location (s / section 
                        :mod (p2 / paraffin-embedd))) 
            :mod (i / impregnation)))

# ::snt Briefly , sections were deparaffinized through xylene and alcohols into tap water before being placed into fresh 20 % silver nitrate solution for 20 min .
# ::tok Briefly , sections were deparaffinized through xylene and alcohols into tap water before being placed into fresh 20 % silver nitrate solution for 20 min .
# ::alignments 24-25|0.0.0.0.0.0 23-24|0.0.0.0.0 21-22|0.0.0.0.1.0.0 20-21|0.0.0.0.1.0.0.0 19-20|0.0.0.0.1.0.0.2 18-19|0.0.0.0.1.0.0.2.0 17-18|0.0.0.0.1.0.0.1.1 16-17|0.0.0.0.1.0.0.1 14-15|0.0.0.0.1.0 12-13|0.0.0.0.1.0.1 11-12|0.0.0.0.1 10-11|0.0.0.0 7-8|0 6-7|0.0.0.0.1.0.0.1.2 4-5|0.0 2-3|0.0.0 0-1|0.0.0.0.1.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:51.582
(a / and 
      :op1 (d / deparaffiniz 
            :domain (s3 / section 
                  :ARG0-of (t / tap-03 
                        :ARG1 (2 / 20 
                              :quant-of (m / min)) 
                        :mod-of (w / water 
                              :ARG1-of (p2 / place-01 
                                    :ARG2 (s / solution 
                                          :mod (n / nitrate) 
                                          :mod (f / fresh-04 
                                                :ARG0 (b2 / briefly) 
                                                :ARG1 20 
                                                :ARG2 (x / xylene)) 
                                          :mod (s2 / silver 
                                                :mod (p / percentage-entity))) 
                                    :op1-of (b / before)))))))

# ::snt After being washed thoroughly with distilled water , slides were immersed in 20 % silver nitrate solution titrated with fresh ammonium hydroxide .
# ::tok After being washed thoroughly with distilled water , slides were immersed in 20 % silver nitrate solution titrated with fresh ammonium hydroxide .
# ::alignments 21-22|0.1.0.2.0.1.0.0 20-21|0.1.0.2.0.1.0.0.0 19-20|0.1.0.2.0.1.0 17-18|0.1.0.2.0.0.2 16-17|0.1.0.2.0.0 15-16|0.1.0.2.0.0.0 14-15|0.1.0.2.0.0.1 13-14|0.1.0.0 12-13|0.0 10-11|0.1.0.2.0 8-9|0.1.0.2.0.1 6-7|0.1 5-6|0 3-4|0.1.0.1 2-3|0.1.0 0-1|0.1.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:51.863
(d / distil-01 
      :ARG0 20 
      :ARG1 (w / water 
            :ARG2-of (w2 / wash-01 
                  :ARG0 (p / percentage-entity) 
                  :manner (t2 / thorough) 
                  :op1-of (a2 / after 
                        :time-of (i / immerse-01 
                              :ARG0 (s / solution 
                                    :mod (n / nitrate) 
                                    :mod (s2 / silver) 
                                    :mod (t / titrate)) 
                              :ARG1 (s3 / slide-01 
                                    :purpose-of (f / fresh-04 
                                          :ARG1 (h / hydroxide 
                                                :mod (a / ammonium)))))))))

# ::snt After 20 min , slides were washed with ammonia water before being individually developed with 100 l of developer ( 20 ml of 37 % formaldehyde , 100 ml of distilled water , 50 l of concentrated nitric acid , and 0.5 g of citric acid ) added to 50 ml of titrated silver nitrate solution .
# ::tok After 20 min , slides were washed with ammonia water before being individually developed with 100 l of developer ( 20 ml of 37 % formaldehyde , 100 ml of distilled water , 50 l of concentrated nitric acid , and 0.5 g of citric acid ) added to 50 ml of titrated silver nitrate solution .
# ::alignments 55-56|0.1 54-55|0.1.0 53-54|0.1.2 52-53|0.1.1 49-50|0.0.0.1.3.0.0 47-48|0 45-46|0.0.0.1.4.0 44-45|0.0.0.1.4.0.0 42-43|0.0.0.1.4 41-42|0.0.0.1.1.3 40-41|0.0.0.1 38-39|0.0.0 37-38|0.0.0.0 36-37|0.0 33-34|0.0.0.1.1.4.0.0 31-32|0.0.0.1.3 30-31|0.0.0.1.3.0 27-28|0.0.0.1.1.4.0.1 25-26|0.0.0.1.1.0.0 24-25|0.0.0.1.0 23-24|0.0.0.1.0.0 21-22|0.0.0.1.2 20-21|0.0.0.1.2.0 18-19|0.0.0.1.1.1.0.0+0.0.0.1.1.1.0 16-17|0.0.0.1.1.1 15-16|0.0.0.1.1.1.1 13-14|0.0.0.1.1 12-13|0.0.0.1.1.2 10-11|0.0.0.1.1.4 9-10|0.0.0.1.1.4.0.2 8-9|0.0.0.1.1.4.0.2.0 6-7|0.0.0.1.1.4.0 4-5|0.0.0.1.1.0 2-3|0.0.0.1.1.4.0.3.0 1-2|0.0.0.1.1.4.0.3.0.0 0-1|0.0.0.1.1.4.0.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:53.174
(a / add-01 
      :ARG1 (c2 / concentrate-02 
            :ARG1 (a4 / acid 
                  :mod (n2 / nitric) 
                  :op4-of (a3 / and 
                        :mod (p / percentage-entity 
                              :value 37) 
                        :op1 (d3 / develop-02 
                              :ARG0 (s3 / slide-01 
                                    :ARG0 (f / formaldehyde)) 
                              :ARG1 (l / l 
                                    :poss (p2 / person 
                                          :ARG0-of (d2 / develop-02)) 
                                    :quant 100) 
                              :manner (i / individual) 
                              :op1-of 0.5 
                              :op1-of (b / before 
                                    :time-of (w3 / wash-01 
                                          :ARG0 50 
                                          :ARG1 100 
                                          :ARG2 (w2 / water 
                                                :mod (a5 / ammonia)) 
                                          :time (a6 / after 
                                                :op1 (m2 / min 
                                                      :quant 20))))) 
                        :op2 (m / ml 
                              :quant 20) 
                        :op3 (w / water 
                              :ARG1-of (d / distil-01 
                                    :ARG2 50)) 
                        :op5 (g / g 
                              :mod (a2 / acid 
                                    :mod (c / citric)))))) 
      :ARG2 (s / solution 
            :mod (n / nitrate) 
            :mod (t / titrate) 
            :mod (s2 / silver)))

# ::snt Slides were then rinsed in tap water , fixed in 5 % sodium thiosulfate , and dehydrated through alcohols and xylene .
# ::tok Slides were then rinsed in tap water , fixed in 5 % sodium thiosulfate , and dehydrated through alcohols and xylene .
# ::alignments 20-21|0.1.1.1 19-20|0.1.1 18-19|0.1.1.0 16-17|0.1 15-16|0 13-14|0.0.1 12-13|0.0.1.0 11-12|0.0.1.0.0 10-11|0.1.0 8-9|0.0 6-7|0.0.0.0.0 5-6|0.0.0.0 3-4|0.0.0.1 2-3|0.0.0.1.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:53.295
(a3 / and 
      :op1 (f / fix-03 
            :ARG1 (s2 / slide-01 
                  :ARG1-of (t2 / tap-03 
                        :mod-of (w / water)) 
                  :ARG1-of (r / rinse-01 
                        :time (t3 / then))) 
            :ARG2 (t / thiosulfate 
                  :mod (s / sodium 
                        :mod (p / percentage-entity)))) 
      :op2 (d / dehydrate-01 
            :ARG1 5 
            :ARG2 (a / and 
                  :op1 (a2 / alcohol) 
                  :op2 (x / xylene))))

# ::snt Following deparaffinization of sections through xylene and alcohols , amyloid impregnation with thioflavin-S was performed according to the Guntern modification of the standard protocol .
# ::tok Following deparaffinization of sections through xylene and alcohols , amyloid impregnation with thioflavin-S was performed according to the Guntern modification of the standard protocol .
# ::alignments 23-24|0.0.0 22-23|0.0.0.0 19-20|0.0 18-19|0.0.1.0.0+0.0.1.0+0.0.1 15-16|0 14-15|0.1 12-13|0.1.1.1.0 10-11|0.1.0 9-10|0.1.0.0 7-8|0.1.1.0.1 6-7|0.1.1.0 5-6|0.1.1.0.0 3-4|0.1.1.1.0.0 1-2|0.1.1.1 0-1|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:53.702
(s2 / say-01 
      :ARG0 (m / modify-01 
            :ARG0 (p / protocol 
                  :ARG1-of (s / standard-02)) 
            :ARG1 (t / thing 
                  :name (n / name 
                        :op1 "Guntern"))) 
      :ARG1 (p2 / perform-02 
            :ARG1 (i / impregnation 
                  :mod (a / amyloid)) 
            :purpose (f / follow-01 
                  :ARG1 (a3 / and 
                        :op1 (x / xylene) 
                        :op2 (a2 / alcohol)) 
                  :ARG2 (d / deparaffinization 
                        :mod (t2 / thioflavin- 
                              :mod-of (s3 / section))))))

# ::snt Slides holding 10-m paraffin sections were washed twice in distilled water , then immersed for 5 min in a 0.25 % potassium permanganate solution , followed by 5 min in a 1 % potassium metabisulfate/1 % oxalic acid solution .
# ::tok Slides holding 10-m paraffin sections were washed twice in distilled water , then immersed for 5 min in a 0.25 % potassium permanganate solution , followed by 5 min in a 1 % potassium metabisulfate/1 % oxalic acid solution .
# ::alignments 38-39|0.0.2.0.1.0 37-38|0.0.2.0.1 35-36|0.0.2.3 33-34|0.0.4.0.0.0 32-33|0.0.4.0.0 31-32|0.0.4.0 28-29|0.0.1.0 27-28|0.0.0 25-26|0.0.1 23-24|0.0.2.2 22-23|0.0.2.2.0 21-22|0.0.1.1.0 20-21|0.0.1.1 16-17|0.0.2.1 15-16|0.0.3 13-14|0.0.2 12-13|0.0.2.4 10-11|0.0.2.0.0 9-10|0.0.2.0 6-7|0.0.4 4-5|0.1 3-4|0.1.0 1-2|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:54.422
(h / hold-01 
      :ARG0 (s4 / slide-01 
            :ARG0 5 
            :ARG0-of (f / follow-01 
                  :ARG1 (m / min) 
                  :purpose (p6 / percentage-entity 
                        :mod-of (p5 / potassium))) 
            :ARG0-of (i / immerse-01 
                  :ARG1 (d / distil-01 
                        :ARG1 (w / water) 
                        :op1-of (a / acid 
                              :mod-of (s / solution))) 
                  :ARG2 (m2 / min) 
                  :manner (s2 / solution 
                        :mod (p4 / permanganate)) 
                  :op1-of (p / percentage-entity) 
                  :time (t / then)) 
            :ARG1 5 
            :ARG1-of (w2 / wash-01 
                  :ARG0 (1 / 1 
                        :value-of (p3 / percentage-entity 
                              :mod-of (p2 / potassium))))) 
      :ARG1 (s3 / section 
            :mod (p7 / paraffin)))

# ::snt After this preparation , slides were placed into a filtered aqueous 0.02 % thioflavin-S solution ( Chroma-Gesellschaft Schmid , Kongen , Germany ) for 8 min .
# ::tok After this preparation , slides were placed into a filtered aqueous 0.02 % thioflavin-S solution ( Chroma-Gesellschaft Schmid , Kongen , Germany ) for 8 min .
# ::alignments 25-26|0.0.0 24-25|0.0.0.0 21-22|0.1.0.0.1+0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 19-20|0.2.0.0.0.0+0.2.0.0.0+0.2.0.0 16-18|0.2.0.1.0.1+0.2.0.1.0.0+0.2.0.1.0+0.2.0.1 14-15|0.1 13-14|0.1.1 12-13|0.1.1.0 10-11|0.1.0.1 9-10|0.1.0 6-7|0 4-5|0.0 2-3|0.2.0 1-2|0.2.0.2 0-1|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:54.801
(p3 / place-01 
      :ARG1 (s2 / slide-01 
            :ARG0 (m / min 
                  :quant 8)) 
      :ARG2 (s / solution 
            :mod (f / filter-02 
                  :ARG0 (c / country 
                        :name (n / name 
                              :op1 "Germany") 
                        :wiki "Germany") 
                  :ARG1 (a / aqueou)) 
            :mod (t / thioflavin- 
                  :quant (p2 / percentage-entity))) 
      :time (a2 / after 
            :op1 (p4 / prepare-02 
                  :ARG0 (c2 / country 
                        :name (n2 / name 
                              :op1 "Kongen")) 
                  :ARG1 (p / person 
                        :name (n3 / name 
                              :op1 "Chroma-Gesellschaft" 
                              :op2 "Schmid")) 
                  :mod (t2 / this))))

# ::snt Excess stain was removed by two brief rinses in 80 % ethanol , then two in distilled water , after which slides were finished in aqueous mounting medium for florescence photomicrography .
# ::tok Excess stain was removed by two brief rinses in 80 % ethanol , then two in distilled water , after which slides were finished in aqueous mounting medium for florescence photomicrography .
# ::alignments 30-31|0.1 29-30|0 27-28|0.0.0.1.1 26-27|0.0.0.1 25-26|0.0.0.1.1.0 23-24|0.0.1 21-22|0.0.1.0 19-20|0.0.1.1 17-18|0.0.1.0.0.0 16-17|0.0.1.0.0 14-15|0.0.0.0.0.0 13-14|0.0.0.0.0 11-12|0.0.2.0 10-11|0.0.2 9-10|0.0.0.1.0 7-8|0.0 6-7|0.0.3 5-6|0.0.4 3-4|0.0.0 1-2|0.0.0.0 0-1|0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:55.630
(f / florescence 
      :ARG1-of (r / rinse-01 
            :ARG0-of (r2 / remove-01 
                  :ARG1 (s2 / stain-01 
                        :ARG0 (t / then 
                              :op1 2) 
                        :ARG1 (e2 / exces)) 
                  :ARG2-of (m2 / mount-02 
                        :ARG0 80 
                        :ARG1 (m / medium 
                              :mod (a / aqueou)))) 
            :ARG0-of (f2 / finish-01 
                  :ARG1 (s / slide-01 
                        :ARG1 (d / distil-01 
                              :ARG1 (w / water))) 
                  :time (a2 / after)) 
            :ARG2 (p2 / percentage-entity 
                  :mod-of (e / ethanol)) 
            :duration (b / brief) 
            :quant 2) 
      :mod-of (p / photomicrography))

# ::snt Ubiquitin , glial fibrillary acidic protein , and A immunohistochemistry .
# ::tok Ubiquitin , glial fibrillary acidic protein , and A immunohistochemistry .
# ::alignments 9-10|0.1 7-8|0 5-6|0.0 4-5|0.0.0 2-3|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:55.654
(a / and 
      :op1 (p / protein 
            :mod (a2 / acidic) 
            :mod (g / glial)) 
      :op2 (i / immunohistochemistry))

# ::snt Prior to immunostaining , slides were deparaffinized by oven heating followed by immersion in xylene .
# ::tok Prior to immunostaining , slides were deparaffinized by oven heating followed by immersion in xylene .
# ::alignments 14-15|0.0.2 12-13|0.0.0 10-11|0.0 9-10|0.0.1 8-9|0.0.1.1 4-5|0 2-3|0.0.1.0 0-1|0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:55.757
(s / slide-01 
      :ARG1 (f / follow-01 
            :ARG0 (i / immersion) 
            :ARG1 (h / heat-01 
                  :ARG1 (i2 / immunostain 
                        :op1-of (p / prior)) 
                  :mod (o / oven)) 
            :location (x / xylene)))

# ::snt After rehydration through graded alcohols into tap water , endogenous peroxidase activity was quenched by incubation with 3 % hydrogen peroxide in methanol .
# ::tok After rehydration through graded alcohols into tap water , endogenous peroxidase activity was quenched by incubation with 3 % hydrogen peroxide in methanol .
# ::alignments 22-23|0.2.0.0.0 20-21|0.2.0.0 19-20|0.2.0 18-19|0.2.0.1 17-18|0.2.0.1.0 15-16|0.0 13-14|0 11-12|0.1 10-11|0.1.0 9-10|0.1.1 7-8|0.2.1 6-7|0.2 4-5|0.2.1.0.0 3-4|0.2.1.0 1-2|0.3.0 0-1|0.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:55.977
(q / quench-01 
      :ARG0 (i / incubation) 
      :ARG1 (a / activity-06 
            :ARG1 (p3 / peroxidase) 
            :mod (e / endogenou)) 
      :ARG2 (t / tap-03 
            :ARG1 (h / hydrogen 
                  :mod-of (p / peroxide 
                        :location (m / methanol)) 
                  :quant (p2 / percentage-entity 
                        :value 3)) 
            :mod-of (w / water 
                  :ARG2-of (g / grade-01 
                        :ARG1 (a2 / alcohol)))) 
      :time (a3 / after 
            :op1 (r / rehydration)))

# ::snt Slides were microwaved for 5 -- 7 min in water , cooled for 5 min , then washed in TBS .
# ::tok Slides were microwaved for 5 -- 7 min in water , cooled for 5 min , then washed in TBS .
# ::alignments 19-20|0.2.1.0+0.2.1+0.2 17-18|0.2.0 16-17|0.2.0.1 14-15|0 13-14|0.0.0 11-12|0.1 9-10|0.2.0.0.0 7-8|0.2.0.0 6-7|0.2.0.2 4-5|0.1.0 2-3|0.0.1 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:56.165
(m / min 
      :ARG0-of (s / slide-01 
            :ARG1 5 
            :ARG1-of (m3 / microwave-01)) 
      :ARG1-of (c / cool-01 
            :ARG0 5) 
      :op1 (o / organization 
            :ARG0-of (w / wash-01 
                  :ARG1 (m2 / min 
                        :location (w2 / water)) 
                  :time (t / then) 
                  :time 7) 
            :name (n / name 
                  :op1 "TBS")))

# ::snt Nonspecific staining was blocked for 1 h with 3 % normal goat serum and 0.1 % Triton-X 100 in TBS .
# ::tok Nonspecific staining was blocked for 1 h with 3 % normal goat serum and 0.1 % Triton-X 100 in TBS .
# ::alignments 19-20|0.1.0.0.0+0.1.0.0+0.1.0 17-18|0.1.1.0.0 15-16|0.1.1.0 14-15|0.1.1 13-14|0.0 12-13|0.0.0 11-12|0.0.0.1 10-11|0.0.0.0 9-10|0.0.0.0.0 8-9|0.0.0.0.0.0 6-7|0.2 5-6|0.2.0 3-4|0 1-2|0.1 0-1|0.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:56.435
(b / block-01 
      :ARG0 (a / and 
            :op1 (s / serum 
                  :ARG1-of (n2 / normal-02 
                        :ARG2 (p2 / percentage-entity 
                              :value 3)) 
                  :mod (g / goat))) 
      :ARG1 (s2 / stain-01 
            :ARG0 (o / organization 
                  :name (n / name 
                        :op1 "TBS")) 
            :ARG1 (0 / 0.1 
                  :value-of (p / percentage-entity 
                        :value 100)) 
            :mod (n3 / nonspecific)) 
      :ARG2 (h / h 
            :quant 1))

# ::snt Slides were then placed into primary antibody ( rabbit anti-A peptide polyclonal antibody , Zymed Laboratories , South San Francisco , California , United States ; rabbit anti-ubiquitin and rabbit anti -- glial fibrillary acidic protein ( GFAP ) polyclonal antibodies , Dako , Carpinteria , California , United States ) diluted 1:500 in TBS with 2 % normal goat serum and incubated overnight at room temperature .
# ::tok Slides were then placed into primary antibody ( rabbit anti-A peptide polyclonal antibody , Zymed Laboratories , South San Francisco , California , United States ; rabbit anti-ubiquitin and rabbit anti -- glial fibrillary acidic protein ( GFAP ) polyclonal antibodies , Dako , Carpinteria , California , United States ) diluted 1:500 in TBS with 2 % normal goat serum and incubated overnight at room temperature .
# ::alignments 66-67|0.2.3.0.2.1 65-66|0.2.3.0.2.1.0 63-64|0.2.3.0.2.2 62-63|0.2.3.0.2 61-62|0.2.3.0 60-61|0.2.3.0.1 59-60|0.2.3.0.1.1 58-59|0.2.3.0.1.0 57-58|0.2.3.0.1.0.1 56-57|0.2.3.0.1.0.1.0 54-55|0.2.4.0.0.0+0.2.4.0.0+0.2.4.0 51-52|0.2.3.0.0 48-50|0.2.2.0.1+0.2.2.0.0.1+0.2.2.0.0.0+0.2.2.0.0+0.2.2.0 46-47|0.2.2.1.1+0.2.2.1.0.0+0.2.2.1.0+0.2.2.1 44-45|0.2.3.0.1.0.0.0.0+0.2.3.0.1.0.0.0+0.2.3.0.1.0.0 42-43|0.2.4.1.0.0.0+0.2.4.1.0.0+0.2.4.1.0 40-41|0.2.3.0.2.0 35-36|0 34-35|0.0 32-33|0.1 30-31|0.2.4 29-30|0.2.4.1 28-29|0.2.3 26-27|0.2.2 25-26|0.2 23-25|0.2.1.1+0.2.1.0.1+0.2.1.0.0+0.2.1.0+0.2.1 21-22|0.2.0.1.1.1+0.2.0.1.1.0.0+0.2.0.1.1.0+0.2.0.1.1 18-20|0.2.0.0.0.1+0.2.0.0.0.0.1+0.2.0.0.0.0.0+0.2.0.0.0.0+0.2.0.0.0 17-18|0.2.0.0.1.0+0.2.0.0.1+0.2.0.0 14-16|0.2.0.1.0.0.1+0.2.0.1.0.0.0+0.2.0.1.0.0+0.2.0.1.0 12-13|0.2.4.1.1.0 11-12|0.2.4.1.1.0.0 10-11|0.2.4.1.1.0.1 8-9|0.2.4.1.1 6-7|0.2.0.2 5-6|0.2.0.2.0 3-4|0.2.0 2-3|0.2.0.3 0-1|0.2.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:22:59.599
(p2 / protein 
      :mod (a3 / acidic) 
      :mod (g2 / glial) 
      :op6-of (a5 / and 
            :op1 (p6 / place-01 
                  :ARG0 (c5 / country 
                        :location-of (c4 / city 
                              :name (n9 / name 
                                    :op1 "San" 
                                    :op2 "Francisco") 
                              :wiki "San_Francisco") 
                        :name (n10 / name 
                              :op1 "South")) 
                  :ARG1 (s4 / slide-01 
                        :ARG0 (o5 / organization 
                              :name (n11 / name 
                                    :op1 "Zymed" 
                                    :op2 "Laboratories")) 
                        :ARG1 (s3 / state 
                              :name (n8 / name 
                                    :op1 "California") 
                              :wiki "California")) 
                  :ARG2 (a7 / antibody 
                        :mod (p5 / primary)) 
                  :time (t2 / then)) 
            :op2 (c3 / country 
                  :name (n7 / name 
                        :op1 "United" 
                        :op2 "States") 
                  :wiki "United_States") 
            :op3 (r3 / rabbit-01 
                  :ARG0 (c / country 
                        :name (n3 / name 
                              :op1 "United" 
                              :op2 "States") 
                        :wiki "United_States") 
                  :ARG1 (s2 / state 
                        :name (n4 / name 
                              :op1 "California") 
                        :wiki "California")) 
            :op4 (a4 / and 
                  :op1-of (a / and 
                        :op2 (d / dilute-01) 
                        :op3 (s / serum 
                              :ARG1-of (n / normal-02 
                                    :ARG0 (c2 / country 
                                          :name (n5 / name 
                                                :op1 "Carpinteria")) 
                                    :ARG2 (p / percentage-entity 
                                          :value 2)) 
                              :mod (g / goat)) 
                        :op4 (i / incubate-01 
                              :ARG0 (a2 / antibodi) 
                              :ARG1 (t / temperature 
                                    :consist-of (r / room)) 
                              :time (o / overnight)))) 
            :op5 (o4 / oppose-01 
                  :ARG0 (o2 / organization 
                        :name (n2 / name 
                              :op1 "TBS")) 
                  :ARG1 (r2 / rabbit-01 
                        :ARG1 (o3 / organization 
                              :name (n6 / name 
                                    :op1 "Dako")) 
                        :ARG2-of (r4 / rabbit-01 
                              :ARG1 (a6 / antibody 
                                    :mod (p3 / polyclonal) 
                                    :mod (p4 / peptide)))))))

# ::snt After being washed of excess primary antibody with several changes of TBS , slides were incubated with either the Vectastain Elite anti-rabbit secondary system ( anti-A ; Vector Laboratories , Burlingame , California , United States ) or peroxidase/anti-peroxidase reagents ( anti-ubitquitin and anti-GFAP ; Sternberger Monoclonals , Lutherville , Maryland , United States ) according to the manufacturers ' directions .
# ::tok After being washed of excess primary antibody with several changes of TBS , slides were incubated with either the Vectastain Elite anti-rabbit secondary system ( anti-A ; Vector Laboratories , Burlingame , California , United States ) or peroxidase/anti-peroxidase reagents ( anti-ubitquitin and anti-GFAP ; Sternberger Monoclonals , Lutherville , Maryland , United States ) according to the manufacturers ' directions .
# ::alignments 60-61|0.0 58-59|0.0.0.0+0.0.0 55-56|0 52-54|0.1.2.1.4.1+0.1.2.1.4.0.1+0.1.2.1.4.0.0+0.1.2.1.4.0+0.1.2.1.4 50-51|0.1.0.1+0.1.0.0.0+0.1.0.0+0.1.0 48-49|0.0.0.1.1.0.0+0.0.0.1.1.0+0.0.0.1.1 45-47|0.0.0.1.0.0.1+0.0.0.1.0.0.0+0.0.0.1.0.0+0.0.0.1.0 42-43|0.0.0.1 39-40|0.1.2.2 37-38|0.1.2 34-36|0.1.1.0.1+0.1.1.0.0.1+0.1.1.0.0.0+0.1.1.0.0+0.1.1.0 32-33|0.1.3.0.1.0.1+0.1.3.0.1.0.0.0+0.1.3.0.1.0.0+0.1.3.0.1.0 30-31|0.1.2.1.3.0.0+0.1.2.1.3.0+0.1.2.1.3 27-29|0.1.2.1.2.0.1+0.1.2.1.2.0.0+0.1.2.1.2.0+0.1.2.1.2 26-27|0.1.2.1 23-24|0.1.2.0 22-23|0.1.2.1.1 20-21|0.1.2.1.0 17-18|0.1.3.0.1.2 15-16|0.1 13-14|0.1.1 11-12|0.1.3.0.1.1.0.0+0.1.3.0.1.1.0+0.1.3.0.1.1 9-10|0.1.3.0.1 8-9|0.1.3.0.1.3 6-7|0.1.3.0.0 5-6|0.1.3.0.0.1 4-5|0.1.3.0.0.0 2-3|0.1.3.0 0-1|0.1.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:01.571
(s / say-01 
      :ARG0 (d / direction 
            :poss (p / person 
                  :ARG0-of (m / manufacture-01) 
                  :op3-of (a / and 
                        :op1 (p2 / person 
                              :name (n4 / name 
                                    :op1 "Sternberger" 
                                    :op2 "Monoclonals")) 
                        :op2 (c2 / country 
                              :name (n3 / name 
                                    :op1 "Lutherville"))))) 
      :ARG1 (i / incubate-01 
            :ARG0 (s2 / state 
                  :name (n2 / name 
                        :op1 "Maryland") 
                  :wiki "Maryland") 
            :ARG1 (s6 / slide-01 
                  :ARG1 (c3 / country 
                        :name (n5 / name 
                              :op1 "United" 
                              :op2 "States") 
                        :wiki "United_States")) 
            :ARG2 (o / or 
                  :op1 (s4 / system) 
                  :op2 (a2 / and 
                        :op1 (e / elite) 
                        :op2 (s5 / secondary) 
                        :op3 (o2 / organization 
                              :name (n8 / name 
                                    :op1 "Vector" 
                                    :op2 "Laboratories")) 
                        :op4 (c4 / country 
                              :name (n7 / name 
                                    :op1 "Burlingame")) 
                        :op5 (c / country 
                              :name (n / name 
                                    :op1 "United" 
                                    :op2 "States") 
                              :wiki "United_States")) 
                  :op3 (r / reagent)) 
            :time (a4 / after 
                  :op1 (w / wash-01 
                        :ARG1 (a3 / antibody 
                              :ARG1-of (e3 / exceed-01) 
                              :mod (p3 / primary)) 
                        :ARG2 (c5 / change-01 
                              :ARG0 (s3 / state 
                                    :name (n6 / name 
                                          :op1 "California") 
                                    :wiki "California") 
                              :ARG1 (o3 / organization 
                                    :name (n9 / name 
                                          :op1 "TBS")) 
                              :op1-of (e2 / either) 
                              :quant (s7 / several))))))

# ::snt Antibody binding was visualized with diaminobenzidene , and sections were counterstained with hematoxylin .
# ::tok Antibody binding was visualized with diaminobenzidene , and sections were counterstained with hematoxylin .
# ::alignments 12-13|0.0.1.0 10-11|0.1 8-9|0.1.0 7-8|0 5-6|0.0.2 3-4|0.0 1-2|0.0.1 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:01.656
(a / and 
      :op1 (v / visualize-01 
            :ARG1 (a2 / antibody) 
            :ARG1-of (b / binding-07 
                  :ARG0 (h / hematoxylin)) 
            :ARG2 (d / diaminobenzidene)) 
      :op2 (c / counterstain 
            :domain (s / section)))

# ::snt An aliquot of each cortical homogenate used for Western blotting above was partially solubilized by the addition of SDS to a final concentration of 1 % .
# ::tok An aliquot of each cortical homogenate used for Western blotting above was partially solubilized by the addition of SDS to a final concentration of 1 % .
# ::alignments 25-26|0.0.0.3.0.0 24-25|0.0.0.3.0.0.0 22-23|0.0.0.3.0 21-22|0.0.0.3.0.1 18-19|0.0.0.2.0.0+0.0.0.2.0+0.0.0.2 16-17|0.0.0.2.1 12-13|0 10-11|0.0.2 9-10|0.0.1 8-9|0.0.1.0.1+0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 6-7|0.0 5-6|0.0.0 4-5|0.0.0.1 3-4|0.0.0.0 1-2|0.0.0.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:02.056
(p2 / partial 
      :ARG0-of (u / use-01 
            :ARG1 (h / homogenate 
                  :mod (e / each) 
                  :mod (c2 / cortical) 
                  :mod-of (o / organization 
                        :name (n / name 
                              :op1 "SDS") 
                        :poss-of (a / addition)) 
                  :poss-of (a3 / aliquot 
                        :ARG1-of (c / concentrate-02 
                              :ARG2 (p / percentage-entity 
                                    :value 1) 
                              :mod (f / final)))) 
            :ARG2 (b / blot-01 
                  :mod (w / world-region 
                        :name (n2 / name 
                              :op1 "West") 
                        :wiki "Western_world")) 
            :path (a2 / above)))

# ::snt Serial 1:2 dilutions were made with 1  PBS/1 % SDS , and 100 l of each dilution was then vacuum-filtered through a pre-wet 0.22-m cellulose acetate membrane ( Schleicher and Schuell ) [ 22 ] .
# ::tok Serial 1:2 dilutions were made with 1  PBS/1 % SDS , and 100 l of each dilution was then vacuum-filtered through a pre-wet 0.22-m cellulose acetate membrane ( Schleicher and Schuell ) [ 22 ] .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:02.059
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Each well was washed several times with PBS , after which blots were incubated overnight with polyclonal anti-A antibody ( Zymed Laboratories ) diluted 1:600 in a blocking solution of 1  TBS/5 % nonfat dry milk powder .
# ::tok Each well was washed several times with PBS , after which blots were incubated overnight with polyclonal anti-A antibody ( Zymed Laboratories ) diluted 1:600 in a blocking solution of 1  TBS/5 % nonfat dry milk powder .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:02.064
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt After washing the blots three times for 10 min each in 1  TBS/0 .1 % Tween-20 , the membrane was incubated for 1 h with HRP-conjugated protein A ( Sigma ) diluted 1:5,000 in blocking solution .
# ::tok After washing the blots three times for 10 min each in 1  TBS/0 .1 % Tween-20 , the membrane was incubated for 1 h with HRP-conjugated protein A ( Sigma ) diluted 1:5,000 in blocking solution .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:02.074
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt The membranes were again washed three times with 1  TBS/0 .1 % Tween-20 , before antibody binding was detected with enhanced chemiluminescence ( PerkinElmer , Boston , Massachusetts , United States ) .
# ::tok The membranes were again washed three times with 1  TBS/0 .1 % Tween-20 , before antibody binding was detected with enhanced chemiluminescence ( PerkinElmer , Boston , Massachusetts , United States ) .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:02.077
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Digital images of each blot were captured with a Molecular Imager FX gel documentation system , and the intensity of A staining was quantified using Quantity One image analysis software .
# ::tok Digital images of each blot were captured with a Molecular Imager FX gel documentation system , and the intensity of A staining was quantified using Quantity One image analysis software .
# ::alignments 29-30|0.2.0.0 28-29|0.2.0.0.0 27-28|0.2.0.1 26-27|0.2.0.0.0.0 25-26|0.0.0.0 24-25|0.2.0 23-24|0.2 21-22|0.2.0.2.0 18-19|0.2.0.2 16-17|0 14-15|0.1 13-14|0.1.0 12-13|0.1.1.0 10-12|0.1.1.1.1+0.1.1.1.0+0.1.1.1+0.1.1 6-7|0.0 4-5|0.0.0 3-4|0.0.0.1 1-2|0.0.0.2 0-1|0.0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:03.024
(a2 / and 
      :op1 (c / capture-01 
            :ARG1 (b / blot-01 
                  :ARG1 (q / quantity) 
                  :mod (e / each) 
                  :topic-of (i4 / image 
                        :mod (d2 / digital)))) 
      :op2 (s3 / system 
            :mod (d / documentation) 
            :mod (t / thing 
                  :mod-of (g / gel) 
                  :name (n / name 
                        :op1 (i3 / Imager) 
                        :op2 (f / FX)))) 
      :op3 (q2 / quantify-01 
            :ARG1 (u / use-01 
                  :ARG0 (s / software 
                        :ARG0-of (a / analyze-01 
                              :ARG1 1)) 
                  :ARG1 (i / image) 
                  :ARG2 (i2 / intensity 
                        :poss (s2 / stain-01)))))

# ::snt An aliquot of cortical homogenate generated for Western analysis described above was subjected to a three-step sequential extraction using PBS , 2 % SDS , and 70 % formic acid ( FA ) .
# ::tok An aliquot of cortical homogenate generated for Western analysis described above was subjected to a three-step sequential extraction using PBS , 2 % SDS , and 70 % formic acid ( FA ) .
# ::alignments 31-32|0.0.0.0.1+0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 29-30|0.1.1.0.2 28-29|0.1.1.0.2.0 27-28|0.1.2.0 26-27|0.1.2 25-26|0.1.1.0 23-24|0.1.1.0.1.1.0+0.1.1.0.1.1+0.1.1.0.1 22-23|0.1.1.0.1.0 21-22|0.1.1.0.1.0.0 19-20|0.1.1.0.0 18-19|0.1.1 17-18|0.1 16-17|0.1.3 12-13|0 10-11|0.0.0.1 9-10|0.0.0 8-9|0.0 7-8|0.0.2.1+0.0.2.0.0+0.0.2.0+0.0.2 5-6|0.0.1 4-5|0.0.1.0 3-4|0.0.1.0.0 1-2|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:03.909
(s2 / subject-01 
      :ARG1 (a4 / analyze-01 
            :ARG1-of (d / describe-01 
                  :ARG0 (l / league 
                        :name (n / name 
                              :op1 "FA") 
                        :wiki "The_Football_Association") 
                  :ARG2 (a3 / above)) 
            :ARG1-of (g / generate-01 
                  :ARG0 (h / homogenate 
                        :mod (c / cortical))) 
            :mod (w / world-region 
                  :name (n3 / name 
                        :op1 "West") 
                  :wiki "Western_world")) 
      :ARG2 (e / extract-01 
            :ARG0 (a5 / aliquot) 
            :ARG0-of (u / use-01 
                  :ARG1 (a2 / and 
                        :op1 (p3 / pb) 
                        :op2 (o / organization 
                              :mod (p2 / percentage-entity 
                                    :value 2) 
                              :name (n2 / name 
                                    :op1 "SDS")) 
                        :op3 (a / acid 
                              :mod (f / formic)))) 
            :ARG1 (7 / 70 
                  :value-of (p / percentage-entity)) 
            :mod (s / sequential)))

# ::snt At each step , the sample was sonicated in appropriate buffer and centrifuged at 100,000 g for 30 min ( 1 - to 1.5-mo samples ) or 60 min ( 6 - to 12-mo samples ) at 4 C as previously described [ 23 -- 25 ] .
# ::tok At each step , the sample was sonicated in appropriate buffer and centrifuged at 100,000 g for 30 min ( 1 - to 1.5-mo samples ) or 60 min ( 6 - to 12-mo samples ) at 4 C as previously described [ 23 -- 25 ] .
# ::alignments 45-46|0.0.0.1.2 43-44|0.0.0.1.3 41-42|0.0.0.3 40-41|0.0.0.3.2 38-39|0.0.0.1.4.0 37-38|0.0.0.1.4 34-35|0+0.0 30-31|0.0.0.1.1.0 28-29|0.0.0.2.2 27-28|0.0.0.0.0 26-27|0.0.0.2 24-25|0.0.0.3.1.0+0.0.0.3.1 20-21|0.0.0.3.0 18-19|0.0.0.2.1 17-18|0.0.0.2.1.0 15-16|0.0.0.2.0 11-12|0.0.0 10-11|0.0.0.1 9-10|0.0.0.1.1 5-6|0.0.0.0 2-3|0.0.0.1.0 1-2|0.0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:04.511
(s / sample-01 
      :ARG1 (t / thing 
            :op2-of (a / and 
                  :ARG2-of (s3 / sample-01 
                        :ARG1 60) 
                  :op1 (b / buffer-01 
                        :ARG0 (s4 / step 
                              :mod (e / each)) 
                        :ARG1-of (a2 / appropriate-02 
                              :ARG2 6) 
                        :op1-of 25 
                        :op1-of 23 
                        :op1-of (4 / 4 
                              :era (c / C))) 
                  :op1-of (o / or 
                        :op2 (g / g) 
                        :op3 (m2 / min 
                              :quant 30) 
                        :op4 (m / min)) 
                  :time (d / describe-01 
                        :ARG0 1 
                        :ARG2 (t2 / thing 
                              :ARG1-of (s2 / sample-01)) 
                        :time (p / previous)))))

# ::snt The supernatant was removed for analysis , and the pellet was sonicated in the next solution in sequence .
# ::tok The supernatant was removed for analysis , and the pellet was sonicated in the next solution in sequence .
# ::alignments 17-18|0.0.1.0 15-16|0.1.1 14-15|0.1.1.0 11-12|0.1 9-10|0.1.0 7-8|0 5-6|0.0.1 3-4|0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:04.630
(a / and 
      :op1 (r / remove-01 
            :ARG1 (s4 / supernatant) 
            :ARG2 (a2 / analyze-01 
                  :ARG1 (s / sequence))) 
      :op2 (s3 / sonicat 
            :domain (p / pellet) 
            :domain (s2 / solution 
                  :mod (n / next))))

# ::snt The 2 % SDS extracts were diluted in EC buffer , and the FA extracts neutralized with 1M Tris-phosphate buffer ( pH 11 ) then diluted with EC buffer prior to testing .
# ::tok The 2 % SDS extracts were diluted in EC buffer , and the FA extracts neutralized with 1M Tris-phosphate buffer ( pH 11 ) then diluted with EC buffer prior to testing .
# ::alignments 31-32|0.1.1.0.1 29-30|0.1.1.0.1.0 28-29|0.1.1.0.0 25-26|0.1.1.0 24-25|0.1.1.0.2 22-23|0.1.1.0.0.0 21-22|0.0.1.1 19-20|0.1.1 15-16|0.1 14-15|0.1.0.0+0.1.0 13-14|0.1.0.0.0.1+0.1.0.0.0.0.0+0.1.0.0.0.0+0.1.0.0.0 11-12|0 9-10|0.0.1 8-9|0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 6-7|0.0 4-5|0.0.0.0+0.0.0 3-4|0.0.0.0.0.0.0+0.0.0.0.0.0+0.0.0.0.0 2-3|0.0.0.0.1 1-2|0.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:05.370
(a / and 
      :op1 (d2 / dilute-01 
            :ARG1 (t4 / thing 
                  :ARG1-of (e2 / extract-01 
                        :ARG0 (o2 / organization 
                              :name (n4 / name 
                                    :op1 "SDS")) 
                        :ARG2 (p3 / percentage-entity 
                              :value 2))) 
            :ARG2 (b3 / buffer-01 
                  :ARG0 (o / organization 
                        :name (n3 / name 
                              :op1 "EC")) 
                  :ARG1 (p2 / ph))) 
      :op2 (n / neutralize-01 
            :ARG0 (t3 / thing 
                  :ARG1-of (e / extract-01 
                        :ARG0 (l / league 
                              :name (n2 / name 
                                    :op1 "FA") 
                              :wiki "The_Football_Association"))) 
            :ARG1 (b2 / buffer-01 
                  :ARG1 (d / dilute-01 
                        :ARG1 (b / buffer-01 
                              :ARG1 11) 
                        :ARG2 (t / test-01 
                              :op1-of (p / prior)) 
                        :time (t2 / then)))))

# ::snt Human A was measured in each fraction using BAN50 for capture ( epitope A1 -- 16 ) and BA27 and BC05 for detection ( A40 and A42 , respectively ) ( Takeda Chemical Industries , Osaka , Japan ) .
# ::tok Human A was measured in each fraction using BAN50 for capture ( epitope A1 -- 16 ) and BA27 and BC05 for detection ( A40 and A42 , respectively ) ( Takeda Chemical Industries , Osaka , Japan ) .
# ::alignments 37-38|0.1.2.0.0.1+0.1.2.0.0.0.0+0.1.2.0.0.0+0.1.2.0.0 35-36|0.1.1.0.2.1.0+0.1.1.0.2.1 31-34|0.1.2.0.1.0.2+0.1.2.0.1.0.1+0.1.2.0.1.0.0+0.1.2.0.1.0+0.1.2.0.1 28-29|0.0 26-27|0.3.0.0+0.3.0+0.3 25-26|0 24-25|0.2.0.0+0.2.0+0.2 22-23|0.1.1.0.2 19-20|0.1.2 18-19|0.1.0.0+0.1.0+0.1 17-18|0.1.1 15-16|0.1.1.0.3.0 12-13|0.1.1.0.2.0 10-11|0.1.2.0 8-9|0.1.1.0.1.0.0+0.1.1.0.1.0+0.1.1.0.1 7-8|0.1.1.0 6-7|0.1.1.0.0 5-6|0.1.1.0.0.0 3-4|0.1.1.0.3 0-2|0.1.1.0.3.1.0.1+0.1.1.0.3.1.0.0+0.1.1.0.3.1.0+0.1.1.0.3.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:06.681
(a / and 
      :mod (r / respective) 
      :op1 (p / person 
            :name (n6 / name 
                  :op1 "BA27") 
            :op1-of (a3 / and 
                  :ARG3-of (u / use-01 
                        :ARG0 (f / fraction 
                              :mod (e2 / each)) 
                        :ARG1 (t / thing 
                              :name (n7 / name 
                                    :op1 "BAN50")) 
                        :ARG2 (d / detect-01 
                              :ARG0 (e / epitope) 
                              :ARG1 (n2 / name 
                                    :op1 "Osaka")) 
                        :manner-of (m / measure-01 
                              :ARG0 16 
                              :ARG1 (t2 / thing 
                                    :name (n8 / name 
                                          :op1 (h / Human) 
                                          :op2 (a4 / A)))))) 
            :op2-of (a2 / and 
                  :op1 (c2 / capture-01 
                        :ARG0 (c / country 
                              :name (n / name 
                                    :op1 "Japan") 
                              :wiki "Japan") 
                        :ARG1 (o / organization 
                              :name (n3 / name 
                                    :op1 "Takeda" 
                                    :op2 "Chemical" 
                                    :op3 "Industries"))))) 
      :op2 (o3 / organization 
            :name (n5 / name 
                  :op1 "A40")) 
      :op3 (o2 / organization 
            :name (n4 / name 
                  :op1 "A42")))

# ::snt Total A ( mouse + human ; 1 - to 1.5-mo samples only ) was measured in each fraction using BNT77 for capture ( epitope A11 -- 28 ) and BA27 and BC05 for detection .
# ::tok Total A ( mouse + human ; 1 - to 1.5-mo samples only ) was measured in each fraction using BNT77 for capture ( epitope A11 -- 28 ) and BA27 and BC05 for detection .
# ::alignments 34-35|0.0.0.0.0.2 31-32|0.0.0.0.0.3.0.1 30-31|0.0.0.0.0.3.0.0.0+0.0.0.0.0.3.0.0+0.0.0.0.0.3.0 29-30|0.0.0.0.0.3 27-28|0.0.0.0.0.2.1 25-26|0.0.0.0.0.3.0.2.0.0.0 24-25|0.0.0.0.0.3.0.2.0.0 22-23|0.0.0.0.0.3.0.1.0 20-21|0.0.0.0.0.1.0.0+0.0.0.0.0.1.0+0.0.0.0.0.1 19-20|0.0.0.0.0 18-19|0.0.0.0.0.0 17-18|0.0.0.0.0.0.0 15-16|0.0.0.0 12-13|0.0.1 11-12|0+0.0 7-8|0.0.0.0.0.2.0 6-7|0.0.0.0.0.3.0.2 5-6|0.0.0 3-4|0.0.0.1 0-1|0.0.0.0.0.3.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:07.423
(s / sample-01 
      :ARG1 (t2 / thing 
            :beneficiary-of (h / human 
                  :ARG1-of (m / measure-01 
                        :manner (u / use-01 
                              :ARG0 (f / fraction 
                                    :mod (e2 / each)) 
                              :ARG1 (t / thing 
                                    :name (n2 / name 
                                          :op1 "BNT77")) 
                              :ARG2 (d / detect-01 
                                    :ARG0 1 
                                    :ARG1 28) 
                              :ARG3 (a2 / and 
                                    :op1 (p / person 
                                          :name (n / name 
                                                :op1 "BA27") 
                                          :op2-of (a / and 
                                                :op1 (c / capture-01)) 
                                          :op2-of (a4 / and 
                                                :op1 (t3 / total-01 
                                                      :ARG1 (e / epitope 
                                                            :mod-of (a3 / A11)))))))) 
                  :mod (m2 / mouse)) 
            :mod (o / only)))

# ::snt All values were calculated as picomoles per gram based on the initial weight of cortical tissue .
# ::tok All values were calculated as picomoles per gram based on the initial weight of cortical tissue .
# ::alignments 15-16|0.0 14-15|0 12-13|0.0.0 11-12|0.0.0.1 8-9|0.0.0.0 7-8|0.0.0.0.0.0+0.0.0.0.0 5-6|0.0.0.0.1 3-4|0.0.0.0.1.0 1-2|0.0.0.0.1.0.0 0-1|0.0.0.0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:07.537
(c / cortical 
      :mod-of (t / tissue 
            :mod-of (w / weight 
                  :ARG2-of (b / base-02 
                        :ARG0 (m / mass-quantity 
                              :unit (g / gram)) 
                        :ARG1 (p / picomol 
                              :ARG2-of (c2 / calculate-01 
                                    :ARG1 (v / value 
                                          :quant (a / all))))) 
                  :mod (i / initial))))

# ::snt Daily basal activity was studied in 28 CaMKII-tTA  tet-APPswe/ind line 107 mice between 4 and 5 mo of age .
# ::tok Daily basal activity was studied in 28 CaMKII-tTA  tet-APPswe/ind line 107 mice between 4 and 5 mo of age .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:07.538
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Animals were separated into individual cages immediately before the start of each experiment ( n = 3 -- 6 per genotype untreated , 2 -- 5 per genotype dox-reared ) .
# ::tok Animals were separated into individual cages immediately before the start of each experiment ( n = 3 -- 6 per genotype untreated , 2 -- 5 per genotype dox-reared ) .
# ::alignments 28-29|0.0.0.0.0.0 27-28|0.0.0.0.0 25-26|0.0.0.2.0.4 23-24|0.0.0.2.0.3 21-22|0.0 20-21|0 18-19|0.0.0.0.1 16-17|0.0.0.1 14-15|0.0.0.2.0.0 12-13|0.0.0.0 11-12|0.0.0.0.2 9-10|0.0.0 7-8|0.0.0.2 6-7|0.0.0.2.0.5 5-6|0.0.0.2.0.2 4-5|0.0.0.2.0.2.0 2-3|0.0.0.2.0 0-1|0.0.0.2.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:07.856
(g2 / genotype 
      :mod-of (u / untreat 
            :ARG0-of (s / start-01 
                  :ARG1 (e / experiment-01 
                        :ARG0 (g / genotype 
                              :mod-of (d / dox-rear)) 
                        :ARG1 6 
                        :mod (e2 / each)) 
                  :ARG2 3 
                  :op1-of (b / before 
                        :time-of (s2 / separate-01 
                              :ARG0 (n / n) 
                              :ARG1 (a / animal) 
                              :ARG2 (c / cage 
                                    :mod (i2 / individual)) 
                              :op1-of 2 
                              :op1-of 5 
                              :time (i / immediate))))))

# ::snt The cages were placed inside activity-monitoring frames designed to count every time the animal passed through one of three photobeams spanning the width of the cage ( San Diego Instruments , San Diego , California , United States ) .
# ::tok The cages were placed inside activity-monitoring frames designed to count every time the animal passed through one of three photobeams spanning the width of the cage ( San Diego Instruments , San Diego , California , United States ) .
# ::alignments 36-38|0.3.0.1.0.1.0.1+0.3.0.1.0.1.0.0.1+0.3.0.1.0.1.0.0.0+0.3.0.1.0.1.0.0+0.3.0.1.0.1.0 34-35|0.3.0.0.1+0.3.0.0.0.0+0.3.0.0.0+0.3.0.0 31-33|0.3.0.1.0.0.1+0.3.0.1.0.0.0.1+0.3.0.1.0.0.0.0+0.3.0.1.0.0.0+0.3.0.1.0.0 28-30|0.1.0.1+0.1.0.0+0.1.0+0.1 25-26|0.2.1.0 22-23|0.2.1 20-21|0.2 19-20|0.2.0 18-19|0.2.0.0 14-15|0 13-14|0.0 11-12|0.3 10-11|0.3.1 9-10|0.3.0 7-8|0.3.0.1 6-7|0.3.0.1.0 5-6|0.3.0.1.0.2 4-5|0.3.0.1.0.3 3-4|0.3.0.1.0.1 1-2|0.3.0.1.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:08.990
(p2 / pass-01 
      :ARG0 (a / animal) 
      :ARG1 (t / thing 
            :name (n4 / name 
                  :op1 (d / Diego) 
                  :op2 (i / Instruments))) 
      :purpose-of (s2 / span-01 
            :ARG0 (p / photobeam 
                  :quant 3) 
            :ARG1 (w / width 
                  :poss (c3 / cage))) 
      :time (t2 / time 
            :ARG1-of (c4 / count-01 
                  :ARG0 (s / state 
                        :name (n2 / name 
                              :op1 "California") 
                        :wiki "California") 
                  :ARG3-of (d2 / design-01 
                        :ARG1 (f / frame-01 
                              :ARG1 (c2 / city 
                                    :name (n3 / name 
                                          :op1 "San" 
                                          :op2 "Diego") 
                                    :wiki "San_Diego") 
                              :ARG2-of (p3 / place-01 
                                    :ARG0 (c / country 
                                          :name (n / name 
                                                :op1 "United" 
                                                :op2 "States") 
                                          :wiki "United_States") 
                                    :ARG1 (c5 / cage)) 
                              :mod (a2 / activity-monitor) 
                              :op1-of (i2 / inside)))) 
            :mod (e / every)))

# ::snt Experiments were started midway through the light phase of the day , and data were collected in 1-h bins for the following 48 h. Testing rooms were maintained on the same 13:11 h day : night cycle as the main animal housing areas and were closed to entry during the experiment .
# ::tok Experiments were started midway through the light phase of the day , and data were collected in 1-h bins for the following 48 h. Testing rooms were maintained on the same 13:11 h day : night cycle as the main animal housing areas and were closed to entry during the experiment .
# ::alignments 50-51|0.2.0 47-48|0.2.2.0 45-46|0.2.2 43-44|0.2 42-43|0.2.1.1.0 41-42|0.2.1.1 40-41|0.2.1.1.1 39-40|0.2.1.1.1.0 36-37|0.2.1 35-36|0.2.1.0 33-34|0.1.2.1 32-33|0.1.2.1.2 30-31|0.1.2.1.0 27-28|0.1.2 25-26|0.1.2.0 24-25|0.1.2.0.1 22-23|0.1.2.1.1 21-22|0.1.2.0.0 18-19|0.1.1 15-16|0.1 13-14|0.1.0 12-13|0 10-11|0.0.1.1 7-8|0.0.1 6-7|0.0.1.0 3-4|0.0.2 2-3|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:09.957
(a4 / and 
      :op1 (s2 / start-01 
            :ARG1 (e3 / experiment-01) 
            :ARG2 (p / phase 
                  :ARG1-of (l / light-06) 
                  :part-of (d3 / day)) 
            :mod-of (m3 / midway)) 
      :op2 (c3 / collect-01 
            :ARG1 (d2 / data) 
            :ARG2 (b / bin-01) 
            :time (m2 / maintain-01 
                  :ARG1 (r / room 
                        :ARG1-of (f / follow-01) 
                        :purpose (t / test-01)) 
                  :time (d / day 
                        :ARG1-of (s / same-01) 
                        :mod-of 48 
                        :time-of (h2 / h)))) 
      :op3 (a / and 
            :ARG0-of (e / experiment-01) 
            :ARG0-of (c2 / cycle-02 
                  :ARG1 (n / night) 
                  :ARG2-of (h / house-01 
                        :ARG0 (a2 / area) 
                        :ARG1 (a3 / animal 
                              :mod (m / main)))) 
            :op1 (c / close-01 
                  :ARG2 (e2 / entry))))

# ::snt Statistical analyses of protein expression , ELISA data , and filter trap assays were performed by ANOVA with Tukey 's honest significant difference post-hoc test applied to significant main effects or interactions ( Statistica 6.0 , StatSoft , Tulsa , Oklahoma , United States ) .
# ::tok Statistical analyses of protein expression , ELISA data , and filter trap assays were performed by ANOVA with Tukey 's honest significant difference post-hoc test applied to significant main effects or interactions ( Statistica 6.0 , StatSoft , Tulsa , Oklahoma , United States ) .
# ::alignments 42-44|0.0.0.1.1+0.0.0.1.0.1+0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 40-41|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 38-39|0.0.1.1.0.0.0.0+0.0.1.1.0.0.0+0.0.1.1.0.0 36-37|0.0.1.0.1.2.0.0.0+0.0.1.0.1.2.0.0+0.0.1.0.1.2.0 34-35|0.0.1.1.0.1.0 33-34|0.0.1.0.1.3.0.0.0.0+0.0.1.0.1.3.0.0.0+0.0.1.0.1.3.0.0 31-32|0.0.1.0.1.3.0.2 30-31|0.0.1.0.1.3.0 29-30|0.0.1.0.1.3.0.1 28-29|0.0.1.0.1.3.0.1.1 27-28|0.0.1.0.1.3.0.1.0 25-26|0.0.1.0.1.3 24-25|0.0.1.0.1 22-23|0.0.1.0.1.1 21-22|0.0.1.0.1.2 20-21|0.0.1.0.1.4 18-19|0.0.0.2.0+0.0.0.2+0.0.0 16-17|0.0.1.0.0.0.0+0.0.1.0.0.0+0.0.1.0.0 14-15|0.0.1.0 12-13|0.0.1.1 11-12|0.0.1.1.0.1 10-11|0.0.1.1.0 9-10|0.0.1 7-8|0.0.1.0.1.3.0.1.0.0.1 6-7|0.0.1.0.1.3.0.1.0.0.0.0+0.0.1.0.1.3.0.1.0.0.0+0.0.1.0.1.3.0.1.0.0 4-5|0.0 3-4|0 1-2|0.0.1.0.1.0 0-1|0.0.1.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:12.629
(p3 / protein 
      :ARG1-of (e2 / express-01 
            :ARG0 (p / person 
                  :mod (c2 / country 
                        :name (n2 / name 
                              :op1 "Oklahoma")) 
                  :mod (c / country 
                        :name (n / name 
                              :op1 "United" 
                              :op2 "States") 
                        :wiki "United_States") 
                  :name (n6 / name 
                        :op1 "Tukey")) 
            :op1-of (a3 / and 
                  :ARG1-of (p2 / perform-02 
                        :ARG0 (o4 / organization 
                              :name (n7 / name 
                                    :op1 "ANOVA")) 
                        :ARG2 (t / test-01 
                              :ARG1 (a4 / analysis 
                                    :mod (s3 / statistical)) 
                              :ARG1-of (d / differ-02) 
                              :ARG1-of (s2 / significant-02 
                                    :ARG0 (o / organization 
                                          :name (n4 / name 
                                                :op1 "StatSoft"))) 
                              :ARG1-of (a / apply-01 
                                    :ARG2 (o3 / or 
                                          :domain (o2 / organization 
                                                :name (n5 / name 
                                                      :op1 "Statistica")) 
                                          :op1 (e / effect 
                                                :ARG1-of (s / significant-02 
                                                      :ARG0 (o5 / organization 
                                                            :name (n8 / name 
                                                                  :op1 "ELISA") 
                                                            :poss-of (d2 / data))) 
                                                :mod (m / main)) 
                                          :op2 (i / interaction))) 
                              :mod (h / honest))) 
                  :op2 (a2 / assay 
                        :ARG1-of (f / filter-02 
                              :ARG0 (c3 / country 
                                    :name (n3 / name 
                                          :op1 "Tulsa")) 
                              :ARG1-of (t2 / trap-01 
                                    :ARG0 6.0))))))

# ::snt In cases of positively skewed data distribution , log10 ( x + 0.5 ) transformation was applied to the raw data before submitting them to ANOVA .
# ::tok In cases of positively skewed data distribution , log10 ( x + 0.5 ) transformation was applied to the raw data before submitting them to ANOVA .
# ::alignments 25-26|0.0.0.0.0+0.0.0.0+0.0.0 22-23|0.0 21-22|0.0.1 20-21|0.0.1.0.1 19-20|0.0.1.0.1.0 16-17|0.0.1.0 14-15|0.0.1.0.0 12-13|0.0.1.0.0.0 10-11|0 6-7|0.0.1.0.2.0 5-6|0.0.1.0.2.0.0 4-5|0.0.1.0.2.0.1 3-4|0.0.1.0.2.0.1.0 1-2|0.0.1.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:12.818
(x / x 
      :ARG1-of (s / submit-02 
            :ARG2 (o / organization 
                  :name (n / name 
                        :op1 "ANOVA")) 
            :op1-of (b / before 
                  :time-of (a / apply-01 
                        :ARG1 (t / transform-01 
                              :ARG1 0.5) 
                        :ARG2 (d / data 
                              :mod (r / raw)) 
                        :time (c / case-03 
                              :ARG1 (d2 / distribute-01 
                                    :ARG1 (d3 / data) 
                                    :ARG1-of (s2 / skew-01 
                                          :degree (p / positive))))))))

# ::snt We used the tet-off transgene system to express a double mutant version of chimeric mo/huAPP695 ( swe/ind KM570 , 571NL , and V617F ) from a tetracycline-responsive promoter [ 12,13 ] .
# ::tok We used the tet-off transgene system to express a double mutant version of chimeric mo/huAPP695 ( swe/ind KM570 , 571NL , and V617F ) from a tetracycline-responsive promoter [ 12,13 ] .
# ::alignments 27-28|0.0.2.0.0 22-23|0.2.0.0+0.2.0+0.2 21-22|0 17-18|0.1.0.0+0.1.0+0.1 13-14|0.0.2.0.0.0 11-12|0.0.2.0 10-11|0.0.2.0.1 9-10|0.0.2.0.2 7-8|0.0.2 5-6|0.0.1 4-5|0.0.1.0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:13.053
(a / and 
      :op1 (u / use-01 
            :ARG0 (w / we) 
            :ARG1 (s / system 
                  :mod (t3 / transgene)) 
            :ARG2 (e / express-01 
                  :ARG1 (v / version 
                        :ARG1-of (p / promote-01 
                              :ARG0 (c / chimeric)) 
                        :mod (m / mutant) 
                        :mod (d / double)) 
                  :ARG0 w)) 
      :op2 (t2 / thing 
            :name (n2 / name 
                  :op1 "KM570")) 
      :op3 (t / thing 
            :name (n / name 
                  :op1 "V617F")))

# ::snt Transgenic APP expression was activated by crossing the APPswe/ind mice to animals producing tTA under control of the CaMKII promoter [ 16 ] .
# ::tok Transgenic APP expression was activated by crossing the APPswe/ind mice to animals producing tTA under control of the CaMKII promoter [ 16 ] .
# ::alignments 21-22|0.0.1.2.0.1 19-20|0.0.1.2.0.2 18-19|0.1.0+0.1+0 15-16|0.0.0 13-14|0.0.0.0 12-13|0.0 11-12|0.0.1.1 9-10|0.0.1.0 6-7|0.0.1 4-5|0.0.1.2 2-3|0.0.1.2.0 0-2|0.0.1.2.0.0.0.1+0.0.1.2.0.0.0.0+0.0.1.2.0.0.0+0.0.1.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:13.349
(t / thing 
      :ARG1-of (p2 / produce-01 
            :ARG2 (c / control-01 
                  :ARG1 (t2 / tTA)) 
            :purpose-of (c2 / cross-02 
                  :ARG1 (m / mouse) 
                  :ARG2 (a / animal) 
                  :ARG2-of (a2 / activate-01 
                        :ARG1 (e / express-01 
                              :ARG0 (t3 / thing 
                                    :name (n2 / name 
                                          :op1 (t4 / Transgenic) 
                                          :op2 (a3 / APP))) 
                              :ARG1 16 
                              :ARG1-of (p / promote-01))))) 
      :name (n / name 
            :op1 "CaMKII"))

# ::snt After initial screening of founders , we identified four lines of tet-APPswe/ind mice that produced very high levels of transgene product in offspring coexpressing tTA ( Figures 1 and Figure S1 ) .
# ::tok After initial screening of founders , we identified four lines of tet-APPswe/ind mice that produced very high levels of transgene product in offspring coexpressing tTA ( Figures 1 and Figure S1 ) .
# ::alignments 29-31|0.2.0.1+0.2.0.0+0.2.0+0.2 28-29|0 27-28|0.2.1 26-27|0.1 24-25|0.0.1.0 22-23|0.0.1.1.0.1.0.0.1.0 20-21|0.0.1.1.0.1.0.0.1 19-20|0.0.1.1.0.1.0.0.1.1 17-18|0.0.1.1.0.1.0.0 16-17|0.0.1.1.0.1.0.0.0 15-16|0.0.1.1.0.1.0.0.0.0 14-15|0.0.1.1.0.1.0 12-13|0.0.1.1.0.1.1 9-10|0.0.1.1.0.1 8-9|0.0.1.1.0.1.2 7-8|0.0.1.1.0 6-7|0.0.1.1.0.0 4-5|0.0.0+0.0 2-3|0.0.1 1-2|0.0.1.2 0-1|0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:14.154
(a / and 
      :op1 (p3 / person 
            :ARG0-of (f3 / found-01) 
            :ARG1-of (s2 / screen-01 
                  :ARG0 (t2 / tTA) 
                  :op1-of (a2 / after 
                        :time-of (i / identify-01 
                              :ARG0 (w / we) 
                              :ARG1 (l2 / line 
                                    :ARG0-of (p2 / produce-01 
                                          :ARG1 (l / level 
                                                :ARG1-of (h / high-02 
                                                      :degree (v / very)) 
                                                :mod (p / product 
                                                      :location (o / offspr) 
                                                      :mod (t3 / transgene)))) 
                                    :consist-of (m / mouse) 
                                    :quant 4))) 
                  :time (i2 / initial))) 
      :op2 (f2 / figure) 
      :op3 (t / thing 
            :name (n / name 
                  :op1 (f / Figure) 
                  :op2 (s / S1)) 
            :quant 1))

# ::snt Compared to a standard APP transgenic line used for previous amyloid studies by our laboratory ( line C3 -- 3 ; [ 15,26,27 ] ) , we estimated that the four controllable lines produce transgenic APP protein at 10 - to 30-fold over endogenous levels ( Figure S1 ) .
# ::tok Compared to a standard APP transgenic line used for previous amyloid studies by our laboratory ( line C3 -- 3 ; [ 15,26,27 ] ) , we estimated that the four controllable lines produce transgenic APP protein at 10 - to 30-fold over endogenous levels ( Figure S1 ) .
# ::alignments 46-48|0.2.0.1+0.2.0.0+0.2.0+0.2 44-45|0.0.1.1.1 43-44|0.0.1.1.1.0 38-39|0.0.2.0 36-37|0.0.1.1.0.0.0.1 33-34|0.0.1.1.0.0.0 32-33|0.0.1.1.0.0.0.0 31-32|0.0.1.1.0.0.0.0.0 30-31|0.0.1.1.0.0.0.0.1 27-28|0.0.1.1.0.0 26-27|0.0.1.1.0 20-21|0 19-20|0.1 16-17|0.0.1.0.0 14-15|0.0.0 13-14|0.0.0.0 11-12|0.0.2 10-11|0.0.2.1 9-10|0.0.2.2 7-8|0.0 6-7|0.0.1 4-5|0.0.1.2.0.0+0.0.1.2.0+0.0.1.2 3-4|0.0.1.0 0-1|0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:15.149
(a / and 
      :op1 (u / use-01 
            :ARG0 (l4 / laboratory 
                  :poss (w2 / we)) 
            :ARG1 (l5 / line 
                  :ARG1-of (s3 / standard-02 
                        :ARG0 (l3 / line)) 
                  :ARG2-of (c2 / compare-01 
                        :ARG0 (w / we 
                              :ARG0-of (e2 / estimate-01 
                                    :ARG1 (p2 / produce-01 
                                          :ARG0 (l2 / line 
                                                :mod (c / controllable) 
                                                :quant 4) 
                                          :ARG1 (p / protein)))) 
                        :ARG1 (l / level 
                              :mod (e / endogenou))) 
                  :mod (o / organization 
                        :name (n2 / name 
                              :op1 "APP"))) 
            :ARG2 (s2 / study-01 
                  :ARG0 10 
                  :mod (a2 / amyloid) 
                  :time (p3 / previous))) 
      :op2 3 
      :op3 (t / thing 
            :name (n / name 
                  :op1 (f / Figure) 
                  :op2 (s / S1))))

# ::snt This estimate was confirmed by direct comparison of APP levels in nontransgenic and tet-off APP mice using an antibody that recognizes both endogenous APP ( and amyloid precursor-like protein 2 ) and the transgenic protein ( monoclonal antibody 22C11 ; Figure 1D ) .
# ::tok This estimate was confirmed by direct comparison of APP levels in nontransgenic and tet-off APP mice using an antibody that recognizes both endogenous APP ( and amyloid precursor-like protein 2 ) and the transgenic protein ( monoclonal antibody 22C11 ; Figure 1D ) .
# ::alignments 40-41|0.0.0.1.0.1.1 39-40|0.0.0.1.0.1 37-38|0.0.0.1.2.0.3.0 36-37|0.0.0.1.2.0.3 34-35|0.0.0.1.1.0 31-32|0.0.0.1.1 29-30|0.0.0.1.2.0.2 28-29|0 25-26|0.0 22-23|0.0.1 21-22|0.0.0.1.0.1.0 20-21|0.0.0 18-19|0.0.0.0 16-17|0.0.0.1 15-16|0.0.0.1.0.0 12-13|0.0.0.1.0 9-10|0.0.0.1.2.0.0 8-9|0.0.0.1.2.0.0.0.0.0+0.0.0.1.2.0.0.0.0+0.0.0.1.2.0.0.0 6-7|0.0.0.1.2.0 5-6|0.0.0.1.2.0.1 3-4|0.0.0.1.2 1-2|0.0.0.1.2.1 0-1|0.0.0.1.2.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:17.376
(p2 / protein 
      :op2-of (a4 / and 
            :ARG1-of (r / recognize-02 
                  :ARG0 (a5 / antibody) 
                  :ARG2-of (u / use-01 
                        :ARG0 (a6 / and 
                              :op1 (m2 / mouse) 
                              :op2 (a / and 
                                    :mod (b / both) 
                                    :op1 (f / figure))) 
                        :ARG1 (a3 / and 
                              :op1 (p / protein)) 
                        :ARG2-of (c2 / confirm-01 
                              :ARG0 (c / compare-01 
                                    :ARG1 (l / level 
                                          :mod (o / organization 
                                                :name (n / name 
                                                      :op1 "APP"))) 
                                    :ARG1-of (d / direct-02) 
                                    :ARG2 2 
                                    :op1-of (m / monoclonal 
                                          :mod-of (a2 / antibody))) 
                              :ARG1 (e2 / estimate-01 
                                    :mod (t / this))))) 
            :op1 (e / endogenou)))

# ::snt Importantly , all four new lines of tet-off APP mice showed nearly complete suppression of the transgene following dox treatment ( Figures 1 and Figure S1 ) .
# ::tok Importantly , all four new lines of tet-off APP mice showed nearly complete suppression of the transgene following dox treatment ( Figures 1 and Figure S1 ) .
# ::alignments 24-26|0.1.1.1.0.0.0.1+0.1.1.1.0.0.0.0+0.1.1.1.0.0.0+0.1.1.1.0.0 23-24|0.1.1.1.0 22-23|0.1.1.1.0.0.1 21-22|0.1.1.2 19-20|0.1.1.1 18-19|0.1.1.1.1 17-18|0.1.1 16-17|0.1.0 13-14|0.1 12-13|0.1.2 11-12|0.1.2.0 10-11|0 9-10|0.0.0 8-9|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 5-6|0.0 4-5|0.0.1 3-4|0.0.3 2-3|0.0.2 0-1|0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:18.731
(s3 / show-01 
      :ARG0 (l / line 
            :consist-of (m / mouse 
                  :mod (o / organization 
                        :name (n3 / name 
                              :op1 "APP"))) 
            :mod (n4 / new) 
            :quant (a2 / all) 
            :quant 4) 
      :ARG1 (s2 / suppress-01 
            :ARG1 (t3 / transgene) 
            :ARG1-of (f3 / follow-01 
                  :ARG0 (i / importantly) 
                  :ARG2 (t2 / treat-03 
                        :ARG1 (a / and 
                              :op1 (t / thing 
                                    :name (n / name 
                                          :op1 (f / Figure) 
                                          :op2 (s / S1)) 
                                    :quant 1)) 
                        :ARG2 (d / dox)) 
                  :time (f2 / figure)) 
            :ARG1-of (c / complete-02 
                  :degree (n2 / nearly))))

# ::snt We focused on one of the four lines , line 107 , to examine in more detail the time dependence and extent of transgene suppression following either acute or chronic treatment with dox .
# ::tok We focused on one of the four lines , line 107 , to examine in more detail the time dependence and extent of transgene suppression following either acute or chronic treatment with dox .
# ::alignments 32-33|0.2.1 30-31|0.2 29-30|0.1 28-29|0 27-28|0.0 26-27|0.2.2.1 25-26|0.2.2 24-25|0.2.2.0.0.0.0 23-24|0.2.2.0.0.0.0.2 21-22|0.2.2.0 20-21|0.2.2.0.0 19-20|0.2.2.0.0.0 18-19|0.2.2.0.0.0.0.1 16-17|0.2.2.0.0.0.2 15-16|0.2.2.0.0.0.2.0 13-14|0.2.2.0.0.0.1 10-11|0.2.2.0.0.0.0.0 9-10|0.2.0 7-8|0.2.2.0.0.0.1.0.0.0.0 6-7|0.2.2.0.0.0.1.0.0.0 1-2|0.2.2.0.0.0.1.0.0 0-1|0.2.2.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:19.850
(o / or 
      :op1 (a / acute) 
      :op2 (c / chronic) 
      :op3 (t / treat-03 
            :ARG0 (l / line) 
            :ARG1 (d / dox) 
            :ARG2-of (f / follow-01 
                  :ARG0 (e2 / extent 
                        :op2-of (a2 / and 
                              :op1 (d2 / depend-01 
                                    :ARG1 (s / suppress-01 
                                          :ARG1 107 
                                          :ARG2 (t3 / time) 
                                          :mod (t2 / transgene)) 
                                    :ARG1-of (e3 / examine-01 
                                          :ARG0 (w / we 
                                                :ARG0-of (f2 / focus-01 
                                                      :ARG1 (4 / 4 
                                                            :quant-of (l2 / line))))) 
                                    :time (d3 / detail-01 
                                          :degree (m / more))))) 
                  :ARG1 (e / either))))

# ::snt Two dox-treated groups were compared to two untreated groups : one group of mice was born and raised on dox , a second group was treated with dox for 2 wk starting at 1 mo of age ( 4 wk + 2 wk dox ) ; two untreated groups kept on normal chow were harvested at either 4 or 6 wk of age .
# ::tok Two dox-treated groups were compared to two untreated groups : one group of mice was born and raised on dox , a second group was treated with dox for 2 wk starting at 1 mo of age ( 4 wk + 2 wk dox ) ; two untreated groups kept on normal chow were harvested at either 4 or 6 wk of age .
# ::alignments 62-63|0.0.0.0.0.0.0.1 59-60|0.0.0.0.1.1.1 58-59|0.0.0.0.1.1 57-58|0.0.0.0.1.1.0 56-57|0.0.0.1.0 54-55|0.0.0.0.0 52-53|0.0.0.0.0.0.0.0 51-52|0.0.0.0.0.0.0.0.0 49-50|0.0.0.0.0.0.0 48-49|0.0.0.0.0.0 46-47|0.0.0.0.0.0.1 45-46|0.0.0.0 41-42|0.0.0.0.0.0.0.1.0 38-39|0.0.0.0.1.2.0 36-37|0 34-35|0.0.0.1.1 33-34|0.0.0.0.1.3.0 31-32|0.0.0.1 29-30|0.0.0.0.1.0.0.0 25-26|0.0.0 23-24|0.0 19-20|0.0.0.0.1.2.2 17-18|0.0.0.0.1.3 16-17|0.0.0.0.1 15-16|0.0.0.0.1.2 13-14|0.0.0.0.1.3.1 11-12|0.0.0.0.1.2.1 8-9|0.0.0.0.1.0.0.1 7-8|0.0.0.0.1.0.0.1.0 6-7|0.0.0.0.1.0.0.1.1 4-5|0.0.0.0.1.0.0 2-3|0.0.0.0.1.0 1-2|0.0.0.0.1.0.1 0-1|0.0.0.0.1.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:21.724
(a3 / age-01 
      :ARG1 (g2 / group 
            :ARG1-of (t / treat-01 
                  :ARG0 (a2 / and 
                        :ARG0-of (h / harvest-01 
                              :ARG1 (g / group 
                                    :ARG0-of (k / keep-01 
                                          :ARG1 (c / chow 
                                                :ARG1-of (n / normal-02)) 
                                          :ARG1-of (a / age-01 
                                                :ARG0 2)) 
                                    :quant 2)) 
                        :op1 (a4 / and 
                              :op1 (g5 / group 
                                    :ARG0-of (c2 / compare-01 
                                          :ARG1 2 
                                          :ARG2 (g4 / group 
                                                :mod (u / untreat) 
                                                :quant 2)) 
                                    :mod (d2 / dox-treat) 
                                    :quant 2) 
                              :op1-of (o / or 
                                    :op2 4 
                                    :op3 6) 
                              :op2 (b / bear-02 
                                    :ARG0 4 
                                    :ARG1 (g3 / group) 
                                    :location (d / dox)) 
                              :op3 (r / raise-01 
                                    :ARG0 1 
                                    :ARG1 (m2 / mouse)))) 
                  :ARG1-of (s / start-01 
                        :ARG0 (e / either) 
                        :ARG4 (m / mo)))))

# ::snt Animals born and raised on dox harbored no transgenic APP ( Figure 1A ) .
# ::tok Animals born and raised on dox harbored no transgenic APP ( Figure 1A ) .
# ::alignments 11-12|0.2 9-10|0.1.0.0+0.1.0+0.1 7-8|0.3 6-7|0 5-6|0.0.0.0 3-4|0.0.0.1.0 2-3|0.0.0.1 1-2|0.0.0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:21.960
(h / harbor-01 
      :ARG0 (a2 / animal 
            :ARG1-of (b / bear-02 
                  :location (d / dox) 
                  :op1-of (a / and 
                        :op2 (r / raise-01)))) 
      :ARG1 (o / organization 
            :name (n / name 
                  :op1 "APP")) 
      :ARG2 (f / figure) 
      :polarity -)

# ::snt Following as little as 2 wk of dox treatment , transgenic APP expression was reduced by more than 95 % compared to pre-dox levels .
# ::tok Following as little as 2 wk of dox treatment , transgenic APP expression was reduced by more than 95 % compared to pre-dox levels .
# ::alignments 23-24|0.0.0.2 20-21|0.0.0 19-20|0.0.0.1 18-19|0.0.0.1.0 16-17|0.0.1.0.1 14-15|0.0.1.0 12-13|0.0.1.0.0 11-12|0.0.1.0.0.0.0.0+0.0.1.0.0.0.0+0.0.1.0.0.0 8-9|0.0 7-8|0 4-5|0.0.0.0 2-3|0.0.1.0.0.1 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:22.144
(d / dox 
      :ARG2-of (t / treat-03 
            :ARG1 (c / compare-01 
                  :ARG0 2 
                  :ARG1 (p / percentage-entity 
                        :value 95) 
                  :ARG2 (l / level)) 
            :ARG2-of (f / follow-01 
                  :ARG1 (r / reduce-01 
                        :ARG1 (e / express-01 
                              :ARG0 (o / organization 
                                    :name (n / name 
                                          :op1 "APP")) 
                              :ARG1 (l2 / little)) 
                        :ARG2 (m / more)))))

# ::snt The residual expression remaining in acutely treated mice represents less than 4 % of the transgenic protein produced in the absence of dox ( Figure 1C ) , and likely results from slight leakage at the level of transcription ( data not shown ) .
# ::tok The residual expression remaining in acutely treated mice represents less than 4 % of the transgenic protein produced in the absence of dox ( Figure 1C ) , and likely results from slight leakage at the level of transcription ( data not shown ) .
# ::alignments 42-43|0 41-42|0.2 40-41|0.1 38-39|0.0.1.1.0.0 36-37|0.0.1.1.0 33-34|0.0.1.1 32-33|0.0.1.1.1 30-31|0.0.1 29-30|0.0.1.2 28-29|0.0 24-25|0.0.0.1.0.1.0 22-23|0.0.0.0.3.0 20-21|0.0.0.0.3 17-18|0.0.0.0 16-17|0.0.0.0.1 12-13|0.0.0.0.2 11-12|0.0.0.0.2.0 9-10|0.0.0.0.0 8-9|0.0.0 7-8|0.0.1.0 6-7|0.0.0.1 5-6|0.0.0.1.0.0 3-4|0.0.0.1.0.1 2-3|0.0.0.1.0 1-2|0.0.0.1.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:23.290
(s / show-01 
      :ARG0 (a / and 
            :ARG0-of (r2 / represent-01 
                  :ARG1 (p / produce-01 
                        :ARG0 (l4 / less) 
                        :ARG1 (p2 / protein) 
                        :instrument (p3 / percentage-entity 
                              :value 4) 
                        :manner (a2 / absent-01 
                              :ARG1 (d2 / dox))) 
                  :ARG1-of (t2 / treat-01 
                        :ARG0 (e / express-01 
                              :ARG1 (a3 / acute) 
                              :ARG1-of (r3 / remain-01 
                                    :ARG0 (f / figure)) 
                              :mod (r4 / residual)))) 
            :op1 (r / result-01 
                  :ARG0 (m / mouse) 
                  :ARG1 (l2 / leakage 
                        :location (l / level 
                              :mod (t / transcription)) 
                        :mod (s2 / slight)) 
                  :ARG1-of (l3 / likely-01))) 
      :ARG1 (d / data) 
      :polarity -)

# ::snt Importantly , the total amount of APP ( endogenous plus transgenic ) and related APLPs in both acute and chronically treated animals was statistically indistinguishable from that in nontransgenic mice ( Figure 1D ; statistical analyses for experiments throughout the study are presented in the accompanying figure legends ) .
# ::tok Importantly , the total amount of APP ( endogenous plus transgenic ) and related APLPs in both acute and chronically treated animals was statistically indistinguishable from that in nontransgenic mice ( Figure 1D ; statistical analyses for experiments throughout the study are presented in the accompanying figure legends ) .
# ::alignments 47-48|0.1.3.1.1.0.1.0 46-47|0.1.3.1.1.0.1.0.1 45-46|0.1.3.1.1.0.1.0.0 42-43|0.1.3.1.1.0.1 40-41|0.1.3.1.1.0.0 38-39|0.1.3.1.1.0.0.1 37-38|0.1.3.1.1.0.0.0 35-36|0.1.3.1.1.0 34-35|0.1.3.1.1 33-34|0.1.3.1 31-32|0.1.3.1.0 29-30|0.4 26-27|0.1.3.1.1.0.1.0.0.0.0 24-25|0.1.3.1.1.0.1.0.0.0 23-24|0.1.3.1.1.0.1.0.0.0.1 21-22|0.3.0 20-21|0.3 19-20|0.3.1 18-19|0 17-18|0.2 16-17|0.0 14-15|0.1.2.0+0.1.2+0.1 13-14|0.1.0 12-13|0.1.3 10-11|0.1.3.1.1.0.0.0.0 9-10|0.1.3.1.1.0.0.0.1 8-9|0.1.1.0 6-7|0.1.3.0.0.0.0+0.1.3.0.0.0+0.1.3.0.0 4-5|0.1.3.0 3-4|0.1.1 0-1|0.3.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:25.109
(a5 / and 
      :mod (b / both) 
      :op1 (p2 / person 
            :ARG1-of (r / relate-01) 
            :ARG2-of (t5 / total-01 
                  :ARG1 (e2 / endogenou)) 
            :name (n / name 
                  :op1 "APLPs") 
            :op2-of (a7 / and 
                  :op1 (a8 / amount 
                        :quant-of (o / organization 
                              :name (n2 / name 
                                    :op1 "APP"))) 
                  :op1-of (a3 / and 
                        :op2 (f2 / figure) 
                        :op3 (s2 / statistic 
                              :mod-of (a2 / analysis 
                                    :ARG0-of (s / study-01 
                                          :ARG2-of (e / experiment-01 
                                                :op1-of (t4 / transgenic) 
                                                :op1-of (p3 / plus)) 
                                          :op1-of (t / throughout)) 
                                    :ARG1-of (p / present-01 
                                          :ARG2 (l / legend 
                                                :ARG0-of (a / accompany-01 
                                                      :ARG1 (i / indistinguishable 
                                                            :domain (t2 / that) 
                                                            :mod (s3 / statistics))) 
                                                :mod (f / figure)))))))) 
      :op2 (a6 / acute) 
      :op3 (t3 / treat-01 
            :ARG1 (a4 / animal) 
            :degree (c / chronic) 
            :op1-of (i2 / importantly)) 
      :op4 (m / mouse))

# ::snt To ensure that A production was suppressed in concert with the dox-mediated inhibition of its precursor APPswe/ind , we measured A40 and A42 levels by ELISA in forebrain homogenates from young tet-off animals .
# ::tok To ensure that A production was suppressed in concert with the dox-mediated inhibition of its precursor APPswe/ind , we measured A40 and A42 levels by ELISA in forebrain homogenates from young tet-off animals .
# ::alignments 32-33|0.0.0.1.0.1 30-31|0.0.0.1.0.1.0 28-29|0.0.0.1.0.0.0 27-28|0.0.0.1.0.0.0.0 25-26|0.0.0.1.0.2.0.0.0+0.0.0.1.0.2.0.0+0.0.0.1.0.2.0 23-24|0.0.0.1.0.2 22-23|0.0.0.1.0.0.1.1.0.0+0.0.0.1.0.0.1.1.0+0.0.0.1.0.0.1.1 21-22|0.0.0.1.0.0.1 20-21|0.0.0.1.0.0.1.0.0.0+0.0.0.1.0.0.1.0.0+0.0.0.1.0.0.1.0 19-20|0.0.0.1.0.0 18-19|0.0.0.1.0 15-16|0.0.0.0.0 12-13|0.0 11-12|0 8-9|0.0.0.2 6-7|0.0.0 4-5|0.0.0.0 1-2|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:25.983
(d / dox-mediat 
      :mod-of (i / inhibition 
            :ARG0-of (s / suppress-01 
                  :ARG1 (p2 / produce-01 
                        :ARG1 (p / precursor)) 
                  :ARG1-of (e / ensure-01 
                        :ARG0 (w / we 
                              :ARG0-of (m / measure-01 
                                    :ARG1 (h / homogenat 
                                          :mod (f / forebrain)) 
                                    :op1-of (a2 / and 
                                          :op2 (o3 / organization 
                                                :name (n3 / name 
                                                      :op1 "A40")) 
                                          :op3 (o2 / organization 
                                                :name (n2 / name 
                                                      :op1 "A42")))) 
                              :poss-of (a / animal 
                                    :mod (y / young)) 
                              :poss-of (l / level 
                                    :mod (o / organization 
                                          :name (n / name 
                                                :op1 "ELISA"))))) 
                  :manner (c / concert))))

# ::snt At 1 mo of age , the mice lacked visible amyloid aggregates that might act as an intractable reservoir of peptide remaining in the brain after the transgene had been suppressed .
# ::tok At 1 mo of age , the mice lacked visible amyloid aggregates that might act as an intractable reservoir of peptide remaining in the brain after the transgene had been suppressed .
# ::alignments 30-31|0.0 27-28|0 25-26|0.0.1 24-25|0.0.1.0.1 21-22|0.0.1.0 20-21|0.0.1.0.0 18-19|0.0.1.1.0 17-18|0.0.1.1.0.0 14-15|0.0.1.1 13-14|0.0.1.1.1 11-12|0.0.1.1.1.0 10-11|0.0.1.1.1.0.1 9-10|0.0.1.1.1.0.2 8-9|0.0.1.1.1.0.0 7-8|0.0.1.1.1.0.0.0 4-5|0.0.1.1.1.0.0.0.0 2-3|0.0.1.1.1.0.0.1 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:26.427
(t / transgene 
      :ARG1-of (s / suppress-01 
            :ARG0 1 
            :op1-of (a / after 
                  :time-of (r / remain-01 
                        :ARG1 (p / peptide) 
                        :ARG2 (b / brain)) 
                  :time-of (a2 / act-02 
                        :ARG1 (r2 / reservoir 
                              :mod (i / intractable)) 
                        :ARG1-of (p2 / possible-01 
                              :ARG1-of (a3 / aggregate-01 
                                    :ARG1-of (l / lack-01 
                                          :ARG0 (m / mouse 
                                                :ARG1-of (a5 / age-01)) 
                                          :time (m2 / mo)) 
                                    :mod (a4 / amyloid) 
                                    :mod (v / visible)))))))

# ::snt To further ensure we could detect any such insoluble aggregates that might bias our measure of changes in peptide synthesis , we performed a sequential three-step extraction with PBS , 2 % SDS , and 70 % FA that would separate peptides by solubility .
# ::tok To further ensure we could detect any such insoluble aggregates that might bias our measure of changes in peptide synthesis , we performed a sequential three-step extraction with PBS , 2 % SDS , and 70 % FA that would separate peptides by solubility .
# ::alignments 43-44|0.1.1.1.0.0.0.0.0.0.1 41-42|0.1.1.1.0.0.0.0.0.0.0 40-41|0.1.1.1.0.0.0.0.0.0 37-38|0.1.1.1.0.0.0.0.0.2.1+0.1.1.1.0.0.0.0.0.2.0.0+0.1.1.1.0.0.0.0.0.2.0+0.1.1.1.0.0.0.0.0.2 36-37|0.1.1.1.0.0.0.1 35-36|0.1.1.1.0.0.0.1.0 34-35|0.1.1.1.0.0.0.0.0 32-33|0.1.1.1.0.0.0.0.0.1.0.0+0.1.1.1.0.0.0.0.0.1.0+0.1.1.1.0.0.0.0.0.1 31-32|0.1.0.0 30-31|0.1.0 28-29|0.1.1.1.0.0.0.0 26-27|0.1.1.1.0.0.0 24-25|0.1.1.1.0.0.0.2 22-23|0.1.1.1.0.0 21-22|0.1.1.1.0 19-20|0.0.0.1.0 18-19|0.0.0.1.0.0 16-17|0.0.0.1 14-15|0.0.0 13-14|0.0.0.0 12-13|0.0 11-12|0 9-10|0.1 8-9|0.1.3 7-8|0.1.2 6-7|0.1.4 5-6|0.1.1 4-5|0.1.1.2 3-4|0.1.1.0 2-3|0.1.1.1 1-2|0.1.1.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:29.951
(p7 / possible-01 
      :ARG1 (b / bias-01 
            :ARG1 (m / measure-01 
                  :ARG0 (w2 / we) 
                  :ARG1 (c / change-01 
                        :ARG1 (s4 / synthesi 
                              :mod (p6 / peptide))))) 
      :ARG1-of (a2 / aggregate-01 
            :ARG0 (2 / 2 
                  :value-of (p3 / percentage-entity)) 
            :ARG1-of (d / detect-01 
                  :ARG0 (w3 / we) 
                  :ARG1-of (e2 / ensure-01 
                        :ARG0 (w / we 
                              :ARG0-of (p5 / perform-02 
                                    :ARG1 (e / extract-01 
                                          :ARG1 (p4 / pb 
                                                :op1-of (a / and 
                                                      :ARG0-of (s2 / separate-02 
                                                            :ARG1 (p / peptid) 
                                                            :manner (s / solubility)) 
                                                      :op2 (o / organization 
                                                            :name (n2 / name 
                                                                  :op1 "SDS")) 
                                                      :op3 (l / league 
                                                            :name (n / name 
                                                                  :op1 "FA") 
                                                            :wiki "The_Football_Association"))) 
                                          :ARG2 (p2 / percentage-entity 
                                                :value 70) 
                                          :mod (s3 / sequential)))) 
                        :degree (f / further)) 
                  :ARG1-of (p8 / possible-01)) 
            :mod (s5 / such) 
            :mod (i / insoluble) 
            :mod (a3 / any)))

# ::snt We compared the levels of human transgene-derived A40 and A42 in untreated mice at 4 and 6 wk of age to animals that had either been born and raised on dox or that had been left untreated for 4 wk and then placed on dox chow for 2 wk prior to harvest ( the same groups described above for immunoblot analysis of APPswe/ind levels , line 107 ) .
# ::tok We compared the levels of human transgene-derived A40 and A42 in untreated mice at 4 and 6 wk of age to animals that had either been born and raised on dox or that had been left untreated for 4 wk and then placed on dox chow for 2 wk prior to harvest ( the same groups described above for immunoblot analysis of APPswe/ind levels , line 107 ) .
# ::alignments 66-67|0.3.1 65-66|0.3.2 63-64|0.2.2.1.1 60-61|0.2.2.1 59-60|0.2.2.1.0 57-58|0.2.2.2 56-57|0.2.2 55-56|0.2.2.0 54-55|0.2.2.0.0 51-52|0.2.3.0.0 49-50|0.2.3.0 47-48|0.2.0.0.0 45-46|0.3.0 42-43|0.3 41-42|0.3.3 40-41|0 38-39|0.2.3.0.0.0 35-36|0.2 31-32|0.2.3 30-31|0.2.4.1.1 28-29|0.2.4.2 27-28|0.2.4 26-27|0.2.4.1 24-25|0.2.4.0 21-22|0.2.0 19-20|0.2.0.0 16-17|0.0.0 15-16|0.0 14-15|0.2.1 12-13|0.2.4.1.2.0.0 11-12|0.2.4.2.0 8-9|0.1 6-7|0.2.4.1.0.0 5-6|0.2.4.1.0 3-4|0.2.4.1.2.1 1-2|0.2.4.1.2 0-1|0.2.4.1.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:33.024
(a3 / and 
      :op1 (a7 / and 
            :op1 6) 
      :op1-of (a8 / and) 
      :op2 (l3 / leave-11 
            :ARG0 (a5 / animal 
                  :ARG1-of (a6 / age-01 
                        :ARG0 2)) 
            :ARG1 4 
            :ARG2 (d / describe-01 
                  :ARG0 (g / group 
                        :ARG1-of (s / same-01)) 
                  :ARG1 (a / analyze-01 
                        :ARG0 (i / immunoblot) 
                        :ARG1 (l2 / level)) 
                  :mod (a2 / above)) 
            :op1-of (o / or 
                  :op2 (p / prior 
                        :op1 (h / harvest-01 
                              :ARG1 4))) 
            :op3-of (a4 / and 
                  :mod (e / either) 
                  :op1 (b / bear-02 
                        :ARG0 (h2 / human 
                              :mod-of (t2 / transgene-deriv)) 
                        :location (d2 / dox) 
                        :time-of (c2 / compare-01 
                              :ARG0 (w / we 
                                    :poss-of (m / mouse)) 
                              :ARG1 (l4 / level))) 
                  :op2 (r / raise-01 
                        :ARG0 (u / untreat)))) 
      :op3 (p2 / place-01 
            :ARG2 (c / chow) 
            :op1-of 107 
            :op1-of (l / line) 
            :time (t / then)))

# ::snt Consistent with the reduction in full-length APPswe/ind synthesis shown by immunoblot ( see Figure 1 ) , we found that transgene-derived A levels were completely suppressed in animals born and raised on dox , and were sharply reduced following acute ( 2 wk ) antibiotic treatment .
# ::tok Consistent with the reduction in full-length APPswe/ind synthesis shown by immunoblot ( see Figure 1 ) , we found that transgene-derived A levels were completely suppressed in animals born and raised on dox , and were sharply reduced following acute ( 2 wk ) antibiotic treatment .
# ::alignments 45-46|0.0.0.0.2.1.1.0 44-45|0.0.0.0.2.1.1.0.1 41-42|0.1.0 39-40|0.0.0.0.1.0 38-39|0.0.0.0.2.1.1 37-38|0.0.0.0.2.1 36-37|0.0.0.0.2.1.1.1 34-35|0.0.0.0.2 32-33|0.0.1 30-31|0.1 29-30|0 28-29|0.0 27-28|0.0.0 25-26|0.0.0.0 24-25|0.0.0.0.1 22-23|0.0.0.0.0 20-21|0.0.0.0.2.1.1.0.0 18-19|0.0.0.0.2.0 17-18|0.0.0.0.2.0.0 14-15|0.0.0.0.2.1.0 13-14|0.0.0.0.2.0.0.0.0.0.0 12-13|0.0.0.0.2.0.0.0.0.0 10-11|0.0.0.0.2.0.0.0.2 8-9|0.0.0.0.2.0.0.0 7-8|0.0.0.0.2.0.0.0.1.0 5-6|0.0.0.0.2.0.0.0.1.0.0 3-4|0.0.0.0.2.0.0.0.1 0-1|0.0.0.0.2.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:35.130
(a4 / and 
      :op1 (b / bear-02 
            :ARG1 (a5 / animal 
                  :ARG2-of (s2 / suppress-01 
                        :ARG1 (l / level) 
                        :ARG1-of (c / complete-02 
                              :ARG0 (a2 / acute)) 
                        :op1-of (a3 / and 
                              :ARG1-of (f2 / find-01 
                                    :ARG0 (w / we 
                                          :ARG0-of (s4 / show-01 
                                                :ARG1 (c2 / consistent 
                                                      :ARG0-of (s3 / see-01 
                                                            :ARG1 (f3 / figure))) 
                                                :ARG2 (r3 / reduce-01 
                                                      :ARG1 (s5 / synthesi 
                                                            :mod (f4 / full-length))) 
                                                :degree (i / immunoblot)))) 
                              :op2 (r / reduce-01 
                                    :ARG1 1 
                                    :time (f / follow-01 
                                          :ARG2 (t / treat-03 
                                                :ARG1 (t2 / transgene-deriv) 
                                                :ARG3 (a / antibiotic)) 
                                          :time (s / sharp)))))) 
            :location (d / dox)) 
      :op2 (r2 / raise-01 
            :ARG1 2))

# ::snt Compared to the levels in untreated 4-wk-old mice , PBS-soluble A42 dropped by 95.2 % following 2 wk of dox treatment and by 99.2 % with chronic treatment ( Figure 2A ) .
# ::tok Compared to the levels in untreated 4-wk-old mice , PBS-soluble A42 dropped by 95.2 % following 2 wk of dox treatment and by 99.2 % with chronic treatment ( Figure 2A ) .
# ::alignments 29-30|0.2.0 27-28|0.2.1.0 26-27|0.2.1.0.3 24-25|0.2.1.0.1 21-22|0.1 20-21|0.2.1 19-20|0.2.1.1 16-17|0.2.1.0.2.0 15-16|0.2 14-15|0.3 11-12|0 9-11|0.0.0.1+0.0.0.0+0.0.0+0.0 7-8|0.2.1.0.0.0 5-6|0.2.1.0.0 3-4|0.2.1.0.2.1 0-1|0.2.1.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:35.769
(d2 / drop-01 
      :ARG0 (o / organization 
            :name (n / name 
                  :op1 "PBS-soluble" 
                  :op2 "A42")) 
      :ARG1 (a / and) 
      :ARG1-of (f2 / follow-01 
            :ARG0 (f / figure) 
            :ARG2 (t2 / treat-03 
                  :ARG1 (t / treat-03 
                        :ARG0 (u / untreat 
                              :mod-of (m / mouse)) 
                        :ARG1 (p / percentage-entity) 
                        :ARG2 (c2 / compare-01 
                              :ARG0 2 
                              :ARG1 (l / level)) 
                        :mod (c / chronic)) 
                  :ARG2 (d / dox))) 
      :degree (p2 / percentage-entity))

# ::snt Similarly , SDS-soluble A42 decreased by 75.2 % and 94.8 % following 2-wk or lifelong dox treatment ( Figure 2B ) .
# ::tok Similarly , SDS-soluble A42 decreased by 75.2 % and 94.8 % following 2-wk or lifelong dox treatment ( Figure 2B ) .
# ::alignments 18-19|0.0.1.0 16-17|0.3 15-16|0.2 14-15|0.1 13-14|0 11-12|0.0 10-11|0.0.0 8-9|0.0.1.2 7-8|0.0.1.2.0 4-5|0.0.1 2-4|0.0.1.1.0.1+0.0.1.1.0.0+0.0.1.1.0+0.0.1.1 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:35.896
(o / or 
      :ARG2-of (f2 / follow-01 
            :ARG0 (p / percentage-entity) 
            :ARG1 (d2 / decrease-01 
                  :ARG0 (f / figure) 
                  :ARG1 (t2 / thing 
                        :name (n / name 
                              :op1 "SDS-soluble" 
                              :op2 "A42")) 
                  :op1-of (a / and 
                        :op2 (p2 / percentage-entity))) 
            :time (s / similarly)) 
      :op1 (l / lifelong) 
      :op2 (d / dox) 
      :op3 (t / treat-03))

# ::snt Only the FA fraction revealed a small dox-resistant pool of peptide in acutely treated animals that we believe represents stable predeposit aggregates that have already accumulated by 4 wk of age when treatment was begun ( Figure 2C ) .
# ::tok Only the FA fraction revealed a small dox-resistant pool of peptide in acutely treated animals that we believe represents stable predeposit aggregates that have already accumulated by 4 wk of age when treatment was begun ( Figure 2C ) .
# ::alignments 36-37|0.1.0.1.0.1.2.0.0 34-35|0.0 32-33|0.0.0 30-31|0 27-28|0.0.0.0 25-26|0.1 24-25|0.1.1 21-22|0.1.0 20-21|0.1.0.0 19-20|0.1.0.2 18-19|0.1.0.1 17-18|0.1.0.1.0 16-17|0.1.0.1.0.0 14-15|0.1.0.1.0.1.2 13-14|0.1.0.1.0.1.2.0 12-13|0.1.0.1.0.1.2.0.1 10-11|0.1.0.1.0.1.1.0 8-9|0.1.0.1.0.1.1 6-7|0.1.0.1.0.1.1.1 4-5|0.1.0.1.0.1 3-4|0.1.0.1.0.1.0 2-3|0.1.0.1.0.1.0.1.1+0.1.0.1.0.1.0.1.0.0+0.1.0.1.0.1.0.1.0+0.1.0.1.0.1.0.1 0-1|0.1.0.1.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:38.629
(a / age-01 
      :ARG0-of (b / begin-01 
            :ARG1 (t / treat-03 
                  :ARG1 4)) 
      :purpose-of (a2 / accumulate-01 
            :ARG1 (a4 / aggregate-01 
                  :ARG1 (p / predeposit) 
                  :ARG1-of (r / represent-01 
                        :ARG1-of (b2 / believe-01 
                              :ARG0 (w / we) 
                              :ARG1-of (r2 / reveal-01 
                                    :ARG0 (f2 / fraction 
                                          :mod (o / only) 
                                          :mod (l / league 
                                                :name (n / name 
                                                      :op1 "FA") 
                                                :wiki "The_Football_Association")) 
                                    :ARG2 (p3 / pool 
                                          :consist-of (p2 / peptide) 
                                          :mod (s2 / small)) 
                                    :medium (a5 / animal 
                                          :mod (t2 / treat-01 
                                                :ARG0 (f / figure) 
                                                :degree (a6 / acute)))))) 
                  :ARG1-of (s / stable-03)) 
            :time (a3 / already)))

# ::snt Indeed , animals that were born and raised on dox did not harbor this reservoir of treatment-resistant peptide , with 96.3 % less A42 than untreated 4-wk-old mice .
# ::tok Indeed , animals that were born and raised on dox did not harbor this reservoir of treatment-resistant peptide , with 96.3 % less A42 than untreated 4-wk-old mice .
# ::alignments 27-28|0.0.1 25-26|0.0.1.0 22-23|0.0.0 21-22|0.1.0 17-18|0.1.1.0.0.1 14-15|0.1.1.0.0 13-14|0.1.1.0.0.0 12-13|0.1.1.0 11-12|0.1.1.0.2 9-10|0.0.2 7-8|0.1 6-7|0 5-6|0.0 2-3|0.1.1 0-1|0.1.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:38.898
(a / and 
      :op1 (b / bear-02 
            :ARG0 (l / less) 
            :ARG2 (m / mouse 
                  :mod (u / untreat)) 
            :location (d / dox)) 
      :op2 (r2 / raise-01 
            :ARG0 (p / percentage-entity) 
            :ARG1 (a2 / animal 
                  :ARG0-of (h / harbor-01 
                        :ARG1 (r / reservoir 
                              :mod (t / this) 
                              :mod (p2 / peptide)) 
                        :mod (i / indeed) 
                        :polarity -))))

# ::snt Measurement of total A in chronically treated mice , including endogenous and transgene-derived peptide , demonstrated that A levels in tet-off APP mice were reduced to the level of endogenous peptide found in nontransgenic animals ( Figure 2D ) .
# ::tok Measurement of total A in chronically treated mice , including endogenous and transgene-derived peptide , demonstrated that A levels in tet-off APP mice were reduced to the level of endogenous peptide found in nontransgenic animals ( Figure 2D ) .
# ::alignments 37-38|0.0.0.0.0 36-37|0.0.3 34-35|0.0.2.1.2.0.0.1 31-32|0.0.2.1.2.0.0 30-31|0.0.2.1.2.0 27-28|0.0.2.1.2 24-25|0.0.2.1 22-23|0.0.2.1.1.0.0 21-22|0.0.2.1.1.0.1.0+0.0.2.1.1.0.1+0.0.2.1.1.0 18-19|0.0.2.1.0 15-16|0.0.2 13-14|0.0.1 12-13|0.0.1.0 11-12|0.0 10-11|0 7-8|0.0.0 6-7|0.0.0.0 5-6|0.0.2.1.2.0.0.0 2-3|0.0.2.1.1 0-1|0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:39.340
(e / endogenou 
      :op1-of (a2 / and 
            :mod (m2 / mouse 
                  :ARG1-of (t2 / treat-01 
                        :ARG0 2d)) 
            :op2 (p2 / peptide 
                  :mod (t / transgene-deriv)) 
            :op3 (d / demonstrate-01 
                  :ARG0 (m3 / measurement) 
                  :ARG1 (r / reduce-01 
                        :ARG1 (l2 / level) 
                        :ARG2-of (t3 / total-01 
                              :ARG1 (o / organization 
                                    :mod-of (m / mouse) 
                                    :name (n / name 
                                          :op1 "APP"))) 
                        :ARG4 (l / level 
                              :mod (p / peptide 
                                    :ARG1-of (f2 / find-01 
                                          :ARG0 (c / chronic) 
                                          :location (a / animal)))))) 
            :op4 (f / figure)))

# ::snt Taken together with the immunoblotting data for full-length APPswe/ind , the ELISA measurements indicate that dox-mediated suppression of transgenic APPswe/ind synthesis leads to parallel reduction of A levels .
# ::tok Taken together with the immunoblotting data for full-length APPswe/ind , the ELISA measurements indicate that dox-mediated suppression of transgenic APPswe/ind synthesis leads to parallel reduction of A levels .
# ::alignments 27-28|0.1.0 24-25|0.1 23-24|0 21-22|0.0.0.0 20-21|0.0 16-17|0.0.0 15-16|0.0.0.1 13-14|0.0.0.0.0 12-13|0.0.0.0.0.0 11-12|0.0.0.0.0.0.0.0.0+0.0.0.0.0.0.0.0+0.0.0.0.0.0.0 7-8|0.0.0.0.0.0.1.0 5-6|0.0.0.0.0.0.1.1 1-2|0.0.0.0.0.0.1.2 0-1|0.0.0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:39.544
(p / parallel-01 
      :ARG0 (s / synthesi 
            :ARG1-of (s2 / suppress-01 
                  :ARG0-of (l2 / lead-03 
                        :ARG1-of (i / indicate-01 
                              :ARG0 (m / measure-01 
                                    :ARG0 (o / organization 
                                          :name (n / name 
                                                :op1 "ELISA")) 
                                    :ARG0-of (t2 / take-01 
                                          :ARG1 (f / full-length) 
                                          :ARG3 (d2 / data) 
                                          :mod (t / together))))) 
                  :mod (d / dox-mediat))) 
      :ARG1 (r / reduce-01 
            :ARG1 (l / level)))

# ::snt The ELISA data also confirmed that incorporation of the Swedish and Indiana mutations led to high levels of A42 , which we predicted would induce rapid plaque formation in untreated animals .
# ::tok The ELISA data also confirmed that incorporation of the Swedish and Indiana mutations led to high levels of A42 , which we predicted would induce rapid plaque formation in untreated animals .
# ::alignments 30-31|0.1.1.2.1.0 29-30|0.1.1.2.1.0.0 27-28|0.1.0 26-27|0.1.0.1 25-26|0.1.0.2 24-25|0.1 22-23|0 21-22|0.0 16-17|0.1.1.2.2 15-16|0.1.1.2.2.0 13-14|0.1.1.2 12-13|0.1.1.2.1 11-12|0.1.1.2.0.1.0.0+0.1.1.2.0.1.0+0.1.1.2.0.1 10-11|0.1.1.2.0 9-10|0.1.1.2.0.0.1+0.1.1.2.0.0.0.0+0.1.1.2.0.0.0+0.1.1.2.0.0 6-7|0.1.0.0 4-5|0.1.1 3-4|0.1.1.1 2-3|0.1.1.0 1-2|0.1.1.0.0.0.0+0.1.1.0.0.0+0.1.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:40.410
(p2 / predict-01 
      :ARG0 (w / we) 
      :ARG1 (i / induce-01 
            :ARG1 (f / form-01 
                  :ARG0 (i2 / incorporation) 
                  :ARG1 (p / plaque) 
                  :manner (r / rapid)) 
            :ARG1-of (c3 / confirm-01 
                  :ARG0 (d / data 
                        :poss (o / organization 
                              :name (n3 / name 
                                    :op1 "ELISA"))) 
                  :mod (a3 / also) 
                  :purpose (l2 / lead-02 
                        :ARG0 (a2 / and 
                              :op1 (c2 / country 
                                    :name (n2 / name 
                                          :op1 "Sweden") 
                                    :wiki "Sweden") 
                              :op2 (c / country 
                                    :name (n / name 
                                          :op1 "Indiana"))) 
                        :ARG1 (m / mutate-01 
                              :ARG1 (a / animal 
                                    :mod (u / untreat))) 
                        :ARG4 (l / level 
                              :ARG1-of (h / high-02))))))

# ::snt Histological characterization of double transgenic ( CaMKII-tTA  tet-APPswe/ind ) mice revealed early-onset amyloid formation in all four new lines .
# ::tok Histological characterization of double transgenic ( CaMKII-tTA  tet-APPswe/ind ) mice revealed early-onset amyloid formation in all four new lines .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:40.411
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Amyloid plaques were seen in mice as young as 8 wk of age ( data not shown ) .
# ::tok Amyloid plaques were seen in mice as young as 8 wk of age ( data not shown ) .
# ::alignments 16-17|0.0.0.1 15-16|0.0.0.1.2 14-15|0.0.0.1.1 12-13|0 9-10|0.0.0.1.0 7-8|0.0.1 5-6|0.0 3-4|0.0.0 1-2|0.0.0.0 0-1|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:40.546
(a / age-01 
      :ARG1 (m / mouse 
            :ARG0-of (s2 / see-01 
                  :ARG1 (p / plaqu 
                        :mod (a2 / amyloid)) 
                  :manner (s / show-01 
                        :ARG0 8 
                        :ARG1 (d / data) 
                        :polarity -)) 
            :mod (y / young)))

# ::snt Plaques were limited to the forebrain , including the cortex , hippocampus , olfactory bulb , and striatum , where the CaMKII promoter is known to be most active [ 16,28 ] ( Figure S2 ) .
# ::tok Plaques were limited to the forebrain , including the cortex , hippocampus , olfactory bulb , and striatum , where the CaMKII promoter is known to be most active [ 16,28 ] ( Figure S2 ) .
# ::alignments 33-35|0.0.1+0+0.0+0.0.0 28-29|0.0.0.0.0 27-28|0.0.0.0.0.0 24-25|0.0.0.0.2 22-23|0.0.0.0 21-22|0.0.0.0.1.0.0+0.0.0.0.1.0+0.0.0.0.1 17-18|0.0.0.0.3.3 16-17|0.0.0.0.3 14-15|0.0.0.0.3.2 13-14|0.0.0.0.3.2.0 11-12|0.0.0.0.3.1 9-10|0.0.0.0.3.0 5-6|0.0.0.0.2.0 2-3|0.0.0.0.2.0.0 0-1|0.0.0.0.2.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:40.951
(f / Figure 
      :op1-of (n / name 
            :name-of (t / thing 
                  :ARG0-of (p / promote-01 
                        :ARG0-of (a / activity-06 
                              :degree (m / most)) 
                        :ARG1 (t2 / thing 
                              :name (n2 / name 
                                    :op1 "CaMKII")) 
                        :ARG1-of (k / know-02 
                              :ARG0 (f2 / forebrain 
                                    :ARG2-of (l / limit-01 
                                          :ARG1 (p2 / plaqu)))) 
                        :op5-of (a2 / and 
                              :op1 (c / cortex) 
                              :op2 (h / hippocampu) 
                              :op3 (b / bulb 
                                    :mod (o / olfactory)) 
                              :op4 (s2 / striatum)))) 
            :op2 (s / S2)))

# ::snt By 6 mo of age , amyloid burden became severe , covering large areas of the cortex and hippocampus ( Figure S3 ) .
# ::tok By 6 mo of age , amyloid burden became severe , covering large areas of the cortex and hippocampus ( Figure S3 ) .
# ::alignments 20-22|0.0.1.0.1+0.0.1.0.0+0.0.1.0+0.0.1 18-19|0.0.0.0.1 17-18|0.0.0.0 16-17|0.0.0.0.0 13-14|0.0.0.1 12-13|0.0.0.1.0 11-12|0.0.0 9-10|0.1 8-9|0 7-8|0.0 6-7|0.0.3 4-5|0.0.2 1-2|0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:41.780
(b / become-01 
      :ARG1 (b2 / burden-01 
            :ARG0-of (c2 / cover-01 
                  :ARG1 (a / and 
                        :op1 (c / cortex) 
                        :op2 (h / hippocampu)) 
                  :ARG2 (a2 / area 
                        :mod (l / large))) 
            :ARG1 (t / thing 
                  :name (n / name 
                        :op1 (f / Figure) 
                        :op2 (s / S3))) 
            :ARG2-of (a4 / age-01 
                  :ARG1 6) 
            :mod (a3 / amyloid)) 
      :ARG2 (s2 / severe))

# ::snt No lesions were seen in the cerebellum or brain stem even at late ages , consistent with CaMKII-controlled transgene expression .
# ::tok No lesions were seen in the cerebellum or brain stem even at late ages , consistent with CaMKII-controlled transgene expression .
# ::alignments 19-20|0 18-19|0.2 17-18|0.0.0.0+0.0.0+0.0 15-16|0.1 13-14|0.1.0.0.1.1.0.0 12-13|0.1.0.0.1.1.0.0.0 10-11|0.1.0.0.1.1.0.1 9-10|0.1.0.0.1.1.0 8-9|0.1.0.0.1.1 7-8|0.1.0.0.1 6-7|0.1.0.0.1.0 3-4|0.1.0.0 1-2|0.1.0.0.0 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:41.989
(e / express-01 
      :ARG1 (t2 / thing 
            :name (n / name 
                  :op1 "CaMKII-controlled")) 
      :ARG2-of (c / consistent-01 
            :ARG1 (- / - 
                  :polarity-of (s2 / see-01 
                        :ARG1 (l2 / lesion) 
                        :ARG2 (o / or 
                              :op1 (c2 / cerebellum) 
                              :op2 (b / brain 
                                    :ARG1-of (s / stem-01 
                                          :ARG2 (a / age 
                                                :mod (l / late)) 
                                          :mod (e2 / even))))))) 
      :mod (t / transgene))

# ::snt Unlike what is thought to occur in the human disease , the first visible plaques in the tet-off APP mice are fibrillar-cored deposits .
# ::tok Unlike what is thought to occur in the human disease , the first visible plaques in the tet-off APP mice are fibrillar-cored deposits .
# ::alignments 22-23|0.1.0.0.0 21-22|0.0 19-20|0.1.0 18-19|0.1.0.1.0.0+0.1.0.1.0+0.1.0.1 14-15|0.1.0.0 13-14|0.1.0.0.1 9-10|0.1.1 8-9|0.1.1.0 5-6|0.1 3-4|0 0-1|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:42.121
(t / think-01 
      :ARG0 (f / fibrillar-cor) 
      :ARG1 (o2 / occur-01 
            :ARG0 (m / mouse 
                  :location-of (p / plaqu 
                        :domain-of (d / deposit) 
                        :mod (v / visible)) 
                  :mod (o / organization 
                        :name (n / name 
                              :op1 "APP"))) 
            :ARG1 (d2 / disease 
                  :mod (h / human))) 
      :op1-of (u / unlike))

# ::snt We have noted the same early appearance of cored deposits in other lines of APP transgenic mice that harbor the Swedish mutation [ 27 ] .
# ::tok We have noted the same early appearance of cored deposits in other lines of APP transgenic mice that harbor the Swedish mutation [ 27 ] .
# ::alignments 23-24|0.1.0 21-22|0.1.4.1 20-21|0.1.4.1.0.1+0.1.4.1.0.0.0+0.1.4.1.0.0+0.1.4.1.0 18-19|0.1.4 16-17|0.1.4.0 14-15|0.1.4.0.0.0.0+0.1.4.0.0.0+0.1.4.0.0 12-13|0.1.3 11-12|0.1.3.0 9-10|0.1.1 8-9|0.1.1.0 6-7|0.1 5-6|0.1.5 4-5|0.1.2 2-3|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:42.523
(n3 / note-01 
      :ARG0 (w / we) 
      :ARG1 (a / appear-01 
            :ARG0 27 
            :ARG1 (d / deposit 
                  :ARG1-of (c2 / core-01)) 
            :ARG1-of (s / same-01) 
            :ARG2 (l / line 
                  :mod (o2 / other)) 
            :ARG2-of (h / harbor-01 
                  :ARG0 (m2 / mouse 
                        :mod (o / organization 
                              :name (n2 / name 
                                    :op1 "APP"))) 
                  :ARG1 (m / mutation 
                        :mod (c / country 
                              :name (n / name 
                                    :op1 "Sweden") 
                              :wiki "Sweden"))) 
            :manner (e / early)))

# ::snt Diffuse plaques were apparent in 6-mo-old tTA/APP mice , and became relatively abundant by 9 mo of age .
# ::tok Diffuse plaques were apparent in 6-mo-old tTA/APP mice , and became relatively abundant by 9 mo of age .
# ::alignments 17-18|0 15-16|0.1.0 14-15|0.1.2.0.0.0.0 12-13|0.1.1 11-12|0.0 10-11|0.1 9-10|0.1.2 7-8|0.1.2.0.1 3-4|0.1.2.0 1-2|0.1.2.0.0 0-1|0.1.2.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:42.597
(a / age-01 
      :ARG1 (r / relative) 
      :ARG1-of (b / become-01 
            :ARG0 (m / mo) 
            :ARG2 (a2 / abundance) 
            :op2-of (a3 / and 
                  :op1 (a4 / apparent 
                        :domain (p / plaqu 
                              :ARG1-of (d / diffuse-01 
                                    :ARG0 9)) 
                        :location (m2 / mouse)))))

# ::snt At older ages ( 9 -- 12 mo ) amyloid deposits were visible in the thalamus , which has also been observed in mice expressing mutant APP via the Thy-1 promoter .
# ::tok At older ages ( 9 -- 12 mo ) amyloid deposits were visible in the thalamus , which has also been observed in mice expressing mutant APP via the Thy-1 promoter .
# ::alignments 30-31|0.3 26-27|0.1.1.0+0.1.1+0.1 25-26|0.1.0 24-25|0 23-24|0.0 21-22|0.0.0 19-20|0.0.0.1 15-16|0.0.0.0 12-13|0.0.0.0.0 10-11|0.0.0.0.0.0 9-10|0.3.3 7-8|0.3.0 6-7|0.3.1 4-5|0.3.2 2-3|0.2 1-2|0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:43.471
(e / express-01 
      :ARG0 (m2 / mouse 
            :location-of (o2 / observe-01 
                  :ARG1 (t / thalamu 
                        :location-of (v / visible 
                              :domain (d / deposit))) 
                  :mod (a / also))) 
      :ARG1 (o / organization 
            :mod (m / mutant) 
            :name (n / name 
                  :op1 "APP")) 
      :ARG2 (a3 / age 
            :mod (o3 / old)) 
      :ARG3 (p / promote-01 
            :op1-of (m3 / mo) 
            :op1-of 12 
            :op1-of 9 
            :op1-of (a2 / amyloid)))

# ::snt The presence of amyloid pathology in this region has been attributed to axonal transport of APP/A to the terminals of cortical neurons in the thalamus [ 29 ] .
# ::tok The presence of amyloid pathology in this region has been attributed to axonal transport of APP/A to the terminals of cortical neurons in the thalamus [ 29 ] .
# ::alignments 26-27|0.0 24-25|0.1.0 21-22|0.3.0 20-21|0.3.0.0 18-19|0.3 15-16|0.2.0.0.0+0.2.0.0+0.2.0 13-14|0.2 12-13|0.2.1 10-11|0 7-8|0.1.1.0 6-7|0.1.1.0.0 4-5|0.1.1 3-4|0.1.1.1 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:43.782
(a2 / attribute-01 
      :ARG0 29 
      :ARG1 (p2 / presence 
            :domain-of (t / thalamu) 
            :mod (p / pathology 
                  :location (r / region 
                        :mod (t4 / this)) 
                  :mod (a3 / amyloid))) 
      :ARG2 (t3 / transport-01 
            :ARG1 (c2 / country 
                  :name (n2 / name 
                        :op1 "APP/A")) 
            :mod (a / axonal)) 
      :ARG3 (t2 / terminal 
            :mod (n / neuron 
                  :mod (c / cortical))))

# ::snt Most importantly , only double transgenic mice , expressing both the tTA and APP transgenes , developed amyloid lesions .
# ::tok Most importantly , only double transgenic mice , expressing both the tTA and APP transgenes , developed amyloid lesions .
# ::alignments 18-19|0.0.2.1 17-18|0.0.2.1.0 16-17|0.0.2 14-15|0.0.1.0 13-14|0.0.1.0.0.0.0+0.0.1.0.0.0+0.0.1.0.0 12-13|0.0.1 11-12|0.0.0 9-10|0.0.2.0 8-9|0.0 6-7|0 4-5|0.2 3-4|0.1 1-2|0.0.1.1.0 0-1|0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:44.518
(m / mouse 
      :ARG0-of (e / express-01 
            :ARG1 (t2 / tTA) 
            :ARG2 (a2 / and 
                  :op1 (t / transgen 
                        :mod (o / organization 
                              :name (n / name 
                                    :op1 "APP"))) 
                  :quant (m2 / most 
                        :degree-of (i / important))) 
            :purpose-of (d / develop-02 
                  :ARG0 (b / both) 
                  :ARG1 (l / lesion 
                        :mod (a / amyloid)))) 
      :mod (o2 / only) 
      :mod (d2 / double))

# ::snt Single transgenic mice up to 15 mo of age showed no sign of pathology ( Figure S3 ) .
# ::tok Single transgenic mice up to 15 mo of age showed no sign of pathology ( Figure S3 ) .
# ::alignments 15-17|0.0.0.0.1+0.0.0.0.0+0.0.0.0+0.0.0 13-14|0.1.1.1 11-12|0.1.1 10-11|0.1.1.2 9-10|0.1 8-9|0 6-7|0.1.1.0 5-6|0.1.1.0.0 2-3|0.1.0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:44.745
(a / age-01 
      :ARG1-of (s4 / single-02 
            :ARG0 (t / thing 
                  :name (n / name 
                        :op1 (f / Figure) 
                        :op2 (s / S3)))) 
      :manner-of (s3 / show-01 
            :ARG0 (m2 / mouse) 
            :ARG1 (s2 / sign-02 
                  :ARG0 (m / mo 
                        :quant 15) 
                  :ARG1 (p / pathology) 
                  :polarity -)))

# ::snt Similarly , amyloid pathology can be completely prevented in double transgenic animals born and raised on dox .
# ::tok Similarly , amyloid pathology can be completely prevented in double transgenic animals born and raised on dox .
# ::alignments 16-17|0.0.0.0.1 14-15|0.0.0.0.2.0 13-14|0.0.0.0.2 12-13|0.0.0.0 11-12|0.0.0 9-10|0.0.0.1 7-8|0.0 6-7|0.0.1 4-5|0 3-4|0.0.1.0 2-3|0.0.1.0.0 0-1|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:44.847
(p2 / possible-01 
      :ARG1 (p / prevent-01 
            :ARG1 (a2 / animal 
                  :ARG1-of (b / bear-02 
                        :ARG0 (s / similarly) 
                        :location (d / dox) 
                        :op1-of (a / and 
                              :op2 (r / raise-01))) 
                  :mod (d2 / double)) 
            :ARG1-of (c / complete-02 
                  :ARG0 (p3 / pathology 
                        :mod (a3 / amyloid)))))

# ::snt Animals from our highest expressing line ( line 885 ) maintained on dox for up to 1 y harbored no amyloid pathology ( data not shown ) , indicating that residual leakage of transgene expression in the presence of dox does not provide sufficient A peptide to induce amyloid formation even over long periods .
# ::tok Animals from our highest expressing line ( line 885 ) maintained on dox for up to 1 y harbored no amyloid pathology ( data not shown ) , indicating that residual leakage of transgene expression in the presence of dox does not provide sufficient A peptide to induce amyloid formation even over long periods .
# ::alignments 53-54|0.2.0.0.0.1.0 52-53|0.2.0.0.0.1 50-51|0.2.0.0.0.1.0.0 49-50|0.2.0.0.1.0 48-49|0.2.0.0.1.0.1 47-48|0.2.0.0.1 45-46|0.2.0 43-44|0.2 42-43|0.2.0.0 41-42|0.2.2 37-38|0.0 34-35|0 33-34|0.1 31-32|0.2.1 30-31|0.2.1.0 28-29|0.2.0.0.0 25-26|0.2.0.0.1.0.0 24-25|0.2.0.0.1.0.0.1 23-24|0.2.0.0.1.0.0.0 21-22|0.2.0.0.0.2.1 20-21|0.2.0.0.0.2.1.0 19-20|0.2.0.0.0.2.2 18-19|0.2.0.0.0.2 17-18|0.2.0.0.0.2.0 16-17|0.2.0.0.0.2.0.0.1.0.0 12-13|0.2.0.0.0.2.0.0.0 10-11|0.2.0.0.0.2.0.0 7-8|0.2.0.0.0.2.0.0.1.1.0.0 5-6|0.2.0.0.0.2.0.0.1 4-5|0.2.0.0.0.2.0.0.1.0 3-4|0.2.0.0.0.2.0.0.1.1.0.1+0.2.0.0.0.2.0.0.1.1.0 2-3|0.2.0.0.0.2.0.0.1.1 0-1|0.2.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:46.175
(e2 / express-01 
      :ARG1 (p4 / presence) 
      :mod (t / transgene) 
      :time-of (s / suffice-01 
            :ARG0 (p2 / peptide 
                  :ARG1-of (p3 / provide-01 
                        :ARG1-of (i2 / indicate-01 
                              :ARG0 (a3 / animal) 
                              :ARG2-of (l / long-03 
                                    :ARG1 (p / period 
                                          :mod (e / even))) 
                              :purpose-of (h / harbor-01 
                                    :ARG0 (y / y 
                                          :duration-of (m / maintain-01 
                                                :ARG0 (d2 / dox) 
                                                :ARG1 (l4 / line 
                                                      :ARG1-of (e3 / express-01 
                                                            :ARG0 1) 
                                                      :poss (w / we 
                                                            :ARG2-of (h2 / high-02 
                                                                  :ARG1 (l3 / line) 
                                                                  :degree (m2 / most)))))) 
                                    :ARG1 (p5 / pathology 
                                          :mod (a2 / amyloid)) 
                                    :polarity -)) 
                        :purpose (i / induce-01 
                              :ARG1 (f / form-01 
                                    :ARG1 (s2 / show-01 
                                          :ARG1 (d / data) 
                                          :polarity -) 
                                    :mod (a / amyloid))))) 
            :ARG1 (l2 / leakage 
                  :mod (r / residual)) 
            :polarity -))

# ::snt To mimic therapeutic intervention with inhibitors of A production , we raised a group of 25 double transgenic mice ( CaMKII-tTA  APP line 107 ) on normal food until 6 mo of age , when we knew amyloid formation was already well underway in the brain .
# ::tok To mimic therapeutic intervention with inhibitors of A production , we raised a group of 25 double transgenic mice ( CaMKII-tTA  APP line 107 ) on normal food until 6 mo of age , when we knew amyloid formation was already well underway in the brain .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:46.184
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt At 6 mo , half of the animals were switched from normal chow to food containing dox at 200 mg/kg until they were sacrificed at 9 or 12 mo of age .
# ::tok At 6 mo , half of the animals were switched from normal chow to food containing dox at 200 mg/kg until they were sacrificed at 9 or 12 mo of age .
# ::alignments 30-31|0 27-28|0.1.1.0.1.0.2.0 26-27|0.1.1.0.1.0.2 25-26|0.1.2.0.0 23-24|0.1.1.0.1.0 21-22|0.1.1.0.1.0.1 20-21|0.1.1.0.1 18-19|0.0 16-17|0.1.1.0.0 15-16|0.1.1.0 14-15|0.1.1 12-13|0.1.2 11-12|0.1.2.0 9-10|0.1 7-8|0.1.0.0 4-5|0.1.0 2-3|0.1.3 1-2|0.1.1.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:46.548
(a / age-01 
      :ARG0 200 
      :ARG1 (s2 / switch-01 
            :ARG1 (h / half 
                  :mod (a2 / animal)) 
            :ARG2 (f / food 
                  :ARG0-of (c / contain-01 
                        :ARG1 (d / dox) 
                        :time (u / until 
                              :op1 (s / sacrifice-01 
                                    :ARG0 6 
                                    :ARG1 (t / they) 
                                    :op1-of (o / or 
                                          :op2 12))))) 
            :ARG3 (c2 / chow 
                  :ARG1-of (n / normal-02 
                        :ARG0 9)) 
            :time (m / mo)))

# ::snt The remaining control animals were kept on standard chow ( untreated ) .
# ::tok The remaining control animals were kept on standard chow ( untreated ) .
# ::alignments 10-11|0.0 8-9|0.2 7-8|0.2.0 5-6|0 3-4|0.1 2-3|0.1.1 1-2|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:46.602
(k / keep-01 
      :ARG0 (u / untreat) 
      :ARG1 (a / animal 
            :ARG1-of (r / remain-01) 
            :ARG1-of (c2 / control-01)) 
      :ARG2 (c / chow 
            :ARG1-of (s / standard-02)))

# ::snt In all , four cohorts were created : 6 mo untreated ( n = 7 ) , 9 mo untreated ( n = 5 ) , 6 mo + 3 mo treated ( n = 8 ) , and 6 mo + 6 mo treated ( n = 5 ) .
# ::tok In all , four cohorts were created : 6 mo untreated ( n = 7 ) , 9 mo untreated ( n = 5 ) , 6 mo + 3 mo treated ( n = 8 ) , and 6 mo + 6 mo treated ( n = 5 ) .
# ::alignments 48-49|0.1.1 44-45|0.2 42-43|0.1.3 39-40|0.2.1 38-39|0 35-36|0.0.2 31-32|0.1 29-30|0.2.4 26-27|0.0.1 23-24|0.2.2 19-20|0.4 17-18|0.2.3 14-15|0.2.5 10-11|0.2.0 9-10|0.2.0.0 8-9|0.1.0 6-7|0.0 4-5|0.0.0 3-4|0.1.2 1-2|0.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:46.992
(a / and 
      :ARG0-of (c / create-01 
            :ARG1 (c2 / cohort) 
            :op1-of 6 
            :op1-of 8) 
      :ARG1-of (t2 / treat-01 
            :ARG0 6 
            :op1-of 5 
            :op1-of 4 
            :op1-of 6) 
      :ARG1-of (t / treat-01 
            :ARG0 (u2 / untreat 
                  :mod (m / mo)) 
            :ARG2 6 
            :op1-of 5 
            :op1-of 9 
            :op1-of 3 
            :op1-of 7) 
      :mod (a2 / all) 
      :op1 (u / untreat))

# ::snt Full suppression ( > 95 % ) of transgenic APPswe/ind levels in the dox-treated animals was confirmed by immunoblot ( Figure 3 ) .
# ::tok Full suppression ( > 95 % ) of transgenic APPswe/ind levels in the dox-treated animals was confirmed by immunoblot ( Figure 3 ) .
# ::alignments 21-22|0.1.0 20-21|0.1.2.0 18-19|0.0 16-17|0 14-15|0.1.2.0.0 13-14|0.1.2.0.0.0 10-11|0.1.1 5-6|0.1.0.0 4-5|0.1.0.0.0 1-2|0.1 0-1|0.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:47.199
(c / confirm-01 
      :ARG0 (i / immunoblot) 
      :ARG1 (s / suppress-01 
            :ARG0 (3 / 3 
                  :value-of (p / percentage-entity 
                        :value 95)) 
            :ARG1 (l / level) 
            :mod (f2 / full 
                  :poss-of (f / figure 
                        :op1 (a / animal 
                              :mod (d / dox-treat))))))

# ::snt To ensure that the transgene could be suppressed as rapidly in 6-mo-old mice with fulminant pathology as it can in young , predeposit animals , we treated an additional set of 6-mo-old animals with dox for 1 wk prior to harvest .
# ::tok To ensure that the transgene could be suppressed as rapidly in 6-mo-old mice with fulminant pathology as it can in young , predeposit animals , we treated an additional set of 6-mo-old animals with dox for 1 wk prior to harvest .
# ::alignments 40-41|0.0 38-39|0.0.0 36-37|0.0.1.0.0.0.0 34-35|0.0.1.2 32-33|0.0.1.1.0 29-30|0.0.1.1 28-29|0.0.1.1.1 26-27|0.0.1 25-26|0.0.1.0 23-24|0.0.1.1.2 20-21|0.0.1.1.2.0 18-19|0 15-16|0.0.1.0.0.0.4 14-15|0.0.1.0.0.0.4.0 12-13|0.0.1.0.0.0.4.1 9-10|0.0.1.0.0.0.3 7-8|0.0.1.0.0.0 5-6|0.0.1.0.0.0.2 4-5|0.0.1.0.0.0.1 1-2|0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:47.717
(p2 / possible-01 
      :ARG1 (h / harvest-01 
            :op1-of (p / prior) 
            :purpose (t / treat-01 
                  :ARG0 (w / we 
                        :ARG0-of (e / ensure-01 
                              :ARG1 (s2 / suppress-01 
                                    :ARG0 1 
                                    :ARG1 (t2 / transgene) 
                                    :ARG1-of (p4 / possible-01) 
                                    :ARG2 (r / rapid) 
                                    :manner (p3 / pathology 
                                          :mod (f / fulminant) 
                                          :poss-of (m / mouse))))) 
                  :ARG1 (s / set 
                        :consist-of (a / animal) 
                        :mod (a2 / additional) 
                        :op1-of (a3 / animal 
                              :mod (y / young))) 
                  :manner (d / dox))))

# ::snt Importantly , both APPswe/ind and APP -- C-terminal fragment levels were fully suppressed after only 1 wk of treatment , indicating that the in vivo half-life of APPswe/ind and its processed C-terminal fragments are relatively short ( Figure 3D ) .
# ::tok Importantly , both APPswe/ind and APP -- C-terminal fragment levels were fully suppressed after only 1 wk of treatment , indicating that the in vivo half-life of APPswe/ind and its processed C-terminal fragments are relatively short ( Figure 3D ) .
# ::alignments 38-39|0.1.1.1.0.0.0.2.0.0 37-38|0.1.1.1.0.0.0.0.0.0 35-36|0.1.1.1 34-35|0.1.1.1.0.0.0.0.0.1 32-33|0.1 30-31|0.1.1 28-29|0 25-26|0.0 20-21|0.1.1.1.0 18-19|0.1.1.1.0.0.0.2.0 15-16|0.1.0 14-15|0.1.0.0 13-14|0.1.1.1.0.0.0.2 12-13|0.1.1.1.0.0.0 11-12|0.1.1.1.0.0.0.1 9-10|0.1.1.1.0.0.0.0 8-9|0.1.1.1.0.0.0.0.0 5-6|0.1.1.1.0.0.2.0.0+0.1.1.1.0.0.2.0+0.1.1.1.0.0.2 4-5|0.1.1.1.0.0 2-3|0.1.1.1.0.0.1 0-1|0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:48.604
(a / and 
      :op1 (h / half-life) 
      :op2 (f2 / fragment-01 
            :ARG0 (1 / 1 
                  :mod (o / only)) 
            :ARG1-of (p / process-01 
                  :ARG0 (i2 / importantly) 
                  :op1-of (s / short 
                        :ARG1-of (i / indicate-01 
                              :op2-of (a3 / and 
                                    :ARG1-of (s2 / suppress-01 
                                          :ARG0 (l / level 
                                                :mod (f4 / fragment-01 
                                                      :ARG0 (f / figure) 
                                                      :ARG1 (r / relative))) 
                                          :degree (f3 / full) 
                                          :time (a2 / after 
                                                :op1 (t / treat-03 
                                                      :ARG0 3D))) 
                                    :mod (b / both) 
                                    :op1 (o2 / organization 
                                          :name (n / name 
                                                :op1 "APP"))))))))

# ::snt Tissue sections from each animal in the four treatment groups were stained for amyloid pathology by Hirano silver , Campbell-Switzer silver , thioflavin-S , and A immunohistochemistry .
# ::tok Tissue sections from each animal in the four treatment groups were stained for amyloid pathology by Hirano silver , Campbell-Switzer silver , thioflavin-S , and A immunohistochemistry .
# ::alignments 26-27|0.0.1.4 24-25|0.0.1 22-23|0.0.1.3 20-21|0.0.1.2 19-20|0.0.1.2.0 17-18|0.0.1.1 16-17|0.0.0.0+0.0.0+0.0 14-15|0.0.1.0.1 13-14|0.0.1.0.1.0 11-12|0.0.1.0 9-10|0.1 8-9|0 7-8|0.1.0 4-5|0.0.1.0.0.1 3-4|0.0.1.0.0.1.0 1-2|0.0.1.0.0 0-1|0.0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:48.938
(t2 / treat-03 
      :ARG1 (p / person 
            :name (n / name 
                  :op1 "Hirano") 
            :op1-of (a / and 
                  :ARG0-of (s3 / stain-01 
                        :ARG1 (s4 / section 
                              :mod (t3 / tissue) 
                              :source (a3 / animal 
                                    :mod (e / each))) 
                        :ARG2 (p2 / pathology 
                              :mod (a2 / amyloid))) 
                  :op2 (s2 / silver) 
                  :op3 (s / silver 
                        :mod (c / campbell-switz)) 
                  :op4 (t / thioflavin-) 
                  :op5 (i / immunohistochemistry))) 
      :mod-of (g / group 
            :quant 4))

# ::snt As expected , the 6 mo untreated cohort displayed moderate amyloid pathology , and the 9 mo untreated cohort progressed to a severe amyloid burden .
# ::tok As expected , the 6 mo untreated cohort displayed moderate amyloid pathology , and the 9 mo untreated cohort progressed to a severe amyloid burden .
# ::alignments 24-25|0.2.0.1 23-24|0.2.0.1.2 22-23|0.2.0.1.1 19-20|0.2.0+0.2 18-19|0.2.0.0 15-16|0.0.0 13-14|0 11-12|0.1.1 10-11|0.1.1.1 9-10|0.1.1.0 8-9|0.1 7-8|0.1.0 6-7|0.1.0.0 5-6|0.2.0.1.0 4-5|0.1.1.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:49.261
(a2 / and 
      :ARG1-of (e / expect-01 
            :ARG0 9) 
      :op1 (d / display-01 
            :ARG0 (c2 / cohort 
                  :mod (u / untreat)) 
            :ARG1 (p2 / pathology 
                  :ARG1-of (m / moderate-03 
                        :ARG0 6) 
                  :mod (a3 / amyloid))) 
      :op2 (t / thing 
            :ARG4-of (p / progress-01 
                  :ARG1 (c / cohort) 
                  :ARG2 (b / burden-01 
                        :ARG0 (m2 / mo) 
                        :mod (s / severe) 
                        :mod (a / amyloid)))))

# ::snt In contrast , the extent of amyloid pathology in mice from the 6 mo + 3 mo treated or 6 mo + 6 mo treated cohorts closely resembled that of the 6 mo untreated cohort , despite the significant age difference between the treated and untreated groups ( Figures 4 and Figure S3 ) .
# ::tok In contrast , the extent of amyloid pathology in mice from the 6 mo + 3 mo treated or 6 mo + 6 mo treated cohorts closely resembled that of the 6 mo untreated cohort , despite the significant age difference between the treated and untreated groups ( Figures 4 and Figure S3 ) .
# ::alignments 51-53|0.1.1.1.2.0.1+0.1.1.1.2.0.0+0.1.1.1.2.0+0.1.1.1.2 50-51|0.1.1.1.2.1 49-50|0.1.1.1.6 48-49|0.1.1.1.2.1.0 46-47|0.1.2 44-45|0.1 43-44|0.1.1 40-41|0.1.0 39-40|0.1.0.2 38-39|0.1.0.0 34-35|0.1.0.2.0 33-34|0.1.0.2.0.0 31-32|0.1.1.1.3.0 28-29|0.1.1.1.1 27-28|0.1.1.1 26-27|0.1.1.1.4 25-26|0.1.1.1.0 24-25|0.1.1.1.0.0 22-23|0.1.1.0 19-20|0.1.0.1 18-19|0.1.1.1.0.1 17-18|0.1.1.1.3 15-16|0.1.0.2.1 12-13|0.1.0.0.0 9-10|0.1.1.1.3.1 7-8|0.1.1.1.5 4-5|0.0 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:50.627
(c4 / contrast-01 
      :ARG1 (e / extent) 
      :ARG2 (a2 / and 
            :ARG1-of (d / differ-02 
                  :ARG1-of (s2 / significant-02 
                        :op1-of 6) 
                  :ARG2 6 
                  :ARG3 (a3 / age-01 
                        :ARG0 (c / cohort 
                              :mod (u / untreat)) 
                        :ARG2 3)) 
            :op1 (t2 / treat-01 
                  :ARG1 6 
                  :ARG2 (r / resemble-01 
                        :ARG0 (c3 / cohort 
                              :ARG1-of (t4 / treat-01) 
                              :op1-of (o / or)) 
                        :ARG1 (t3 / that) 
                        :ARG2 (t / thing 
                              :name (n / name 
                                    :op1 (f / Figure) 
                                    :op2 (s / S3)) 
                              :op2-of (a / and 
                                    :op1 (f2 / figure))) 
                        :ARG2-of (t5 / treat-01 
                              :ARG0 6 
                              :ARG1 (m / mouse)) 
                        :manner (c2 / close) 
                        :op1-of (p / pathology) 
                        :op1-of 4)) 
            :op2 (g / group)))

# ::snt Well-formed plaques remained in the treated animals after 6 mo of transgene suppression , even though as much time was given to clear the lesions as they had taken to form .
# ::tok Well-formed plaques remained in the treated animals after 6 mo of transgene suppression , even though as much time was given to clear the lesions as they had taken to form .
# ::alignments 30-31|0 28-29|0.2 26-27|0.0 24-25|0.1 22-23|0.1.0 20-21|0.1.0.1 18-19|0.1.0.1.1 17-18|0.1.0.1.1.0 14-15|0.1.0.1.0.0.0.0.0 12-13|0.1.0.1.0.0.1.1 11-12|0.1.0.1.0.0.1.1.0 9-10|0.1.0.1.0.0.1.0 8-9|0.1.0.0 7-8|0.1.0.1.0.0.1 6-7|0.1.0.1.0.0.0 5-6|0.1.0.1.0.0.0.0 2-3|0.1.0.1.0.0 1-2|0.1.0.1.0 0-1|0.1.0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:50.952
(f / form-01 
      :ARG0 (t2 / they) 
      :ARG1 (l / lesion 
            :ARG1-of (c / clear-06 
                  :ARG0 6 
                  :ARG1-of (g / give-01 
                        :ARG0 (p / plaqu 
                              :ARG1-of (r / remain-01 
                                    :ARG2 (a2 / animal 
                                          :mod (t5 / treat-01 
                                                :ARG1 (e / even))) 
                                    :time (a / after 
                                          :op1 (m2 / mo) 
                                          :op2 (s / suppress-01 
                                                :ARG1 (t4 / transgene)))) 
                              :mod (w / well-form)) 
                        :ARG2 (t3 / time 
                              :quant (m / much))))) 
      :ARG1-of (t / take-01 
            :ARG0 t2))

# ::snt Moreover , both types of amyloid , diffuse and fibrillar , remained intact throughout treatment .
# ::tok Moreover , both types of amyloid , diffuse and fibrillar , remained intact throughout treatment .
# ::alignments 14-15|0.2.0.0 13-14|0.2.0 12-13|0.2 11-12|0 9-10|0.0.2 8-9|0.0 7-8|0.0.1 5-6|0.0.0 3-4|0.1 2-3|0.1.0 0-1|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:51.149
(r / remain-01 
      :ARG0 (a / and 
            :op1 (a2 / amyloid) 
            :op2 (d / diffuse-01 
                  :ARG1 (m / moreover)) 
            :op3 (f / fibrillar)) 
      :ARG1 (t3 / type 
            :mod (b / both)) 
      :ARG3 (i / intact 
            :location (t2 / throughout 
                  :op1 (t / treat-03))))

# ::snt Using the Campbell-Switzer silver stain to distinguish different forms of amyloid , we found diffuse plaques were as persistent as cored deposits ( Figure S4 ) .
# ::tok Using the Campbell-Switzer silver stain to distinguish different forms of amyloid , we found diffuse plaques were as persistent as cored deposits ( Figure S4 ) .
# ::alignments 23-25|0.0.1+0+0.0+0.0.0 21-22|0.0.0.0.0.1.0 20-21|0.0.0.0 18-19|0.0.0.0.0.1 15-16|0.0.0.0.0 14-15|0.0.0.0.0.2 13-14|0.0.0.0.0.0 12-13|0.0.0.0.0.0.0 10-11|0.0.0.0.0.0.0.0.0.0 8-9|0.0.0.0.0.0.0.0.0.1.0 7-8|0.0.0.0.0.0.0.0.0.1.0.0 6-7|0.0.0.0.0.0.0.0.0.1 4-5|0.0.0.0.0.0.0.0.0 3-4|0.0.0.0.0.0.0.0.0.2 2-3|0.0.0.0.0.0.0.0.0.3 0-1|0.0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:51.701
(f / Figure 
      :op1-of (n / name 
            :name-of (t / thing 
                  :ARG1-of (c / core-01 
                        :ARG0 (p2 / plaqu 
                              :ARG1-of (f2 / find-01 
                                    :ARG0 (w / we 
                                          :ARG0-of (u / use-01 
                                                :ARG1 (s2 / stain-01 
                                                      :ARG0 (a / amyloid) 
                                                      :ARG1 (d4 / distinguish-01 
                                                            :ARG1 (f3 / form 
                                                                  :ARG1-of (d3 / differ-02))) 
                                                      :mod (s3 / silver) 
                                                      :mod (c2 / campbell-switz))))) 
                              :ARG1-of (p / persist-01 
                                    :ARG0 (d / deposit)) 
                              :ARG1-of (d2 / diffuse-01)))) 
            :op2 (s / S4)))

# ::snt It was nevertheless clear that dox-induced suppression of transgenic APP had completely halted the progression of pathology .
# ::tok It was nevertheless clear that dox-induced suppression of transgenic APP had completely halted the progression of pathology .
# ::alignments 16-17|0.0.0.0.0 14-15|0.0.0.0 12-13|0.0.0 11-12|0.0.0.1 9-10|0.0.1.0.0+0.0.1.0+0.0.1 6-7|0.0 5-6|0 3-4|0.0.0.2 2-3|0.0.0.2.1 0-1|0.0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:51.782
(d / dox-induc 
      :mod-of (s / suppress-01 
            :ARG0-of (h / halt-01 
                  :ARG1 (p2 / progress-01 
                        :ARG1 (p / pathology)) 
                  :ARG1-of (c / complete-02) 
                  :ARG1-of (c2 / clear-06 
                        :ARG0 (i / it) 
                        :mod (n2 / nevertheles))) 
            :ARG1 (o / organization 
                  :name (n / name 
                        :op1 "APP"))))

# ::snt To confirm that the arrest of plaques without any sign of clearance was not unique to the line 107 mice , we repeated the dox-suppression experiment in a second line of tet-off APP mice ( CaMKII-tTA  tet-APPswe/ind line 18 ; n = 22 ) .
# ::tok To confirm that the arrest of plaques without any sign of clearance was not unique to the line 107 mice , we repeated the dox-suppression experiment in a second line of tet-off APP mice ( CaMKII-tTA  tet-APPswe/ind line 18 ; n = 22 ) .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:51.786
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Again , long-term dox treatment was begun at 6 mo of age , and mice were harvested after 3 mo of transgene suppression ( 6 mo untreated , n = 8 ; 9 mo untreated , n = 6 ; 6 mo + 3 mo treated , n = 8 ) .
# ::tok Again , long-term dox treatment was begun at 6 mo of age , and mice were harvested after 3 mo of transgene suppression ( 6 mo untreated , n = 8 ; 9 mo untreated , n = 6 ; 6 mo + 3 mo treated , n = 8 ) .
# ::alignments 49-50|0.0.2.2 45-46|0.0.3 43-44|0.0.4.0.2 40-41|0.0.2.1 38-39|0.0.2.3 32-33|0.0.1.1.3.0 31-32|0 30-31|0.1 28-29|0.0.1.0 26-27|0.0.1.1.2 24-25|0.0.3.0 22-23|0.0.4.0 21-22|0.0.4.0.1 18-19|0.0.3.1 17-18|0.0.4 16-17|0.0.2 14-15|0.0.2.0 13-14|0.0 11-12|0.0.1.1.3 9-10|0.0.1.2 8-9|0.0.4.0.0 6-7|0.0.1 4-5|0.0.1.1 3-4|0.0.1.1.0 2-3|0.0.1.1.1 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:52.568
(a / and 
      :op1 (a3 / and 
            :mod (a5 / again) 
            :op1 (b / begin-01 
                  :ARG0 (n / n) 
                  :ARG1 (t3 / treat-03 
                        :ARG2 (d / dox) 
                        :manner (l / long-term) 
                        :op1-of (u / untreat) 
                        :purpose (a4 / age-01 
                              :ARG0 9)) 
                  :ARG2 (m2 / mo)) 
            :op2 (h / harvest-01 
                  :ARG1 (m / mouse) 
                  :op1-of 6 
                  :op1-of 8 
                  :op1-of 6) 
            :op3 (t / treat-01 
                  :ARG1 6 
                  :op1-of 3) 
            :time (a2 / after 
                  :op1 (s / suppress-01 
                        :ARG0 6 
                        :ARG1 (t2 / transgene) 
                        :ARG2 3))) 
      :op2 8)

# ::snt Immunoblotting for APP confirmed full transgene suppression in the treated animals ( Figure S5 ) .
# ::tok Immunoblotting for APP confirmed full transgene suppression in the treated animals ( Figure S5 ) .
# ::alignments 12-14|0.1.0.0.0.0.1+0.1.0.0.0.0.0+0.1.0.0.0.0+0.1.0.0.0 10-11|0.1.0 9-10|0.1.0.0 6-7|0.1 5-6|0.1.2 4-5|0.1.1 3-4|0 2-3|0.0.0.0.0+0.0.0.0+0.0.0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:53.203
(c / confirm-01 
      :ARG0 (i / immunoblott 
            :beneficiary (o / organization 
                  :name (n2 / name 
                        :op1 "APP"))) 
      :ARG1 (s2 / suppress-01 
            :ARG1 (a / animal 
                  :mod (t2 / treat-01 
                        :ARG1 (t / thing 
                              :name (n / name 
                                    :op1 (f / Figure) 
                                    :op2 (s / S5))))) 
            :mod (f2 / full) 
            :mod (t3 / transgene)))

# ::snt As in the line 107 mice described above , amyloid burden worsened substantially in the untreated mice between 6 and 9 mo of age .
# ::tok As in the line 107 mice described above , amyloid burden worsened substantially in the untreated mice between 6 and 9 mo of age .
# ::alignments 23-24|0.0.3.0.1 21-22|0.0.3.0.1.1 20-21|0.0.3.0.0 19-20|0 18-19|0.0.3.1 16-17|0.0.3.3 15-16|0.0.3.3.0 12-13|0.0.3.2 11-12|0.0.3 10-11|0.0.3.0 9-10|0.0.3.0.2 7-8|0.0.2 6-7|0.0 5-6|0.0.0 4-5|0.0.3.0.1.0 3-4|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:53.483
(a2 / and 
      :ARG1-of (d / describe-01 
            :ARG0 (m3 / mouse) 
            :ARG2 (l / line) 
            :manner (a4 / above) 
            :time-of (w / worsen-01 
                  :ARG0 (b / burden-01 
                        :ARG1 9 
                        :ARG1-of (a / age-01 
                              :ARG0 107 
                              :time-of (m / mo)) 
                        :mod (a3 / amyloid)) 
                  :ARG1 6 
                  :manner (s / substantial) 
                  :manner (m2 / mouse 
                        :mod (u / untreat)))))

# ::snt Suppression of transgene expression abruptly arrested progression of pathology ( Figure S6 ) , but again without any sign of reduction .
# ::tok Suppression of transgene expression abruptly arrested progression of pathology ( Figure S6 ) , but again without any sign of reduction .
# ::alignments 20-21|0.0.2.0 18-19|0.0.2 17-18|0.0.2.1 15-16|0.0.0.0.0 14-15|0 10-12|0.0.2.0.0.0.1+0.0.2.0.0.0.0+0.0.2.0.0.0+0.0.2.0.0 8-9|0.0.1.0 6-7|0.0.1 5-6|0.0 4-5|0.0.3 3-4|0.0.0.0 2-3|0.0.0.0.1 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:53.893
(c / contrast-01 
      :ARG1 (a3 / arrest-01 
            :ARG0 (s3 / suppression 
                  :ARG1-of (e / express-01 
                        :ARG0 (a2 / again) 
                        :mod (t2 / transgene))) 
            :ARG1 (p2 / progress-01 
                  :ARG1 (p / pathology)) 
            :ARG2 (s / sign-02 
                  :ARG1 (r / reduce-01 
                        :ARG1 (t / thing 
                              :name (n / name 
                                    :op1 (f / Figure) 
                                    :op2 (s2 / S6)))) 
                  :mod (a / any)) 
            :manner (a4 / abrupt)))

# ::snt Both silver - and thioflavin-S-positive plaques could still be found in each of the dox-treated animals .
# ::tok Both silver - and thioflavin-S-positive plaques could still be found in each of the dox-treated animals .
# ::alignments 15-16|0.0.2.0 14-15|0.0.2.0.0 11-12|0.0.2 9-10|0.0 7-8|0.0.3 6-7|0.0.1 5-6|0.0.0 3-4|0 1-2|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:54.022
(a2 / and 
      :ARG0-of (f / find-01 
            :ARG1 (p2 / plaqu) 
            :ARG1-of (p / possible-01) 
            :ARG2 (e / each 
                  :mod-of (a / animal 
                        :mod (d / dox-treat))) 
            :time (s / still)) 
      :op1 (s2 / silver 
            :mod (b / both)))

# ::snt We biochemically measured the amount of aggregated A in the brains of our mice before and after transgene suppression using filter trap analysis of cortical tissue from each animal .
# ::tok We biochemically measured the amount of aggregated A in the brains of our mice before and after transgene suppression using filter trap analysis of cortical tissue from each animal .
# ::alignments 28-29|0.3.0.0.0.0.2 27-28|0.3.0.0.0.0.2.0 25-26|0.3.0.0.0.0.0.0 24-25|0.3.0.0.0.0.0.0.0 22-23|0.3.0.0.0.0.0 21-22|0.3.0.0.0.0.0.1.0 20-21|0.3.0.0.0.0.0.1 19-20|0.3.0.0.0.0 18-19|0.3.0.0.0 17-18|0.3.0.0.0.1 16-17|0.3.0.0 15-16|0.3.0 14-15|0.3 13-14|0.1.0 12-13|0.1.0.0 10-11|0.1 6-7|0.3.0.0.0.0.1 4-5|0.0.0 2-3|0 1-2|0.2 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:54.985
(m2 / measure-01 
      :ARG0 (w2 / we 
            :poss-of (a6 / amount)) 
      :ARG1 (b2 / brain 
            :part-of (m / mouse 
                  :poss (w / we))) 
      :manner (b3 / biochemically) 
      :time (b / before 
            :op1-of (a4 / and 
                  :op2 (a3 / after 
                        :op1 (s / suppress-01 
                              :ARG0-of (u / use-01 
                                    :ARG1 (a2 / analyze-01 
                                          :ARG1 (t / tissue 
                                                :mod (c / cortical)) 
                                          :ARG1-of (f / filter-02 
                                                :ARG1-of (t2 / trap-01))) 
                                    :ARG1-of (a5 / aggregate-01) 
                                    :ARG2 (a / animal 
                                          :mod (e / each))) 
                              :mod (t3 / transgene))))))

# ::snt In this assay , serial dilutions of protein homogenate are passed through a cellulose acetate filter ; particles larger than the pore size of the filter become trapped in the membrane and are revealed by immunoblotting [ 22 ] .
# ::tok In this assay , serial dilutions of protein homogenate are passed through a cellulose acetate filter ; particles larger than the pore size of the filter become trapped in the membrane and are revealed by immunoblotting [ 22 ] .
# ::alignments 37-38|0.0.0.0.2.0.1.0.0.0 33-34|0.0.0.0.2.0 31-32|0.0.0.0.2.0.1 30-31|0.0.0.0.2.0.1.0.1.0 27-28|0.0.0.0.2.0.1.0.1 26-27|0.0.0.0.2.0.1.0 25-26|0.0.0.0.2.0.1.0.0 22-23|0.0.0.0.2.0.1.0.0.1 21-22|0.0.0.0.2.0.1.0.0.1.0 18-19|0.0.0.0.2.0.0.0 17-18|0.0.0.0.2.0.0 16-17|0.0.0.0.2 15-16|0.0.0.0.0 14-15|0.0.0.0.0.0 13-14|0.0.0.0.0.0.0 10-11|0.0.0.0 8-9|0.0 7-8|0 5-6|0.0.0 4-5|0.0.0.1 2-3|0.0.0.0.1 1-2|0.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:55.517
(p4 / protein 
      :mod-of (h / homogenate 
            :mod-of (d / dilution 
                  :ARG1-of (p3 / pass-01 
                        :manner (f2 / filter-02 
                              :ARG1 (a3 / acetate 
                                    :mod (c / cellulose))) 
                        :manner (a4 / assay 
                              :mod (t2 / this)) 
                        :op1-of (a2 / and 
                              :op2 (r / reveal-01 
                                    :ARG0 (p2 / particle 
                                          :mod (l / large)) 
                                    :ARG1 (a / and 
                                          :op1 (b / become-01 
                                                :ARG1 (f / filter-02 
                                                      :ARG1 22 
                                                      :poss-of (s / size 
                                                            :ARG1-of (p / pore-01))) 
                                                :ARG2 (t / trap-01 
                                                      :ARG2 (m / membrane))))))) 
                  :mod (s2 / serial))))

# ::snt Consistent with our visual analysis of the histological sections , line 107 tTA/APP mice treated with dox for 3 or 6 mo had the same amount of aggregated A as when they started treatment at 6 mo of age ( Figure 4A and 4B ) .
# ::tok Consistent with our visual analysis of the histological sections , line 107 tTA/APP mice treated with dox for 3 or 6 mo had the same amount of aggregated A as when they started treatment at 6 mo of age ( Figure 4A and 4B ) .
# ::alignments 42-43|0 40-41|0.0.1.0.0 38-39|0.0.0.0.0.0.2 35-36|0.0.0.0.0.0.0 33-34|0.0.0.0 32-33|0.0 31-32|0.0.0 27-28|0.0.0.0.0.0.2.1 25-26|0.0.1 24-25|0.0.1.0 21-22|0.0.0.0.0.0.4 20-21|0.0.0.0.0.0.3.0 19-20|0.0.0.0.0.0.3 18-19|0.0.0.0.0.0.2.0 16-17|0.0.0.0.0.0.1 14-15|0.0.0.0.0.0 13-14|0.0.0.0.0 11-12|0.0.0.0.0.0.2.1.0 10-11|0.0.0.0.0.1 8-9|0.0.0.0.0.0.2.1.1.1 7-8|0.0.0.0.0.0.2.1.1.1.0 4-5|0.0.0.0.0.0.2.1.1 3-4|0.0.0.0.0.0.2.1.1.2 2-3|0.0.0.0.0.0.2.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:56.212
(a / and 
      :op1 (s / start-01 
            :ARG0 (t2 / they 
                  :ARG1-of (t / treat-03 
                        :ARG0 (m2 / mouse 
                              :ARG1-of (t3 / treat-01 
                                    :ARG0 6 
                                    :ARG2 (d / dox) 
                                    :ARG2-of (a2 / age-01 
                                          :ARG0 3 
                                          :ARG1 (a3 / aggregate-01 
                                                :ARG0 107 
                                                :ARG2 (a5 / analyze-01 
                                                      :ARG0 (w / we) 
                                                      :ARG1 (s3 / section 
                                                            :mod (h / histological)) 
                                                      :mod (v / visual)))) 
                                    :duration (o / or 
                                          :op1 6) 
                                    :purpose (m / mo)) 
                              :mod (l / line)))) 
            :ARG1 (a4 / amount 
                  :ARG1-of (s2 / same-01 
                        :ARG0 (f / figure)))))

# ::snt In contrast , untreated 9-mo-old mice had almost twice as much aggregated A as either of the treated groups .
# ::tok In contrast , untreated 9-mo-old mice had almost twice as much aggregated A as either of the treated groups .
# ::alignments 18-19|0.3.1 17-18|0.3 14-15|0.3.1.0 11-12|0.1.0 10-11|0.2 7-8|0.0 5-6|0.1 3-4|0.3.0 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:56.308
(c / contrast-01 
      :ARG0 (a2 / almost) 
      :ARG1 (m2 / mouse 
            :ARG0-of (a / aggregate-01)) 
      :ARG2 (m / much) 
      :purpose (t / treat-01 
            :ARG0 (u / untreat) 
            :ARG1 (g / group 
                  :mod (e / either))))

# ::snt Filter trap analysis of line 18 tTA/APP mice yielded similar results : the increase in aggregated A observed in untreated animals between 6 and 9 mo of age was completely arrested by transgene suppression ( Figure S5C and S5D ) .
# ::tok Filter trap analysis of line 18 tTA/APP mice yielded similar results : the increase in aggregated A observed in untreated animals between 6 and 9 mo of age was completely arrested by transgene suppression ( Figure S5C and S5D ) .
# ::alignments 37-38|0.1.0.1 35-37|0.1.0.1.1.2.1+0.1.0.1.1.2.0+0.1.0.1.1.2+0.1.0.1.1 33-34|0.1.0 32-33|0.1.0.3 30-31|0.1 29-30|0.1.1 27-28|0 25-26|0.1.0.0 24-25|0.1.0.0.0 23-24|0.1.0.1.0 22-23|0.1.0.1.1.1.0.0.0.2.0.0 20-21|0.1.0.2.0 19-20|0.1.0.2.0.0 17-18|0.1.0.2 15-16|0.1.0.1.1.1.0.0.0.1 13-14|0.1.0.1.1.0 10-11|0.1.0.1.1.1.0.1+0.1.0.1.1.1.0 9-10|0.1.0.1.1.1 8-9|0.1.0.1.1.1.0.0 7-8|0.1.0.1.1.1.0.0.0.0 5-6|0.0 4-5|0.1.0.1.1.1.0.0.0.0.0 2-3|0.1.0.1.1.1.0.0.0 1-2|0.1.0.1.1.1.0.0.0.2 0-1|0.1.0.1.1.1.0.0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:57.849
(a3 / age-01 
      :ARG1 18 
      :ARG1-of (a2 / arrest-01 
            :ARG0 (s2 / suppress-01 
                  :ARG0 (m / mo 
                        :quant 9) 
                  :ARG1 (a / and 
                        :op1 (a4 / and) 
                        :op2 (t / thing 
                              :ARG1-of (i / increase-01) 
                              :ARG2-of (r2 / resemble-01 
                                    :ARG1 (t3 / thing 
                                          :ARG1-of (y / yield-01 
                                                :ARG0 (a7 / analyze-01 
                                                      :ARG1 (m2 / mouse 
                                                            :mod (l / line)) 
                                                      :ARG1-of (a6 / aggregate-01) 
                                                      :ARG2 (t4 / trap-01 
                                                            :ARG1 (f2 / filter-01 
                                                                  :ARG1 6)))) 
                                          :ARG2-of (r / result-01))) 
                              :name (n / name 
                                    :op1 (f / Figure) 
                                    :op2 (s / S5C)))) 
                  :ARG1-of (o / observe-01 
                        :ARG0 (a5 / animal 
                              :mod (u / untreat))) 
                  :mod (t2 / transgene)) 
            :ARG1-of (c / complete-02)))

# ::snt We next used ELISA to measure total A in the brains of each group to determine whether any change in the amount or solubility of peptide occurred while APPswe/ind expression was suppressed .
# ::tok We next used ELISA to measure total A in the brains of each group to determine whether any change in the amount or solubility of peptide occurred while APPswe/ind expression was suppressed .
# ::alignments 31-32|0.0 29-30|0 26-27|0.0.1 25-26|0.0.1.0 23-24|0.0.0.0.0.0 22-23|0.0.0.0.0 21-22|0.0.0.0 18-19|0.0.0 17-18|0.0.0.1 15-16|0.0.1.1 13-14|0.0.1.1.0 12-13|0.0.1.1.0.1 10-11|0.0.1.1.0.2 6-7|0.0.1.1.0.0 5-6|0.0.1.1.1 3-4|0.0.1.1.1.0.0.0+0.0.1.1.1.0.0+0.0.1.1.1.0 2-3|0.0.1.1.1.1 1-2|0.0.1.1.1.1.1 0-1|0.0.1.1.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:58.159
(e / express-01 
      :ARG1-of (s / suppress-01 
            :ARG0 (c / change-01 
                  :ARG1 (a / amount 
                        :op1-of (o2 / or 
                              :op2 (s2 / solubility))) 
                  :mod (a2 / any)) 
            :ARG1-of (o / occur-01 
                  :ARG0 (p / peptide) 
                  :ARG1-of (d / determine-01 
                        :ARG0 (g / group 
                              :ARG1-of (t / total-01) 
                              :mod (e2 / each) 
                              :part (b / brain)) 
                        :ARG1-of (m / measure-01 
                              :ARG0 (o3 / organization 
                                    :name (n / name 
                                          :op1 "ELISA")) 
                              :ARG2-of (u / use-01 
                                    :ARG0 (w / we) 
                                    :manner (n2 / next)))))))

# ::snt Cortical homogenates were sequentially extracted to separate peptide into PBS - , SDS - , and FA-soluble fractions , then transgene-derived A40 and A42 were measured by human-specific ELISA [ 23 ] .
# ::tok Cortical homogenates were sequentially extracted to separate peptide into PBS - , SDS - , and FA-soluble fractions , then transgene-derived A40 and A42 were measured by human-specific ELISA [ 23 ] .
# ::alignments 30-31|0.0.0.0.2.0 28-29|0.0.0.0.1.0.0+0.0.0.0.1.0+0.0.0.0.1 25-26|0.0 23-24|0.2.0.0+0.2.0+0.2 22-23|0 21-22|0.1.1.0+0.1.1+0.1 19-20|0.0.0.0.3 17-18|0.1.0 15-16|0.0.0.0.2.2 12-13|0.0.0.0.1.1.0.0+0.0.0.0.1.1.0+0.0.0.0.1.1 9-10|0.0.1 7-8|0.0.0.0.0 6-7|0.0.0.0 4-5|0.0.0.0.2 3-4|0.0.0.0.2.1 1-2|0.0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:59.026
(a / and 
      :ARG1-of (m / measure-01 
            :ARG0 (h / homogenat 
                  :ARG0-of (s / separate-02 
                        :ARG1 (p3 / peptide) 
                        :ARG2 (o / organization 
                              :name (n / name 
                                    :op1 "ELISA") 
                              :part (o2 / organization 
                                    :name (n4 / name 
                                          :op1 "SDS"))) 
                        :ARG2-of (e / extract-01 
                              :ARG0 23 
                              :manner (s2 / sequentially) 
                              :op1-of (a2 / and)) 
                        :time (t / then)) 
                  :mod (c2 / cortical)) 
            :ARG2 (p2 / pb)) 
      :op1 (p / person 
            :ARG0-of (f / fraction-01) 
            :name (n3 / name 
                  :op1 "A40")) 
      :op2 (c / country 
            :name (n2 / name 
                  :op1 "A42")))

# ::snt In all animals harboring amyloid deposits , we found that the vast majority of A ( > 99 % ) was extracted into the SDS and FA fractions ( Figure 5A and 5B ) .
# ::tok In all animals harboring amyloid deposits , we found that the vast majority of A ( > 99 % ) was extracted into the SDS and FA fractions ( Figure 5A and 5B ) .
# ::alignments 31-32|0.0.0.1.0.0.0.1 29-30|0.0.0.1.0.1 27-28|0.3 26-27|0.2.1+0.2.0.0+0.2.0+0.2 25-26|0 24-25|0.1.0.0+0.1.0+0.1 21-22|0.0 18-19|0.3.1.0 17-18|0.3.1 12-13|0.0.0 11-12|0.0.0.0 8-9|0.0.0.1.0.0.0 7-8|0.0.0.1.0.0.0.0 5-6|0.0.0.1 4-5|0.3.0 3-4|0.0.0.1.0 2-3|0.0.0.1.0.0 1-2|0.0.0.1.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:23:59.937
(a2 / and 
      :ARG0-of (e / extract-01 
            :ARG1 (m / majority 
                  :degree (v / vast) 
                  :poss (d / deposit 
                        :ARG1-of (h / harbor-01 
                              :ARG0 (a4 / animal 
                                    :location-of (f3 / find-01 
                                          :ARG0 (w / we) 
                                          :op1-of (a / and)) 
                                    :quant (a5 / all)) 
                              :ARG2 (f / figure))))) 
      :op1 (o / organization 
            :name (n2 / name 
                  :op1 "SDS")) 
      :op2 (l / league 
            :name (n / name 
                  :op1 "FA") 
            :wiki "The_Football_Association") 
      :op3 (f2 / fraction-01 
            :ARG0 (a3 / amyloid) 
            :ARG1 (9 / 99 
                  :value-of (p / percentage-entity))))

# ::snt Consistent with the filter trap results presented above , there were no significant differences in SDS - or FA-soluble A between the 6 mo untreated cohort and either the 6 mo + 3 mo treated or 6 mo + 6 mo treated cohorts .
# ::tok Consistent with the filter trap results presented above , there were no significant differences in SDS - or FA-soluble A between the 6 mo untreated cohort and either the 6 mo + 3 mo treated or 6 mo + 6 mo treated cohorts .
# ::alignments 42-43|0.3.1 41-42|0.3 39-40|0.2.1.2.1 36-37|0.2.1.2.0.0 35-36|0.2 34-35|0.2.1 32-33|0.0.1 29-30|0.3.0 27-28|0.1.0 26-27|0 25-26|0.1 24-25|0.0.2.0.0 23-24|0.2.1.1 22-23|0.2.1.0 18-20|0.2.0.0.1+0.2.0.0.0+0.2.0.0+0.2.0 17-18|0.2.0.1 15-16|0.2.0.1.0.0.0+0.2.0.1.0.0+0.2.0.1.0 13-14|0.2.1.2 12-13|0.2.1.2.0 11-12|0.2.1.2.0.1 7-8|0.0.2 6-7|0.0 5-6|0.0.0.0+0.0.0 4-5|0.0.0.0.0 3-4|0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:01.440
(a / and 
      :op1 (p / present-01 
            :ARG1 (t4 / thing 
                  :ARG2-of (r / result-01 
                        :ARG1 (t5 / trap-01))) 
            :op1-of 3 
            :path (a3 / above 
                  :time-of (f2 / filter-02 
                        :ARG1 (u / untreat)))) 
      :op2 (c2 / cohort 
            :mod (e / either)) 
      :op2-of (o / or 
            :op1 (t3 / thing 
                  :name (n / name 
                        :op1 (f / FA-soluble) 
                        :op2 (a2 / A)) 
                  :op2-of (o2 / or 
                        :op1 (o3 / organization 
                              :name (n2 / name 
                                    :op1 "SDS")))) 
            :op3 (t2 / treat-01 
                  :ARG0 6 
                  :ARG1 (m / mo) 
                  :ARG2 (d / differ-01 
                        :ARG1-of (s / significant-02 
                              :ARG2 6 
                              :degree -) 
                        :op1-of 6))) 
      :op3 (t / treat-01 
            :ARG0 6 
            :ARG1 (c / cohort)))

# ::snt However , brains of both 6 mo + 3 mo and 6 mo + 6 mo treated cohorts contained roughly twice as much PBS-soluble A40 as untreated 6-mo-old mice ( Figure 5C ) .
# ::tok However , brains of both 6 mo + 3 mo and 6 mo + 6 mo treated cohorts contained roughly twice as much PBS-soluble A40 as untreated 6-mo-old mice ( Figure 5C ) .
# ::alignments 30-31|0.0.0.2.0.1 28-29|0.0 26-27|0 23-25|0.0.0.1.0.1+0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 22-23|0.0.0.1.1 19-20|0.0.0.3 18-19|0.0.0 17-18|0.0.0.0 16-17|0.0.0.2 14-15|0.0.1 11-12|0.0.0.6 10-11|0.0.0.2.0 8-9|0.0.0.5 5-6|0.0.0.2.1 4-5|0.0.0.4 2-3|0.0.0.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:01.931
(u / untreat 
      :mod-of (m / mouse 
            :ARG2-of (c / contain-01 
                  :ARG0 (c2 / cohort) 
                  :ARG1 (p / person 
                        :name (n / name 
                              :op1 "PBS-soluble" 
                              :op2 "A40") 
                        :quant (m2 / much)) 
                  :ARG1-of (t / treat-01 
                        :ARG0 (a / and 
                              :op1 (b2 / brain) 
                              :op2 (f / figure)) 
                        :ARG2 6) 
                  :mod (r / roughly) 
                  :op1-of (b / both) 
                  :op1-of 3 
                  :time 6) 
            :mod-of 6))

# ::snt Levels of A42 showed a similar trend , but did not reach statistical significance .
# ::tok Levels of A42 showed a similar trend , but did not reach statistical significance .
# ::alignments 13-14|0.1.0 12-13|0.1.0.0 11-12|0.1 10-11|0.1.1 8-9|0 6-7|0.0.1 5-6|0.0.1.0 3-4|0.0 2-3|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:01.984
(c / contrast-01 
      :ARG1 (s3 / show-01 
            :ARG0 (l / level-01 
                  :ARG1 (c2 / country 
                        :name (n / name 
                              :op1 "A42"))) 
            :ARG1 (t / trend-01 
                  :ARG1-of (r2 / resemble-01))) 
      :ARG2 (r / reach-01 
            :ARG1 (s / significant-02 
                  :mod (s2 / statistic)) 
            :polarity -))

# ::snt In fact , levels of PBS-soluble A40 and A42 in the 6 mo + 3 mo and 6 mo + 6 mo treated cohorts were most similar to that of the 9 mo untreated cohort , suggesting that age , as opposed to synthetic rate ( which would be negligible in the treated animals ) , may determine the fraction of PBS-soluble A in these animals .
# ::tok In fact , levels of PBS-soluble A40 and A42 in the 6 mo + 3 mo and 6 mo + 6 mo treated cohorts were most similar to that of the 9 mo untreated cohort , suggesting that age , as opposed to synthetic rate ( which would be negligible in the treated animals ) , may determine the fraction of PBS-soluble A in these animals .
# ::alignments 65-66|0.2 64-65|0.2.0 61-63|0.0.0.0.1+0.0.0.0.0+0.0.0.0+0.0.0 59-60|0.0 57-58|0 56-57|0.1 53-54|0.1.1.0.0.1.0.0.1 52-53|0.1.1.0.0.1.0.0 49-50|0.1.1.0.0.1.0.0.1.0 44-45|0.1.1.0.0.1.0.0.1.0.0.1.1 43-44|0.1.1.0.0.1.0.0.1.0.0.1.1.0 41-42|0.1.1.0.0.1.0.0.1.0.0.1 38-39|0.1.1.0.0.1.0.0.1.0.0 36-37|0.1.1 34-35|0.1.0 33-34|0.1.0.0 31-32|0.1.1.0.0.1.0.0.0 28-29|0.1.1.0.0.2 26-27|0.1.1.0.0 25-26|0.1.1.0.0.3 23-24|0.1.1.0 22-23|0.1.1.0.0.1 20-21|0.1.1.0.0.1.0.0.1.0.0.1.0 17-18|0.1.1.0.0.1.0.0.1.0.0.0 16-17|0.1.2 14-15|0.1.1.1 11-12|0.1.1.0.0.0 8-9|0.1.1.0.0.1.0.2.1.0.0+0.1.1.0.0.1.0.2.1.0+0.1.1.0.0.1.0.2.1 7-8|0.1.1.0.0.1.0.2 5-7|0.1.1.0.0.1.0.1.1+0.1.1.0.0.1.0.1.0+0.1.1.0.0.1.0.1+0.1.1.0.0.1.0 3-4|0.1.1.0.0.1.0.2.0 1-2|0.1.1.0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:03.773
(d / determine-01 
      :ARG1 (f / fraction 
            :part-of (t2 / thing 
                  :name (n / name 
                        :op1 "PBS-soluble" 
                        :op2 "A"))) 
      :ARG1-of (p / possible-01 
            :ARG0 (c / cohort 
                  :mod (u / untreat)) 
            :ARG1-of (s2 / suggest-01 
                  :ARG0 (c2 / cohort 
                        :ARG1-of (r2 / resemble-01 
                              :ARG0 6 
                              :ARG1-of (t5 / treat-01 
                                    :ARG0 (p2 / person 
                                          :ARG1-of (t3 / treat-01 
                                                :ARG0 9 
                                                :mod-of (a2 / animal 
                                                      :domain-of (n2 / negligible 
                                                            :ARG1-of (a3 / age-01 
                                                                  :ARG0 6 
                                                                  :ARG1-of (o / oppose-01 
                                                                        :ARG0 6 
                                                                        :ARG4 (r / rate 
                                                                              :quant-of (s / synthetic))))))) 
                                          :name (n4 / name 
                                                :op1 "PBS-soluble" 
                                                :op2 "A40") 
                                          :op2-of (a5 / and 
                                                :op1 (l / level) 
                                                :op3 (c3 / country 
                                                      :name (n3 / name 
                                                            :op1 "A42")))) 
                                    :prep-in (f2 / fact)) 
                              :ARG2 (t4 / that) 
                              :degree (m / most))) 
                  :ARG2 3) 
            :op1-of (a4 / and)) 
      :location (a / animal 
            :mod (t / this)))

# ::snt We also assessed neuritic and glial pathology surrounding the plaques to determine whether there were any changes in nearby tissue following long-term transgene suppression .
# ::tok We also assessed neuritic and glial pathology surrounding the plaques to determine whether there were any changes in nearby tissue following long-term transgene suppression .
# ::alignments 23-24|0.0 22-23|0.0.0 21-22|0 20-21|0.0.1 19-20|0.0.1.0 18-19|0.0.1.0.1 16-17|0.0.1.0.0 15-16|0.0.1.0.0.1 11-12|0.0.1.0.0.0 9-10|0.0.1.0.0.0.0 7-8|0.0.1.0.0.0.0.0 6-7|0.0.1.0.0.0.0.0.1 5-6|0.0.1.0.0.0.0.0.0.0.0.0 4-5|0.0.1.0.0.0.0.0.0.0.0 2-3|0.0.1.0.0.0.0.0.0.0 1-2|0.0.1.0.0.0.0.0.0.0.1 0-1|0.0.1.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:04.056
(l / long-term 
      :mod-of (s / suppress-01 
            :ARG1 (t / transgene) 
            :ARG2-of (f / follow-01 
                  :ARG1 (t2 / tissue 
                        :ARG1-of (c / change-01 
                              :ARG1-of (d / determine-01 
                                    :ARG0 (p / plaqu 
                                          :ARG2-of (s2 / surround-01 
                                                :ARG0 (w / we 
                                                      :ARG0-of (a3 / assess-01 
                                                            :ARG1 (a2 / and 
                                                                  :op1 (g / glial)) 
                                                            :mod (a4 / also))) 
                                                :ARG1 (p2 / pathology)))) 
                              :mod (a / any)) 
                        :mod (n / nearby)))))

# ::snt Both Hirano silver stain and ubiquitin immunostaining showed neuritic pathology in all treatment groups ( Figure 6 ) .
# ::tok Both Hirano silver stain and ubiquitin immunostaining showed neuritic pathology in all treatment groups ( Figure 6 ) .
# ::alignments 16-17|0.0.1.0 15-16|0.0.3 13-14|0.2 12-13|0.2.0 11-12|0.0.0.1 9-10|0.1 7-8|0 6-7|0.0.2 5-6|0.0.2.0 4-5|0.0 3-4|0.0.1 2-3|0.0.1.1 1-2|0.0.0.0.0+0.0.0.0+0.0.0 0-1|0.0.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:04.155
(s / show-01 
      :ARG0 (a2 / and 
            :op1 (p2 / person 
                  :name (n / name 
                        :op1 "Hirano") 
                  :quant (a / all)) 
            :op2 (s2 / stain-01 
                  :ARG1 6 
                  :mod (s3 / silver) 
                  :mod (b / both)) 
            :op3 (i / immunostain 
                  :mod (u / ubiquitin)) 
            :op4 (f / figure)) 
      :ARG1 (p / pathology) 
      :prep-in (g / group 
            :ARG1-of (t / treat-03)))

# ::snt Similarly , activated astrocytes immunostained for GFAP were found near plaques in all animals ( Figure 6 ) .
# ::tok Similarly , activated astrocytes immunostained for GFAP were found near plaques in all animals ( Figure 6 ) .
# ::alignments 16-17|0.1.0 15-16|0.0.0 13-14|0.2 12-13|0.2.0 10-11|0.1.1 9-10|0.1 8-9|0 4-5|0.0.1.0 3-4|0.0.1 2-3|0.0 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:04.293
(f2 / find-01 
      :ARG1 (a4 / activate-01 
            :ARG0 (f / figure) 
            :ARG1 (a3 / astrocyt 
                  :mod (i / immunostain)) 
            :manner (s / similarly)) 
      :ARG1-of (n / near-02 
            :ARG0 6 
            :ARG2 (p / plaqu)) 
      :location (a / animal 
            :quant (a2 / all)))

# ::snt Neuritic and glial pathology were more severe in the older untreated mice .
# ::tok Neuritic and glial pathology were more severe in the older untreated mice .
# ::alignments 11-12|0.0.3 10-11|0.0.3.0 9-10|0.0.1 6-7|0.0.0 5-6|0.0.0.0 3-4|0.1 2-3|0.1.0 1-2|0 0-1|0.0.2.0+0.0.2+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:04.339
(a / and 
      :op1 (t / thing 
            :domain-of (s / severe 
                  :degree (m2 / more)) 
            :mod (o / old) 
            :name (n / name 
                  :op1 "Neuritic") 
            :poss-of (m / mouse 
                  :mod (u / untreat))) 
      :op2 (p / pathology 
            :mod (g / glial)))

# ::snt In contrast , transgene suppression prevented the growth of individual deposits apparent in untreated mice , and limited the surrounding pathology to what was already present when treatment began .
# ::tok In contrast , transgene suppression prevented the growth of individual deposits apparent in untreated mice , and limited the surrounding pathology to what was already present when treatment began .
# ::alignments 28-29|0.0.1 27-28|0.0 25-26|0.0.1.1 24-25|0.0.1.1.0 20-21|0.1.1.0.1 19-20|0.1.1.0.1.0 17-18|0.1.1.0 16-17|0.1.1 14-15|0.1.0.0 13-14|0.1.0.0.0 11-12|0.0.1.0 10-11|0.1.0.1 9-10|0.0.0 7-8|0.1.0 5-6|0.1 4-5|0.1.1.0.0 3-4|0.1.1.0.0.0 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:04.983
(c / contrast-01 
      :ARG1 (t / treat-03 
            :ARG1 (i / individual) 
            :ARG1-of (b / begin-01 
                  :ARG0 (a3 / apparent) 
                  :time-of (p / present 
                        :time (a / already)))) 
      :time-of (p3 / prevent-01 
            :ARG1 (g / grow-01 
                  :ARG0 (m / mouse 
                        :mod (u / untreat)) 
                  :ARG1 (d / deposit)) 
            :op1-of (a2 / and 
                  :op2 (l / limit-01 
                        :ARG0 (s2 / suppress-01 
                              :ARG1 (t2 / transgene)) 
                        :ARG1 (p2 / pathology 
                              :ARG1-of (s / surround-01))))))

# ::snt An obvious question we sought to address was whether the deposition of A diminished cognitive ability in untreated mice , and what might happen to cognition when the process was interrupted .
# ::tok An obvious question we sought to address was whether the deposition of A diminished cognitive ability in untreated mice , and what might happen to cognition when the process was interrupted .
# ::alignments 30-31|0.1.1.1.0.0 28-29|0.1.1.1.0 22-23|0.0.2.0 20-21|0.0.2 18-19|0.0.2.1 17-18|0.0.2.1.0 15-16|0.0 14-15|0.0.0 13-14|0 10-11|0.0.1 6-7|0.1.1.1 4-5|0.1.1 3-4|0.1.1.0 2-3|0.1 1-2|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:05.441
(d / diminish-01 
      :ARG1 (a2 / ability 
            :mod (c / cognitive) 
            :mod-of (d2 / deposition) 
            :op1-of (a / and 
                  :ARG1-of (p2 / possible-01) 
                  :op2 (m / mouse 
                        :mod (u / untreat)))) 
      :ARG1-of (q / question-01 
            :ARG1-of (o / obvious-01) 
            :ARG1-of (s / seek-01 
                  :ARG0 (w / we) 
                  :ARG2 (a3 / address-02 
                        :ARG1-of (p / process-02 
                              :ARG1-of (i / interrupt-01)) 
                        :ARG0 w))))

# ::snt Unfortunately , efforts to characterize cognitive behavior were compromised by severe hyperactivity in untreated double transgenic mice .
# ::tok Unfortunately , efforts to characterize cognitive behavior were compromised by severe hyperactivity in untreated double transgenic mice .
# ::alignments 16-17|0.0.0.0.0.2 14-15|0.0.0.0.0.2.0 13-14|0.0.1 11-12|0.0.0.0.0.0 10-11|0.0.0.0.0.0.0 8-9|0.0.0.0.0 6-7|0.0 5-6|0 4-5|0.0.0 2-3|0.0.0.0 0-1|0.0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:05.532
(c2 / cognitive 
      :ARG1-of (b / behave-01 
            :ARG1-of (c3 / characterize-01 
                  :purpose-of (e / effort 
                        :ARG1-of (c / compromise-02 
                              :ARG0 (h / hyperactivity 
                                    :mod (s / severe)) 
                              :ARG2-of (f / fortunate-01) 
                              :location (m / mouse 
                                    :mod (d / double))))) 
            :ARG2 (u / untreat)))

# ::snt The tTA/APP animals were often seen running in circles around the perimeter of their cages , and a similar swimming pattern was noted when the mice were tested in the Morris water maze .
# ::tok The tTA/APP animals were often seen running in circles around the perimeter of their cages , and a similar swimming pattern was noted when the mice were tested in the Morris water maze .
# ::alignments 32-33|0.2.1 31-32|0.1.0.1.0 30-31|0.3.0.0+0.3.0+0.3 27-28|0.2 25-26|0.2.0 22-23|0.1 20-21|0.1.0 19-20|0.1.0.1 18-19|0.1.0.0 16-17|0 14-15|0.0.0.0.0.0.0.0 11-12|0.0.0.0.0.0.0 9-10|0.0.0.0.0.0 8-9|0.0.0.0.0 6-7|0.0.0.0 5-6|0.0 4-5|0.0.0.0.1 2-3|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:06.298
(a / and 
      :op1 (s2 / see-01 
            :ARG1 (a3 / animal 
                  :ARG1-of (r2 / run-01 
                        :ARG0 (c2 / circle 
                              :location (a2 / around 
                                    :op1 (p3 / perimet 
                                          :poss (c / cage)))) 
                        :frequency (o / often)))) 
      :op2 (n2 / note-01 
            :ARG1 (p2 / pattern 
                  :ARG1-of (r / resemble-01) 
                  :ARG1-of (s / swim-01 
                        :ARG2 (w / water)))) 
      :op3 (t / test-01 
            :ARG1 (m2 / mouse) 
            :ARG2 (m / maze)) 
      :op4 (p / person 
            :name (n / name 
                  :op1 "Morris")))

# ::snt In the radial water maze , repetitive swim patterns were noted with no evidence of choice-motivated actions .
# ::tok In the radial water maze , repetitive swim patterns were noted with no evidence of choice-motivated actions .
# ::alignments 16-17|0.1.0 15-16|0.1.0.0 13-14|0.1 12-13|0.1.2 10-11|0 8-9|0.0 7-8|0.0.0 6-7|0.0.1 4-5|0.1.1 3-4|0.0.0.0 2-3|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:06.436
(n / note-01 
      :ARG1 (p / pattern-01 
            :mod (s / swim-01 
                  :ARG2 (w / water 
                        :mod (r2 / radial))) 
            :mod (r / repetitive)) 
      :ARG2 (e / evidence-01 
            :ARG0 (a / action 
                  :mod (c / choice-motivat)) 
            :ARG2 (m / maze) 
            :polarity -))

# ::snt Other studies have dealt with similar problems by excluding animals that do not show adequate attention to the task , retaining only those mice that meet certain performance criteria [ 30 ] .
# ::tok Other studies have dealt with similar problems by excluding animals that do not show adequate attention to the task , retaining only those mice that meet certain performance criteria [ 30 ] .
# ::alignments 30-31|0.0.0.0.0.0.0.0.0 28-29|0.1 27-28|0.1.0 26-27|0.1.1 25-26|0 23-24|0.0 21-22|0.0.1 20-21|0.0.0 18-19|0.0.0.0.0.1 15-16|0.0.0.0 14-15|0.0.0.0.1 13-14|0.0.0.0.0 12-13|0.0.0.0.0.2 9-10|0.0.0.0.0.0 8-9|0.0.0.0.0.0.0 6-7|0.0.0.0.0.0.0.0.1.0 5-6|0.0.0.0.0.0.0.0.1.0.0 3-4|0.0.0.0.0.0.0.0.1 1-2|0.0.0.0.0.0.0.0 0-1|0.0.0.0.0.0.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:07.246
(m / meet-03 
      :ARG0 (m2 / mouse 
            :ARG1-of (r / retain-01 
                  :ARG1-of (a / attend-02 
                        :ARG1-of (s / show-01 
                              :ARG0 (a3 / animal 
                                    :ARG1-of (e / exclude-01 
                                          :ARG0 (s2 / study-01 
                                                :ARG1 30 
                                                :ARG1-of (d / deal-01 
                                                      :ARG2 (p2 / problem 
                                                            :ARG1-of (r2 / resemble-01))) 
                                                :mod (o2 / other)))) 
                              :ARG2 (t / task) 
                              :polarity -) 
                        :mod (a2 / adequate))) 
            :mod (o / only)) 
      :ARG1 (c / criteria 
            :ARG1-of (p / perform-02) 
            :mod (c2 / certain)))

# ::snt In our case , the penetrance of hyperactivity was close to 100 % , leaving us with no testable animals .
# ::tok In our case , the penetrance of hyperactivity was close to 100 % , leaving us with no testable animals .
# ::alignments 19-20|0.0.1 18-19|0.0.1.0 17-18|0.0.0.0.0 14-15|0.0 12-13|0.0.1.0.0 11-12|0.0.1.0.0.0 7-8|0.1 5-6|0 2-3|0.0.0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:07.342
(p2 / penetrance 
      :ARG1-of (l / leave-11 
            :ARG0 (w / we 
                  :ARG1-of (c / case-03 
                        :ARG2 -)) 
            :ARG2 (a / animal 
                  :mod (t / testable 
                        :quant (p / percentage-entity 
                              :value 100)))) 
      :mod (h / hyperactivity))

# ::snt This phenotype has not affected previous lines of APPswe mice we have produced , such as lines E1 -- 2 or C3 -- 3 , that express lower levels of transgenic protein .
# ::tok This phenotype has not affected previous lines of APPswe mice we have produced , such as lines E1 -- 2 or C3 -- 3 , that express lower levels of transgenic protein .
# ::alignments 31-32|0 28-29|0.0 27-28|0.0.1 26-27|0.0.0 23-24|0.0.1.1.1.0.0.2 20-21|0.0.1.1.1.0.1.1 19-20|0.0.1.1.1.0.0.1 17-18|0.0.0.0 16-17|0.0.0.0.0 14-15|0.0.1.0 12-13|0.0.1.1.1.0.0 10-11|0.0.1.1.1.0.0.0 9-10|0.0.1.1.1.0 8-9|0.0.1.1.1.0.1.0.0+0.0.1.1.1.0.1.0+0.0.1.1.1.0.1 6-7|0.0.1.1.1 5-6|0.0.1.1.1.1 4-5|0.0.1.1 3-4|0.0.1.1.2 1-2|0.0.1.1.0 0-1|0.0.1.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:08.023
(p / protein 
      :mod-of (l / level 
            :ARG1-of (e / express-01 
                  :ARG0 (e2 / E1 
                        :mod (l3 / line))) 
            :ARG1-of (l2 / low-04 
                  :ARG0 (s / such) 
                  :ARG2 (a / affect-01 
                        :ARG0 (p4 / phenotype 
                              :mod (t2 / this)) 
                        :ARG1 (l4 / line 
                              :consist-of (m / mouse 
                                    :ARG1-of (p2 / produce-01 
                                          :ARG0 (w / we) 
                                          :manner 2 
                                          :op1-of 3) 
                                    :mod (t / thing 
                                          :name (n / name 
                                                :op1 "APPswe") 
                                          :op1-of (o / or))) 
                              :mod (p3 / previous)) 
                        :polarity -))))

# ::snt Indeed , in past studies where hyperactivity was not a factor , we established a clear relationship between amyloid load and cognitive ability [ 31 ] .
# ::tok Indeed , in past studies where hyperactivity was not a factor , we established a clear relationship between amyloid load and cognitive ability [ 31 ] .
# ::alignments 24-25|0.1.0 22-23|0.2.1.0 21-22|0.0.0.1 20-21|0.2.1 19-20|0.2 18-19|0.2.0 16-17|0.1 15-16|0.1.1 13-14|0 12-13|0.0 10-11|0.0.0.3 8-9|0.0.0.0 6-7|0.0.0.3.0 4-5|0.0.0 3-4|0.0.0.2 0-1|0.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:08.544
(e / establish-01 
      :ARG0 (w / we 
            :ARG0-of (s / study-01 
                  :ARG1 - 
                  :ARG2 (c / cognitive) 
                  :time (p / past) 
                  :time (f / factor 
                        :domain (h / hyperactivity)))) 
      :ARG1 (r / relation-03 
            :ARG0 31 
            :ARG1-of (c2 / clear-06)) 
      :location (l / load 
            :mod (a3 / amyloid) 
            :op1-of (a2 / and 
                  :op2 (a / ability))) 
      :mod (i / indeed))

# ::snt However , in the current study , we feel that although the poor performance of the tTA/APP mice in the maze tests could technically be scored as cognitive impairment , the animals ' severe hyperactivity made interpretation of the cognitive tasks impossible .
# ::tok However , in the current study , we feel that although the poor performance of the tTA/APP mice in the maze tests could technically be scored as cognitive impairment , the animals ' severe hyperactivity made interpretation of the cognitive tasks impossible .
# ::alignments 40-41|0.0.1.1.0.1 39-40|0.0.1.1.0.1.1 36-37|0.0.1.1.0 34-35|0.0.1.1.0.0 33-34|0.0.1.1.0.0.0 31-32|0.0.1.1.0.1.0 28-29|0.0.1.2 27-28|0.0.1.2.0 25-26|0.0.1 23-24|0.0.1.3 22-23|0.0.1.1 21-22|0.0.1.0.2.0 20-21|0.0.1.0.2 17-18|0.0.1.0.0 13-14|0.0.1.0 12-13|0.0.1.0.1 8-9|0 7-8|0.0 5-6|0.0.0 4-5|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:09.311
(f / feel-01 
      :ARG0 (w / we 
            :ARG0-of (s3 / study-01 
                  :time (c3 / current)) 
            :ARG0-of (s2 / score-01 
                  :ARG1 (p2 / perform-02 
                        :ARG1 (m2 / mouse) 
                        :ARG2 (p3 / poor) 
                        :duration (m / maze 
                              :ARG1-of (t3 / test-01))) 
                  :ARG1-of (p / possible-01 
                        :condition-of (i / interpret-01 
                              :ARG0 (h / hyperactivity 
                                    :mod (s / severe)) 
                              :ARG1 (t / task-01 
                                    :ARG1 (a / animal) 
                                    :mod (c / cognitive)))) 
                  :ARG2 (i2 / impairment 
                        :mod (c2 / cognitive)) 
                  :manner (t2 / technical))))

# ::snt In order to understand the nature and extent of hyperactivity in the tTA/APP mice , we quantified daily activity levels in double transgenic animals along with their single transgenic and nontransgenic siblings using four-beam frames designed to monitor ambulation within an enclosed cage .
# ::tok In order to understand the nature and extent of hyperactivity in the tTA/APP mice , we quantified daily activity levels in double transgenic animals along with their single transgenic and nontransgenic siblings using four-beam frames designed to monitor ambulation within an enclosed cage .
# ::alignments 42-43|0.0.0.1.0.1 41-42|0.0.0.1.0.1.0 38-39|0.0.0.1.0.0 37-38|0.0.0.1.0 35-36|0.0.0.1 34-35|0.0.0 32-33|0.0 31-32|0.0.0.0 29-30|0 27-28|0.0.0.0.0 24-25|0.0.1.2 23-24|0.0.0.0.0.0.0 21-22|0.0.0.0.0.0 19-20|0.0.1.0.1 18-19|0.0.1.0.0 16-17|0.0.1 15-16|0.0.1.0 13-14|0.0.1.1.0.0 9-10|0.0.1.1.1.0 7-8|0.0.1.1.2 6-7|0.0.1.1 5-6|0.0.1.1.1 3-4|0.0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:11.389
(a2 / and 
      :ARG0-of (u / use-01 
            :ARG1 (f / frame-01 
                  :ARG0 (s / sibling 
                        :mod (s2 / single-02 
                              :ARG1 (d2 / double 
                                    :mod-of (a4 / animal)))) 
                  :ARG1-of (d / design-01 
                        :ARG3 (m / monitor-01 
                              :ARG1 (a / ambulation) 
                              :ARG2 (c / cage 
                                    :ARG1-of (e / enclose-01))))) 
            :manner-of (q / quantify-01 
                  :ARG0 (w / we 
                        :ARG0-of (a5 / activity-06) 
                        :poss-of (l / level)) 
                  :ARG1 (a6 / and 
                        :ARG1-of (u2 / understand-01 
                              :medium (m2 / mouse)) 
                        :op1 (n / nature 
                              :poss (h / hyperactivity)) 
                        :op2 (e2 / extent)) 
                  :ARG2 (a3 / along))))

# ::snt As shown in Figure 7 , the double transgenic mice were up to 10-fold more active during the dark phase of the day -- night cycle than any of the control groups .
# ::tok As shown in Figure 7 , the double transgenic mice were up to 10-fold more active during the dark phase of the day -- night cycle than any of the control groups .
# ::alignments 31-32|0.0 30-31|0 27-28|0.0.0 25-26|0.2.2 24-25|0.2.2.0 22-23|0.2.1.1 19-20|0.2.1 18-19|0.2.1.0 15-16|0.2 14-15|0.2.3 9-10|0.2.0 7-8|0.2.0.1 4-5|0.1 3-4|0.2.0.0.0 1-2|0.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:11.539
(c / control-01 
      :ARG0 (g / group 
            :quant (a / any)) 
      :ARG1 7 
      :compared-to-of (a2 / activity-06 
            :ARG0 (m2 / mouse 
                  :ARG1-of (s / show-01 
                        :ARG0 (f / figure)) 
                  :mod (d3 / double)) 
            :ARG1 (p / phase 
                  :ARG1-of (d2 / dark-02) 
                  :part-of (d / day)) 
            :compared-to (c2 / cycle-02 
                  :ARG1 (n / night)) 
            :degree (m / more)))

# ::snt Activity levels appeared to follow a relatively normal diurnal cycle , decreasing substantially during the daylight hours .
# ::tok Activity levels appeared to follow a relatively normal diurnal cycle , decreasing substantially during the daylight hours .
# ::alignments 16-17|0.0.2.1+0.0.2.1.0 15-16|0.0.2.1.0.0 12-13|0.0.2.0 11-12|0.0.2 9-10|0.0.1 8-9|0.0.1.0 7-8|0.0.1.1 6-7|0.0.1.1.0 4-5|0.0 2-3|0 1-2|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:11.715
(a / appear-01 
      :ARG1 (f / follow-02 
            :ARG0 (l / level 
                  :mod (a2 / activity)) 
            :ARG1 (c / cycle-02 
                  :ARG1 (d3 / diurnal) 
                  :ARG1-of (n / normal-02 
                        :degree (r / relative))) 
            :purpose (d2 / decrease-01 
                  :degree (s / substantial) 
                  :time (h / hour 
                        :unit-of (t / temporal-quantity 
                              :quant (d / daylight))))))

# ::snt However , even during the light phase , the tTA/APP mice remained many-fold more active than normal controls .
# ::tok However , even during the light phase , the tTA/APP mice remained many-fold more active than normal controls .
# ::alignments 17-18|0.0.0.0 16-17|0.0.0.0.0 14-15|0.0.0 13-14|0.0.0.1 11-12|0 10-11|0.0 6-7|0.1 5-6|0.1.0 2-3|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:11.761
(r / remain-01 
      :ARG1 (m2 / mouse 
            :ARG1-of (a / activity-06 
                  :compared-to (c / control-01 
                        :ARG1-of (n / normal-02)) 
                  :degree (m / more))) 
      :time (p / phase 
            :ARG1-of (l / light-06) 
            :mod (e / even)))

# ::snt This behavior was partially , but not consistently , reversed by 1 mo of transgene suppression beginning at 4 -- 5 mo of age ( data not shown ) .
# ::tok This behavior was partially , but not consistently , reversed by 1 mo of transgene suppression beginning at 4 -- 5 mo of age ( data not shown ) .
# ::alignments 27-28|0.2.0.1.0 26-27|0.2.0.1.0.1 25-26|0.2.0.1.0.0 23-24|0.2.1.1 20-21|0.0 18-19|0.2.1.2 16-17|0.2.1 15-16|0.2.1.0 14-15|0.2.1.0.1 12-13|0.2.1.0.2 11-12|0.2.0.0 9-10|0.2 7-8|0.1 6-7|0.1.0 5-6|0 3-4|0.2.1.0.0 1-2|0.2.0 0-1|0.2.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:12.445
(c2 / contrast-01 
      :ARG0 5 
      :ARG1 (c / consistent 
            :polarity -) 
      :ARG2 (r / reverse-01 
            :ARG0 (b2 / behave-01 
                  :ARG1 1 
                  :mod (t2 / this 
                        :ARG0-of (s / show-01 
                              :ARG1 (d / data) 
                              :polarity -))) 
            :ARG1-of (b / begin-01 
                  :ARG0 (s2 / suppress-01 
                        :ARG0 (p / partial) 
                        :ARG1 (t / transgene) 
                        :mod-of (m / mo)) 
                  :ARG1-of (a / age-01) 
                  :time 4)))

# ::snt In contrast , hyperactivity was completely abolished by rearing tTA/APP mice on dox .
# ::tok In contrast , hyperactivity was completely abolished by rearing tTA/APP mice on dox .
# ::alignments 12-13|0.0.2.0.0 10-11|0.0.2.0 8-9|0.0.2 6-7|0.0 5-6|0.0.1 3-4|0.0.0 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:12.532
(c2 / contrast-01 
      :ARG1 (a / abolish-01 
            :ARG1 (h / hyperactivity) 
            :ARG1-of (c / complete-02) 
            :ARG2 (r / rear-01 
                  :ARG1 (m / mouse 
                        :location (d / dox)))))

# ::snt Animals born and raised on dox showed activity levels similar to the untreated controls ( Figure 7C ) .
# ::tok Animals born and raised on dox showed activity levels similar to the untreated controls ( Figure 7C ) .
# ::alignments 15-16|0.1.0 13-14|0.0.0.0.0.0.0 12-13|0.0.0.0.0.0.0.0 9-10|0.0.0.0.0.0 8-9|0.0.0.0.0 7-8|0.0.1.0 6-7|0.0.0.0 5-6|0.0.1 3-4|0.1 2-3|0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:12.613
(a2 / and 
      :op1 (b / bear-02 
            :ARG1 (a3 / animal 
                  :ARG0-of (s / show-01 
                        :ARG1 (l / level 
                              :ARG1-of (r / resemble-01 
                                    :ARG2 (c / control-01 
                                          :mod (u / untreat)))))) 
            :location (d / dox 
                  :ARG1-of (a / activity-06))) 
      :op2 (r2 / raise-01 
            :ARG1 (f / figure)))

# ::snt Intriguingly , all of the dox-reared animals , both transgenic and wild-type , showed altered circadian rhythms with far less distinction between their day - and nighttime activity levels .
# ::tok Intriguingly , all of the dox-reared animals , both transgenic and wild-type , showed altered circadian rhythms with far less distinction between their day - and nighttime activity levels .
# ::alignments 28-29|0.2.1.0 27-28|0.2.1.0.0 26-27|0.2.1.0.0.0 25-26|0.2.1 23-24|0.2.0 20-21|0.2 19-20|0.1.1 18-19|0.1.1.0 16-17|0.1.0 15-16|0.1.0.0 14-15|0.1 13-14|0 10-11|0.3 8-9|0.3.0 6-7|0.4 5-6|0.4.0 2-3|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:13.141
(s / show-01 
      :ARG0 (a6 / all) 
      :ARG1 (a3 / alter-01 
            :ARG1 (r / rhythm 
                  :mod (c / circadian)) 
            :op1-of (l2 / less 
                  :degree (f / far))) 
      :ARG2 (d2 / distinguish-01 
            :ARG1 (d / day) 
            :op1-of (a2 / and 
                  :op2 (l / level 
                        :mod (a / activity-06 
                              :ARG0 (n / nighttime))))) 
      :manner (a4 / and 
            :mod (b / both)) 
      :manner (a5 / animal 
            :mod (d3 / dox-rear)))

# ::snt We present a new mouse model for AD that was designed to test the consequences of inhibiting A production after the onset of amyloid pathology .
# ::tok We present a new mouse model for AD that was designed to test the consequences of inhibiting A production after the onset of amyloid pathology .
# ::alignments 24-25|0.0.0.0.0 23-24|0.0.0.0.0.0 21-22|0 19-20|0.0 18-19|0.0.0.0 16-17|0.0.0 14-15|0.0.0.1 12-13|0.0.0.1.0 10-11|0.0.0.1.0.0 7-8|0.0.0.1.0.0.0 5-6|0.0.0.1.0.0.1 4-5|0.0.0.1.0.0.1.1 3-4|0.0.0.1.0.0.1.2 1-2|0.0.0.1.0.0.1.0 0-1|0.0.0.1.0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:13.394
(o / onset 
      :op1-of (a2 / after 
            :time-of (i / inhibit-01 
                  :ARG1 (p2 / produce-01 
                        :ARG1 (p / pathology 
                              :mod (a / amyloid))) 
                  :mod-of (c / consequence 
                        :ARG1-of (t / test-01 
                              :ARG3-of (d / design-01 
                                    :ARG0 "AD" 
                                    :ARG1 (m / model 
                                          :manner-of (p3 / present 
                                                :ARG0 (w / we)) 
                                          :mod (m2 / mouse) 
                                          :mod (n / new))))))))

# ::snt New lines of transgenic mice were developed for this study that express high levels of APPswe/ind under the control of a tetracycline-responsive promoter .
# ::tok New lines of transgenic mice were developed for this study that express high levels of APPswe/ind under the control of a tetracycline-responsive promoter .
# ::alignments 22-23|0.1 18-19|0.1.0 13-14|0.2.0.0 12-13|0.2.0.0.0 11-12|0.2.0 9-10|0.2 8-9|0.2.1 6-7|0 4-5|0.0 1-2|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:13.553
(d / develop-02 
      :ARG1 (m / mouse 
            :consist (l2 / line 
                  :mod (n / new))) 
      :ARG1-of (p / promote-01 
            :ARG1-of (c / control-01)) 
      :ARG2 (s / study-01 
            :ARG0-of (e / express-01 
                  :ARG1 (l / level 
                        :ARG1-of (h / high-02))) 
            :mod (t / this)))

# ::snt We demonstrate that treatment with dox suppresses steady-state levels of both APPswe/ind and its C-terminal fragments , indicating that the mutant proteins have a relatively short half-life in vivo .
# ::tok We demonstrate that treatment with dox suppresses steady-state levels of both APPswe/ind and its C-terminal fragments , indicating that the mutant proteins have a relatively short half-life in vivo .
# ::alignments 28-29|0.0.0.0.0.0.1.0.0 26-27|0.0.0.0.0.0.1.0 25-26|0.0.0.0.0.0.1.0.1 24-25|0.0.0.0.0.0.0 21-22|0 20-21|0.0 17-18|0.0.0.0.0.0.1 15-16|0.0.0 12-13|0.0.0.0 10-11|0.0.0.0.2 8-9|0.0.0.0.1 6-7|0.0.0.0.0 5-6|0.0.0.0.0.0.2 3-4|0.0.0.0.0.0 1-2|0.0.0.0.0.1 0-1|0.0.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:13.729
(p / protein 
      :mod (m / mutant 
            :ARG1-of (f / fragment-01 
                  :op1-of (a / and 
                        :ARG1-of (s2 / suppress-01 
                              :ARG0 (t / treat-03 
                                    :ARG0 (r / relative) 
                                    :ARG0-of (i / indicate-01 
                                          :ARG1 (h / half-life 
                                                :location (v / vivo) 
                                                :mod (s / short))) 
                                    :ARG1 (d / dox)) 
                              :ARG1-of (d2 / demonstrate-01 
                                    :ARG0 (w / we))) 
                        :extent (l / level) 
                        :mod (b / both)))))

# ::snt Transgenic expression of APPswe/ind and consequent overproduction of A42 cause early-onset amyloid deposition in untreated mice , in which deposits appear as early as 2 mo of age .
# ::tok Transgenic expression of APPswe/ind and consequent overproduction of A42 cause early-onset amyloid deposition in untreated mice , in which deposits appear as early as 2 mo of age .
# ::alignments 27-28|0.0.0.0 25-26|0.0.0.0.1 24-25|0.0.0.0.1.0 22-23|0.0.0.0.0.1 20-21|0.0.0.0.0 19-20|0.0.0.0.0.0 15-16|0.2 14-15|0.2.0 12-13|0.1 11-12|0.1.0 9-10|0 8-9|0.0.1.1.0.0+0.0.1.1.0+0.0.1.1 6-7|0.0.1 5-6|0.0.1.0 4-5|0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:13.910
(c / cause-01 
      :ARG0 (a4 / and 
            :ARG1-of (e2 / express-01 
                  :ARG1-of (a / age-01 
                        :time-of (a2 / appear-02 
                              :ARG1 (d / deposit) 
                              :time (e / early)) 
                        :time-of (m / mo 
                              :quant 2))) 
            :op1 (o / overproduction 
                  :mod (c3 / consequent) 
                  :poss (c2 / country 
                        :name (n / name 
                              :op1 "A42")))) 
      :ARG1 (d2 / deposition 
            :mod (a3 / amyloid)) 
      :location (m2 / mouse 
            :mod (u / untreat)))

# ::snt Amyloid burden worsens significantly with age , and by 9 mo , the hippocampus and cortex of untreated mice are largely filled with aggregated peptide .
# ::tok Amyloid burden worsens significantly with age , and by 9 mo , the hippocampus and cortex of untreated mice are largely filled with aggregated peptide .
# ::alignments 24-25|0.0.0 23-24|0.0.0.0 21-22|0.0 20-21|0.0.1 18-19|0.1.0 17-18|0.1.0.0 15-16|0.2 14-15|0 13-14|0.1 9-10|0.0.2.0.1.0 7-8|0.0.2 5-6|0.0.2.0.2 3-4|0.0.2.0.1 2-3|0.0.2.0 1-2|0.0.2.0.0 0-1|0.0.2.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:14.207
(a2 / and 
      :ARG1-of (f / fill-01 
            :ARG2 (p / peptide 
                  :ARG1-of (a / aggregate-01)) 
            :degree (l / large) 
            :op2-of (a3 / and 
                  :op1 (w / worsen-01 
                        :ARG0 (b / burden-01 
                              :mod (a5 / amyloid)) 
                        :ARG2 (s / significant-02 
                              :ARG1 9) 
                        :manner (a4 / age-01)))) 
      :op1 (h / hippocampu 
            :poss (m / mouse 
                  :mod (u / untreat))) 
      :op2 (c / cortex))

# ::snt We find that suppression of transgenic APP by more than 95 % abruptly halts the progression of amyloid pathology .
# ::tok We find that suppression of transgenic APP by more than 95 % abruptly halts the progression of amyloid pathology .
# ::alignments 18-19|0.0.1 17-18|0.0.1.0 15-16|0.0 13-14|0 12-13|0.1 11-12|0.0.1.1 10-11|0.0.1.1.0 8-9|0.0.0.0 6-7|0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 3-4|0.0.0 1-2|0.0.2 0-1|0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:14.577
(h / halt-01 
      :ARG1 (p2 / progress-01 
            :ARG0 (s / suppress-01 
                  :ARG0 (m / more) 
                  :ARG1 (o / organization 
                        :name (n / name 
                              :op1 "APP"))) 
            :ARG1 (p / pathology 
                  :mod (a / amyloid) 
                  :poss (p3 / percentage-entity 
                        :value 95)) 
            :ARG1-of (f / find-01 
                  :ARG0 (w / we))) 
      :manner (a2 / abrupt))

# ::snt Importantly , this outcome occurs in animals already harboring considerable amyloid pathology , a situation similar to what might be expected in patients to be treated with secretase inhibitors .
# ::tok Importantly , this outcome occurs in animals already harboring considerable amyloid pathology , a situation similar to what might be expected in patients to be treated with secretase inhibitors .
# ::alignments 28-29|0.0.3 27-28|0.0.3.0 25-26|0.0 22-23|0.0.1.0.0+0.0.1.0+0.0.1 20-21|0 18-19|0.1 15-16|0.2 14-15|0.2.0 11-12|0.0.2.1.1 10-11|0.0.2.1.1.1 9-10|0.0.2.1.1.0 8-9|0.0.2.1 7-8|0.0.2.1.2 6-7|0.0.2.1.0 4-5|0.0.2 3-4|0.0.2.0 2-3|0.0.2.0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:15.146
(e / expect-01 
      :ARG1 (t / treat-01 
            :ARG0 (i2 / importantly) 
            :ARG1 (p / person 
                  :ARG0-of (h / have-rel-role-91 
                        :ARG2 (p2 / patient))) 
            :ARG1-of (o / occur-01 
                  :ARG0 (o2 / outcome 
                        :mod (t2 / this)) 
                  :manner (h2 / harbor-01 
                        :ARG0 (a3 / animal) 
                        :ARG1 (p4 / pathology 
                              :mod (c / considerable) 
                              :mod (a / amyloid)) 
                        :time (a2 / already))) 
            :ARG2 (i / inhibitor 
                  :mod (s / secretase))) 
      :ARG1-of (p3 / possible-01) 
      :ARG2-of (r / resemble-01 
            :ARG1 (s2 / situation)))

# ::snt Somewhat unexpectedly , we observe no appreciable clearance of deposited amyloid even following periods of transgene suppression equal to the time taken for plaques to form .
# ::tok Somewhat unexpectedly , we observe no appreciable clearance of deposited amyloid even following periods of transgene suppression equal to the time taken for plaques to form .
# ::alignments 25-26|0.1.0.0 23-24|0.1.0.0.0 21-22|0.1.0 20-21|0.1 17-18|0 16-17|0.0 15-16|0.0.0 13-14|0.0.1 12-13|0.0.1.0 11-12|0.0.1.0.1 9-10|0.0.1.0.0.1.0 7-8|0.0.1.0.0.1 6-7|0.0.1.0.0.1.1 5-6|0.0.1.0.0.2 4-5|0.0.1.0.0 3-4|0.0.1.0.0.0 1-2|0.1.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:15.465
(e / equal-01 
      :ARG1 (s / suppress-01 
            :mod (t3 / transgene) 
            :mod-of (p2 / period 
                  :ARG2-of (f2 / follow-01 
                        :ARG1 (o / observe-01 
                              :ARG0 (w / we) 
                              :ARG1 (c / clear-02 
                                    :ARG1 (d / deposit-01) 
                                    :ARG1-of (a / appreciate-03)) 
                              :polarity -) 
                        :time (e2 / even)))) 
      :ARG2 (t2 / time 
            :time-of (t / take-01 
                  :ARG1 (f / form-01 
                        :ARG0 (p / plaqu) 
                        :ARG1 (u / unexpectedly)))))

# ::snt This latter finding indicates that compared to other disease-associated protein aggregates such as mutant huntingtin , which clear in less than 3 mo [ 32 ] , the disaggregation of extracellular amyloid is relatively slow .
# ::tok This latter finding indicates that compared to other disease-associated protein aggregates such as mutant huntingtin , which clear in less than 3 mo [ 32 ] , the disaggregation of extracellular amyloid is relatively slow .
# ::alignments 34-35|0.1.0.0 33-34|0.1.0.0.0 31-32|0.1.0.1 30-31|0.1.0.1.0 28-29|0.1.0 24-25|0.0.0 22-23|0.0.3 21-22|0.2 19-20|0.1.1.2.0.0 17-18|0.1.1.2.0 14-15|0.1.1.2 13-14|0.1.1.2.1 11-12|0.1.1.0 10-11|0.1.1 9-10|0.1.1.1 8-9|0.1.1.4 7-8|0.1.1.3 5-6|0.1 3-4|0 2-3|0.0 1-2|0.0.1 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:16.279
(i / indicate-01 
      :ARG0 (f / find-01 
            :ARG0 32 
            :mod (l2 / latter) 
            :mod (t / this) 
            :op1-of (m / mo)) 
      :ARG1 (c2 / compare-01 
            :ARG1 (d / disaggregation 
                  :domain-of (s / slow 
                        :mod (r / relative)) 
                  :mod (a / amyloid 
                        :mod (e / extracellular))) 
            :ARG2 (a2 / aggregate-01 
                  :ARG0 (s2 / such) 
                  :ARG1 (p / protein) 
                  :example (h / huntingtin 
                        :ARG1-of (c / clear-06 
                              :ARG2 (l / less)) 
                        :mod (m2 / mutant)) 
                  :mod (o / other) 
                  :mod (d2 / disease-associat))) 
      :ARG2 3)

# ::snt Notably , pharmaceutical -secretase inhibitors published to date show less strict regulation of A production following chronic administration than we have attained here .
# ::tok Notably , pharmaceutical -secretase inhibitors published to date show less strict regulation of A production following chronic administration than we have attained here .
# ::alignments 22-23|0.1.1.1 21-22|0.1.1 19-20|0.1.1.0 17-18|0.1.0.0.0 16-17|0.0.0.0 15-16|0.1.0.0 14-15|0.1.0 11-12|0.1 10-11|0.1.2 9-10|0.1.2.0 8-9|0 7-8|0.0.0.1 5-6|0.0.0 4-5|0.0 2-3|0.0.1 0-1|0.1.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:16.443
(s2 / show-01 
      :ARG0 (i / inhibitor 
            :ARG1-of (p2 / publish-01 
                  :ARG0 (c / chronic) 
                  :ARG2 (d / date)) 
            :mod (p3 / pharmacy)) 
      :ARG1 (r / regulate-01 
            :ARG1 (p / produce-01 
                  :ARG1-of (f / follow-01 
                        :ARG2 (a2 / administrate-01 
                              :ARG1 (n / notably)))) 
            :condition (a / attain-01 
                  :ARG0 (w / we) 
                  :location (h / here)) 
            :mod (s / strict 
                  :extent (l / less))))

# ::snt Two independent compounds tested in Tg2576 [ 33 ] and TgCRND8 [ 34 ] transgenic mice show no more than 85 % suppression of A40 levels , and where measured , even less suppression of A42 ( approximately 60 % ) [ 35,36 ] .
# ::tok Two independent compounds tested in Tg2576 [ 33 ] and TgCRND8 [ 34 ] transgenic mice show no more than 85 % suppression of A40 levels , and where measured , even less suppression of A42 ( approximately 60 % ) [ 35,36 ] .
# ::alignments 39-40|0.1.0 38-39|0.1.0.1 37-38|0.1.0.0 35-36|0.1.1.0.0+0.1.1.0+0.1.1 33-34|0.1 32-33|0.1.3 31-32|0.1.3.0 29-30|0.1.2 27-28|0 25-26|0.0.1.1 24-25|0.0.1.1.0.0.0+0.0.1.1.0.0+0.0.1.1.0 22-23|0.0.1 21-22|0.0.1.0 20-21|0.1.2.0.0.0 18-19|0.0.1.1.0.1 17-18|0.1.2.0.0.2 16-17|0.0 15-16|0.0.0 12-13|0.0.0.0 10-11|0.0.2.0.0.0.0+0.0.2.0.0.0+0.0.2.0.0 9-10|0.0.2.0 7-8|0.1.2.1 5-6|0.1.2.0.1.0.0+0.1.2.0.1.0+0.1.2.0.1 3-4|0.0.2 2-3|0.1.2.0 1-2|0.1.2.0.0.1+0.1.2.0.0 0-1|0.1.2.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:17.514
(a2 / and 
      :op1 (s3 / show-01 
            :ARG0 (m3 / mouse 
                  :quant 34) 
            :ARG1 (s2 / suppress-01 
                  :ARG0 (p4 / percentage-entity) 
                  :ARG1 (l2 / level 
                        :mod (p3 / person 
                              :name (n2 / name 
                                    :op1 "A40") 
                              :quant (m2 / more)))) 
            :ARG1-of (t / test-01 
                  :op1-of (a3 / and 
                        :op2 (p5 / person 
                              :name (n3 / name 
                                    :op1 "TgCRND8"))))) 
      :op2 (s / suppress-01 
            :ARG0 (p / percentage-entity 
                  :op1-of (a / approximately) 
                  :value 60) 
            :ARG1 (p2 / person 
                  :name (n / name 
                        :op1 "A42")) 
            :ARG1-of (m / measure-01 
                  :ARG0 (c2 / compound-01 
                        :ARG0-of (d / depend-01 
                              :ARG1 85 
                              :polarity - 
                              :polarity -) 
                        :ARG1 (c / country 
                              :name (n4 / name 
                                    :op1 "Tg2576")) 
                        :quant 2) 
                  :ARG2 33) 
            :degree (l / less 
                  :mod (e / even))))

# ::snt Thus , even after accounting for the much higher APP expression levels in our mice than in the Tg2576 and TgCRND8 lines , we have achieved better absolute suppression of A production with the tet-off system than is currently possible with published -secretase inhibitors .
# ::tok Thus , even after accounting for the much higher APP expression levels in our mice than in the Tg2576 and TgCRND8 lines , we have achieved better absolute suppression of A production with the tet-off system than is currently possible with published -secretase inhibitors .
# ::alignments 43-44|0.2.0.0 41-42|0.2.0 39-40|0.2 38-39|0.2.1 35-36|0.1.0.1.0.0.1 31-32|0.1.0.1.0.0.0.0.0 28-29|0.1.0.1.0.0.0.0 27-28|0.1.0.1.0.0.0.0.2 26-27|0.1.0.1.0.0.0.0.1 25-26|0.1.0.1.0.0.0 23-24|0.1.0.1.0.0 21-22|0.1.1 20-21|0.1.2.0+0.1.2+0.1 19-20|0 18-19|0.0.0.0+0.0.0+0.0 14-15|0.1.0.1.2 13-14|0.1.0.1.2.0 11-12|0.1.0.1 10-11|0.1.0 9-10|0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 8-9|0.1.0.1.1 7-8|0.1.0.1.0.0.0.0.0.0 4-5|0.1.0.1.0 3-4|0.1.0.1.0.1 2-3|0.1.0.1.0.1.0 0-1|0.1.0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:18.204
(a3 / and 
      :op1 (c2 / country 
            :name (n2 / name 
                  :op1 "Tg2576")) 
      :op2 (p4 / person 
            :ARG0-of (e / express-01 
                  :ARG1 (o / organization 
                        :name (n3 / name 
                              :op1 "APP")) 
                  :mod-of (l2 / level 
                        :ARG1-of (a4 / account-01 
                              :ARG0 (w / we 
                                    :ARG0-of (a2 / achieve-01 
                                          :ARG1 (s2 / suppress-01 
                                                :ARG1 (p3 / produce-01 
                                                      :ARG1 (m2 / much)) 
                                                :mod (g / good) 
                                                :mod (a / absolute))) 
                                    :poss-of (s / system)) 
                              :op1-of (a5 / after 
                                    :op1-of (e2 / even))) 
                        :ARG1-of (h / high-02 
                              :ARG0 (t / thu)) 
                        :poss (m / mouse 
                              :poss (w2 / we)))) 
            :mod-of (l / line) 
            :name (n / name 
                  :op1 "TgCRND8")) 
      :op3 (p2 / possible-01 
            :ARG1 (p / publish-01 
                  :ARG1 (i / inhibitor)) 
            :time (c / current)))

# ::snt Since even the most advanced future pharmaceutical agents are unlikely to attain more complete control of A production than achieved here , this system provides a salient test of therapeutic intervention with A-lowering compounds .
# ::tok Since even the most advanced future pharmaceutical agents are unlikely to attain more complete control of A production than achieved here , this system provides a salient test of therapeutic intervention with A-lowering compounds .
# ::alignments 33-34|0.0.0.0.0.2.2.0.0.0 32-33|0.0.0.0.0.2.2.0.0.0.0 30-31|0.0.0.0.0.2.2.1 29-30|0.0.0.0.0.2.2.1.0 27-28|0.0.0.0.0.2.2 26-27|0.0.0.0.0.2.2.2 24-25|0.0.0.0.0.2.2.0.0 23-24|0.0.0.0.0.2.2.0 22-23|0.0.0.0.0.2.2.0.1 20-21|0.0.0.0.0.0.0.0.0 19-20|0.0.0.0.0.0.0.0 17-18|0.0.0.0.0.0.0 14-15|0.0.0.0.0.0 13-14|0.0.0.0.0.0.1 12-13|0.0.0.0.0.0.1.0 11-12|0.0.0.0.0 9-10|0.0.0.0.0.1.0+0.0.0.0.0.1 7-8|0.0+0.0.0+0.0.0.0 6-7|0 5-6|0.0.0.0.0.2 4-5|0.0.0.0.0.2.0 3-4|0.0.0.0.0.2.0.0 1-2|0.0.0.0.0.2.1 0-1|0.0.0.0.0.2.2.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:18.977
(p4 / pharmacy 
      :mod-of (a4 / agent 
            :ARG2-of (h2 / have-org-role-91 
                  :ARG0 (p3 / person 
                        :ARG0-of (a3 / attain-01 
                              :ARG1 (c2 / control-01 
                                    :ARG1 (p2 / produce-01 
                                          :ARG2 (a2 / achieve-01 
                                                :location (h / here))) 
                                    :ARG1-of (c3 / complete-02 
                                          :degree (m / more))) 
                              :ARG1-of (l / likely-01 
                                    :polarity -) 
                              :ARG2 (f / future 
                                    :ARG1-of (a5 / advanced-02 
                                          :degree (m2 / most)) 
                                    :mod (e / even) 
                                    :time-of (t2 / test-01 
                                          :ARG0 (s2 / system 
                                                :ARG0-of (p / provide-01 
                                                      :ARG1 (c / compound-01 
                                                            :mod (a / a-lower)) 
                                                      :time (s3 / since)) 
                                                :mod (t3 / this)) 
                                          :ARG1 (i / intervene-01 
                                                :ARG0 (t / therapeutic)) 
                                          :mod (s / salient))))))))

# ::snt Although the progression of amyloid deposition was sharply arrested by this approach , we found that a substantial amyloid burden remained even after long periods of transgene suppression .
# ::tok Although the progression of amyloid deposition was sharply arrested by this approach , we found that a substantial amyloid burden remained even after long periods of transgene suppression .
# ::alignments 27-28|0.0.0.0.2.1.1.0.1 26-27|0.0.0.0.2.1.1.0.1.0 24-25|0.0.0.0.2.1.1.0 23-24|0.0.0.0.2.1.1.0.0 22-23|0.0.0.0.2.1.1 21-22|0.0.0.0.2.1.1.1 20-21|0.0.0.0.2.1 19-20|0.0.0.0.2.1.0 18-19|0.0.0.0.0.1 17-18|0.0.0.0.2.1.0.0 14-15|0.0.0.0.2 13-14|0.0.0.0.2.0 11-12|0.0.0.0.0 10-11|0.0.0.0.0.0 8-9|0.0.0.0 7-8|0.0.0.0.1 5-6|0.0 4-5|0 2-3|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:19.136
(a5 / amyloid 
      :mod-of (d / deposition 
            :ARG1-of (p2 / progress-01 
                  :ARG1-of (a4 / arrest-01 
                        :ARG0 (a3 / approach-02 
                              :mod (t2 / this) 
                              :poss-of (a2 / amyloid)) 
                        :manner (s3 / sharp) 
                        :time-of (f / find-01 
                              :ARG0 (w / we) 
                              :ARG1 (r / remain-01 
                                    :ARG1 (b / burden-01 
                                          :mod (s2 / substantial)) 
                                    :time (a / after 
                                          :op1 (p / period 
                                                :ARG1-of (l / long-03) 
                                                :mod (s / suppress-01 
                                                      :ARG1 (t / transgene))) 
                                          :op1-of (e / even))))))))

# ::snt We examined a small number of animals after 12 mo of dox treatment ( beginning at 6 mo of age ) , and found that amyloid deposits were still relatively abundant .
# ::tok We examined a small number of animals after 12 mo of dox treatment ( beginning at 6 mo of age ) , and found that amyloid deposits were still relatively abundant .
# ::alignments 30-31|0.0.2.2.0.1 29-30|0.0.0 28-29|0.0.2.2.0.1.1 26-27|0.0.2.2.0.1.0 25-26|0.0.2.2.1 23-24|0.0.2.2.0 22-23|0.0.2.2 19-20|0 16-17|0.0.2.2.0.0 14-15|0.0.2.1.0 12-13|0.0 11-12|0.0.1 9-10|0.0.2.1 8-9|0.0.2.0 7-8|0.0.2 6-7|0.0.2.3.1.1 4-5|0.0.2.3.1 3-4|0.0.2.3.1.0 1-2|0.0.2.3 0-1|0.0.2.3.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:19.469
(a4 / age-01 
      :ARG1 (t / treat-03 
            :ARG0 (r / relative) 
            :ARG2 (d2 / dox) 
            :op3-of (a5 / after 
                  :op1 12 
                  :op2 (m / mo 
                        :ARG1-of (b / begin-01)) 
                  :time-of (a3 / and 
                        :op1 (f / find-01 
                              :ARG0 6 
                              :ARG1 (a / abundance 
                                    :domain (d / deposit) 
                                    :mod (s / still))) 
                        :op2 (a2 / amyloid)) 
                  :time-of (e / examine-01 
                        :ARG0 (w / we) 
                        :ARG1 (n / number 
                              :mod (s2 / small) 
                              :quant-of (a6 / animal))))))

# ::snt Longer-term treatments are now in progress .
# ::tok Longer-term treatments are now in progress .
# ::alignments 5-6|0.0 3-4|0.1 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:19.479
(t / treat-03 
      :ARG1-of (p / progress-01) 
      :time (n / now))

# ::snt At the latest treatment interval analyzed by ELISA , animals administered dox for 6 mo showed elevated levels of PBS-soluble A ( see Figure 5 ) that could be interpreted as an indication that the plaques are slowly releasing peptide ( or oligomeric A ) into the soluble pool and might eventually dissolve .
# ::tok At the latest treatment interval analyzed by ELISA , animals administered dox for 6 mo showed elevated levels of PBS-soluble A ( see Figure 5 ) that could be interpreted as an indication that the plaques are slowly releasing peptide ( or oligomeric A ) into the soluble pool and might eventually dissolve .
# ::alignments 52-53|0.0.0 51-52|0.0.0.3 50-51|0.0.0.1 49-50|0.0.0.1.0 48-49|0.0.0.2 47-48|0.0.0.2.0 41-42|0.0.0.1.0.0.1.0 39-40|0.0.0.1.0.0.1 38-39|0.0.0.1.0.0 37-38|0.0.0.1.0.0.2 35-36|0.0.0.1.0.0.0 32-33|0.0.1.2 29-30|0.0.1 27-28|0.0.1.1 24-25|0.2.1.0 23-24|0.0.0.0.0 22-23|0.0.0.0 19-21|0.0.1.0.0.1+0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 17-18|0.1 16-17|0.1.0 15-16|0 14-15|0.0.2.1 13-14|0.0.1.1.0 11-12|0.0.2.0 10-11|0.0.2 9-10|0.0 7-8|0.2.0.0.0.0+0.2.0.0.0+0.2.0.0 5-6|0.2.0 4-5|0.2 3-4|0.2.1 2-3|0.2.2.0+0.2.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:21.931
(s4 / show-01 
      :ARG0 (a4 / animal 
            :ARG0-of (d / dissolve-01 
                  :ARG1 (s3 / see-01 
                        :ARG1 (f / figure)) 
                  :ARG1-of (p / possible-01 
                        :op2-of (a / and 
                              :op1 (r / release-01 
                                    :ARG0 (p4 / plaqu) 
                                    :ARG1 (p3 / peptide 
                                          :op1-of (o / or)) 
                                    :manner (s2 / slow)))) 
                  :ARG2 (p2 / pool 
                        :mod (s / soluble)) 
                  :time (e / eventual)) 
            :ARG0-of (i2 / interpret-01 
                  :ARG1 (t / thing 
                        :name (n / name 
                              :op1 (p6 / PBS-soluble) 
                              :op2 (a2 / A))) 
                  :ARG1-of (p5 / possible-01 
                        :ARG0 6) 
                  :ARG2 (i / indicate-01)) 
            :ARG0-of (a3 / administer-01 
                  :ARG1 (d2 / dox) 
                  :duration (m / mo))) 
      :ARG1 (l / level 
            :ARG1-of (e2 / elevate-01)) 
      :time (i3 / interval 
            :ARG1-of (a5 / analyze-01 
                  :ARG0 (o2 / organization 
                        :name (n2 / name 
                              :op1 "ELISA"))) 
            :mod (t2 / treat-03 
                  :ARG1 5) 
            :time (l2 / late 
                  :degree (m2 / most))))

# ::snt Whether inhibiting A production longer than 6 ( or 12 ) mo may ultimately result in clearance of amyloid is under investigation ; unfortunately , the life span of the model eventually limits this experiment .
# ::tok Whether inhibiting A production longer than 6 ( or 12 ) mo may ultimately result in clearance of amyloid is under investigation ; unfortunately , the life span of the model eventually limits this experiment .
# ::alignments 34-35|0.0.0.0.1.1.0 33-34|0.0.0.0.1.1.0.2 32-33|0.0.0.0.1.1 31-32|0.0.0.0.1.1.1 30-31|0.0.0.0.1.2 27-28|0.0.0.0.1 26-27|0.0.0.0.1.0 23-24|0.0.0.0.1.1.0.1.0+0.0.0.0.1.1.0.1 22-23|0.0.0.0.1.1.0.0 21-22|0.0.2.1 18-19|0.0.2.0 16-17|0.0.2 14-15|0.0 13-14|0.0.1 12-13|0 9-10|0.0.0.0.0.0 8-9|0.0.0.0.0 6-7|0.0.2.1.0 3-4|0.0.0.0 1-2|0.0.0 0-1|0.0.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:22.317
(p / possible-01 
      :ARG1 (r / result-01 
            :ARG0 (i2 / inhibit-01 
                  :ARG1 (p2 / produce-01 
                        :ARG0 (o / or 
                              :op1 12) 
                        :ARG1 (s / span-01 
                              :ARG0 (l2 / life) 
                              :ARG0-of (l / limit-01 
                                    :ARG1 (e / experiment-01 
                                          :ARG1 (a / and) 
                                          :ARG2-of (f / fortunate-01 
                                                :polarity -) 
                                          :mod (t / this)) 
                                    :time (e2 / eventual)) 
                              :ARG1 (m / model)))) 
            :ARG1 (u / ultimate) 
            :ARG2 (c / clear-02 
                  :ARG1 (a2 / amyloid) 
                  :condition (i / investigate-01 
                        :ARG1 6)) 
            :op1-of (w / wheth)))

# ::snt Therapeutics used in humans will have considerably more time to act than is possible within the life span of rodent models .
# ::tok Therapeutics used in humans will have considerably more time to act than is possible within the life span of rodent models .
# ::alignments 20-21|0.0 19-20|0 17-18|0.0.0 16-17|0.0.0.0 13-14|0.0.0.1 10-11|0.0.0.1.1 8-9|0.0.0.1.1.1 7-8|0.0.0.1.1.1.0 6-7|0.0.0.1.0 3-4|0.0.0.1.1.0.0.0 1-2|0.0.0.1.1.0.0 0-1|0.0.0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:22.475
(r / rodent 
      :mod-of (m / model 
            :ARG1-of (s / span-01 
                  :ARG0 (l / life) 
                  :ARG2-of (p / possible-01 
                        :ARG0 (c / considerable) 
                        :ARG1 (a / act-02 
                              :ARG0 (t2 / therapeutic 
                                    :ARG1-of (u / use-01 
                                          :ARG2 (h / human))) 
                              :purpose-of (t / time 
                                    :quant (m2 / more)))))))

# ::snt Long-term treatments would certainly be possible and could be a key to effective therapy .
# ::tok Long-term treatments would certainly be possible and could be a key to effective therapy .
# ::alignments 13-14|0.0.0 12-13|0.0.0.0 10-11|0.0 7-8|0 6-7|0.0.1 5-6|0.0.1.0 3-4|0.0.1.0.1 1-2|0.0.1.0.0 0-1|0.0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:22.551
(p / possible-01 
      :ARG1 (k / key-02 
            :ARG2 (t / therapy 
                  :ARG0-of (e / effective-04)) 
            :op2-of (a / and 
                  :op1 (p2 / possible-01 
                        :ARG1 (t2 / treat-03 
                              :mod (l / long-term)) 
                        :mod (c / certain)))))

# ::snt Overall , however , we interpret our findings as evidence that AD therapies that significantly lower the production of A ( by either inhibiting secretase activity or inhibiting APP expression ) may not quickly reverse preexisting pathology , but should effectively halt further deposition of amyloid .
# ::tok Overall , however , we interpret our findings as evidence that AD therapies that significantly lower the production of A ( by either inhibiting secretase activity or inhibiting APP expression ) may not quickly reverse preexisting pathology , but should effectively halt further deposition of amyloid .
# ::alignments 45-46|0.1.2.2.0.1.1 43-44|0.1.2.2.0.1 42-43|0.1.2.2.0.1.0 41-42|0.1.2.2.0 40-41|0.1.2.2.0.2 39-40|0.1.2.2 38-39|0.1.2 36-37|0.1.2.1.0 35-36|0.1.2.1.0.0 34-35|0.1.2.1 33-34|0.1.2.1.1 32-33|0.1.2.1.3 31-32|0.1.2.1.2 29-30|0 28-29|0.0.0.0+0.0.0+0.0 27-28|0.2 26-27|0.3 25-26|0.3.0 24-25|0.3.0.3 23-24|0.3.0.1 22-23|0.3.0.2 17-18|0.1.2.2.0.0 15-16|0.1.2.2.0.0.0 14-15|0.1.2.2.0.0.0.0 11-12|0.1.2.0 9-10|0.1.1.0.0.0 7-8|0.1.1.0+0.1.1 6-7|0.1.0 5-6|0.1 4-5|0.1.1.0.0 0-1|0.3.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:25.323
(e2 / express-01 
      :ARG0 (o / organization 
            :name (n / name 
                  :op1 "APP")) 
      :ARG1 (i3 / interpret-01 
            :ARG0 (w / we) 
            :ARG1 (t / thing 
                  :ARG1-of (f2 / find-01 
                        :ARG0 (w2 / we 
                              :ARG0-of (e4 / evidence-01)))) 
            :ARG2 (c / contrast-01 
                  :ARG0 "AD" 
                  :ARG1 (r2 / reverse-01 
                        :ARG1 (p / pathology 
                              :mod (p2 / preexist)) 
                        :ARG1-of (q / quick-02) 
                        :ARG1-of (p3 / possible-01) 
                        :polarity -) 
                  :ARG2 (r / recommend-01 
                        :ARG1 (h / halt-01 
                              :ARG0 (p4 / produce-01 
                                    :ARG1-of (l / low-04 
                                          :ARG1-of (s2 / significant-02))) 
                              :ARG1 (d / deposition 
                                    :mod (f / further) 
                                    :mod (a / amyloid)) 
                              :ARG1-of (e / effective-04))))) 
      :ARG1-of (i / inhibit-01) 
      :op2-of (o2 / or 
            :op1 (a2 / activity-06 
                  :ARG1 (o3 / overall) 
                  :ARG1-of (i2 / inhibit-01) 
                  :mod (e3 / either) 
                  :mod (s / secretase))))

# ::snt In interpreting our study , it should be remembered that the earliest plaques to appear in these mice , like other APP transgenics harboring the Swedish mutation [ 27 ] , are predominantly fibrillar deposits , which may be less tractable than the diffuse aggregates thought to come first in the course of the human disease .
# ::tok In interpreting our study , it should be remembered that the earliest plaques to appear in these mice , like other APP transgenics harboring the Swedish mutation [ 27 ] , are predominantly fibrillar deposits , which may be less tractable than the diffuse aggregates thought to come first in the course of the human disease .
# ::alignments 55-56|0.1.0.0.0 54-55|0.1.0.0 47-48|0.0 45-46|0 44-45|0.0.0 43-44|0.0.0.2 40-41|0.1 39-40|0.1.1 37-38|0.1.0 34-35|0.1.0.1 32-33|0.0.0.0 28-29|0.0.0.1.0.0.1.1.1.0 26-27|0.0.0.1.1 25-26|0.0.0.1.1.0.1+0.0.0.1.1.0.0.0+0.0.0.1.1.0.0+0.0.0.1.1.0 23-24|0.0.0.1 22-23|0.0.0.1.0 21-22|0.0.0.1.0.1.0.0+0.0.0.1.0.1.0+0.0.0.1.0.1 20-21|0.0.0.1.0.2 19-20|0.0.0.1.0.0 17-18|0.0.0.1.0.0.1.0 16-17|0.0.0.1.0.0.1.0.0 14-15|0.0.0.1.0.0.1 12-13|0.0.0.1.0.0.0 11-12|0.0.0.1.0.0.0.0.0+0.0.0.1.0.0.0.0 8-9|0.0.0.1.0.0.1.1 6-7|0.0.0.1.0.0.1.1.1 3-4|0.0.0.1.0.0.1.1.0.0 2-3|0.0.0.1.0.0.1.1.0 1-2|0.0.0.1.0.0.1.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:27.377
(t / think-01 
      :ARG1 (c / come-01 
            :ARG1 (a / aggregate-01 
                  :ARG0 (p2 / predominant) 
                  :ARG1 (h2 / harbor-01 
                        :ARG0 (t3 / transgenic 
                              :ARG2-of (r / resemble-01 
                                    :ARG1 (p3 / plaqu 
                                          :mod (e / early 
                                                :degree (m3 / most))) 
                                    :manner-of (a2 / appear-02 
                                          :ARG1 (m2 / mouse 
                                                :mod (t4 / this)) 
                                          :ARG1-of (r2 / remember-01 
                                                :ARG0 (w / we 
                                                      :ARG1-of (s / study-01 
                                                            :ARG1-of (i / interpret-01))) 
                                                :ARG1-of (r3 / recommend-01 
                                                      :ARG0 27)))) 
                              :mod (o / organization 
                                    :name (n2 / name 
                                          :op1 "APP")) 
                              :mod (o2 / other)) 
                        :ARG1 (m / mutation 
                              :mod (c2 / country 
                                    :name (n / name 
                                          :op1 "Sweden") 
                                    :wiki "Sweden"))) 
                  :ARG1-of (d2 / diffuse-01))) 
      :domain-of (t2 / tractable 
            :ARG1-of (p / possible-01 
                  :ARG0 (h / human 
                        :mod-of (d / disease)) 
                  :op1-of (d3 / deposit)) 
            :degree (l / less)))

# ::snt However , our data suggest that once diffuse deposits are formed in these mice , they are no more easily cleared in our system than cored plaques ( see Figure S4 ) .
# ::tok However , our data suggest that once diffuse deposits are formed in these mice , they are no more easily cleared in our system than cored plaques ( see Figure S4 ) .
# ::alignments 29-31|0.1.0.0.0.0.1+0.1.0.0.0.0.0+0.1.0.0.0.0+0.1.0.0.0 28-29|0.1.0.0 26-27|0.2.0 25-26|0.2 23-24|0.1.1 22-23|0.1.1.0 20-21|0.1 18-19|0.1.0.1.1 17-18|0.1.0.1.1.0 15-16|0.1.0 13-14|0.1.0.1.2 12-13|0.1.0.1.2.0 10-11|0.1.0.1 8-9|0.1.0.1.0 7-8|0.1.0.1.0.0 6-7|0.1.2 4-5|0 3-4|0.0 2-3|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:28.022
(s4 / suggest-01 
      :ARG0 (d3 / data 
            :poss (w2 / we)) 
      :ARG1 (c2 / clear-01 
            :ARG1 (t2 / they 
                  :ARG0-of (s2 / see-01 
                        :ARG1 (t / thing 
                              :name (n / name 
                                    :op1 (f / Figure) 
                                    :op2 (s / S4)))) 
                  :ARG0-of (f2 / form-01 
                        :ARG1 (d / deposit 
                              :ARG1-of (d2 / diffuse-01)) 
                        :degree (m / more 
                              :polarity -) 
                        :location (m2 / mouse 
                              :mod (t3 / this)))) 
            :location (s3 / system 
                  :poss (w / we)) 
            :time (o / once)) 
      :ARG2-of (c / core-01 
            :ARG1 (p / plaqu)))

# ::snt An additional consideration we recognize is that a small amount of transgene expression continues in the presence of dox and that endogenous mouse A continues to be produced .
# ::tok An additional consideration we recognize is that a small amount of transgene expression continues in the presence of dox and that endogenous mouse A continues to be produced .
# ::alignments 27-28|0.0 24-25|0.0.0 22-23|0 21-22|0.0.0.0.0 19-20|0.0.0.1 18-19|0.0.0.1.0.1.0 16-17|0.0.0.1.0.1 13-14|0.0.0.1.0 12-13|0.0.0.1.0.0.1 11-12|0.0.0.1.0.0.1.0 9-10|0.0.0.1.0.0 8-9|0.0.0.1.0.0.0 4-5|0.0.0.0.1 3-4|0.0.0.0.1.0 2-3|0.0.0.0 1-2|0.0.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:28.242
(m / mouse 
      :ARG1-of (p / produce-01 
            :ARG1-of (c / continue-01 
                  :ARG0 (c3 / consider-02 
                        :ARG1 (e / endogenou) 
                        :ARG1-of (r / recognize-02 
                              :ARG0 (w / we)) 
                        :mod (a3 / additional)) 
                  :op2-of (a / and 
                        :op1 (c2 / continue-01 
                              :ARG1 (a2 / amount 
                                    :mod (s / small) 
                                    :quant-of (e2 / express-01 
                                          :mod (t / transgene))) 
                              :location (p2 / presence 
                                    :mod (d / dox)))))))

# ::snt It is possible that the combined low levels of endogenous mouse A and nonsuppressed human peptide are sufficient to maintain existing deposits .
# ::tok It is possible that the combined low levels of endogenous mouse A and nonsuppressed human peptide are sufficient to maintain existing deposits .
# ::alignments 21-22|0.0.0.0 20-21|0.0.0.0.0 19-20|0.0.0 17-18|0.0.0.1 15-16|0.2 14-15|0.2.0 13-14|0.2.1 12-13|0 10-11|0.1.1 9-10|0.0.0.0.0.0 7-8|0.0 6-7|0.0.1 5-6|0.0.2 2-3|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:28.641
(a / and 
      :extent (l / level 
            :ARG0-of (m / maintain-01 
                  :ARG1 (d / deposit 
                        :ARG1-of (e / exist-01 
                              :ARG0 (e2 / endogenou))) 
                  :ARG1-of (s / suffice-01)) 
            :ARG1-of (l2 / low-04) 
            :ARG1-of (c / combine-01)) 
      :op1 (p2 / possible-01 
            :ARG1 (i / it) 
            :prep-with (m2 / mouse)) 
      :op2 (p / peptide 
            :mod (h / human) 
            :mod (n / nonsuppress)))

# ::snt However , these low levels of peptide are not sufficient to induce new amyloid formation , as CaMKII-tTA  tetAPPswe/ind mice raised on dox for up to a year do not develop amyloid lesions ( data not shown ) .
# ::tok However , these low levels of peptide are not sufficient to induce new amyloid formation , as CaMKII-tTA  tetAPPswe/ind mice raised on dox for up to a year do not develop amyloid lesions ( data not shown ) .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:28.643
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt It is also clear that in this genetic system , we have raised the production of A to levels not found in humans to accelerate pathology into an experimentally feasible time frame .
# ::tok It is also clear that in this genetic system , we have raised the production of A to levels not found in humans to accelerate pathology into an experimentally feasible time frame .
# ::alignments 31-32|0.0 30-31|0.0.1 29-30|0 28-29|0.0.0.0.0.0.0 25-26|0.0.0.1 24-25|0.0.0 22-23|0.0.0.0.0.2.0.1 20-21|0.0.0.0.0.2.0 19-20|0.0.0.0.0.2.0.2 18-19|0.0.0.0.0.2 14-15|0.0.0.0.0.0 12-13|0.0.0.0.0 10-11|0.0.0.0 8-9|0.0.0.0.0.3 7-8|0.0.0.0.0.2.0.0 6-7|0.0.0.0.0.3.0 3-4|0.0.0.0.0.1 2-3|0.0.0.0.0.1.1 0-1|0.0.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:28.892
(f2 / feasible 
      :mod-of (f / frame 
            :ARG2-of (a / accelerate-01 
                  :ARG0 (w / we 
                        :ARG0-of (r / raise-01 
                              :ARG1 (p2 / produce-01 
                                    :ARG1 (e / experimentally)) 
                              :ARG1-of (c / clear-06 
                                    :ARG0 (i / it) 
                                    :mod (a2 / also)) 
                              :ARG4 (l / level 
                                    :ARG1-of (f3 / find-01 
                                          :ARG0 (g / gene) 
                                          :location (h / human) 
                                          :polarity -)) 
                              :location (s / system 
                                    :mod (t2 / this)))) 
                  :time (p / pathology)) 
            :mod (t / time)))

# ::snt This system allowed us to create an approximately 20-fold differential between APP/A synthetic rates before and after treatment , yet the in vivo equilibrium between aggregated and disaggregated states of A still favored the maintenance of amyloid deposits .
# ::tok This system allowed us to create an approximately 20-fold differential between APP/A synthetic rates before and after treatment , yet the in vivo equilibrium between aggregated and disaggregated states of A still favored the maintenance of amyloid deposits .
# ::alignments 37-38|0.3.1.1 36-37|0.3.0.0.0.1.0.1.0.0 34-35|0.3.1 32-33|0.3 31-32|0.3.2 28-29|0.2 27-28|0.1 26-27|0 25-26|0.0 23-24|0.3.1.0 19-20|0.3.0.0.1 17-18|0.3.0.0.0.1.0.1.0 16-17|0.3.0.0.0.1.0.1 15-16|0.3.0.0.0.1.0 14-15|0.3.0.0.0.1 13-14|0.3.0.0.0.1.0.0 12-13|0.3.0.0.1.0 9-10|0.3.0.0.0.0 7-8|0.0.0 5-6|0.3.0.0.0 2-3|0.3.0.0 1-2|0.3.0 0-1|0.3.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:29.694
(a2 / and 
      :op1 (a3 / aggregate-01 
            :ARG1 (a6 / approximately)) 
      :op2 (d2 / disaggregat) 
      :op3 (s2 / state) 
      :op4 (f / favor-01 
            :ARG0 (s4 / system 
                  :ARG0-of (a7 / allow-01 
                        :ARG1 (c / create-01 
                              :ARG1 (d3 / differential) 
                              :time (b / before 
                                    :op1-of (a5 / and 
                                          :location-of (r / rate) 
                                          :op2 (a4 / after 
                                                :op1 (t / treat-03 
                                                      :ARG1 (a / amyloid)))))) 
                        :ARG2 (y / yet 
                              :location-of (s3 / synthetic))) 
                  :mod (t2 / this)) 
            :ARG1 (m / maintain-01 
                  :ARG0 (e / equilibrium) 
                  :ARG1 (d / deposit)) 
            :mod (s / still)))

# ::snt In our opinion , it seems unlikely that amyloid deposits in human brain would be inherently any less stable than those formed in mouse brain .
# ::tok In our opinion , it seems unlikely that amyloid deposits in human brain would be inherently any less stable than those formed in mouse brain .
# ::alignments 24-25|0.0.1.1.1.0 23-24|0.0.1.1.1 21-22|0.0.1 18-19|0.0.1.1 17-18|0.0.1.1.2 16-17|0.1 15-16|0.0.1.1.3 12-13|0.0.0.0.0.0 11-12|0.0.0.0.0 9-10|0.0.1.1.0 8-9|0.0.1.0 6-7|0.0.0.0.1+0.0.0.0 5-6|0.0.0 2-3|0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:29.892
(o / opine-01 
      :ARG0 (w / we 
            :ARG0-of (s2 / seem-01 
                  :ARG1 (l2 / likely-01 
                        :ARG1 (h / human 
                              :mod-of (b2 / brain)) 
                        :polarity -)) 
            :ARG0-of (f / form-01 
                  :ARG1 (a2 / amyloid) 
                  :ARG2 (s / stable-03 
                        :ARG1 (d / deposit) 
                        :compared-to (m / mouse 
                              :part (b / brain)) 
                        :degree (l / less) 
                        :mod (i / inherent)))) 
      :ARG1 (a / any))

# ::snt However , the human brain may harbor clearance mechanisms not shared by mice that would allow more efficient removal of preexisting amyloid .
# ::tok However , the human brain may harbor clearance mechanisms not shared by mice that would allow more efficient removal of preexisting amyloid .
# ::alignments 21-22|0.0.1.0.0.0 20-21|0.0.1.0.0.0.0 18-19|0.0.1.0.0 17-18|0.0.1.0.0.1 16-17|0.0.1.0.0.1.1 15-16|0.0.1.0 12-13|0.0.1.1.0.0 10-11|0.0.1.1.0 9-10|0.0.1.0.0.1.0 8-9|0.0.1 7-8|0.0.1.1 6-7|0.0 5-6|0 4-5|0.0.0 3-4|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:30.296
(p2 / possible-01 
      :ARG1 (h / harbor-01 
            :ARG0 (b / brain 
                  :mod (h2 / human)) 
            :ARG1 (m3 / mechanism 
                  :ARG0-of (a2 / allow-01 
                        :ARG1 (r / remove-01 
                              :ARG1 (a / amyloid 
                                    :mod (p / preexist)) 
                              :ARG1-of (e / efficient-01 
                                    :ARG0 - 
                                    :degree (m / more)))) 
                  :mod (c / clear-02 
                        :ARG1-of (s / share-01 
                              :ARG0 (m2 / mouse))))))

# ::snt One potential mechanism by which amyloid may be more efficiently removed in the human disease than in the mouse models is through microglial phagocytosis .
# ::tok One potential mechanism by which amyloid may be more efficiently removed in the human disease than in the mouse models is through microglial phagocytosis .
# ::alignments 23-24|0.0.0.3.0 19-20|0.1 18-19|0 14-15|0.0.0.2 13-14|0.0.0.2.0 10-11|0.0.0 9-10|0.0.0.3 8-9|0.0.0.3.1 6-7|0.0 5-6|0.0.0.1 2-3|0.0.0.0 1-2|0.0.0.0.0 0-1|0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:30.531
(m2 / mouse 
      :ARG0-of (p2 / possible-01 
            :ARG1 (r / remove-01 
                  :ARG0 (m4 / mechanism 
                        :mod (p3 / potential) 
                        :quant 1) 
                  :ARG1 (a / amyloid) 
                  :ARG2 (d / disease 
                        :mod (h / human)) 
                  :ARG2-of (e / efficient-01 
                        :ARG0 (p / phagocytosi) 
                        :degree (m3 / more)))) 
      :mod-of (m / model))

# ::snt Resident microglia in transgenic mouse models localize to tissue surrounding plaques but show little evidence of amyloid engulfment [ 37 -- 40 ] .
# ::tok Resident microglia in transgenic mouse models localize to tissue surrounding plaques but show little evidence of amyloid engulfment [ 37 -- 40 ] .
# ::alignments 21-22|0.0.0.0.0 19-20|0.0.1 17-18|0.1.1.0 16-17|0.0.2.0.0 14-15|0.1.1 13-14|0.1.1.1 12-13|0.1 11-12|0 10-11|0.0.2.0.1 9-10|0.0.2.0 8-9|0.0.2 6-7|0.0 5-6|0.1.0 4-5|0.1.0.0 1-2|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:30.790
(c / contrast-01 
      :ARG1 (l2 / localize-01 
            :ARG0 (m3 / microglia 
                  :ARG1-of (r / reside-01 
                        :ARG0 40)) 
            :ARG1 37 
            :ARG2 (t / tissue 
                  :ARG1-of (s2 / surround-01 
                        :ARG0 (a / amyloid) 
                        :ARG2 (p / plaqu)))) 
      :ARG2 (s / show-01 
            :ARG0 (m / model 
                  :mod (m2 / mouse)) 
            :ARG1 (e2 / evidence-01 
                  :ARG1 (e / engulfment) 
                  :quant (l / little))))

# ::snt In contrast , microglia surrounding amyloid plaques in human brain show a much higher state of activation with greater expression of complement receptor [ 40 ] .
# ::tok In contrast , microglia surrounding amyloid plaques in human brain show a much higher state of activation with greater expression of complement receptor [ 40 ] .
# ::alignments 24-25|0.0 22-23|0.1.2.0 21-22|0.1.1.1.0 19-20|0.1.2 18-19|0.1.2.1 16-17|0.1.1.1 14-15|0.1.1 13-14|0.1.1.0 12-13|0.1.1.1.0.0 10-11|0.1 9-10|0.1.0.0.0 8-9|0.1.0.0.0.0 6-7|0.1.0.0.1 5-6|0.1.0.0.1.0 4-5|0.1.0.0 3-4|0.1.0 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:31.099
(c2 / contrast-01 
      :ARG0 40 
      :ARG1 (s2 / show-01 
            :ARG0 (m2 / microglia 
                  :ARG1-of (s3 / surround-01 
                        :ARG0 (b / brain 
                              :mod (h2 / human)) 
                        :ARG2 (p / plaqu 
                              :mod (a2 / amyloid)))) 
            :ARG1 (s / state 
                  :ARG1-of (h / high-02) 
                  :mod (a / activation 
                        :prep-with (c / complement-01 
                              :ARG1 (m / much)))) 
            :ARG2 (e / express-01 
                  :ARG1 (r / receptor) 
                  :mod (g / great))))

# ::snt Thus , the role of microglia in amyloid metabolism is minor in transgenic models compared to the human condition .
# ::tok Thus , the role of microglia in amyloid metabolism is minor in transgenic models compared to the human condition .
# ::alignments 18-19|0 17-18|0.1 14-15|0.0 13-14|0.0.0 10-11|0.0.1.0 8-9|0.0.1.1 7-8|0.0.1.1.0 5-6|0.0.1.2 3-4|0.0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:31.158
(c / condition 
      :ARG2-of (c2 / compare-01 
            :ARG0 (m / model) 
            :ARG1 (r / role 
                  :domain-of (m2 / minor) 
                  :mod (m3 / metabolism 
                        :mod (a / amyloid)) 
                  :poss (m4 / microglia))) 
      :mod (h / human 
            :poss-of (t / thu)))

# ::snt Somewhat paradoxically , several studies further demonstrate that treatment with anti-inflammatory drugs to reduce microglial activation actually lowers amyloid load in APP transgenic mice , suggesting a role for mouse microglia in the formation and maintenance of amyloid aggregates [ 41 -- 43 ] .
# ::tok Somewhat paradoxically , several studies further demonstrate that treatment with anti-inflammatory drugs to reduce microglial activation actually lowers amyloid load in APP transgenic mice , suggesting a role for mouse microglia in the formation and maintenance of amyloid aggregates [ 41 -- 43 ] .
# ::alignments 42-43|0.0 40-41|0.1.0.0 38-39|0.1.2.0 37-38|0.1.2.0.1 35-36|0.1.2 34-35|0.1 33-34|0 30-31|0.1.1.1 29-30|0.1.1.1.0 27-28|0.1.1 25-26|0.1.1.0 23-24|0.1.0.3 21-22|0.1.0.3.0.0.0+0.1.0.3.0.0+0.1.0.3.0 19-20|0.1.0.1 18-19|0.1.0.1.0 17-18|0.1.0 16-17|0.1.0.4 15-16|0.1.1.0.0.1.0 13-14|0.1.1.0.0.1 11-12|0.1.1.0.0.0 10-11|0.1.0.2.0.0 8-9|0.1.1.0.0 6-7|0.1.0.2 5-6|0.1.0.2.1 4-5|0.1.0.2.0 3-4|0.1.0.2.0.1 1-2|0.1.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:31.931
(f / form-01 
      :ARG1 43 
      :op3-of (a3 / and 
            :op1 (l2 / lower-01 
                  :ARG0 41 
                  :ARG1 (l / load 
                        :mod (a4 / amyloid)) 
                  :ARG1-of (d2 / demonstrate-01 
                        :ARG0 (s2 / study-01 
                              :ARG1 (a7 / anti-inflammatory) 
                              :quant (s3 / several)) 
                        :degree (f2 / further)) 
                  :location (m4 / mouse 
                        :mod (o / organization 
                              :name (n / name 
                                    :op1 "APP"))) 
                  :mod (a5 / actual)) 
            :op2 (r / role 
                  :ARG1-of (s / suggest-01 
                        :ARG0 (t / treat-03 
                              :ARG1 (d / drug) 
                              :ARG2 (r2 / reduce-01 
                                    :ARG1 (a6 / activation)))) 
                  :mod (m2 / microglia 
                        :mod (m3 / mouse))) 
            :op4 (m / maintain-01 
                  :ARG1 (a / aggregate-01 
                        :ARG1 (p / paradoxically) 
                        :mod (a2 / amyloid)))))

# ::snt However , this outcome may be alternatively explained by direct effects of many anti-inflammatory drugs on -secretase cleavage [ 44 -- 47 ] .
# ::tok However , this outcome may be alternatively explained by direct effects of many anti-inflammatory drugs on -secretase cleavage [ 44 -- 47 ] .
# ::alignments 21-22|0.0.4 19-20|0.0.2 17-18|0.0.0.0.0 14-15|0.0.0.1 13-14|0.0.0.1.0 12-13|0.0.0.1.1 10-11|0.0.0 9-10|0.0.0.0 7-8|0.0 6-7|0.0.3 4-5|0 3-4|0.0.1 2-3|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:32.256
(p / possible-01 
      :ARG1 (e2 / explain-01 
            :ARG0 (e / effect 
                  :ARG1-of (d2 / direct-02 
                        :ARG0 (c / cleavage)) 
                  :poss (d / drug 
                        :mod (a / anti-inflammatory) 
                        :quant (m / many))) 
            :ARG1 (o / outcome 
                  :mod (t / this)) 
            :ARG2 44 
            :manner (a2 / alternatively) 
            :op1-of 47))

# ::snt Nonetheless , the role of microglia in both the human condition and the mouse models is poorly understood , and differences in microglial reactivity between the two could lead to significantly faster amyloid clearance in the brains of patients with AD than we observe in the tet-off APP mice .
# ::tok Nonetheless , the role of microglia in both the human condition and the mouse models is poorly understood , and differences in microglial reactivity between the two could lead to significantly faster amyloid clearance in the brains of patients with AD than we observe in the tet-off APP mice .
# ::alignments 48-49|0.2.3.0.0.0 47-48|0.2.3.0.0.0.0.0.0+0.2.3.0.0.0.0.0+0.2.3.0.0.0.0 43-44|0.2.3.0.0 42-43|0.2.3.0 40-41|0.2.3.2.0.0.0.0 38-39|0.2.3.2.0.0.0.1+0.2.3.2.0.0.0+0.2.3.2.0.0 36-37|0.2.3.2.0 33-34|0.2.3.2 32-33|0.2.3.2.1 31-32|0.0.1 30-31|0.0 28-29|0.2.3 27-28|0.2.2 26-27|0.2.2.0 23-24|0.2.1.0 20-21|0.2.1 19-20|0.2 17-18|0 16-17|0.1 14-15|0.2.0 13-14|0.2.0.0 11-12|0.2.0.1 10-11|0.2.0.1.1 9-10|0.2.0.1.1.0 7-8|0.2.0.1.0 5-6|0.2.3.1.0 3-4|0.2.3.1 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:33.818
(u / understand-01 
      :ARG1 (s / significant-02 
            :ARG0 (n2 / nonetheles) 
            :ARG1 (f / fast)) 
      :manner (p4 / poor) 
      :op2-of (a2 / and 
            :op1 (m2 / model 
                  :mod (m3 / mouse) 
                  :op2-of (a3 / and 
                        :mod (b2 / both) 
                        :op1 (c2 / condition 
                              :mod (h2 / human)))) 
            :op3 (d / differ-01 
                  :ARG2 (r / reactivity)) 
            :op4 (p3 / possible-01 
                  :ARG1 2) 
            :op5 (l / lead-03 
                  :ARG0 (w / we 
                        :ARG0-of (o2 / observe-01 
                              :medium (m / mouse 
                                    :mod (o / organization 
                                          :name (n / name 
                                                :op1 "APP"))))) 
                  :ARG1 (r2 / role 
                        :poss (m4 / microglia)) 
                  :ARG2 (c / clear-02 
                        :ARG1 (b / brain 
                              :part-of (p / person 
                                    :ARG0-of (h / have-rel-role-91 
                                          :ARG1 "AD" 
                                          :ARG2 (p2 / patient)))) 
                        :mod (a / amyloid)))))

# ::snt Given the relatively minor role played by microglia in other mouse models of amyloidosis , we think it unlikely that these cells have influenced the rate of amyloid clearance in the tet-off APP mice .
# ::tok Given the relatively minor role played by microglia in other mouse models of amyloidosis , we think it unlikely that these cells have influenced the rate of amyloid clearance in the tet-off APP mice .
# ::alignments 33-34|0.1.1.0 32-33|0.1.1.0.0.0.0+0.1.1.0.0.0+0.1.1.0.0 28-29|0.1.1 27-28|0.1.1.1 25-26|0.0.1.1 23-24|0.0.1 21-22|0.0.1.0 20-21|0.0.1.0.0 18-19|0.1.3+0.1 16-17|0 15-16|0.0 13-14|0.1.2 11-12|0.1.2.0 10-11|0.1.2.0.2 9-10|0.1.2.0.1 7-8|0.1.2.0.0.0 5-6|0.1.2.0.0 4-5|0.1.2.0.0.1 3-4|0.1.2.0.0.1.0 2-3|0.1.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:35.312
(t2 / think-01 
      :ARG0 (w / we 
            :ARG0-of (g / give-01) 
            :ARG2-of (i / influence-01 
                  :ARG0 (c2 / cell 
                        :mod (t / this)) 
                  :ARG1 (r / rate))) 
      :ARG1 (l / likely-01 
            :ARG0 (r3 / relative) 
            :ARG0-of (c / clear-02 
                  :ARG1 (m / mouse 
                        :mod (o / organization 
                              :name (n / name 
                                    :op1 "APP"))) 
                  :mod (a / amyloid)) 
            :ARG1 (a2 / amyloidosi 
                  :topic-of (m2 / model 
                        :ARG2-of (p / play-01 
                              :ARG0 (m4 / microglia) 
                              :ARG1 (r2 / role 
                                    :mod (m5 / minor))) 
                        :mod (o2 / other) 
                        :mod (m3 / mouse))) 
            :polarity -))

# ::snt Even so , we considered the possibility that chronic dox treatment may have altered the activation state of microglia in our treated mice .
# ::tok Even so , we considered the possibility that chronic dox treatment may have altered the activation state of microglia in our treated mice .
# ::alignments 22-23|0.1.0.1.0.0 21-22|0.1.0.1.0.0.0 20-21|0.1.0.1.0.0.1 18-19|0.1.0.1.0 16-17|0.1.0.1 15-16|0.1.0.1.1 13-14|0.1.0 11-12|0.1.0.2 10-11|0.1.0.0 9-10|0.1.0.0.0 8-9|0.1.0.0.1 6-7|0.1 4-5|0 3-4|0.0 0-1|0.1.0.1.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:35.457
(c2 / consider-01 
      :ARG0 (w2 / we) 
      :ARG1 (p2 / possible-01 
            :ARG1 (a2 / alter-01 
                  :ARG0 (t2 / treat-03 
                        :ARG2 (d / dox) 
                        :mod (c / chronic)) 
                  :ARG1 (s / state 
                        :mod (m2 / microglia 
                              :poss (m / mouse 
                                    :ARG1-of (t / treat-01 
                                          :ARG0 (e / even)) 
                                    :poss (w / we))) 
                        :mod (a / activation)) 
                  :ARG1-of (p / possible-01))))

# ::snt Dox is structurally similar to minocycline , a reported anti-inflammatory drug and inhibitor of microglial activation [ 48 ] .
# ::tok Dox is structurally similar to minocycline , a reported anti-inflammatory drug and inhibitor of microglial activation [ 48 ] .
# ::alignments 17-18|0.0 15-16|0.1.0.0 12-13|0.1.1.1 11-12|0.1.1 10-11|0.1 9-10|0.1.0 8-9|0 5-6|0.1.1.0 3-4|0.1.1.0.0 2-3|0.1.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:35.689
(r / report-01 
      :ARG0 48 
      :ARG1 (d / drug 
            :mod (a3 / anti-inflammatory 
                  :mod-of (a / activation)) 
            :op2-of (a2 / and 
                  :op1 (m / minocycline 
                        :ARG2-of (r2 / resemble-01 
                              :degree (s / structurally))) 
                  :op3 (i / inhibitor))))

# ::snt However , if dox does have anti-inflammatory activity , then , based on previous studies with other anti-inflammatories , we would have expected to find less amyloid in the dox-treated animals .
# ::tok However , if dox does have anti-inflammatory activity , then , based on previous studies with other anti-inflammatories , we would have expected to find less amyloid in the dox-treated animals .
# ::alignments 30-31|0.0.0.0.0 29-30|0.0.0.0 26-27|0.1.1 25-26|0.2.1.1 24-25|0.1 22-23|0 19-20|0.1.0 17-18|0.2.1.0 16-17|0.2.1.0.0 14-15|0.2.1 13-14|0.2.1.2 11-12|0.2 9-10|0.2.0 7-8|0.0.0 6-7|0.0.0.1 3-4|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:36.120
(e / expect-01 
      :ARG0 (d2 / dox 
            :ARG0-of (a4 / activity-06 
                  :ARG1 (d / dox-treat 
                        :mod-of (a / animal)) 
                  :mod (a5 / anti-inflammatory))) 
      :ARG1 (f / find-01 
            :ARG0 (w / we) 
            :ARG1 (a2 / amyloid)) 
      :ARG1-of (b / base-02 
            :ARG0 (t / then) 
            :ARG2 (s / study-01 
                  :ARG0 (a3 / anti-inflammatori 
                        :mod (o / other)) 
                  :ARG1 (l / less) 
                  :time (p / previous))))

# ::snt Clearly , that was not the case .
# ::tok Clearly , that was not the case .
# ::alignments 6-7|0.0 4-5|0.0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:36.130
(c2 / clear-06 
      :ARG1 (c / case-03 
            :polarity -))

# ::snt While it is possible that dox acts in some other way to slow amyloid clearance , data from multiple studies demonstrate that microglial responses are normally weak in the mouse AD models [ 37 -- 40 ] , and thus it is doubtful that dox-mediated microglial inhibition affected the outcome of our study .
# ::tok While it is possible that dox acts in some other way to slow amyloid clearance , data from multiple studies demonstrate that microglial responses are normally weak in the mouse AD models [ 37 -- 40 ] , and thus it is doubtful that dox-mediated microglial inhibition affected the outcome of our study .
# ::alignments 52-53|0.2.0.1.0 51-52|0.2.0.1.0.0 49-50|0.2.0.1 47-48|0.2.0 46-47|0.2.0.0 44-45|0.2.0.0.0 42-43|0.2 39-40|0.2.1 38-39|0 35-36|0.0.2.0.0.0.0.0 33-34|0.0.1 31-32|0.1.0.1.0 30-31|0.1.0.1.0.0 29-30|0.1.0.1 26-27|0.1.0 25-26|0.1 23-24|0.1.0.0.0+0.1.0.0 20-21|0.0 19-20|0.0.0.0 18-19|0.0.0.0.0 16-17|0.0.0 14-15|0.0.2.0.0.0.0 13-14|0.0.2.0.0.0.0.1 12-13|0.0.2.0.0.0 10-11|0.0.2.0.1 9-10|0.0.2.0.1.1 8-9|0.0.2.0.1.0 6-7|0.0.2.0 5-6|0.0.2.0.0 3-4|0.0.2 0-1|0.0.2.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:36.812
(a2 / and 
      :op1 (d3 / demonstrate-01 
            :ARG0 (d4 / data 
                  :source (s2 / study-01 
                        :ARG1 (m3 / multiple))) 
            :ARG1 37 
            :condition (p / possible-01 
                  :ARG1 (a4 / act-02 
                        :ARG0 (d5 / dox 
                              :ARG0-of (s3 / slow-01 
                                    :ARG1 (c / clear-02 
                                          :ARG1 40 
                                          :mod (a3 / amyloid)))) 
                        :ARG1 (w3 / way 
                              :mod (s4 / some) 
                              :mod (o2 / other)) 
                        :ARG1-of (w4 / while-01)))) 
      :op2 (n / normal-02 
            :ARG1 (w2 / weak-02 
                  :ARG1 (t2 / thing 
                        :ARG2-of (r / respond-01)) 
                  :ARG2 (m2 / mouse 
                        :mod-of (m / model 
                              :mod "AD")))) 
      :op3 (d2 / doubt-01 
            :ARG1 (a / affect-01 
                  :ARG0 (i / inhibition 
                        :mod (d / dox-mediat)) 
                  :ARG1 (o / outcome 
                        :poss (s / study-01 
                              :ARG1 (w / we)))) 
            :mod (t / thus-far)))

# ::snt The persistence and stability of amyloid deposits in our system is unexpected given the speed with which A aggregates are cleared in other mouse models of therapeutic intervention .
# ::tok The persistence and stability of amyloid deposits in our system is unexpected given the speed with which A aggregates are cleared in other mouse models of therapeutic intervention .
# ::alignments 27-28|0.1.0.1.2 26-27|0.1.0.1.2.0 24-25|0.1.0.1 23-24|0.1.0.1.1 22-23|0.1.0.1.0 20-21|0.1.0 18-19|0.1.0.0 14-15|0.1 12-13|0.1.1 11-12|0.2+0 9-10|0.0.1.0.0 8-9|0.0.1.0.0.0 6-7|0.0.1.0 5-6|0.1.0.1.2.1 3-4|0.0.1 2-3|0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:37.298
(e / expect-01 
      :ARG1 (a3 / and 
            :op1 (p / persistence) 
            :op2 (s3 / stability 
                  :poss (d / deposit 
                        :topic (s2 / system 
                              :poss (w / we))))) 
      :condition (s / speed 
            :ARG0-of (c / clear-01 
                  :ARG1 (a / aggregate-01) 
                  :ARG2 (m / model 
                        :mod (o / other) 
                        :mod (m2 / mouse) 
                        :topic (i / intervene-01 
                              :ARG0 (t / therapeutic) 
                              :ARG1 (a2 / amyloid)))) 
            :ARG1-of (g / give-01)) 
      :polarity -)

# ::snt Anti-A antibodies injected directly into the brain have been shown to eliminate amyloid deposits in as little as 1 wk after treatment [ 49 -- 51 ] .
# ::tok Anti-A antibodies injected directly into the brain have been shown to eliminate amyloid deposits in as little as 1 wk after treatment [ 49 -- 51 ] .
# ::alignments 25-26|0.1.0.0.1.0 23-24|0.0 21-22|0.1.0.0.3 20-21|0.1.3 18-19|0.1.0.0.0 16-17|0.1.2 13-14|0.1.1 12-13|0.1.0.0.3.0 11-12|0.1 9-10|0 6-7|0.1.0.0.2 3-4|0.1.0.0.1 2-3|0.1.0.0 1-2|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:37.476
(s / show-01 
      :ARG0 49 
      :ARG1 (e / eliminate-01 
            :ARG0 (a3 / antibodi 
                  :ARG1-of (i / inject-01 
                        :ARG0 1 
                        :ARG1-of (d2 / direct-02 
                              :ARG0 51) 
                        :ARG2 (b / brain) 
                        :ARG3-of (t / treat-03 
                              :ARG0 (a2 / amyloid)))) 
            :ARG1 (d / deposit) 
            :op1-of (l / little) 
            :time (a / after)))

# ::snt Peripheral antibody injection decreases amyloid load more broadly , and although it does not appear to act as quickly as local injection , can significantly reduce amyloid load within 2 mo of initial treatment [ 52,53 ] .
# ::tok Peripheral antibody injection decreases amyloid load more broadly , and although it does not appear to act as quickly as local injection , can significantly reduce amyloid load within 2 mo of initial treatment [ 52,53 ] .
# ::alignments 33-34|0.2.0.0 32-33|0.2.1.0 30-31|0.2.2 29-30|0.2.2.0 27-28|0.2.0 26-27|0.2.0.1 25-26|0.2 24-25|0.2.1 23-24|0.1 21-22|0.1.0.0.1 20-21|0.1.0.0.1.1 18-19|0.1.0.0.0 16-17|0.1.0.0 14-15|0.1.0 13-14|0.2.0.0.0 9-10|0 7-8|0.1.0.0.1.0 6-7|0.1.0.0.1.0.0 5-6|0.0.0 4-5|0.0.0.0 3-4|0.0 2-3|0.0.1 1-2|0.0.1.0 0-1|0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:38.628
(a4 / and 
      :op1 (d / decrease-01 
            :ARG1 (l3 / load 
                  :mod (a5 / amyloid)) 
            :ARG2 (i3 / inject-01 
                  :mod (a6 / antibody) 
                  :mod (p2 / peripheral))) 
      :op2 (p / possible-01 
            :ARG1 (a3 / appear-02 
                  :ARG1 (a2 / act-02 
                        :ARG1-of (q / quick-02) 
                        :manner (i2 / inject-01 
                              :ARG0 (b / broad 
                                    :degree (m2 / more)) 
                              :ARG1-of (l2 / local-02))))) 
      :op3 (r / reduce-01 
            :ARG1 (l / load 
                  :ARG0-of (t / treat-03 
                        :ARG1 -) 
                  :mod (a / amyloid)) 
            :ARG2 (s / significant-02 
                  :ARG1 (i / initial)) 
            :location (m / mo 
                  :quant 2)))

# ::snt More recently , an alternative approach has shown that lentiviral transfer of neprilysin can also reduce the number of aggregates in the area of the injection site [ 54 ] .
# ::tok More recently , an alternative approach has shown that lentiviral transfer of neprilysin can also reduce the number of aggregates in the area of the injection site [ 54 ] .
# ::alignments 28-29|0.0.0 26-27|0.1.0.2.0 25-26|0.1.0.2.0.0 22-23|0.1.0.2 19-20|0.1.0.1.0 17-18|0.1.0.1 15-16|0.1.0 14-15|0.1.0.3 13-14|0.1 12-13|0.1.0.0.0 10-11|0.1.0.0 7-8|0 5-6|0.0 4-5|0.0.1 1-2|0.2 0-1|0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:38.807
(s2 / show-01 
      :ARG0 (a4 / approach-02 
            :ARG1 54 
            :mod (a5 / alternative)) 
      :ARG1 (p / possible-01 
            :ARG1 (r / reduce-01 
                  :ARG0 (t / transfer-01 
                        :ARG1 (n2 / neprilysin)) 
                  :ARG1 (n / number 
                        :quant-of (a2 / aggregate-01)) 
                  :location (a / area 
                        :domain (s / site 
                              :mod (i / inject-01))) 
                  :mod (a3 / also))) 
      :time (r2 / recent 
            :degree (m / more)))

# ::snt Careful study of the mechanism behind several of the antibody-mediated therapies has suggested that activated microglia play an important role in the removal of fibrillar plaques after immunization [ 50,52,55 ] .
# ::tok Careful study of the mechanism behind several of the antibody-mediated therapies has suggested that activated microglia play an important role in the removal of fibrillar plaques after immunization [ 50,52,55 ] .
# ::alignments 27-28|0.1.2.0 26-27|0.1.2 25-26|0.1.1.0.0 24-25|0.1.1.0.0.0 22-23|0.1.1.0 19-20|0.1.1 18-19|0.1.1.1 16-17|0.1 15-16|0.1.0 14-15|0.1.0.0 12-13|0 10-11|0.1.0.0.0 9-10|0.1.0.0.0.0 6-7|0.1.0.0.0.1 5-6|0.1.0.0.0.1.0 4-5|0.0.0 1-2|0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:39.166
(s / suggest-01 
      :ARG0 (s3 / study-01 
            :ARG1 (m2 / mechanism) 
            :ARG1-of (c / care-04)) 
      :ARG1 (p2 / play-01 
            :ARG0 (m / microglia 
                  :ARG1-of (a2 / activate-01 
                        :ARG0 (t / therapi 
                              :mod (a3 / antibody-mediat) 
                              :topic-of (s2 / several 
                                    :op1-of (b / behind))))) 
            :ARG1 (r2 / role 
                  :ARG2-of (r / remove-01 
                        :ARG1 (p / plaqu 
                              :mod (f / fibrillar))) 
                  :mod (i2 / important)) 
            :time (a / after 
                  :op1 (i / immunization))))

# ::snt However , it has been noted that deletion of the Fc receptor ( the primary receptor for microglial opsinization of antibody -- antigen complexes ) in APP transgenic mouse models has no impact on the effectiveness of antibody-mediated therapy [ 56,57 ] .
# ::tok However , it has been noted that deletion of the Fc receptor ( the primary receptor for microglial opsinization of antibody -- antigen complexes ) in APP transgenic mouse models has no impact on the effectiveness of antibody-mediated therapy [ 56,57 ] .
# ::alignments 38-39|0.1.0.0.1 37-38|0.0 35-36|0.1.0.0 32-33|0.1.0.0.2 31-32|0.1.0.0.2.1 29-30|0.1.0 28-29|0.1.0.1 26-27|0.1.1.0+0.1.1+0.1 23-24|0.1.0.0.2.0.1.0.0 22-23|0.1.0.0.2.0.1.0 20-21|0.1.0.0.2.0.1 18-19|0.1.0.0.2.0 15-16|0.1.0.0.2.0.0 14-15|0.1.0.0.2.0.0.0 11-12|0.1.0.0.0.0 7-8|0.1.0.0.0 5-6|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:39.526
(n2 / note-01 
      :ARG0 (a / antibody-mediat) 
      :ARG1 (o / organization 
            :mod-of (m / model 
                  :consist-of (e / effective-04 
                        :ARG0 (d / deletion 
                              :poss (r2 / receptor)) 
                        :ARG1 (t / therapy) 
                        :ARG1-of (i / impact-01 
                              :ARG0 (o2 / opsinization 
                                    :beneficiary-of (r / receptor 
                                          :mod (p / primary)) 
                                    :mod (a3 / antibody 
                                          :mod-of (a2 / antigen 
                                                :mod-of (c / complex)))) 
                              :polarity -)) 
                  :mod (m2 / mouse)) 
            :name (n / name 
                  :op1 "APP")))

# ::snt It is , nevertheless , possible that lack of microglia activation is the major difference between the slow clearance described here , where no perturbation of the immune system is expected , and the rapid clearance described in studies involving antibody or viral injection .
# ::tok It is , nevertheless , possible that lack of microglia activation is the major difference between the slow clearance described here , where no perturbation of the immune system is expected , and the rapid clearance described in studies involving antibody or viral injection .
# ::alignments 43-44|0.0.0.0.2.0.0.0.2 42-43|0.0.0.0.2.0.0.0.2.0 41-42|0.0.0.0.2.0.0.0 40-41|0.0.0.0.2.0.0.0.1 39-40|0.0.0.0.2.0.0.0.0 38-39|0.0.0.0.2.0.1 36-37|0.0.0.0.2.0 35-36|0.0.0.0.2.0.0 34-35|0.0.0.0.2.0.0.1 32-33|0.0.0.0.2.0.2 30-31|0 28-29|0.0.0.0.2.0.2.1 27-28|0.0.0.0.2.0.2.1.0 24-25|0.0.0.0.2.0.2.1.1 23-24|0.1 20-21|0.0.1 19-20|0.0 18-19|0.0.0 17-18|0.0.0.1 14-15|0.0.0.0 13-14|0.0.0.0.1 10-11|0.0.0.0.0.0 9-10|0.0.0.0.0.0.0 7-8|0.0.0.0.0 5-6|0.0.0.0.2.0.2.0 3-4|0.0.0.0.2.0.2.1.0.0 0-1|0.0.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:40.495
(e / expect-01 
      :ARG1 (d2 / describe-01 
            :ARG1 (c2 / clear-02 
                  :ARG1-of (d3 / differ-02 
                        :ARG0-of (l / lack-01 
                              :ARG1 (a3 / activation 
                                    :mod (m2 / microglia))) 
                        :ARG1-of (m / major-02) 
                        :domain (i4 / it 
                              :ARG1-of (d / describe-01 
                                    :ARG0 (c / clear-02 
                                          :location-of (o / or 
                                                :ARG1-of (i2 / involve-01) 
                                                :op1 (a / antibody) 
                                                :op2 (i / inject-01 
                                                      :mod (v / viral))) 
                                          :manner (r / rapid)) 
                                    :ARG2 (s / study-01) 
                                    :op2-of (a2 / and 
                                          :ARG1-of (p2 / possible-01) 
                                          :op1 (s2 / system 
                                                :ARG1-of (i3 / immune-02 
                                                      :ARG0 (n / nevertheles)) 
                                                :mod (p / perturbation)))))) 
                  :manner (s3 / slow)) 
            :location (h / here)) 
      :polarity -)

# ::snt In isolation , mild activation of microglia by injection damage or opsinization may not be adequate to induce substantial phagocytosis , but when combined with an A-lowering agent , such as neprilysin or A-targeted antibodies , the two may work in concert to clear peptide deposits .
# ::tok In isolation , mild activation of microglia by injection damage or opsinization may not be adequate to induce substantial phagocytosis , but when combined with an A-lowering agent , such as neprilysin or A-targeted antibodies , the two may work in concert to clear peptide deposits .
# ::alignments 45-46|0.1.0.0 44-45|0.2.0 43-44|0.2 41-42|0.1.0.1 39-40|0.1.0 38-39|0.1 37-38|0.0.1.0.0 34-35|0.1.1.1.0.1 33-34|0.1.1.1.0.1.0 32-33|0.1.1.1.0 31-32|0.1.1.1.0.0 29-30|0.0.1.0.1.0 27-28|0.1.1.1 26-27|0.1.1.1.1 23-24|0.1.1 21-22|0 19-20|0.0.0.0.1 18-19|0.0.0.0.1.0 17-18|0.0.0.0 15-16|0.0.0 13-14|0.1.1.0 12-13|0.0 11-12|0.0.1.1 10-11|0.0.1 9-10|0.0.1.0 8-9|0.0.1.0.1 6-7|0.0.0.0.0.2 4-5|0.0.0.0.0 3-4|0.0.0.0.0.1 1-2|0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:41.908
(c4 / contrast-01 
      :ARG1 (p4 / possible-01 
            :ARG1 (a5 / adequate 
                  :domain (i / induce-01 
                        :ARG1 (a6 / activation 
                              :ARG0-of (i3 / isolate-01) 
                              :mod (m2 / mild) 
                              :mod (m / microglia)) 
                        :ARG2 (p3 / phagocytosi 
                              :mod (s2 / substantial)))) 
            :op3-of (o3 / or 
                  :op1 (d2 / damage-01 
                        :ARG0 2 
                        :ARG1 (i2 / inject-01 
                              :ARG1 (s / such))) 
                  :op2 (o2 / opsinization))) 
      :ARG2 (p2 / possible-01 
            :ARG1 (w / work-01 
                  :ARG1 (d / deposit) 
                  :location (c2 / concert)) 
            :condition (c3 / combine-01 
                  :ARG1 - 
                  :ARG2 (a3 / agent 
                        :example (o / or 
                              :op1 (n / neprilysin) 
                              :op2 (a / antibodi 
                                    :mod (a2 / a-target))) 
                        :mod (a4 / a-lower)))) 
      :ARG2-of (c / clear-06 
            :ARG1 (p / peptide)))

# ::snt Consistent with this hypothesis , strong activation of microglia through transgenic expression of TGF [ 58 ] or central injection of lipopolysaccharide [ 59,60 ] can by itself substantially reduce plaque burden in APP transgenic mice .
# ::tok Consistent with this hypothesis , strong activation of microglia through transgenic expression of TGF [ 58 ] or central injection of lipopolysaccharide [ 59,60 ] can by itself substantially reduce plaque burden in APP transgenic mice .
# ::alignments 35-36|0.2.2 33-34|0.2.2.0.0.0+0.2.2.0.0+0.2.2.0 31-32|0.2.0 30-31|0.2.0.1 29-30|0.2 28-29|0.2.3 25-26|0.2.1 19-20|0.0.0 18-19|0.0.0.1 17-18|0.0 15-16|0.2.1.0 13-14|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 11-12|0 8-9|0.1.0.1 6-7|0.1.0 5-6|0.1 3-4|0.1.0.2 2-3|0.1.0.0 0-1|0.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:42.505
(e / express-01 
      :ARG1 (o2 / or 
            :op1 (i / inject-01 
                  :ARG1 (o3 / organization 
                        :name (n2 / name 
                              :op1 "TGF")) 
                  :mod (c / central))) 
      :ARG2-of (s2 / strong-02 
            :ARG1 (a / activation 
                  :mod (t / this) 
                  :mod (m2 / microglia) 
                  :mod (h / hypothesi))) 
      :purpose-of (r / reduce-01 
            :ARG1 (b / burden-01 
                  :ARG0 (c2 / consistent) 
                  :ARG1 (p / plaque)) 
            :ARG1-of (p2 / possible-01 
                  :ARG0 58) 
            :location (m / mouse 
                  :mod (o / organization 
                        :name (n / name 
                              :op1 "APP"))) 
            :manner (s / substantial)))

# ::snt But in the case of acute antibody - and/or injury-mediated activation , once the inflammation has passed , and the antibody and bound peptide have been cleared and degraded , the remaining A quickly reaggregates and amyloid pathology is reestablished [ 49 ] .
# ::tok But in the case of acute antibody - and/or injury-mediated activation , once the inflammation has passed , and the antibody and bound peptide have been cleared and degraded , the remaining A quickly reaggregates and amyloid pathology is reestablished [ 49 ] .
# ::alignments 41-42|0.1.0.0.0.0.0 39-40|0.2.1 37-38|0.2.1.0 36-37|0.2.0.0 35-36|0.2 33-34|0.2.0 31-32|0.1.0.1.1 28-29|0.1.0.1 27-28|0.1.0 26-27|0.1.0.0 23-24|0.1.0.0.1 22-23|0.1.0.0.1.0 21-22|0.1.0.0.1.0.0 20-21|0.1.0.0.1.0.0.0 18-19|0.1 16-17|0.1.0.0.0.0 14-15|0.1.0.0.0 12-13|0.0 10-11|0.1.0.1.0.0 9-10|0.1.0.1.0.0.0 6-7|0.1.0.1.0.1 5-6|0.1.0.1.0.1.0 3-4|0.1.0.1.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:43.189
(c3 / contrast-01 
      :ARG0 (o / once) 
      :ARG1 (a6 / and 
            :op1 (a3 / and 
                  :op1 (c / clear-01 
                        :ARG0 (i / inflammation 
                              :ARG0-of (p3 / pass-01 
                                    :ARG1 49)) 
                        :ARG1 (p2 / peptide 
                              :ARG1-of (b / bind-01 
                                    :op2-of (a4 / and 
                                          :op1 (a5 / antibody))))) 
                  :op2 (d / degrade-01 
                        :ARG1 (c2 / case-03 
                              :ARG0 (a7 / activation 
                                    :mod (i2 / injury-mediat)) 
                              :ARG1 (a8 / antibody 
                                    :mod (a9 / acute))) 
                        :ARG1-of (r2 / remain-01)))) 
      :ARG2 (a2 / and 
            :ARG1-of (q / quick-02 
                  :mod-of (a / amyloid)) 
            :op1 (r / reestablish-01 
                  :ARG1 (p / pathology))))

# ::snt This finding reinforces the notion that without continued stimulation , microglia in mouse models do not maintain the same level of sustained activation that may occur in humans .
# ::tok This finding reinforces the notion that without continued stimulation , microglia in mouse models do not maintain the same level of sustained activation that may occur in humans .
# ::alignments 27-28|0.0.1 25-26|0.0 24-25|0 22-23|0.0.0 21-22|0.0.0.0 19-20|0.0.0.1 18-19|0.0.0.1.0 16-17|0.0.0.1.1 15-16|0.0.0.1.1.2 13-14|0.0.0.0.0 12-13|0.0.0.0.0.0 10-11|0.0.0.1.1.0 8-9|0.0.0.1.1.1 7-8|0.0.0.1.1.1.0 4-5|0.1 2-3|0.1.0 1-2|0.1.0.0 0-1|0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:43.810
(p / possible-01 
      :ARG1 (o / occur-01 
            :ARG0 (a / activation 
                  :ARG1-of (s / sustain-01 
                        :ARG0 (m2 / model 
                              :mod (m3 / mouse))) 
                  :mod-of (l / level 
                        :ARG1-of (s2 / same-01) 
                        :ARG1-of (m / maintain-01 
                              :ARG0 (m4 / microglia) 
                              :manner (s3 / stimulation 
                                    :ARG1-of (c / continue-01)) 
                              :polarity -))) 
            :location (h / human)) 
      :ARG2 (n / notion 
            :ARG1-of (r / reinforce-01 
                  :ARG0 (f / find-01 
                        :mod (t / this)))))

# ::snt SantaCruz et al. recently published a study of mice that express P301L human tau via a similar vector system [ 61 ] .
# ::tok SantaCruz et al. recently published a study of mice that express P301L human tau via a similar vector system [ 61 ] .
# ::alignments 20-21|0.1.0.0.0 18-19|0.0 17-18|0.0.0 16-17|0 13-14|0.1.0.0.1.0.0 12-13|0.1.0.0.1.0.0.0 10-11|0.1.0.0.1.0 8-9|0.1.0.0.1 6-7|0.1.0.0 4-5|0.1.0 3-4|0.1.0.1 0-3|0.1.1.2+0.1.1.1+0.1.1.0+0.1.1+0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:43.920
(r / resemble-01 
      :ARG1 (s / system 
            :mod (v / vector)) 
      :ARG2 (t2 / thing 
            :ARG0-of (p / publish-01 
                  :ARG1 (s2 / study-01 
                        :ARG0 61 
                        :ARG1 (m / mouse 
                              :ARG0-of (e / express-01 
                                    :ARG1 (t / tau 
                                          :mod (h / human))))) 
                  :time (r2 / recent)) 
            :name (n / name 
                  :op1 "SantaCruz" 
                  :op2 "et" 
                  :op3 "al.")))

# ::snt As in our tet-off APP mice , SantaCruz et al. found that tau neurofibrillary tangles , like amyloid plaques , are not cleared efficiently following transgene suppression .
# ::tok As in our tet-off APP mice , SantaCruz et al. found that tau neurofibrillary tangles , like amyloid plaques , are not cleared efficiently following transgene suppression .
# ::alignments 26-27|0.0 25-26|0 24-25|0.0.0 23-24|0.0.0.1 22-23|0.0.0.0 21-22|0.0.0.0.2 18-19|0.0.0.0.1.1.0 17-18|0.0.0.0.1.1.0.0 16-17|0.0.0.0.1.1 14-15|0.0.0.0.0 13-14|0.0.0.0.0.0 12-13|0.0.0.0.0.0.0 10-11|0.0.0.0.1 7-10|0.0.0.0.1.0.0.2+0.0.0.0.1.0.0.1+0.0.0.0.1.0.0.0+0.0.0.0.1.0.0+0.0.0.0.1.0 5-6|0.0.0.1.0.0 4-5|0.0.0.1.0.0.0.0.0+0.0.0.1.0.0.0.0+0.0.0.1.0.0.0 2-3|0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:44.543
(t / transgene 
      :mod-of (s / suppress-01 
            :ARG2-of (f / follow-01 
                  :ARG1 (c / clear-01 
                        :ARG1 (t2 / tangle-01 
                              :ARG1 (n / neurofibrillary 
                                    :mod (t3 / tau))) 
                        :ARG1-of (f2 / find-01 
                              :ARG0 (t4 / thing 
                                    :name (n2 / name 
                                          :op1 "SantaCruz" 
                                          :op2 "et" 
                                          :op3 "al.")) 
                              :ARG1-of (r / resemble-01 
                                    :ARG2 (p / plaqu 
                                          :mod (a / amyloid)))) 
                        :polarity -) 
                  :time (e / efficient-01 
                        :ARG1 (w / we 
                              :poss-of (m / mouse 
                                    :mod (o / organization 
                                          :name (n3 / name 
                                                :op1 "APP"))))))))

# ::snt The lack of clearance in both models of AD pathology comes as a stark contrast to the rapid removal of protein aggregates found in similar tet-off mouse models of Huntington [ 32 ] and prion disease [ 62 ] .
# ::tok The lack of clearance in both models of AD pathology comes as a stark contrast to the rapid removal of protein aggregates found in similar tet-off mouse models of Huntington [ 32 ] and prion disease [ 62 ] .
# ::alignments 37-38|0.0 35-36|0.2.0.0 34-35|0.2.0 33-34|0.1 31-32|0.2.1.0.0 29-30|0.1.0.1+0.1.0.0.0+0.1.0.0+0.1.0 27-28|0.2.1.0.1.1 26-27|0.2.1.0.1.1.1 24-25|0.2.1.0.1.1.0 22-23|0.2.1.0.1 21-22|0.2.1.0.1.0 20-21|0.2.1.0.1.0.0 18-19|0.2.1.0.1.0.1 17-18|0.2.1.0.1.0.1.0 14-15|0 13-14|0.2.1.0.1.1.0.0 10-11|0.2 9-10|0.2.2 8-9|0.2.1.0.2.1 6-7|0.2.1.0.2 5-6|0.2.1.0.2.0 3-4|0.2.1.0 1-2|0.2.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:45.226
(c / contrast-01 
      :ARG1 62 
      :ARG2 (a / and 
            :op1 (p2 / person 
                  :name (n / name 
                        :op1 "Huntington") 
                  :wiki "Samuel_P._Huntington")) 
      :ARG2-of (c2 / come-01 
            :ARG0 (p / prion 
                  :mod-of (d / disease)) 
            :ARG1 (l / lack-01 
                  :ARG1 (c3 / clear-02 
                        :ARG0 32 
                        :ARG0-of (f / find-01 
                              :ARG1 (a2 / aggregate-01 
                                    :ARG1 (p3 / protein) 
                                    :ARG1-of (r2 / remove-01 
                                          :manner (r3 / rapid))) 
                              :ARG2 (m / model 
                                    :ARG1-of (r / resemble-01 
                                          :ARG0 (s / stark)) 
                                    :mod (m2 / mouse))) 
                        :ARG1 (m3 / model 
                              :mod (b / both) 
                              :topic "AD"))) 
            :manner (p4 / pathology)))

# ::snt In these cases , disrupting the input of new monomer to the system via dox-mediated transgene suppression led to relatively rapid clearance of protein aggregates .
# ::tok In these cases , disrupting the input of new monomer to the system via dox-mediated transgene suppression led to relatively rapid clearance of protein aggregates .
# ::alignments 24-25|0.0 23-24|0 21-22|0.0.0 20-21|0.0.0.1 19-20|0.0.0.0.2.0 17-18|0.0.0.0 16-17|0.0.0.0.1 15-16|0.0.0.0.1.0 14-15|0.0.0.0.1.1 12-13|0.0.0.0.0.0 9-10|0.0.0.0.1.1.0.0 8-9|0.0.0.0.1.1.0 6-7|0.0.0.0.0.1 4-5|0.0.0.0.0 2-3|0.0.0.0.2 1-2|0.0.0.0.2.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:45.495
(p / protein 
      :ARG1-of (a / aggregate-01 
            :ARG1-of (c / clear-02 
                  :ARG2-of (l / lead-02 
                        :ARG0 (d2 / disrupt-01 
                              :ARG0 (s2 / system) 
                              :ARG1 (i / input)) 
                        :ARG1 (s / suppress-01 
                              :mod (t / transgene) 
                              :mod (d / dox-mediat 
                                    :compared-to-of (n / new 
                                          :mod-of (m / monom)))) 
                        :time (c2 / case-03 
                              :ARG1 (r2 / relative) 
                              :mod (t2 / this))) 
                  :manner (r / rapid))))

# ::snt By contrast , our study and that of SantaCruz et al. suggest that protein aggregates in AD may be more tenacious than in other neurodegenerative disorders .
# ::tok By contrast , our study and that of SantaCruz et al. suggest that protein aggregates in AD may be more tenacious than in other neurodegenerative disorders .
# ::alignments 25-26|0.0.0 24-25|0.0 23-24|0.0.0.0 20-21|0.1.0.0.0 19-20|0.1.0.0.0.0 17-18|0.1.0.0 16-17|0.1.0.0.0.1.1 14-15|0.1.0.0.0.1 13-14|0.1.0.0.0.1.0 11-12|0.1.0 8-11|0.1.3.0.2+0.1.3.0.1+0.1.3.0.0+0.1.3.0+0.1.3 6-7|0.1.2 5-6|0.1 4-5|0.1.1 3-4|0.1.1.0 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:45.860
(c / contrast-01 
      :ARG1 (n / neurodegenerative 
            :mod-of (d / disorder 
                  :mod (o / other))) 
      :op1-of (a2 / and 
            :ARG0-of (s / suggest-01 
                  :ARG1 (p / possible-01 
                        :ARG1 (t / tenaciou 
                              :degree (m / more) 
                              :domain (a / aggregate-01 
                                    :ARG1 (p2 / protein) 
                                    :location "AD")))) 
            :op2 (s2 / study-01 
                  :ARG1 (w / we)) 
            :op3 (t3 / that) 
            :op4 (t2 / thing 
                  :name (n2 / name 
                        :op1 "SantaCruz" 
                        :op2 "et" 
                        :op3 "al."))))

# ::snt Perhaps once aggregated , A and tau are either inherently more stable than other protein aggregates or more resistant to intra - and extracellular clearance mechanisms .
# ::tok Perhaps once aggregated , A and tau are either inherently more stable than other protein aggregates or more resistant to intra - and extracellular clearance mechanisms .
# ::alignments 25-26|0.1 24-25|0.1.1 23-24|0.0 22-23|0 18-19|0.1.0 17-18|0.1.0.0 16-17|0.1.0.1 15-16|0.1.0.1.1.1 14-15|0.1.0.1.1.1.0 13-14|0.1.0.1.1.1.1 11-12|0.1.0.1.1 10-11|0.1.0.1.1.2 9-10|0.1.0.1.1.4 8-9|0.1.1.0 6-7|0.1.0.1.0 5-6|0.1.0.1.1.0 2-3|0.1.1.1 1-2|0.1.1.1.0 0-1|0.1.0.1.1.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:46.102
(a / and 
      :op1 (e / extracellular) 
      :op2 (m / mechanism 
            :ARG1-of (r / resist-01 
                  :degree (m2 / more) 
                  :op3-of (o / or 
                        :op1 (t / tau) 
                        :op2 (s / stable-03 
                              :ARG1 (a3 / and) 
                              :ARG2 (a2 / aggregate-01 
                                    :ARG1 (p / protein) 
                                    :mod (o2 / other)) 
                              :degree (m3 / more) 
                              :mod (p2 / perhaps) 
                              :mod (i / inherent)))) 
            :mod (c / clear-02 
                  :ARG1 (e2 / either) 
                  :ARG1-of (a4 / aggregate-01 
                        :time (o3 / once)))))

# ::snt One question we were not able to address in this study is whether abrogating synthesis of new A halts the progression of cognitive decline .
# ::tok One question we were not able to address in this study is whether abrogating synthesis of new A halts the progression of cognitive decline .
# ::alignments 23-24|0.1.1 22-23|0.1.1.1 20-21|0.1.1.0 18-19|0.1.1.0.0 16-17|0.1.0 14-15|0.1.1.0.0.0 13-14|0.1.1.0.0.0.0 10-11|0.1 9-10|0.1.2 7-8|0 5-6|0.2 4-5|0.2.0 2-3|0.0 1-2|0.3 0-1|0.3.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:46.240
(a2 / address-02 
      :ARG0 (w / we) 
      :ARG1 (s2 / study-01 
            :ARG1 (n / new) 
            :ARG1-of (d / decline-01 
                  :ARG1-of (p / progress-01 
                        :ARG1-of (h / halt-01 
                              :ARG0 (s / synthesi 
                                    :mod (a / abrogate)))) 
                  :mod (c / cognitive)) 
            :mod (t / this)) 
      :ARG1-of (p2 / possible-01 
            :polarity -) 
      :ARG2 (q / question-01 
            :quant 1))

# ::snt Studies from the tet-off tau mice suggest that protein clearance may in fact not be required for cognitive improvement following transgene suppression [ 61 ] .
# ::tok Studies from the tet-off tau mice suggest that protein clearance may in fact not be required for cognitive improvement following transgene suppression [ 61 ] .
# ::alignments 23-24|0.0.0 21-22|0.1.1.1 20-21|0.1.1.1.0 19-20|0.1.1.2 18-19|0.1.1.4 17-18|0.1.1.4.0 15-16|0.1.1 13-14|0.1.1.1.1 12-13|0.1.1.0 10-11|0.1 9-10|0.1.1.3 8-9|0.1.1.3.0 6-7|0 5-6|0.1.0 4-5|0.1.0.0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:46.484
(s2 / suggest-01 
      :ARG0 (s3 / study-01 
            :ARG1 61) 
      :ARG1 (p / possible-01 
            :ARG0 (m / mouse 
                  :mod (t2 / tau)) 
            :ARG1 (r / require-01 
                  :ARG0 (f2 / fact) 
                  :ARG1 (s / suppress-01 
                        :ARG1 (t / transgene) 
                        :op1-of -) 
                  :ARG1-of (f / follow-01) 
                  :ARG2 (c2 / clear-02 
                        :ARG1 (p2 / protein)) 
                  :purpose (i / improve-01 
                        :ARG1 (c / cognitive)))))

# ::snt At present , because of unexpected noncognitive behavioral abnormalities , it is not clear whether the tet-off APP mice can be used to address the same question in the context of amyloid pathology .
# ::tok At present , because of unexpected noncognitive behavioral abnormalities , it is not clear whether the tet-off APP mice can be used to address the same question in the context of amyloid pathology .
# ::alignments 32-33|0.1.0.0.0 31-32|0.1.0.0.0.0 29-30|0.1.0.0.1.1.2 26-27|0.1.0.0.1.1 25-26|0.1.0.0.1.1.1 23-24|0.1.0.0.1 21-22|0.1.0.0 19-20|0.1.0 18-19|0.1.0.0.1.0 17-18|0.1.0.0.1.0.0.0.0+0.1.0.0.1.0.0.0+0.1.0.0.1.0.0 13-14|0.1 12-13|0.1.1 8-9|0.0 7-8|0.0.1 5-6|0.0.0.0+0.0.0 3-4|0 1-2|0.1.0.0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:46.811
(c3 / cause-01 
      :ARG0 (a3 / abnormaliti 
            :ARG1-of (e / expect-01 
                  :polarity -) 
            :mod (b / behavioral)) 
      :ARG1 (c2 / clear-06 
            :ARG1 (p2 / possible-01 
                  :ARG1 (u / use-01 
                        :ARG1 (p / pathology 
                              :mod (a / amyloid)) 
                        :ARG2 (a2 / address-02 
                              :ARG0 (m / mouse 
                                    :mod (o / organization 
                                          :name (n / name 
                                                :op1 "APP"))) 
                              :ARG1 (q / question-01 
                                    :ARG1 (p3 / present) 
                                    :ARG1-of (s / same-01) 
                                    :location (c / context))))) 
            :polarity -))

# ::snt Both lines of tTA/APP mice we studied here display extreme hyperactivity visible as cage circling and quantified by activity monitoring ( see Figure 7 ) .
# ::tok Both lines of tTA/APP mice we studied here display extreme hyperactivity visible as cage circling and quantified by activity monitoring ( see Figure 7 ) .
# ::alignments 23-24|0.0.0 22-23|0.2.0.0.0.0.0.0 21-22|0.2.0.0.0.0.0 19-20|0.2.2 18-19|0.0 16-17|0 15-16|0.2 14-15|0.1.0 13-14|0.1 11-12|0.2.1 10-11|0.2.0.1 9-10|0.2.0.0.0.1.0 8-9|0.2.0 7-8|0.2.0.0.0.2 6-7|0.2.0.0.0 5-6|0.2.0.0.0.0 4-5|0.2.0.0.0.1 1-2|0.2.0.0 0-1|0.2.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:47.193
(q / quantify-01 
      :ARG0 (a / activity-06 
            :ARG1 7) 
      :ARG1 (c2 / cage 
            :ARG1-of (c / circle-01)) 
      :op2-of (a2 / and 
            :ARG1-of (d / display-01 
                  :ARG0 (l / line 
                        :location-of (s2 / study-01 
                              :ARG0 (w / we 
                                    :ARG0-of (s / see-01 
                                          :ARG1 (f / figure))) 
                              :ARG1 (m2 / mouse 
                                    :domain-of (e / extreme)) 
                              :location (h2 / here)) 
                        :mod (b / both)) 
                  :manner (h / hyperactivity)) 
            :op1 (v / visible) 
            :op3 (m / monitor-01)))

# ::snt Many of the double transgenic mice showed similar circular patterns of swimming near the edge of the tank when tested in the Morris water maze .
# ::tok Many of the double transgenic mice showed similar circular patterns of swimming near the edge of the tank when tested in the Morris water maze .
# ::alignments 24-25|0.1.1.2.0 23-24|0.1.0 22-23|0.0.0.0+0.0.0+0.0 19-20|0.1.1.2 17-18|0.1.1.1.0.0 14-15|0.1.1.1.0 12-13|0.1.1.1 11-12|0.1.1 9-10|0.1 8-9|0.1.3 7-8|0.1.2 6-7|0 5-6|0.1.1.0 3-4|0.1.1.0.0 0-1|0.1.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:47.455
(s2 / show-01 
      :ARG0 (p / person 
            :name (n / name 
                  :op1 "Morris")) 
      :ARG1 (p2 / pattern-01 
            :ARG0 (w / water) 
            :ARG1 (s / swim-01 
                  :ARG0 (m2 / mouse 
                        :mod (d / double) 
                        :quant (m3 / many)) 
                  :ARG1-of (n2 / near-02 
                        :ARG2 (e / edge-01 
                              :ARG1 (t2 / tank))) 
                  :ARG1-of (t / test-01 
                        :ARG2 (m / maze))) 
            :ARG1-of (r / resemble-01) 
            :mod (c / circular)))

# ::snt Expression of this phenotype makes standard tests of learning and memory uninterpretable .
# ::tok Expression of this phenotype makes standard tests of learning and memory uninterpretable .
# ::alignments 11-12|0.0.0.0.0.1 10-11|0.0.0.0.1 9-10|0.0.0.0 8-9|0.0.0.0.0 6-7|0.0.0 5-6|0.0.0.1 4-5|0 3-4|0.0.0.0.0.0 2-3|0.0.0.0.0.0.0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:47.502
(m2 / make-02 
      :ARG0 (e / expression 
            :ARG0-of (t / test-01 
                  :ARG1 (a / and 
                        :op1 (l / learn-01 
                              :ARG0 (p / phenotype 
                                    :mod (t2 / this)) 
                              :ARG1 (u / uninterpretable)) 
                        :op2 (m / memory)) 
                  :ARG1-of (s / standard-02))))

# ::snt Hyperactivity nonspecifically inhibits choice-driven changes in movement , the key element behind all cognitive behavioral paradigms .
# ::tok Hyperactivity nonspecifically inhibits choice-driven changes in movement , the key element behind all cognitive behavioral paradigms .
# ::alignments 15-16|0.1.0.2.0 14-15|0.1.0.2.0.0 13-14|0.1.0.2.0.1 12-13|0.1.0.2.0.2 11-12|0.1.0.2 10-11|0.1.0 9-10|0.1.0.0 6-7|0.1.0.1 4-5|0.1 2-3|0 1-2|0.2 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:47.741
(i / inhibit-01 
      :ARG0 (h / hyperactivity) 
      :ARG1 (c2 / change-01 
            :ARG1 (e / element 
                  :ARG1-of (k / key-02) 
                  :ARG1-of (m / movement-07) 
                  :location (b2 / behind 
                        :op1 (p / paradigm 
                              :mod (b / behavioral) 
                              :mod (c / cognitive) 
                              :quant (a / all))))) 
      :manner (n / nonspecifically))

# ::snt We are currently working to determine whether hyperactivity correlates with expression of the APPswe/ind holoprotein or its proteolytic derivatives .
# ::tok We are currently working to determine whether hyperactivity correlates with expression of the APPswe/ind holoprotein or its proteolytic derivatives .
# ::alignments 18-19|0.1 17-18|0.1.0 15-16|0 13-14|0.0.0.0.0+0.0.0.0+0.0.0 10-11|0.0 8-9|0.0.1 7-8|0.0.1.0 5-6|0.0.1.1 3-4|0.0.1.1.0 2-3|0.0.1.1.0.1 0-1|0.0.1.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:47.968
(o / or 
      :ARG1-of (e / express-01 
            :ARG0 (t / thing 
                  :name (n / name 
                        :op1 "APPswe/ind")) 
            :ARG1-of (c / correlate-01 
                  :ARG0 (h / hyperactivity) 
                  :ARG1-of (d2 / determine-01 
                        :ARG1-of (w / work-01 
                              :ARG0 (w2 / we) 
                              :time (c2 / current))))) 
      :op1 (d / derive-01 
            :mod (p / proteolytic)))

# ::snt Preliminary studies suggest that hyperactivity does not appear quickly when dox-reared mice are shifted to nonmedicated diets ( J. L. J. , unpublished data ) .
# ::tok Preliminary studies suggest that hyperactivity does not appear quickly when dox-reared mice are shifted to nonmedicated diets ( J. L. J. , unpublished data ) .
# ::alignments 23-24|0.1.1.0.0 22-23|0.1.1.0 18-21|0.0.0.0.2+0.0.0.0.1+0.0.0.0.0+0.0.0.0+0.0.0 16-17|0.1.0.0.1 15-16|0.1.0.0.1.0 13-14|0.1.0.0 11-12|0.1.0.0.0 10-11|0.1.0.0.0.0 8-9|0.1.1 7-8|0.1 6-7|0.1.2 4-5|0.1.0 2-3|0 1-2|0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:48.348
(s2 / suggest-01 
      :ARG0 (s3 / study-01 
            :ARG0 (p / person 
                  :name (n / name 
                        :op1 "J." 
                        :op2 "L." 
                        :op3 "J.")) 
            :mod (p2 / preliminary)) 
      :ARG1 (a / appear-02 
            :ARG1 (h / hyperactivity 
                  :ARG0-of (s / shift-01 
                        :ARG1 (m / mouse 
                              :mod (d3 / dox-rear)) 
                        :ARG2 (d2 / diet 
                              :mod (n2 / nonmedicat)))) 
            :ARG1-of (q / quick-02 
                  :ARG0 (u / unpublish 
                        :mod-of (d / data))) 
            :polarity -))

# ::snt These data may indicate that the neuroactive culprit is not immediately present after transgenic APP synthesis is initiated , but requires additional time to develop .
# ::tok These data may indicate that the neuroactive culprit is not immediately present after transgenic APP synthesis is initiated , but requires additional time to develop .
# ::alignments 24-25|0.2 22-23|0.1.1 21-22|0.1.1.0 20-21|0.1 19-20|0 17-18|0.0.3.0 15-16|0.0.3.0.0 14-15|0.0.3.0.0.0.0.0+0.0.3.0.0.0.0+0.0.3.0.0.0 12-13|0.0.3 11-12|0.0 10-11|0.0.2 9-10|0.0.1 7-8|0.0.0 3-4|0.1.0.0 2-3|0.1.0.0.1 1-2|0.1.0 0-1|0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:48.896
(c / contrast-01 
      :ARG1 (p / present 
            :domain (c2 / culprit) 
            :polarity - 
            :time (i2 / immediate) 
            :time (a2 / after 
                  :op1 (i / initiate-01 
                        :ARG1 (s / synthesi 
                              :mod (o / organization 
                                    :name (n / name 
                                          :op1 "APP")))))) 
      :ARG2 (r / require-01 
            :ARG0 (d2 / data 
                  :ARG1-of (i3 / indicate-01 
                        :ARG0 (t2 / this) 
                        :ARG1-of (p2 / possible-01))) 
            :ARG1 (t / time 
                  :mod (a / additional))) 
      :purpose (d / develop-02))

# ::snt Alternatively , hyperactivity may be caused by neuronal alterations due to transgene expression during early postnatal development .
# ::tok Alternatively , hyperactivity may be caused by neuronal alterations due to transgene expression during early postnatal development .
# ::alignments 16-17|0.0.0.0 15-16|0.0.0.0.0 14-15|0.0.0.0.1 12-13|0.0.0 8-9|0.0 7-8|0.0.1 5-6|0 3-4|0.2 2-3|0.1 0-1|0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:48.950
(c / cause-01 
      :ARG0 (a / alteration 
            :ARG0-of (e2 / express-01 
                  :ARG1 (d / develop-02 
                        :ARG1 (p / postnatal) 
                        :time (e / early))) 
            :mod (n / neuronal)) 
      :ARG1 (h / hyperactivity) 
      :ARG1-of (p2 / possible-01 
            :location (a2 / alternatively)))

# ::snt Further experiments are needed to distinguish between these possibilities .
# ::tok Further experiments are needed to distinguish between these possibilities .
# ::alignments 8-9|0+0.0 7-8|0.0.1 5-6|0.0.0 3-4|0.0.0.0 1-2|0.0.0.0.0 0-1|0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:49.035
(p / possible-01 
      :ARG1 (t / thing 
            :ARG1-of (d / distinguish-01 
                  :purpose-of (n / need-01 
                        :ARG1 (e / experiment-01 
                              :mod (f / further)))) 
            :mod (t2 / this)))

# ::snt In summary , we demonstrate that abrogating A production halts the progression of pathologic changes in a transgenic mouse model of Alzheimer-type amyloidosis .
# ::tok In summary , we demonstrate that abrogating A production halts the progression of pathologic changes in a transgenic mouse model of Alzheimer-type amyloidosis .
# ::alignments 22-23|0.1.1.0.0.1 19-20|0.1.1.0.0 18-19|0.1.1.0.0.0 14-15|0.1.1.0 13-14|0.1.1.0.1 11-12|0.1.1 9-10|0.1 8-9|0.1.0 4-5|0 3-4|0.0 1-2|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:49.108
(d / demonstrate-01 
      :ARG0 (w / we) 
      :ARG1 (h / halt-01 
            :ARG0 (p3 / produce-01) 
            :ARG1 (p2 / progress-01 
                  :ARG1 (c / change-01 
                        :ARG1 (m / model 
                              :mod (m2 / mouse) 
                              :mod (a / amyloidosi)) 
                        :mod (p / pathologic)))) 
      :prep-in (s / summary))

# ::snt However , despite dramatic reductions in A synthesis , neuritic plaques are stable structures in vivo that do not quickly disaggregate .
# ::tok However , despite dramatic reductions in A synthesis , neuritic plaques are stable structures in vivo that do not quickly disaggregate .
# ::alignments 19-20|0.0.0 18-19|0.0.0.0.0.0 15-16|0.0.2 13-14|0.0 12-13|0.0.1 10-11|0 7-8|0.0.0.0 4-5|0.0.0.0.0 3-4|0.0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:49.206
(p / plaqu 
      :domain-of (s / structure 
            :ARG1-of (q / quick-02 
                  :ARG0 (s3 / synthesi 
                        :ARG1-of (r / reduce-01 
                              :ARG0 - 
                              :manner (d / dramatic)))) 
            :ARG1-of (s2 / stable-03) 
            :location (v / vivo)))

# ::snt It is possible that a combination of therapies to limit A production , increase A degradation , and enhance phagocytosis of deposited amyloid may be required to reverse damage associated with AD .
# ::tok It is possible that a combination of therapies to limit A production , increase A degradation , and enhance phagocytosis of deposited amyloid may be required to reverse damage associated with AD .
# ::alignments 31-32|0.0.2.0.0.0.0 29-30|0.0.2.0.0.0 28-29|0.0.2.0.0 27-28|0.0.2.0 25-26|0.0.2.0.1 23-24|0.0.2.0.1.1 22-23|0.3 21-22|0.3.0 19-20|0.2.0 18-19|0.2 17-18|0 15-16|0.1.0 13-14|0.1 11-12|0.0.1 9-10|0.0 7-8|0.0.0 5-6|0.0.2 2-3|0.0.2.0.1.0.0 0-1|0.0.2.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:49.843
(a3 / and 
      :op1 (l / limit-01 
            :ARG0 (t / therapi) 
            :ARG1 (p3 / produce-01) 
            :ARG1-of (c / combine-01 
                  :ARG0-of (r / reverse-01 
                        :ARG1 (d / damage-01 
                              :ARG1-of (a / associate-01 
                                    :ARG2 "AD")) 
                        :ARG1-of (r2 / require-01 
                              :ARG0 (i2 / it 
                                    :ARG1-of (p4 / possible-01)) 
                              :ARG1-of (p / possible-01))))) 
      :op2 (i / increase-01 
            :ARG1 (d3 / degradation)) 
      :op3 (e / enhance-01 
            :ARG1 (p2 / phagocytosi)) 
      :poss (a2 / amyloid 
            :ARG1-of (d2 / deposit-01)))

# ::snt However , if started early enough in the course of disease , secretase inhibitors alone could provide substantial benefit in slowing pathogenic processes linked to amyloid deposition .
# ::tok However , if started early enough in the course of disease , secretase inhibitors alone could provide substantial benefit in slowing pathogenic processes linked to amyloid deposition .
# ::alignments 26-27|0.0.1.0.2.0 25-26|0.0.1.0.2.0.0 23-24|0.0.1.0.2 22-23|0.0.1.0 21-22|0.0.1.0.3 20-21|0.0.1 18-19|0.0.0 17-18|0.0.0.1 16-17|0.0 15-16|0 14-15|0.0.2 13-14|0.0.0.0 12-13|0.0.0.0.0 10-11|0.0.1.0.0 5-6|0.1.0 4-5|0.0.1.0.1 3-4|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:50.261
(p4 / possible-01 
      :ARG1 (p3 / provide-01 
            :ARG1 (b / benefit-01 
                  :ARG1 (i / inhibitor 
                        :mod (s3 / secretase)) 
                  :degree (s2 / substantial)) 
            :ARG2 (s / slow-01 
                  :ARG1 (p / process-02 
                        :ARG0 (d2 / disease) 
                        :ARG1 (e2 / early) 
                        :ARG1-of (l / link-01 
                              :ARG2 (d / deposition 
                                    :mod (a / amyloid))) 
                        :mod (p2 / pathogenic))) 
            :manner (a2 / alone)) 
      :condition (s4 / start-01 
            :ARG1 (e / enough)))

# ::snt Even at later stages in the disease , the presence of substantial microglial activation in human AD [ 40 ] suggests that simply slowing the formation of new amyloid deposits may allow ongoing phagocytosis to diminish preexisting lesions .
# ::tok Even at later stages in the disease , the presence of substantial microglial activation in human AD [ 40 ] suggests that simply slowing the formation of new amyloid deposits may allow ongoing phagocytosis to diminish preexisting lesions .
# ::alignments 37-38|0.1.1.1 36-37|0.1.1.1.0 35-36|0.1.1 33-34|0.1.1.0 32-33|0.1.1.0.0 31-32|0.1 30-31|0.1.2 29-30|0.1.0.1.0 28-29|0.1.1.3 27-28|0.2 25-26|0.1.0.1 23-24|0.1.0 22-23|0.1.0.2 20-21|0 18-19|0.1.1.2 16-17|0.3.0 15-16|0.3 13-14|0.0.0 11-12|0.0.0.0 9-10|0.0 6-7|0.1.2.0 3-4|0.1.0.0.0 2-3|0.1.0.0 0-1|0.1.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:51.103
(s3 / suggest-01 
      :ARG0 (p4 / presence 
            :poss (a3 / activation 
                  :mod (s4 / substantial))) 
      :ARG1 (a / allow-01 
            :ARG0 (s / slow-01 
                  :ARG0 (l2 / late 
                        :time-of (s5 / stage 
                              :mod (e / even))) 
                  :ARG1 (f / form-01 
                        :ARG1 (d2 / deposit)) 
                  :mod (s2 / simple)) 
            :ARG1 (d / diminish-01 
                  :ARG0 (p2 / phagocytosi 
                        :mod (o / ongo)) 
                  :ARG1 (l / lesion 
                        :mod (p / preexist)) 
                  :ARG2 40 
                  :op1-of (a2 / amyloid)) 
            :ARG1-of (p3 / possible-01 
                  :ARG2 (d3 / disease))) 
      :ARG2 (n / new) 
      :time (h / human 
            :mod-of "AD"))

# ::snt However , the development of safe and effective secretase inhibitors will ultimately be required to determine whether the human brain has the capacity to repair amyloid-associated damage of AD once the progression of pathology is arrested .
# ::tok However , the development of safe and effective secretase inhibitors will ultimately be required to determine whether the human brain has the capacity to repair amyloid-associated damage of AD once the progression of pathology is arrested .
# ::alignments 35-36|0.0.0.1.0 33-34|0.0.0.1.0.0.0 31-32|0.0.0.1.0.0 29-30|0.0.0.1.0.1 28-29|0.0.0.1.0.1.0.1.0 26-27|0.0.0.1.0.1.0.1 25-26|0.0.0.1.0.1.0.0.0 24-25|0.0.0.1.0.1.0 22-23|0.0.0.0 19-20|0.0.0.1.0.1.0.0 18-19|0.0.0.1.0.1.0.1.1 15-16|0.0.0 13-14|0.0.0.1 11-12|0.0.0.1.1 9-10|0.0.1 8-9|0.2.0 7-8|0.2 6-7|0 5-6|0.1 3-4|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:52.501
(a3 / and 
      :op1 (d3 / develop-02 
            :ARG0-of (d2 / determine-01 
                  :ARG1 (c / capacity) 
                  :ARG1-of (r2 / require-01 
                        :ARG2 (a / arrest-01 
                              :ARG1 (p2 / progress-01 
                                    :ARG1 (p / pathology)) 
                              :op1-of (o / once 
                                    :time-of (r / repair-01 
                                          :ARG0 (b / brain 
                                                :mod (a2 / amyloid-associat)) 
                                          :ARG1 (d / damage-01 
                                                :ARG1 "AD" 
                                                :mod (h / human))))) 
                        :time (u / ultimate))) 
            :ARG1 (i / inhibitor)) 
      :op2 (s2 / safe-01) 
      :op3 (e / effective-04 
            :ARG1 (s / secretase)))

# ::snt Transgenic APP Expression and Suppression by Dox in the Four New Tet-Off APP Lines .
# ::tok Transgenic APP Expression and Suppression by Dox in the Four New Tet-Off APP Lines .
# ::alignments 11-14|0.0.0.2+0.0.0.1+0.0.0.0+0.0.0+0.0 9-10|0.0.1 6-7|0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 0-5|0.1.4+0.1.3+0.1.2+0.1.1+0.1.0+0.1+0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:52.541
(o2 / organization 
      :location (o / organization 
            :name (n / name 
                  :op1 "Tet-Off" 
                  :op2 "APP" 
                  :op3 "Lines") 
            :quant (4 / 4 
                  :quant-of (p / person 
                        :name (n2 / name 
                              :op1 "Dox")))) 
      :name (n3 / name 
            :op1 "Transgenic" 
            :op2 "APP" 
            :op3 "Expression" 
            :op4 "and" 
            :op5 "Suppression"))

# ::snt Western blotting with human-specific antibody 6E10 reveals transgene-derived full-length APP in cortical homogenates from untreated animals ( left lanes of each panel ) .
# ::tok Western blotting with human-specific antibody 6E10 reveals transgene-derived full-length APP in cortical homogenates from untreated animals ( left lanes of each panel ) .
# ::alignments 21-22|0.0.1.0 20-21|0.0.1.0.0 18-19|0.0.1 17-18|0.0.1.1 15-16|0.2 14-15|0.2.0 12-13|0.2.1 11-12|0.2.1.0 9-10|0.1.2.0+0.1.2+0.1 8-9|0.1.0 7-8|0.1.1 6-7|0 5-6|0.0.0 4-5|0.0.0.0 1-2|0.0 0-1|0.0.2.1+0.0.2.0.0+0.0.2.0+0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:53.113
(r / reveal-01 
      :ARG0 (b / blot-01 
            :ARG1 (6 / 6E10 
                  :mod (a2 / antibody)) 
            :ARG2 (l / lane-01 
                  :ARG1 (p / panel 
                        :mod (e / each)) 
                  :mod (l2 / left)) 
            :mod (w / world-region 
                  :name (n2 / name 
                        :op1 "West") 
                  :wiki "Western_world")) 
      :ARG1 (o / organization 
            :mod (f / full-length) 
            :mod (t / transgene-deriv) 
            :name (n / name 
                  :op1 "APP")) 
      :ARG2 (a / animal 
            :mod (u / untreat) 
            :source-of (h / homogenat 
                  :mod (c / cortical))))

# ::snt The new lines produce exceptionally high levels of transgene expression ; an equal amount of brain homogenate from a standard transgenic APP line is shown for comparison ( extreme left lane , Standard Tg line C3 -- 3 ; [ 15,63 ] ) .
# ::tok The new lines produce exceptionally high levels of transgene expression ; an equal amount of brain homogenate from a standard transgenic APP line is shown for comparison ( extreme left lane , Standard Tg line C3 -- 3 ; [ 15,63 ] ) .
# ::alignments 37-38|0.0.0.2.0 34-35|0.0.0.1.0.1.0 32-34|0.0.0.1.0.1.1.1+0.0.0.1.0.1.1.0+0.0.0.1.0.1.1+0.0.0.1.0.1 30-31|0.0.0.1.0.0.0 29-30|0.0.0.1.0.0.0.0 28-29|0.0.0.1.0.0.0.1 26-27|0.0.0 24-25|0.0.0.1 22-23|0.0.0.2.1 21-22|0.0.0.2.1.0.0.0+0.0.0.2.1.0.0+0.0.0.2.1.0 19-20|0.0.0.2 16-17|0.0.1 15-16|0.0.0.0 13-14|0.0 12-13|0 10-11|0.0.0.1.0 9-10|0.0.0.1.0.0 8-9|0.0.0.1.0.0.1 6-7|0.0.0.1.0.0.2 5-6|0.0.0.1.0.0.2.1 4-5|0.0.0.1.0.0.2.1.0 3-4|0.0.0.1.0.0.2.0 2-3|0.0.0.1.0.0.2.0.0 1-2|0.0.0.1.0.0.2.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:54.095
(e2 / equal-01 
      :ARG1 (a / amount 
            :ARG1-of (c2 / compare-01 
                  :ARG0 (b / brain) 
                  :ARG1-of (s / show-01 
                        :op1-of (a2 / and 
                              :ARG1-of (e3 / express-01 
                                    :ARG1-of (l2 / lane-01 
                                          :mod (l3 / left) 
                                          :mod (e / extreme)) 
                                    :mod (t / transgene) 
                                    :mod-of (l5 / level 
                                          :ARG1-of (p / produce-01 
                                                :ARG0 (l6 / line 
                                                      :mod (n3 / new))) 
                                          :ARG1-of (h2 / high-02 
                                                :degree (e4 / exceptionally)))) 
                              :op2 (c / country 
                                    :mod-of (l / line) 
                                    :name (n / name 
                                          :op1 "Standard" 
                                          :op2 "Tg")))) 
                  :purpose (s2 / standard-02 
                        :ARG0 3 
                        :ARG1 (l4 / line 
                              :mod (o / organization 
                                    :name (n2 / name 
                                          :op1 "APP"))))) 
            :quant-of (h / homogenate)))

# ::snt After 1 mo of dox treatment , transgenic protein in all four new tet-off APP lines is reduced to residual levels ( + dox ; right lanes of each panel ) .
# ::tok After 1 mo of dox treatment , transgenic protein in all four new tet-off APP lines is reduced to residual levels ( + dox ; right lanes of each panel ) .
# ::alignments 29-30|0.1.1 28-29|0.1.1.0 26-27|0.1 25-26|0.1.2 24-25|0 20-21|0.0.0 19-20|0.0 17-18|0.0.0.0 15-16|0.0.0.0.1.1.0.0 14-15|0.0.0.0.1.1.0.0.0.0.0+0.0.0.0.1.1.0.0.0.0+0.0.0.0.1.1.0.0.0 12-13|0.0.0.0.1.1.0 11-12|0.0.0.0.1.1.0.0.1 10-11|0.0.0.0.1.1.0.0.2 8-9|0.0.0.0.0 5-6|0.0.0.0.1.1 4-5|0.0.0.0.1.1.1 2-3|0.0.0.0.1.0 1-2|0.1.0 0-1|0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:54.349
(a / and 
      :op1 (r2 / residual 
            :mod-of (l2 / level 
                  :ARG4-of (r3 / reduce-01 
                        :ARG1 (p2 / protein) 
                        :time (a3 / after 
                              :op1 (m / mo) 
                              :op2 (t / treat-03 
                                    :ARG1 (n2 / new 
                                          :mod-of (l3 / line 
                                                :mod (o / organization 
                                                      :name (n / name 
                                                            :op1 "APP")) 
                                                :quant 4 
                                                :quant (a2 / all))) 
                                    :ARG2 (d / dox)))))) 
      :op2 (l / lane-01 
            :ARG0 1 
            :ARG1 (p / panel 
                  :mod (e / each)) 
            :mod (r / right)))

# ::snt ( 474 KB TIF ) .
# ::tok ( 474 KB TIF ) .
# ::alignments 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:54.354
(4 / 474)

# ::snt Click here for additional data file .
# ::tok Click here for additional data file .
# ::alignments 5-6|0.0 4-5|0.0.0 3-4|0.0.0.0 1-2|0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:54.370
(c / click-01 
      :ARG1 (f / file 
            :mod (d / data 
                  :mod (a / additional))) 
      :location (h / here))

# ::snt Transgenic APP mRNA Is Brain-Specific .
# ::tok Transgenic APP mRNA Is Brain-Specific .
# ::alignments 3-5|0.1.1+0+0.1+0.1.0 1-3|0.0.0.1+0.0.0.0+0.0.0+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:54.396
(i / Is 
      :mod (t2 / thing 
            :name (n2 / name 
                  :op1 (a / APP) 
                  :op2 (m / mRNA))) 
      :op1-of (n / name 
            :name-of (t / thing) 
            :op2 (b / Brain-Specific)))

# ::snt A slot blot of mRNA harvested from various tissues in three of the four new tet-off APP lines and a nontransgenic control was used to examine transgenic mRNA expression .
# ::tok A slot blot of mRNA harvested from various tissues in three of the four new tet-off APP lines and a nontransgenic control was used to examine transgenic mRNA expression .
# ::alignments 28-29|0.0.0.0.1.1 27-28|0.0.0.0.1.1.0 25-26|0.0.0.0.1 23-24|0.0.0.0 21-22|0.0.0.0.0 18-19|0 17-18|0.0 15-17|0.0.0.1.1+0.0.0.1.0+0.0.0.1+0.0.0 14-15|0.0.0.0.0.0 13-14|0.0.1 10-11|0.0.0.0.1.0.2.1 8-9|0.0.0.0.1.0.2.0 7-8|0.0.0.0.1.0.2.0.0 5-6|0.0.0.0.1.0.2 4-5|0.0.0.0.1.0.1 2-3|0.0.0.0.1.0 1-2|0.0.0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:54.893
(a / and 
      :op1 (l / line 
            :mod (t / thing 
                  :ARG3-of (u / use-01 
                        :ARG1 (c / control-01 
                              :ARG1 (n2 / new)) 
                        :ARG2 (e2 / examine-01 
                              :ARG0 (b / blot-01 
                                    :ARG0 (s / slot) 
                                    :ARG1 (m2 / mrna) 
                                    :ARG1-of (h / harvest-01 
                                          :ARG2 (t3 / tissue 
                                                :mod (v / various)) 
                                          :time 3)) 
                              :ARG1 (e / express-01 
                                    :ARG1 (m / mrna)))) 
                  :name (n / name 
                        :op1 (t2 / tet-off) 
                        :op2 (a2 / APP))) 
            :quant 4))

# ::snt Hybridization is seen only in the brain ; no signal above background is seen in any other tissue .
# ::tok Hybridization is seen only in the brain ; no signal above background is seen in any other tissue .
# ::alignments 17-18|0.3.0.1 16-17|0.3.0.1.0 15-16|0.3.0.1.1 13-14|0.3.0 11-12|0.3.0.0 10-11|0.2.0 9-10|0.3.0.0.0 8-9|0.3.0.2 7-8|0.3 6-7|0.1 3-4|0.2 2-3|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:55.118
(s3 / see-01 
      :ARG1 (h / hybridization) 
      :manner (b2 / brain) 
      :mod (o2 / only 
            :mod (a2 / above)) 
      :op1-of (a3 / and 
            :op2 (s / see-01 
                  :ARG1 (b / background 
                        :mod (s2 / signal)) 
                  :ARG2 (t / tissue 
                        :mod (o / other) 
                        :mod (a / any)) 
                  :polarity -)))

# ::snt ( 781 KB PSD ) .
# ::tok ( 781 KB PSD ) .
# ::alignments 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:55.123
(7 / 781)

# ::snt Click here for additional data file .
# ::tok Click here for additional data file .
# ::alignments 5-6|0.0 4-5|0.0.0 3-4|0.0.0.0 1-2|0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:55.138
(c / click-01 
      :ARG1 (f / file 
            :mod (d / data 
                  :mod (a / additional))) 
      :location (h / here))

# ::snt Amyloid Pathology in the Cortex Reiterates That in the Hippocampus .
# ::tok Amyloid Pathology in the Cortex Reiterates That in the Hippocampus .
# ::alignments 6-7|0.1 5-6|0 4-5|0.0.0.0.0+0.0.0.0+0.0.0 0-2|0.0.1.1+0.0.1.0+0.0.1+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:55.171
(r / reiterate-01 
      :ARG0 (t2 / thing 
            :location (o / organization 
                  :name (n / name 
                        :op1 "Cortex")) 
            :name (n2 / name 
                  :op1 (a / Amyloid) 
                  :op2 (p / Pathology))) 
      :ARG1 (t / that))

# ::snt Amyloid histology was performed on sections from line 107 double transgenic mice by Hirano silver stain ( top row ) , thioflavin-S ( middle row ) , and A immunohistochemistry ( bottom row ) to examine the persistence of pathology following transgene suppression .
# ::tok Amyloid histology was performed on sections from line 107 double transgenic mice by Hirano silver stain ( top row ) , thioflavin-S ( middle row ) , and A immunohistochemistry ( bottom row ) to examine the persistence of pathology following transgene suppression .
# ::alignments 42-43|0.0 41-42|0 40-41|0.0.1 39-40|0.0.1.1.1.0 37-38|0.0.1.1.1 35-36|0.0.1.1 32-33|0.0.1.2.1.0 31-32|0.0.1.2.1 29-30|0.0.1.1.2.2 27-28|0.0.1.1.2 24-25|0.0.0 23-24|0.0.1.1.0 21-22|0.0.1.1.2.1 18-19|0.0.1.0.0 17-18|0.0.1.0 15-16|0.0.1.2 14-15|0.0.1.2.2 13-14|0.0.1.2.0.0.0+0.0.1.2.0.0+0.0.1.2.0 11-12|0.0.1.1.2.0 9-10|0.0.1.1.2.0.1 8-9|0.0.2 7-8|0.0.1.1.2.0.0.1 5-6|0.0.1.1.2.0.0.0 3-4|0.0.1.1.2.0.0 1-2|0.0.1.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:56.053
(t / transgene 
      :ARG1-of (s / suppress-01 
            :ARG0 (r2 / row) 
            :ARG2-of (f / follow-01 
                  :ARG0 (t3 / top 
                        :mod-of (r3 / row)) 
                  :ARG1 (e / examine-01 
                        :ARG0 (m / middle) 
                        :ARG1 (p2 / persistence 
                              :mod (p / pathology)) 
                        :op4-of (a / and 
                              :op1 (m2 / mouse 
                                    :ARG0-of (p4 / perform-02 
                                          :ARG1 (s4 / section) 
                                          :ARG2 (l / line)) 
                                    :mod (d / double)) 
                              :op2 (t2 / thioflavin-) 
                              :op3 (i / immunohistochemistry))) 
                  :ARG2-of (s2 / stain-01 
                        :ARG0 (p3 / person 
                              :name (n / name 
                                    :op1 "Hirano")) 
                        :ARG1 (b / bottom 
                              :mod-of (r / row)) 
                        :mod (s3 / silver)) 
                  :op1-of (h / histology)) 
            :op1-of 107))

# ::snt As in the hippocampus ( see Figure 4 and text ) , the progression of amyloid pathology in the cortex worsens substantially between 6 and 9 mo of age in untreated mice .
# ::tok As in the hippocampus ( see Figure 4 and text ) , the progression of amyloid pathology in the cortex worsens substantially between 6 and 9 mo of age in untreated mice .
# ::alignments 31-32|0.3.0.4 30-31|0.3.0.4.1 28-29|0.3.0.4.0 26-27|0.3.0.1 25-26|0.3.0.0.0 24-25|0.3 23-24|0.0.0 21-22|0.3.0.2 20-21|0.3.0 19-20|0.3.0.3 16-17|0.3.0.0.1 15-16|0.3.0.0.1.0 13-14|0.3.0.0 9-10|0.1 8-9|0 7-8|0.3.0.4.0.0 6-7|0.0.1 5-6|0.0 3-4|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:56.891
(a4 / and 
      :ARG1-of (s2 / see-01 
            :ARG0 6 
            :ARG2 (f / figure)) 
      :op1 (t / text) 
      :op1-of (h / hippocampu) 
      :op1-of (a2 / and 
            :ARG2-of (w / worsen-01 
                  :ARG0 (p2 / progress-01 
                        :ARG0 9 
                        :ARG1 (p / pathology 
                              :mod (a3 / amyloid))) 
                  :ARG1 (m2 / mo) 
                  :manner (s / substantial) 
                  :manner (c / cortex) 
                  :time (m / mouse 
                        :ARG2-of (a / age-01 
                              :ARG1 4) 
                        :mod (u / untreat)))))

# ::snt This progression is completely prevented by suppression of the transgene with dox .
# ::tok This progression is completely prevented by suppression of the transgene with dox .
# ::alignments 11-12|0 9-10|0.0.0.0.0 6-7|0.0.0.0 4-5|0.0.0 3-4|0.0.0.1 1-2|0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:56.976
(d / dox 
      :ARG1-of (p2 / progress-01 
            :ARG1-of (p / prevent-01 
                  :ARG0 (s / suppress-01 
                        :ARG1 (t / transgene)) 
                  :ARG1-of (c / complete-02)) 
            :mod (t2 / this)))

# ::snt For comparison , normal neurohistology is shown in an age-matched single transgenic ( tTA only ) animal .
# ::tok For comparison , normal neurohistology is shown in an age-matched single transgenic ( tTA only ) animal .
# ::alignments 16-17|0.0 14-15|0.2.0 10-11|0.0.0 9-10|0.0.0.0 6-7|0 4-5|0.1 3-4|0.1.0 1-2|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:57.030
(s2 / show-01 
      :ARG0 (a / animal 
            :ARG1-of (s / single-02 
                  :mod (a2 / age-match))) 
      :ARG1 (n / neurohistology 
            :ARG1-of (n2 / normal-02)) 
      :purpose (c / compare-01 
            :ARG1 (o / only)))

# ::snt No amyloid pathology has been detected in either APP or tTA single transgenic animals up to 15 mo of age .
# ::tok No amyloid pathology has been detected in either APP or tTA single transgenic animals up to 15 mo of age .
# ::alignments 19-20|0 17-18|0.1 16-17|0.1.0 13-14|0.0.1.2 11-12|0.0.1.2.0 9-10|0.0.1 8-9|0.0.1.1.0.0+0.0.1.1.0+0.0.1.1 7-8|0.0.1.0 5-6|0.0 2-3|0.0.0 1-2|0.0.0.0 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:57.116
(a / age-01 
      :ARG1 (d / detect-01 
            :ARG1 (p / pathology 
                  :mod (a3 / amyloid)) 
            :ARG2 (o / or 
                  :mod (e / either) 
                  :op1 (o2 / organization 
                        :name (n / name 
                              :op1 "APP")) 
                  :op2 (a2 / animal 
                        :ARG1-of (s / single-02))) 
            :polarity -) 
      :time-of (m / mo 
            :quant 15))

# ::snt ( 4.8 MB PSD ) .
# ::tok ( 4.8 MB PSD ) .
# ::alignments 2-4|0.0.1+0.0.0+0.0+0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:57.123
(o / organization 
      :name (n / name 
            :op1 "MB" 
            :op2 "PSD"))

# ::snt Click here for additional data file .
# ::tok Click here for additional data file .
# ::alignments 5-6|0.0 4-5|0.0.0 3-4|0.0.0.0 1-2|0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:57.142
(c / click-01 
      :ARG1 (f / file 
            :mod (d / data 
                  :mod (a / additional))) 
      :location (h / here))

# ::snt Diffuse Deposits Do Not Disperse During A Suppression .
# ::tok Diffuse Deposits Do Not Disperse During A Suppression .
# ::alignments 7-8|0.1.0.0+0.1.0+0.1 4-5|0 3-4|0.2 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:57.168
(d / disperse-01 
      :ARG0 (d2 / deposit-01 
            :ARG1 (d3 / diffuse-01)) 
      :ARG1 (o / organization 
            :name (n / name 
                  :op1 "Suppression")) 
      :polarity -)

# ::snt Campbell -- Switzer silver stain was used to differentiate cored ( brown ) from diffuse ( black ) deposits in line 107 tTA/APP mice .
# ::tok Campbell -- Switzer silver stain was used to differentiate cored ( brown ) from diffuse ( black ) deposits in line 107 tTA/APP mice .
# ::alignments 23-24|0.0.0.0 21-22|0.0.1.1.0.0 20-21|0.0.0.0.0 18-19|0.0.1.1.1 16-17|0.0.1.1.0.1 14-15|0 11-12|0.0.1.1.0.1.0 9-10|0.0.1.1.0 8-9|0.0.1.1 6-7|0.0.1 4-5|0.0 3-4|0.0.2 2-3|0.0.0.1.0+0.0.0.1+0.0.0 0-1|0.0.1.0.1+0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:57.606
(d2 / diffuse-01 
      :ARG1 (s / stain-01 
            :ARG0 (p / person 
                  :mod (m / mouse 
                        :mod (l / line)) 
                  :name (n / name 
                        :op1 "Switzer")) 
            :ARG1-of (u / use-01 
                  :ARG0 (p2 / person 
                        :name (n2 / name 
                              :op1 "Campbell") 
                        :wiki "Glen_Campbell") 
                  :ARG2 (d3 / differentiate-01 
                        :ARG1 (c / core-01 
                              :ARG0 107 
                              :ARG2 (b / black-04 
                                    :ARG1 (b2 / brown))) 
                        :ARG2 (d / deposit))) 
            :mod (s2 / silver)))

# ::snt This stain demonstrates that both types of deposit persist throughout long periods of transgene suppression .
# ::tok This stain demonstrates that both types of deposit persist throughout long periods of transgene suppression .
# ::alignments 14-15|0.1.1.1 13-14|0.1.1.1.0 11-12|0.1.1 10-11|0.1.1.0 9-10|0.1.1.2 8-9|0.1 7-8|0.1.0.1 5-6|0.1.0 4-5|0.1.0.0 2-3|0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:57.679
(d2 / demonstrate-01 
      :ARG0 (s2 / stain-01 
            :mod (t4 / this)) 
      :ARG1 (p2 / persist-01 
            :ARG0 (t3 / type 
                  :mod (b / both) 
                  :mod-of (d / deposit-01)) 
            :ARG1 (p / period 
                  :ARG1-of (l / long-03) 
                  :mod (s / suppress-01 
                        :ARG1 (t / transgene)) 
                  :op1-of (t2 / throughout))))

# ::snt The lower panels , showing low-power images ( 10  ) of frontal cortex from each condition , reveal little change in the extent of diffuse amyloid following up to 6 mo of A suppression .
# ::tok The lower panels , showing low-power images ( 10  ) of frontal cortex from each condition , reveal little change in the extent of diffuse amyloid following up to 6 mo of A suppression .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:57.681
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt High-power images ( 40  ) in the upper panels show that the diffuse halo surrounding individual cored deposits remains relatively unchanged in treated mice .
# ::tok High-power images ( 40  ) in the upper panels show that the diffuse halo surrounding individual cored deposits remains relatively unchanged in treated mice .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:57.684
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Untreated tTA single transgenic animals are shown as a negative control .
# ::tok Untreated tTA single transgenic animals are shown as a negative control .
# ::alignments 10-11|0.1 9-10|0.1.0 6-7|0 4-5|0.0 3-4|0.0.1 2-3|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:57.732
(s / show-01 
      :ARG1 (a / animal 
            :ARG1-of (s2 / single-02 
                  :mod (u / untreat)) 
            :mod (t / transgenic)) 
      :ARG2 (c / control-01 
            :mod (n / negative)))

# ::snt Protocol for the Campbell-Switzer Alzheimer 's Method was kindly shared by Robert Switzer , III ( NeuroScience Associates , Knoxville , Tennessee , United States ) , and can be downloaded at http://www.nsalabs.com/Documents/publications/campbell-switzer_protocol.htm [ 64,65 ] .
# ::tok Protocol for the Campbell-Switzer Alzheimer 's Method was kindly shared by Robert Switzer , III ( NeuroScience Associates , Knoxville , Tennessee , United States ) , and can be downloaded at http://www.nsalabs.com/Documents/publications/campbell-switzer_protocol.htm [ 64,65 ] .
# ::alignments 30-31|0.2.1 28-29|0.2 27-28|0 23-25|0.0.3.1+0.0.3.0.1+0.0.3.0.0+0.0.3.0+0.0.3 21-22|0.1.0.0+0.1.0+0.1 19-20|0.2.1.0.0.0+0.2.1.0.0+0.2.1.0 17-18|0.2.2 16-17|0.2.2.0 14-15|0.2.0 11-13|0.0.0.0.1+0.0.0.0.0+0.0.0.0+0.0.0 9-10|0.0 8-9|0.0.2 6-7|0.0.1.0 4-6|0.0.1.0.0.1+0.0.1.0.0.0.0+0.0.1.0.0.0+0.0.1.0.0 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:58.349
(a / and 
      :op1 (s / share-01 
            :ARG0 (p2 / person 
                  :name (n5 / name 
                        :op1 "Robert" 
                        :op2 "Switzer")) 
            :ARG1 (p3 / protocol 
                  :manner (m / method 
                        :poss (d2 / disease 
                              :name (n6 / name 
                                    :op1 "Alzheimer's") 
                              :wiki "Alzheimer's_disease"))) 
            :manner (k / kindly) 
            :op1-of (c / country 
                  :name (n / name 
                        :op1 "United" 
                        :op2 "States") 
                  :wiki "United_States")) 
      :op2 (c2 / country 
            :name (n2 / name 
                  :op1 "Tennessee")) 
      :op3 (p / possible-01 
            :ARG0 (i / iii) 
            :ARG1 (d / download-01 
                  :ARG0 (c3 / country 
                        :name (n3 / name 
                              :op1 "Knoxville"))) 
            :purpose (a2 / associate-01 
                  :ARG1 (n4 / neuroscience))))

# ::snt ( 923 KB JPG ) .
# ::tok ( 923 KB JPG ) .
# ::alignments 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:58.360
(9 / 923)

# ::snt Click here for additional data file .
# ::tok Click here for additional data file .
# ::alignments 5-6|0.0 4-5|0.0.0 3-4|0.0.0.0 1-2|0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:58.379
(c / click-01 
      :ARG1 (f / file 
            :mod (d / data 
                  :mod (a / additional))) 
      :location (h / here))

# ::snt Chronic Transgene Suppression and Arrest of A Aggregate Formation in an Independent Line of Tet-Off APP Mice ( CaMKII-tTA  tet-APPswe/ind Line 18 ) .
# ::tok Chronic Transgene Suppression and Arrest of A Aggregate Formation in an Independent Line of Tet-Off APP Mice ( CaMKII-tTA  tet-APPswe/ind Line 18 ) .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:58.381
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt ( A ) The experiment presented in the text for line 107 tet-off APP was repeated with a second tet-off APP line ( line 18 ) to control for integration site artifacts .
# ::tok ( A ) The experiment presented in the text for line 107 tet-off APP was repeated with a second tet-off APP line ( line 18 ) to control for integration site artifacts .
# ::alignments 31-32|0.0.0.1 30-31|0.0.0.1.0.0 29-30|0.0.0.1.0 27-28|0.0.0 24-25|0.2.0.0 23-24|0.2.0.1 21-22|0.1 15-16|0 13-14|0.0.2.0+0.0.2+0.0 11-12|0.0.0.0 10-11|0.0.1 8-9|0.2.1 5-6|0.2 4-5|0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:58.763
(r / repeat-01 
      :ARG1 (o / organization 
            :ARG0-of (c / control-01 
                  :ARG1 107 
                  :ARG2 (a / artifact 
                        :ARG1-of (i / integrate-01 
                              :ARG0 (s / site)))) 
            :mod (l3 / line) 
            :name (n / name 
                  :op1 "APP")) 
      :manner (l2 / line) 
      :purpose (p / present-01 
            :ARG0 (e / experiment-01 
                  :ARG1 18 
                  :ARG2 (l / line)) 
            :ARG1 (t / text)))

# ::snt Cortical homogenates from untreated control and dox-treated double transgenic mice were immunoblotted for full-length APP with the human-specific antibody 6E10 to confirm transgene suppression at the time of harvest .
# ::tok Cortical homogenates from untreated control and dox-treated double transgenic mice were immunoblotted for full-length APP with the human-specific antibody 6E10 to confirm transgene suppression at the time of harvest .
# ::alignments 28-29|0.0.0.1 26-27|0.0.0.1.1 23-24|0.0.0.1.1.0 22-23|0.0.0.1.1.0.0 21-22|0.0.0.1.1.0.1 18-19|0.0.0.1.1.0.1.0 14-15|0.0.0.1.0.1.0+0.0.0.1.0.1+0.0.0.1.0 13-14|0.0.0.1.0.0 9-10|0.0.1 7-8|0.0.1.0 6-7|0.0.1.1 5-6|0.0 4-5|0.0.0 3-4|0.0.0.0 1-2|0.0.2 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:59.519
(c3 / cortical 
      :quant-of (a2 / and 
            :op1 (c2 / control-01 
                  :ARG0 (u / untreat) 
                  :ARG1 (h / harvest-01 
                        :ARG1 (o / organization 
                              :mod (f / full-length) 
                              :name (n / name 
                                    :op1 "APP")) 
                        :time (t / time 
                              :time-of (s / suppress-01 
                                    :ARG1 (t2 / transgene) 
                                    :ARG1-of (c / confirm-01 
                                          :ARG0 (a / antibody)))))) 
            :op2 (m / mouse 
                  :mod (d / double) 
                  :mod (d2 / dox-treat)) 
            :topic-of (h2 / homogenat)))

# ::snt Immunostaining for endogenous superoxide dismutase ( SOD1 ) was included as a loading control .
# ::tok Immunostaining for endogenous superoxide dismutase ( SOD1 ) was included as a loading control .
# ::alignments 13-14|0.1 12-13|0.1.0 9-10|0 4-5|0.0.0 3-4|0.0.0.0 2-3|0.0.0.1 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:24:59.561
(i / include-01 
      :ARG1 (i2 / immunostain 
            :beneficiary (d / dismutase 
                  :mod (s / superoxide) 
                  :mod (e / endogenou))) 
      :ARG2 (c / control-01 
            :ARG1 (l / load-01)))

# ::snt ( B ) Quantitation of signal intensity from the Western blot in ( A ) shows transgenic APP levels in line 18 are suppressed by more than 98 % following 3 mo of dox treatment ( significant effect of group ANOVA F2 ,8 = 1559.7 , p < 0.001 ) .
# ::tok ( B ) Quantitation of signal intensity from the Western blot in ( A ) shows transgenic APP levels in line 18 are suppressed by more than 98 % following 3 mo of dox treatment ( significant effect of group ANOVA F2 ,8 = 1559.7 , p < 0.001 ) .
# ::alignments 46-47|0.2.1.0 40-42|0.2.0.0.0.2+0.2.0.0.0.1+0.2.0.0.0+0.2.0.0 39-40|0.2.0.0.0.0 37-38|0.2.0 36-37|0.2 34-35|0.2.1.2.1 33-34|0.2.1.2.1.1 31-32|0.2.1.2.2 30-31|0.2.1.2.2.0 29-30|0.2.1.2 28-29|0.2.1.2.0 27-28|0.2.1.2.0.0 25-26|0.2.1.1 23-24|0.2.1 21-22|0.2.1.2.1.2.0 20-21|0.3 18-19|0.1 17-18|0.1.0.0.0+0.1.0.0+0.1.0 15-16|0 10-11|0.2.1.2.1.2 9-10|0.2.1.2.1.2.1.1+0.2.1.2.1.2.1.0.0+0.2.1.2.1.2.1.0+0.2.1.2.1.2.1 6-7|0.0 5-6|0.0.0 1-2|0.2.1.2.1.0.1+0.2.1.2.1.0.0.0+0.2.1.2.1.0.0+0.2.1.2.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:00.831
(s3 / show-01 
      :ARG0 (i / intensity 
            :mod (s4 / signal)) 
      :ARG1 (l2 / level 
            :mod (o / organization 
                  :name (n2 / name 
                        :op1 "APP"))) 
      :ARG2-of (s / significant-02 
            :ARG1 (e / effect-03 
                  :ARG1 (t / thing 
                        :name (n / name 
                              :name-of (g / group) 
                              :op1 (a / ANOVA) 
                              :op2 (f / F2)))) 
            :ARG1-of (s2 / suppress-01 
                  :ARG0 (p / p) 
                  :ARG2 (m2 / more) 
                  :purpose-of (f2 / follow-01 
                        :ARG0 (p2 / percentage-entity 
                              :value 98) 
                        :ARG1 (t2 / treat-03 
                              :ARG0 (l3 / location 
                                    :name (n4 / name 
                                          :op1 "B") 
                                    :wiki -) 
                              :ARG2 (d / dox) 
                              :ARG2-of (b / blot-01 
                                    :ARG0 18 
                                    :mod (w / world-region 
                                          :name (n3 / name 
                                                :op1 "West") 
                                          :wiki "Western_world"))) 
                        :ARG2 (m / mo 
                              :quant 3)))) 
      :location (l / line))

# ::snt This level of suppression was equal to or better than that attained in line 107 ( see Figure 3B ) .
# ::tok This level of suppression was equal to or better than that attained in line 107 ( see Figure 3B ) .
# ::alignments 17-18|0.1.0.0.0.0.0 16-17|0.1.0.0.0.0 14-15|0.0 13-14|0.1.0.0.0.0.0.0.0 11-12|0.1.0.0.0.0.0.0 8-9|0.1.0 7-8|0.1 5-6|0 3-4|0.1.0.0.0 1-2|0.1.0.0 0-1|0.1.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:00.930
(e / equal-01 
      :ARG1 107 
      :op1-of (o / or 
            :op2 (g / good 
                  :domain (l2 / level 
                        :mod (s2 / suppress-01 
                              :ARG1 (s / see-01 
                                    :ARG1 (f / figure 
                                          :ARG1-of (a / attain-01 
                                                :manner (l / line))))) 
                        :mod (t / this)))))

# ::snt ( C ) Serial dilution filter trap assay was used to quantify aggregated A in cortical homogenates .
# ::tok ( C ) Serial dilution filter trap assay was used to quantify aggregated A in cortical homogenates .
# ::alignments 16-17|0.0.0.1.0.0 15-16|0.0.0.1.0 12-13|0 11-12|0.0.0 9-10|0.0.0.1 7-8|0.0 6-7|0.0.1 5-6|0.0.2 4-5|0.0.0.0 3-4|0.0.0.0.0 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:01.011
(a / aggregate-01 
      :ARG0 (a2 / assay 
            :ARG1-of (q / quantify-01 
                  :ARG0 (d / dilution 
                        :mod (s / serial)) 
                  :ARG2-of (u / use-01 
                        :ARG1 (c / cortical 
                              :mod-of (h / homogenat)))) 
            :ARG1-of (t / trap-01) 
            :ARG1-of (f / filter-02)) 
      :ARG1 (c2 / C))

# ::snt ( D ) Quantitation of signal intensity in the linear range of the dilution series shown in ( C ) .
# ::tok ( D ) Quantitation of signal intensity in the linear range of the dilution series shown in ( C ) .
# ::alignments 18-19|0.1 15-16|0.0.0.0 14-15|0.0 13-14|0 10-11|0.0.0 9-10|0.0.0.1 6-7|0.0.0.0.1 5-6|0.0.0.0.1.0 1-2|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:01.135
(d / dilution 
      :mod-of (s2 / series 
            :ARG1-of (r / range-01 
                  :ARG2 (s / show-01 
                        :ARG0 (d2 / D) 
                        :ARG1 (i / intensity 
                              :mod (s3 / signal))) 
                  :mod (l / linear))) 
      :op1-of (c / C))

# ::snt Consistent with the amyloid histology shown in Figure S5 , aggregate formation was significantly increased between 6 and 9 mo of age in untreated mice ( significant effect of group ANOVA F2 ,18 = 12.14 , p < 0.001 ) .
# ::tok Consistent with the amyloid histology shown in Figure S5 , aggregate formation was significantly increased between 6 and 9 mo of age in untreated mice ( significant effect of group ANOVA F2 ,18 = 12.14 , p < 0.001 ) .
# ::alignments 36-37|0.2.0 30-32|0.2.1.1.1.0.2+0.2.1.1.1.0.1+0.2.1.1.1.0+0.2.1.1.1 29-30|0.2.1.1.1.0.0 27-28|0.2.1.1 26-27|0.2.1 24-25|0.4 23-24|0.4.1 21-22|0.4.0 19-20|0.1 18-19|0.2.1.0 17-18|0.3 16-17|0.2.1.1.0 14-15|0 13-14|0.2 11-12|0.0 10-11|0.0.0 7-9|0.2.1.2.0.0.1+0.2.1.2.0.0.0+0.2.1.2.0.0+0.2.1.2.0 5-6|0.2.1.2 4-5|0.2.1.2.1 3-4|0.2.1.2.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:02.637
(i / increase-01 
      :ARG0 (f2 / form-01 
            :ARG1 (a4 / aggregate)) 
      :ARG1 (m2 / mo) 
      :ARG2 (s2 / significant-02 
            :ARG0 (p / p) 
            :ARG1 (s / significant-02 
                  :ARG0 9 
                  :ARG1 (e / effect-03 
                        :ARG0 6 
                        :ARG1 (t / thing 
                              :name (n / name 
                                    :name-of (g / group) 
                                    :op1 (a / ANOVA) 
                                    :op2 (f / F2)))) 
                  :ARG2-of (s4 / show-01 
                        :ARG0 (t2 / thing 
                              :name (n2 / name 
                                    :op1 (f3 / Figure) 
                                    :op2 (s3 / S5))) 
                        :ARG1 (h / histology 
                              :mod (a5 / amyloid))))) 
      :manner (a3 / and) 
      :time (m / mouse 
            :ARG1-of (a2 / age-01) 
            :mod (u / untreat)))

# ::snt Aggregate formation was completely arrested by transgene suppression , and is identical in 9-mo-old mice treated with dox for 3 mo as in untreated animals harvested when treatment began ( p > 0.5 , Tukey post-hoc test ) .
# ::tok Aggregate formation was completely arrested by transgene suppression , and is identical in 9-mo-old mice treated with dox for 3 mo as in untreated animals harvested when treatment began ( p > 0.5 , Tukey post-hoc test ) .
# ::alignments 36-37|0.1.1.3.0.0.0 34-35|0.1.1.3.0.0.1.0+0.1.1.3.0.0.1+0.1.1.3.0.0 32-33|0.1.0 30-31|0.0.0.0 28-29|0.1.1.3 27-28|0.1.1.3.0 25-26|0.1.1.1 24-25|0.1.1.1.0 23-24|0.1.1.1.0.0 20-21|0.1.1.4 19-20|0.0.1.0 17-18|0.1.1.2 15-16|0.1.1 14-15|0.1.1.0 11-12|0.1 9-10|0 7-8|0.0.0 6-7|0.0.0.1 4-5|0.0 3-4|0.0.2 1-2|0.0.1 0-1|0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:03.239
(a2 / and 
      :op1 (a3 / arrest-01 
            :ARG0 (s / suppress-01 
                  :ARG0 (p2 / p) 
                  :ARG1 (t4 / transgene)) 
            :ARG1 (f / form-01 
                  :ARG1 3 
                  :ARG1-of (a4 / aggregate-01)) 
            :ARG1-of (c / complete-02)) 
      :op2 (i / identical-01 
            :ARG0 0.5 
            :ARG1 (t3 / treat-01 
                  :ARG1 (m2 / mouse) 
                  :ARG1-of (h / harvest-01 
                        :ARG0 (a / animal 
                              :mod (u / untreat))) 
                  :ARG2 (d / dox) 
                  :condition (b / begin-01 
                        :ARG1 (t2 / treat-03 
                              :ARG1 (p / person 
                                    :ARG1-of (t / test-01) 
                                    :name (n / name 
                                          :op1 "Tukey")))) 
                  :purpose (m / mo))))

# ::snt * , p < 0.05 ; ** , p < 0.005 ; *** , p < 0.001 versus 9-mo-old untreated mice , Tukey post-hoc test .
# ::tok * , p < 0.05 ; ** , p < 0.005 ; *** , p < 0.001 versus 9-mo-old untreated mice , Tukey post-hoc test .
# ::alignments 24-25|0.0.0 22-23|0.0.1.0+0.0.1+0.0 20-21|0.0.0.0.0 19-20|0.0.0.0.0.0 17-18|0.0.0.0 5-6|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:03.296
(a / and 
      :op1 (p / person 
            :ARG0-of (t / test-01 
                  :ARG1 (v / versu 
                        :op1 (m / mouse 
                              :mod (u / untreat)))) 
            :name (n / name 
                  :op1 "Tukey")))

# ::snt ( 962 KB TIF ) .
# ::tok ( 962 KB TIF ) .
# ::alignments 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:03.301
(9 / 962)

# ::snt Click here for additional data file .
# ::tok Click here for additional data file .
# ::alignments 5-6|0.0 4-5|0.0.0 3-4|0.0.0.0 1-2|0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:03.317
(c / click-01 
      :ARG1 (f / file 
            :mod (d / data 
                  :mod (a / additional))) 
      :location (h / here))

# ::snt Arrest of Amyloid Progression by Chronic Transgene Suppression in Line 18 Tet-Off APP Mice .
# ::tok Arrest of Amyloid Progression by Chronic Transgene Suppression in Line 18 Tet-Off APP Mice .
# ::alignments 11-14|0.0.0.0.0.2+0.0.0.0.0.1+0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 10-11|0.0.0.0.1 9-10|0.0.0.1.0+0.0.0.1+0.0.0 5-7|0.1.0.1+0.1.0.0+0.1.0+0.1 2-4|0.0.1.1+0.0.1.0+0.0.1+0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:03.410
(a2 / arrest-01 
      :ARG1 (t3 / thing 
            :location (o2 / organization 
                  :mod-of (o / organization 
                        :name (n / name 
                              :op1 "Tet-Off" 
                              :op2 "APP" 
                              :op3 "Mice") 
                        :quant 18) 
                  :name (n2 / name 
                        :op1 "Line")) 
            :name (n4 / name 
                  :op1 (a / Amyloid) 
                  :op2 (p / Progression))) 
      :ARG2 (t / thing 
            :name (n3 / name 
                  :op1 (c / Chronic) 
                  :op2 (t2 / Transgene))))

# ::snt Amyloid histology in cortical ( first and third rows ) and hippocampal ( second and fourth rows ) sections from untreated tTA/APP mice shows a dramatic progression of pathology between 6 and 9 mo of age .
# ::tok Amyloid histology in cortical ( first and third rows ) and hippocampal ( second and fourth rows ) sections from untreated tTA/APP mice shows a dramatic progression of pathology between 6 and 9 mo of age .
# ::alignments 35-36|0.1.0.2 33-34|0.1.0.2.0 32-33|0.1.0.1.0 31-32|0 30-31|0.0.1.0 28-29|0.1.0.1.1 26-27|0.1.0.1 25-26|0.1.0.1.2 23-24|0.1.0 22-23|0.1.0.0 20-21|0.1.0.0.0 18-19|0.1.1 16-17|0.1.1.0 15-16|0.1.1.0.0 14-15|0.1.1.0.1 10-11|0.1 8-9|0.0.1 6-7|0.0 3-4|0.0.0 1-2|0.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:04.415
(a2 / and 
      :op2-of (a5 / and 
            :domain-of (c / cortical) 
            :op1 (r2 / row-01 
                  :ARG0 6)) 
      :op2-of (a4 / and 
            :condition-of (s / show-01 
                  :ARG0 (m2 / mouse 
                        :mod (u / untreat)) 
                  :ARG1 (p2 / progress-01 
                        :ARG0 9 
                        :ARG1 (p / pathology) 
                        :manner (d / dramatic)) 
                  :ARG1-of (a / age-01 
                        :time-of (m / mo))) 
            :op1 (s2 / section 
                  :ARG1-of (r / row-01 
                        :mod (f / fourth) 
                        :op1-of (a3 / and))) 
            :time (h / histology)))

# ::snt Suppression of transgenic APP expression arrests this progression , although without any sign of plaque clearance ( 6 mo + 3 mo dox ) .
# ::tok Suppression of transgenic APP expression arrests this progression , although without any sign of plaque clearance ( 6 mo + 3 mo dox ) .
# ::alignments 22-23|0.0.0.1 20-21|0.0.0.0.1.0.1.1.0 18-19|0 17-18|0.0.0.0.1.0.0 15-16|0.0.0.0.1.0.1 14-15|0.0.0.0.1.0.1.0 12-13|0.0.0.0.1.0.1.1 11-12|0.0.0.0.1.0.1.1.1 7-8|0.0 6-7|0.0.1 5-6|0.0.0 4-5|0.0.0.0.1.0 3-4|0.0.0.0.1.1.0+0.0.0.0.1.1+0.0.0.0.1 0-1|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:04.800
(m / mo 
      :ARG0-of (p2 / progress-01 
            :ARG1-of (a2 / arrest-01 
                  :ARG0 (o2 / organization 
                        :name (n2 / name 
                              :op1 "Suppression") 
                        :poss (o / organization 
                              :ARG0-of (e / express-01 
                                    :ARG1 6 
                                    :purpose (c / clear-02 
                                          :ARG1 (p / plaque) 
                                          :ARG1-of (s / sign-02 
                                                :ARG0 3 
                                                :mod (a / any)))) 
                              :name (n / name 
                                    :op1 "APP"))) 
                  :ARG2 (d / dox)) 
            :mod (t / this)))

# ::snt Hirano silver stain ( top panels ) ; thioflavin-S ( bottom panels ) .
# ::tok Hirano silver stain ( top panels ) ; thioflavin-S ( bottom panels ) .
# ::alignments 11-12|0.0.0.0 10-11|0.0.0.0.0 8-9|0.1 7-8|0 5-6|0.0.1.0 4-5|0.0.1.0.0 2-3|0.0 1-2|0.0.1 0-1|0.0.0.1.0+0.0.0.1+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:04.844
(a / and 
      :op1 (s / stain-01 
            :ARG0 (p3 / person 
                  :ARG1-of (p / panel-01 
                        :mod (b / bottom)) 
                  :name (n / name 
                        :op1 "Hirano")) 
            :mod (s2 / silver 
                  :ARG1-of (p2 / panel-01 
                        :mod (t2 / top)))) 
      :op2 (t / thioflavin-))

# ::snt ( 5.8 MB PSD ) .
# ::tok ( 5.8 MB PSD ) .
# ::alignments 2-4|0.0.1+0.0.0+0.0+0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:04.852
(o / organization 
      :name (n / name 
            :op1 "MB" 
            :op2 "PSD"))

# ::snt Click here for additional data file .
# ::tok Click here for additional data file .
# ::alignments 5-6|0.0 4-5|0.0.0 3-4|0.0.0.0 1-2|0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:04.872
(c / click-01 
      :ARG1 (f / file 
            :mod (d / data 
                  :mod (a / additional))) 
      :location (h / here))

# ::snt Patients with Alzheimer disease ( AD ) have elevated levels of a small protein called amyloid- peptide that sticks together to form what are known as amyloid plaques in their brains .
# ::tok Patients with Alzheimer disease ( AD ) have elevated levels of a small protein called amyloid- peptide that sticks together to form what are known as amyloid plaques in their brains .
# ::alignments 30-31|0.0.0.3 27-28|0.0 26-27|0 24-25|0.0.0 21-22|0.0.0.2 19-20|0.0.0.2.1.1 18-19|0.0.0.2.1 16-17|0.0.0.2.1.0 14-15|0.0.0.1.1.0 13-14|0.0.0.1.1 12-13|0.0.0.1.1.1 9-10|0.0.0.1 8-9|0.0.0.1.0 5-6|0.0.0.0 3-4|0.0.0.2.0.0 2-3|0.0.0.2.0.0.0 0-1|0.0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:05.550
(a / amyloid 
      :mod-of (p / plaqu 
            :ARG2-of (k / know-02 
                  :ARG0 "AD" 
                  :ARG1 (l / level 
                        :ARG1-of (e / elevate-01) 
                        :mod (p3 / protein 
                              :ARG1-of (c / call-01) 
                              :mod (s2 / small))) 
                  :ARG1-of (f / form-01 
                        :ARG0 (p4 / patient 
                              :mod (d / disease 
                                    :mod (a2 / alzheim))) 
                        :ARG1-of (s / stick-01 
                              :ARG0 (p2 / peptide) 
                              :manner (t / together))) 
                  :prep-in (b / brain))))

# ::snt This peptide is normally made at low levels in healthy individuals , and is made when a larger protein called amyloid precursor protein ( APP ) is cut down in size .
# ::tok This peptide is normally made at low levels in healthy individuals , and is made when a larger protein called amyloid precursor protein ( APP ) is cut down in size .
# ::alignments 30-31|0.0.1.0.1 27-28|0.0.1.0 24-25|0.0.1.0.2.0.0.0.0+0.0.1.0.2.0.0.0+0.0.1.0.2.0.0 22-23|0 21-22|0.1 20-21|0.2 19-20|0.0 18-19|0.0.1 17-18|0.0.1.1 12-13|0.0.1.0.2 10-11|0.0.1.0.2.1 9-10|0.0.1.0.2.1.0 7-8|0.0.1.0.0.0 6-7|0.0.1.0.0 3-4|0.0.1.0.2.0 1-2|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:06.247
(p / protein 
      :ARG2-of (c2 / call-01 
            :ARG0 (p4 / peptide 
                  :mod (t / this)) 
            :ARG1 (p3 / protein 
                  :ARG1-of (c / cut-01 
                        :ARG2 (l3 / low-04 
                              :ARG1 (l2 / level)) 
                        :manner (s / size) 
                        :time-of (a2 / and 
                              :ARG1-of (n2 / normal-02 
                                    :ARG0 (o / organization 
                                          :name (n / name 
                                                :op1 "APP"))) 
                              :op1 (i / individual 
                                    :domain-of (h / healthy)))) 
                  :mod (l / large))) 
      :mod (p2 / precursor) 
      :mod (a / amyloid))

# ::snt New treatments are now being developed that will decrease the amount of A produced from APP .
# ::tok New treatments are now being developed that will decrease the amount of A produced from APP .
# ::alignments 15-16|0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 13-14|0.0.0 10-11|0.0.0.0 8-9|0.0 5-6|0 3-4|0.2 1-2|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:06.589
(d2 / develop-02 
      :ARG0 (d / decrease-01 
            :ARG1 (p / produce-01 
                  :ARG1 (a / amount) 
                  :ARG2 (o / organization 
                        :name (n / name 
                              :op1 "APP")))) 
      :ARG1 (t / treat-03 
            :mod (n3 / new)) 
      :time (n2 / now))

# ::snt However , it is not clear whether lowering the production of A will allow the brain to heal itself by clearing the amyloid plaques .
# ::tok However , it is not clear whether lowering the production of A will allow the brain to heal itself by clearing the amyloid plaques .
# ::alignments 23-24|0.0 22-23|0.0.0 20-21|0 17-18|0.1 15-16|0.1.0 13-14|0.1.1 9-10|0.1.1.0.0 7-8|0.1.1.0 5-6|0.1.1.1 4-5|0.1.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:06.650
(c / clear-01 
      :ARG1 (p / plaqu 
            :mod (a / amyloid)) 
      :ARG2-of (h / heal-01 
            :ARG0 (b / brain) 
            :ARG1-of (a2 / allow-01 
                  :ARG0 (l / lower-05 
                        :ARG1 (p2 / produce-01)) 
                  :ARG1-of (c2 / clear-06 
                        :polarity -))))

# ::snt The answer to this question may be important for deciding when A-lowering drugs should be started , and may also determine how effective they are in reversing the mental symptoms of AD .
# ::tok The answer to this question may be important for deciding when A-lowering drugs should be started , and may also determine how effective they are in reversing the mental symptoms of AD .
# ::alignments 31-32|0.0.1.0.0.0.1.1.0 29-30|0.0.1.0.0.0.1.1 28-29|0.0.1.0.0.0.1.1.1 26-27|0.0.1.0.0.0.1 23-24|0.0.1.0.0.0.1.0 22-23|0.0.1.0.0.0 20-21|0.0.1.0.0 19-20|0.0.1.0.0.1 18-19|0.0.1.0 17-18|0.0.1 15-16|0.0.0.0 13-14|0.0.0.0.1 12-13|0.0.0.0.0 11-12|0.0.1.0.0.0.0 9-10|0.0.0.1 7-8|0.0 5-6|0 4-5|0.0.0.2 3-4|0.0.0.2.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:07.443
(p2 / possible-01 
      :ARG1 (i / important 
            :domain (a4 / answer-01 
                  :ARG0-of (s2 / start-01 
                        :ARG1 (d2 / drug) 
                        :ARG1-of (r2 / recommend-01)) 
                  :ARG0-of (d3 / decide-01) 
                  :ARG1 (q / question-01 
                        :ARG1 (t2 / this))) 
            :op1-of (a2 / and 
                  :op2 (p / possible-01 
                        :ARG1 (d / determine-01 
                              :ARG1 (e / effective-04 
                                    :ARG1 (a3 / a-lower) 
                                    :ARG2 (r / reverse-01 
                                          :ARG0 (t / they) 
                                          :ARG1 (s / symptom 
                                                :mod "AD" 
                                                :mod (m / mental)))) 
                              :mod (a / also))))))

# ::snt What Did the Researchers Do and Find ?
# ::tok What Did the Researchers Do and Find ?
# ::alignments 7-8|0.0 6-7|0.2 5-6|0 3-4|0.2.0 1-2|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:07.478
(a / and 
      :mode (i / interrogative) 
      :op1 (d / do-02 
            :ARG1 (a2 / amr-unknown)) 
      :op2 (f / find-01 
            :ARG1 (r / researcher)))

# ::snt Because new drugs designed to lower A levels are still in development , they are not available for testing in animal models of the disease .
# ::tok Because new drugs designed to lower A levels are still in development , they are not available for testing in animal models of the disease .
# ::alignments 24-25|0.1.1.0.1 21-22|0.1.1.0 20-21|0.1.1.0.0 18-19|0.1.1 16-17|0.1 15-16|0.1.2 13-14|0.1.0 11-12|0.0.0.0.0 9-10|0.0.0.1.0 7-8|0.0.0.0 5-6|0.0.0 3-4|0.0.0.1 2-3|0.0 1-2|0.0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:07.824
(c / cause-01 
      :ARG0 (d4 / drug 
            :ARG0-of (l2 / low-04 
                  :ARG1 (l / level 
                        :ARG1-of (d2 / develop-02)) 
                  :ARG3-of (d3 / design-01 
                        :ARG1 (s / still))) 
            :mod (n / new)) 
      :ARG1 (a2 / available-02 
            :ARG0 (t2 / they) 
            :ARG1 (t / test-01 
                  :ARG1 (m / model 
                        :mod (a / animal) 
                        :poss (d / disease))) 
            :polarity -))

# ::snt Instead , basic questions about the effectiveness of this type of treatment must be answered using systems that mimic how the drugs work .
# ::tok Instead , basic questions about the effectiveness of this type of treatment must be answered using systems that mimic how the drugs work .
# ::alignments 22-23|0.0.0.0.0 21-22|0.0.0.0.0.0 18-19|0.0.0.0 16-17|0.0.0 15-16|0.0 14-15|0 11-12|0.0.1.0.0.0 9-10|0.0.1.0.0 8-9|0.1.0 6-7|0.0.1.0 3-4|0.0.1 2-3|0.0.1.1 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:08.244
(a / answer-01 
      :ARG1 (u / use-01 
            :ARG1 (s / system 
                  :ARG0-of (m / mimic-01 
                        :ARG1 (w / work-01 
                              :ARG0 (d / drug)))) 
            :ARG2 (q / question-01 
                  :ARG1 (e / effective-04 
                        :ARG0 (t2 / type 
                              :mod-of (t / treat-03))) 
                  :mod (b / basic))) 
      :ARG1-of (i / instead-of-91 
            :ARG0 (t3 / this)))

# ::snt To do this , the authors created mice that produce too much APP and that develop the same amyloid lesions as do human patients with AD .
# ::tok To do this , the authors created mice that produce too much APP and that develop the same amyloid lesions as do human patients with AD .
# ::alignments 25-26|0.1.2.0.0.0.1 23-24|0.0.1+0.0+0.0.0 22-23|0.0.0.0 19-20|0.1.1 18-19|0.1.1.1 17-18|0.1.1.0 15-16|0.1 13-14|0 12-13|0.1.0.0.0+0.1.0.0+0.1.0 11-12|0.2 10-11|0.2.0 9-10|0.1.2 7-8|0.1.2.0 6-7|0.1.2.0.0 5-6|0.1.2.0.0.0 2-3|0.1.2.0.0.0.0.0 1-2|0.1.2.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:09.839
(a2 / and 
      :ARG1-of (h / have-rel-role-91 
            :ARG0 (p / person 
                  :mod (h2 / human)) 
            :ARG2 (p2 / patient)) 
      :op1 (d / develop-02 
            :ARG0 (o / organization 
                  :name (n / name 
                        :op1 "APP")) 
            :ARG1 (l / lesion 
                  :ARG1-of (s / same-01) 
                  :mod (a / amyloid)) 
            :ARG1-of (p3 / produce-01 
                  :ARG0 (m2 / mouse 
                        :ARG1-of (c / create-01 
                              :ARG0 (a3 / author-01 
                                    :ARG0-of (d2 / do-02 
                                          :ARG1 (t2 / this)) 
                                    :ARG1 "AD"))))) 
      :quant (m / much 
            :degree (t / too)))

# ::snt Unlike normal mice , these mice also carried a `` switch '' gene that allowed the researchers to turn off APP by feeding the mice special food .
# ::tok Unlike normal mice , these mice also carried a `` switch '' gene that allowed the researchers to turn off APP by feeding the mice special food .
# ::alignments 26-27|0.1 25-26|0.1.0 24-25|0.0 22-23|0 18-19|0.2 16-17|0.2.0.0+0.2.0 14-15|0.2.1 12-13|0.2.1.0 10-11|0.2.1.0.1 7-8|0.2.1.0.0 6-7|0.2.1.0.0.1 5-6|0.2.1.0.0.0 4-5|0.2.1.0.0.0.0 2-3|0.2.1.0.0.2.0 1-2|0.2.1.0.0.2.0.0 0-1|0.2.1.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:10.267
(f2 / feed-01 
      :ARG1 (m / mouse) 
      :ARG2 (f / food 
            :ARG1-of (s / special-02)) 
      :manner-of (t / turn-02 
            :ARG0 (p / person 
                  :ARG0-of (r / research-01)) 
            :ARG1-of (a / allow-01 
                  :ARG0 (g / gene 
                        :ARG1-of (c / carry-01 
                              :ARG0 (m2 / mouse 
                                    :mod (t2 / this)) 
                              :mod (a2 / also) 
                              :time (u / unlike 
                                    :op1 (m3 / mouse 
                                          :ARG1-of (n / normal-02)))) 
                        :ARG1-of (s2 / switch-01)))))

# ::snt Turning off APP in these mice had the same effect as treating them with A-lowering drugs , and so the researchers were able to ask what happened to the amyloid plaques after A production was shut down .
# ::tok Turning off APP in these mice had the same effect as treating them with A-lowering drugs , and so the researchers were able to ask what happened to the amyloid plaques after A production was shut down .
# ::alignments 35-36|0.1.0.1.0.0.0 33-34|0.1.0.1.0.0 31-32|0.1.0.1.0.0.0.1 30-31|0.0.0 29-30|0.0 24-25|0.1.1.0 22-23|0.1.1 20-21|0.1.1.0.0.0+0.1.1.0.0 18-19|0 17-18|0.1 15-16|0.1.0.1.0 14-15|0.1.0.1.0.0.0.0 11-12|0.1.0.1 9-10|0.1.0 8-9|0.1.0.2 5-6|0.1.0.0.0.0 4-5|0.1.0.0.0.0.0 2-3|0.1.0.0.1.0+0.1.0.0.1+0.1.0.0 0-1|0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:11.067
(c / cause-01 
      :ARG1 (a2 / amyloid 
            :mod-of (p2 / plaqu)) 
      :op2-of (a4 / and 
            :op1 (e / effect-03 
                  :ARG0 (o / organization 
                        :ARG1-of (t3 / turn-01 
                              :location (m / mouse 
                                    :mod (t2 / this))) 
                        :name (n / name 
                              :op1 "APP")) 
                  :ARG1 (t / treat-02 
                        :ARG1 (d / drug 
                              :ARG1-of (p / produce-01 
                                    :ARG1-of (s / shut-down-05 
                                          :ARG0 (a5 / a-lower) 
                                          :op1-of (a / after))))) 
                  :ARG1-of (s2 / same-01)) 
            :op3 (p3 / possible-01 
                  :ARG1 (a3 / ask-01 
                        :ARG0 (p4 / person 
                              :ARG0-of (r / research-01))))))

# ::snt They showed that lowering A production prevents the amyloid lesions from getting worse as the disease progresses .
# ::tok They showed that lowering A production prevents the amyloid lesions from getting worse as the disease progresses .
# ::alignments 16-17|0.0.1.2 15-16|0.0.1.2.0 12-13|0.0.1.1 9-10|0.0.1.0 8-9|0.0.1.0.0 6-7|0.0.1 5-6|0.0.0.0 3-4|0.0.0 1-2|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:11.152
(s / show-01 
      :ARG0 (t / they 
            :ARG0-of (l2 / lower-05 
                  :ARG1 (p3 / produce-01)) 
            :ARG0-of (p2 / prevent-01 
                  :ARG1 (l / lesion 
                        :mod (a / amyloid)) 
                  :ARG1-of (b / bad-07) 
                  :purpose (p / progress-01 
                        :ARG1 (d / disease)))))

# ::snt This means that treatment with A-lowering drugs may be able to stop the disease from filling the brain with plaques .
# ::tok This means that treatment with A-lowering drugs may be able to stop the disease from filling the brain with plaques .
# ::alignments 19-20|0.1.0.0.0 17-18|0.1.0.2.0 15-16|0.1.0.2 13-14|0.1.0.1 11-12|0.1.0 9-10|0.1 7-8|0.1.1 6-7|0.1.0.0.1 5-6|0.1.0.0.1.0 3-4|0.1.0.0 1-2|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:11.448
(m / mean-01 
      :ARG1 (t2 / this) 
      :ARG2 (p2 / possible-01 
            :ARG1 (s / stop-01 
                  :ARG0 (t / treat-03 
                        :ARG1 (p / plaqu) 
                        :ARG2 (d2 / drug 
                              :mod (a / a-lower))) 
                  :ARG1 (d / disease) 
                  :ARG2 (f / fill-06 
                        :ARG1 (b / brain))) 
            :ARG1-of (p3 / possible-01)))

# ::snt However , the researchers also found that the amyloid lesions that had formed before treatment was started remained intact throughout the experiment .
# ::tok However , the researchers also found that the amyloid lesions that had formed before treatment was started remained intact throughout the experiment .
# ::alignments 21-22|0 19-20|0.0 18-19|0.0.0.1 17-18|0.0.0 16-17|0.0.0.0 14-15|0.0.0.0.0.0.0.0 13-14|0.0.0.0.0.0.0 12-13|0.0.0.0.0.0 9-10|0.0.0.0.0 8-9|0.0.0.0.0.1 5-6|0.0.0.0.0.0.0.0.0.1 4-5|0.0.0.0.0.0.0.0.0.1.0 3-4|0.0.0.0.0.0.0.0.0.0+0.0.0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:11.880
(e / experiment-01 
      :op1-of (t / throughout 
            :ARG0-of (r / remain-01 
                  :ARG1 (s / start-01 
                        :ARG1 (l / lesion 
                              :ARG1-of (f / form-01 
                                    :time (b / before 
                                          :op1 (t2 / treat-03 
                                                :ARG1 (p / person 
                                                      :ARG0-of (r2 / research-01) 
                                                      :ARG0-of (f2 / find-01 
                                                            :mod (a2 / also)))))) 
                              :mod (a / amyloid))) 
                  :ARG3 (i / intact))))

# ::snt What Do These Findings Mean ?
# ::tok What Do These Findings Mean ?
# ::alignments 5-6|0.3 4-5|0 3-4|0.0 2-3|0.2 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:11.900
(m / mean-01 
      :ARG1 (f / finding) 
      :ARG2 (a / amr-unknown) 
      :mod (t / this) 
      :mode (i / interrogative))

# ::snt These results indicate that treatments designed to lower the production of A may be an important part of future AD treatment , as this approach seems to prevents additional amyloid plaques from forming in the mouse brain .
# ::tok These results indicate that treatments designed to lower the production of A may be an important part of future AD treatment , as this approach seems to prevents additional amyloid plaques from forming in the mouse brain .
# ::alignments 36-37|0.0.0.1.0.0.0.0.1 35-36|0.0.0.1.0.0.0.0.1.0 32-33|0.0.0.1.0.0.0.0 30-31|0.0.0.1.0.0.0.0.0 29-30|0.0.0.1.0.0.0.0.0.1 28-29|0.0.0.1.0.0.0.0.0.0 27-28|0.0.0.1.0.0.0 25-26|0.0.0.1.0.0.0.1 24-25|0.0.0.1.0.0 23-24|0.0.0.1.0.0.1 20-21|0.0.0.1.0.0.0.1.0 19-20|0.0.0.1.0.0.0.1.0.0 18-19|0.0.0.1.0.0.0.1.0.1 15-16|0.1.0 12-13|0.1 9-10|0.0.0.0 7-8|0.0.0 5-6|0.0.0.1 4-5|0.0.0.1.0 2-3|0 1-2|0.0.1+0.0 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:12.386
(i2 / indicate-01 
      :ARG0 (t4 / thing 
            :ARG0-of (l / low-04 
                  :ARG1 (p4 / produce-01) 
                  :ARG3-of (d / design-01 
                        :ARG1 (t3 / treat-03 
                              :ARG1-of (a3 / approach-02 
                                    :ARG0-of (p2 / prevent-01 
                                          :ARG1 (f / form-01 
                                                :ARG0 (p / plaqu 
                                                      :mod (a2 / additional) 
                                                      :mod (a / amyloid)) 
                                                :ARG1 (b / brain 
                                                      :part-of (m / mouse))) 
                                          :ARG1-of (s / seem-01 
                                                :ARG1-of (t2 / treat-03 
                                                      :ARG2 "AD" 
                                                      :time (f2 / future)))) 
                                    :mod (t / this))))) 
            :ARG2-of (r / result-01) 
            :mod (t5 / this)) 
      :ARG1 (p3 / possible-01 
            :ARG1 (i / important)))

# ::snt However , by itself , this strategy may not be able to rid the brain of plaques that have already formed in the brain before treatment is started .
# ::tok However , by itself , this strategy may not be able to rid the brain of plaques that have already formed in the brain before treatment is started .
# ::alignments 27-28|0.0.0.1.0.1.0 25-26|0.0.0.1.0.1.0.0 24-25|0.0.0.1.0.1 23-24|0.0.0.1.0.1.0.0.0 20-21|0.0.0.1.0 19-20|0.0.0.1.0.2 16-17|0.0.0.1.0.0 14-15|0.0.0.1 12-13|0.0.0 10-11|0.0 8-9|0.0.1 7-8|0 6-7|0.0.0.0 5-6|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:12.572
(p3 / possible-01 
      :ARG1 (p2 / possible-01 
            :ARG1 (r / rid-01 
                  :ARG0 (s2 / strategy 
                        :mod (t2 / this)) 
                  :ARG1 (b3 / brain 
                        :ARG1-of (f / form-01 
                              :ARG0 (p / plaqu) 
                              :time (b / before 
                                    :op1 (s / start-01 
                                          :ARG1 (t / treat-03 
                                                :ARG0 (b2 / brain)))) 
                              :time (a / already)))) 
            :polarity -))

# ::snt The findings suggest that early treatment may be important for this approach to succeed .
# ::tok The findings suggest that early treatment may be important for this approach to succeed .
# ::alignments 13-14|0.1.1.0 11-12|0.1.1.0.0 10-11|0.1.1.0.0.0 8-9|0.1 6-7|0.1.0 5-6|0.1.1 4-5|0.1.1.1 2-3|0 1-2|0.0.0+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:12.621
(s2 / suggest-01 
      :ARG0 (t3 / thing 
            :ARG1-of (f / find-01)) 
      :ARG1 (i / important 
            :ARG1-of (p / possible-01) 
            :domain (t2 / treat-03 
                  :ARG1-of (s / succeed-01 
                        :ARG0 (a / approach-02 
                              :mod (t / this))) 
                  :time (e / early))))

# ::snt Where Can I Get More Information Online ?
# ::tok Where Can I Get More Information Online ?
# ::alignments 7-8|0.1 6-7|0.0.2 5-6|0.0.1 4-5|0.0.3 3-4|0.0 2-3|0.0.0 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:12.700
(p / possible-01 
      :ARG1 (g / get-05 
            :ARG0 (i3 / i) 
            :ARG1 (i2 / information) 
            :ARG2 (o / online) 
            :location (m / more-than)) 
      :mode (i / interrogative))

# ::snt MedlinePlus has several Web pages of information on Alzheimer disease : http://www.nlm.nih.gov/medlineplus/alzheimersdisease.html . 
# ::tok MedlinePlus has several Web pages of information on Alzheimer disease : http://www.nlm.nih.gov/medlineplus/alzheimersdisease.html . 
# ::alignments 9-10|0.0 8-9|0.0.0 6-7|0.0.1 4-5|0.0.1.0 3-4|0.0.1.0.0 2-3|0.0.1.0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:12.731
(m / medlineplu 
      :part (d / disease 
            :mod (a / alzheim) 
            :topic-of (i / information 
                  :part (p / page 
                        :mod (w / web) 
                        :quant (s / several)))))

# ::snt The ADEAR Center of the US Government 's National Institute on Aging also has information on Alzheimer disease : http://www.alzheimers.org/ .
# ::tok The ADEAR Center of the US Government 's National Institute on Aging also has information on Alzheimer disease : http://www.alzheimers.org/ .
# ::alignments 17-18|0.2 16-17|0.0 14-15|0.1.2.0.1.0 12-13|0.1.2.0.1 11-12|0 8-10|0.1.0.1+0.1.0.0+0.1.0+0.1 6-7|0.1.2.0+0.1.2 5-6|0.1.2.0.0.1+0.1.2.0.0.0.0+0.1.2.0.0.0+0.1.2.0.0 1-3|0.1.1.0.1+0.1.1.0.0+0.1.1.0+0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:12.912
(a3 / age-01 
      :ARG0 (a / alzheim) 
      :ARG1 (o / organization 
            :name (n / name 
                  :op1 "National" 
                  :op2 "Institute") 
            :part (o2 / organization 
                  :name (n3 / name 
                        :op1 "ADEAR" 
                        :op2 "Center")) 
            :poss (g / government-organization 
                  :ARG0-of (g2 / govern-01 
                        :ARG1 (c / country 
                              :name (n2 / name 
                                    :op1 "US") 
                              :wiki "United_States") 
                        :ARG2 (a2 / also 
                              :mod-of (i / information))))) 
      :op1-of (d / disease))

# ::snt The Alzheimer 's Association Web site contains information on both caregiving and research : http://www.alz.org .
# ::tok The Alzheimer 's Association Web site contains information on both caregiving and research : http://www.alz.org .
# ::alignments 12-13|0.1.0.2 11-12|0.1.0 10-11|0.1.0.1 9-10|0.1.0.0 7-8|0.1 6-7|0 5-6|0.0 4-5|0.0.0 1-3|0.0.1.1+0.0.1.0.0+0.0.1.0+0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:13.031
(c2 / contain-01 
      :ARG0 (s / site 
            :mod (w / web) 
            :poss (d / disease 
                  :name (n / name 
                        :op1 "Alzheimer's") 
                  :wiki "Alzheimer's_disease")) 
      :ARG1 (i / information 
            :topic (a / and 
                  :mod (b / both) 
                  :op1 (c / caregiv) 
                  :op2 (r / research-01))))

# ::snt We thank Patrick Tremblay for helpful advice on the tet system at a critical time in the project , and Mark Mayford for sharing the CaMKII-tTA mice through Jackson Laboratory .
# ::tok We thank Patrick Tremblay for helpful advice on the tet system at a critical time in the project , and Mark Mayford for sharing the CaMKII-tTA mice through Jackson Laboratory .
# ::alignments 28-30|0.0.1.0.1+0.0.1.0.0+0.0.1.0+0.0.1 26-27|0.0.0 25-26|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 23-24|0.0 20-22|0.1.0.0.0.1+0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 19-20|0 17-18|0.2 14-15|0.3 13-14|0.3.0 10-11|0.1.2.0 9-10|0.1.2.0.0 6-7|0.1.2 5-6|0.1.2.1 2-4|0.1.1.0.1+0.1.1.0.0+0.1.1.0+0.1.1 1-2|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:14.629
(a / and 
      :ARG0-of (s / share-01 
            :ARG1 (m / mouse 
                  :mod (o2 / organization 
                        :name (n2 / name 
                              :op1 "CaMKII-tTA"))) 
            :ARG2 (o / organization 
                  :name (n / name 
                        :op1 "Jackson" 
                        :op2 "Laboratory"))) 
      :op1 (t3 / thank-01 
            :ARG0 (w / we 
                  :domain-of (p / person 
                        :name (n3 / name 
                              :op1 "Mark" 
                              :op2 "Mayford"))) 
            :ARG1 (p3 / person 
                  :name (n4 / name 
                        :op1 "Patrick" 
                        :op2 "Tremblay")) 
            :ARG3 (a2 / advise-01 
                  :ARG1 (s2 / system 
                        :mod (t2 / tet)) 
                  :ARG1-of (h / helpful-04))) 
      :op2 (p2 / project) 
      :time (t / time 
            :ARG1-of (c / critical-02)))

# ::snt We also thank Fraser Moss for saving several immunoblots with last-minute shipments , Andy Groves for many thoughtful discussions , Neil Segil for generously sharing his laboratory and equipment , Beth Olson , Natasha Bouey , and Yolanda Jackson for outstanding animal care , Debbie Swing for expert microinjection , and Dave Fromholt for genotyping and dissection .
# ::tok We also thank Fraser Moss for saving several immunoblots with last-minute shipments , Andy Groves for many thoughtful discussions , Neil Segil for generously sharing his laboratory and equipment , Beth Olson , Natasha Bouey , and Yolanda Jackson for outstanding animal care , Debbie Swing for expert microinjection , and Dave Fromholt for genotyping and dissection .
# ::alignments 56-57|0.2.0.2.1.3 55-56|0.2.0.2.1 54-55|0.2.0.2.1.2 51-53|0.2.0.2.1.1.0.1+0.2.0.2.1.1.0.0+0.2.0.2.1.1.0+0.2.0.2.1.1 50-51|0.2.0.2.1.1.1 48-49|0.0.0.1 47-48|0.0.0.0+0.0.0 44-46|0.2.0.2.1.1.1.2.0.1+0.2.0.2.1.1.1.2.0.0+0.2.0.2.1.1.1.2.0+0.2.0.2.1.1.1.2 42-43|0.1 41-42|0.1.0 40-41|0.2.0.0.0 38-39|0.2.0.2.2+0.2.0.2.0.0+0.2.0.2.0+0.2.0.2 36-37|0.2.0 33-35|0.4.0.1+0.4.0.0+0.4.0+0.4 30-32|0.2.0.1.0.1+0.2.0.1.0.0+0.2.0.1.0+0.2.0.1 28-29|0.3 27-28|0 26-27|0.2 24-25|0.0 23-24|0.0.1 20-22|0.2.0.2.1.1.1.1.0.1+0.2.0.2.1.1.1.1.0.0+0.2.0.2.1.1.1.1.0+0.2.0.2.1.1.1.1 18-19|0.2.0.0 17-18|0.2.0.0.1 16-17|0.2.0.0.2 13-15|0.2.0.2.1.1.1.0.0.1+0.2.0.2.1.1.1.0.0.0+0.2.0.2.1.1.1.0.0+0.2.0.2.1.1.1.0 11-12|0.2.0.2.1.0 10-11|0.2.0.2.1.0.1 8-9|0.2.0.2.1.0.0.0.1.0 7-8|0.2.0.2.1.0.0.0.1.0.0 6-7|0.2.0.2.1.0.0.0.1 3-5|0.2.0.2.1.0.0.0.0.0.1+0.2.0.2.1.0.0.0.0.0.0+0.2.0.2.1.0.0.0.0.0+0.2.0.2.1.0.0.0.0 2-3|0.2.0.2.1.0.0.0 1-2|0.2.0.2.1.0.0.0.2 0-1|0.2.0.2.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:16.457
(a5 / and 
      :ARG1-of (s / share-01 
            :ARG2 (p2 / person 
                  :ARG1-of (e / expert-01) 
                  :mod-of (m / microinjection)) 
            :manner (g2 / generosity)) 
      :ARG1-of (c / care-03 
            :mod (a3 / animal)) 
      :op1 (l / laboratory 
            :op1-of (a4 / and 
                  :ARG0-of (d2 / discuss-01 
                        :ARG1 (o / outstanding) 
                        :ARG1-of (t / thoughtful) 
                        :quant (m2 / many)) 
                  :op2 (p6 / person 
                        :name (n5 / name 
                              :op1 "Beth" 
                              :op2 "Olson")) 
                  :op3 (p4 / person 
                        :name (n3 / name 
                              :op1 "Jackson") 
                        :op1-of (a / and 
                              :ARG1-of (s2 / ship-01 
                                    :ARG0 (w / we 
                                          :ARG0-of (t2 / thank-01 
                                                :ARG1 (p9 / person 
                                                      :name (n8 / name 
                                                            :op1 "Fraser" 
                                                            :op2 "Moss")) 
                                                :ARG2 (s4 / save-02 
                                                      :ARG1 (i / immunoblot 
                                                            :quant (s3 / several))) 
                                                :mod (a6 / also))) 
                                    :mod (l2 / last-minute)) 
                              :op2 (p / person 
                                    :name (n / name 
                                          :op1 "Dave" 
                                          :op2 "Fromholt") 
                                    :op4-of (a2 / and 
                                          :op1 (p8 / person 
                                                :name (n7 / name 
                                                      :op1 "Andy" 
                                                      :op2 "Groves")) 
                                          :op2 (p7 / person 
                                                :name (n6 / name 
                                                      :op1 "Neil" 
                                                      :op2 "Segil")) 
                                          :op3 (p3 / person 
                                                :name (n2 / name 
                                                      :op1 "Debbie" 
                                                      :op2 "Swing")))) 
                              :op3 (g / genotyp) 
                              :op4 (d / dissection)) 
                        :wiki "Michael_Jackson"))) 
      :op2 (e2 / equipment) 
      :op3 (p5 / person 
            :name (n4 / name 
                  :op1 "Natasha" 
                  :op2 "Bouey")))

# ::snt We gratefully acknowledge Takeda Chemical Industries for providing antibodies BAN50 , BA27 , and BC05 , Konrad Beyreuther and Andreas Weidemann for providing 22C11 antibody , and Ed Koo for sharing CT15 antibody .
# ::tok We gratefully acknowledge Takeda Chemical Industries for providing antibodies BAN50 , BA27 , and BC05 , Konrad Beyreuther and Andreas Weidemann for providing 22C11 antibody , and Ed Koo for sharing CT15 antibody .
# ::alignments 32-33|0.2.0.0 30-31|0.2.0 27-29|0.2.2.0.0.0.0.0.1+0.2.2.0.0.0.0.0.0+0.2.2.0.0.0.0.0+0.2.2.0.0.0.0 26-27|0.2.2.0.0.0 24-25|0.2.2.0.0.1 22-23|0.2.2.0.0 19-21|0.2.2.0.1.1+0.2.2.0.1.0+0.2.2.0.1+0.2.2.0 18-19|0.2.2 16-18|0.2.1.1+0.2.1.0+0.2.1+0.2 14-15|0.1.0.0+0.1.0+0.1 13-14|0 9-10|0.0.0.0.0+0.0.0.0+0.0.0 8-9|0.0.1 7-8|0.0 3-6|0.0.2.1.0.2+0.0.2.1.0.1+0.0.2.1.0.0+0.0.2.1.0+0.0.2.1 2-3|0.0.2 1-2|0.0.2.2 0-1|0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:18.923
(a5 / and 
      :ARG1-of (p5 / provide-01 
            :ARG0 (t2 / thing 
                  :name (n5 / name 
                        :op1 "BAN50")) 
            :ARG2 (a6 / antibodi) 
            :ARG2-of (a7 / acknowledge-01 
                  :ARG0 (w / we) 
                  :ARG1 (o / organization 
                        :name (n6 / name 
                              :op1 "Takeda" 
                              :op2 "Chemical" 
                              :op3 "Industries")) 
                  :manner (g / grateful))) 
      :op1 (t / thing 
            :name (n4 / name 
                  :op1 "BC05")) 
      :op2 (p4 / person 
            :ARG2-of (s / share-01 
                  :ARG1 (a / antibody)) 
            :name (n3 / name 
                  :op1 "Konrad" 
                  :op2 "Beyreuther") 
            :op1-of (a4 / and 
                  :op2 (p3 / person 
                        :ARG0-of (p2 / provide-01 
                              :ARG1 (a2 / and 
                                    :op1 (p / person 
                                          :name (n / name 
                                                :op1 "Ed" 
                                                :op2 "Koo"))) 
                              :ARG2 (a3 / antibody)) 
                        :name (n2 / name 
                              :op1 "Andreas" 
                              :op2 "Weidemann")))))

# ::snt This work was supported by grants from the Johns Hopkins Alzheimer 's Disease Research Center ( JLJ ) , the National Alliance for Research on Schizophrenia and Depression ( Young Investigator Award [ JLJ ] ) , the Rose Hills Foundation ( JLJ ) , the Alzheimer 's Association ( Zenith Award [ DRB ] ) , the National Institute of Aging ( K01 AG26144 -- 01 [ JLJ ] , P50 AGO5146 -- 20 [ DRB ] , R01 AG006656 -- 16 [ SGY ] , and P01 AG015453 [ SGY ] ) , the National Institute of Neurologic Disease and Stoke ( R01 NS 047225 [ DRB ] ) , and the National Cancer Institute ( NAJ and NGC ) .
# ::tok This work was supported by grants from the Johns Hopkins Alzheimer 's Disease Research Center ( JLJ ) , the National Alliance for Research on Schizophrenia and Depression ( Young Investigator Award [ JLJ ] ) , the Rose Hills Foundation ( JLJ ) , the Alzheimer 's Association ( Zenith Award [ DRB ] ) , the National Institute of Aging ( K01 AG26144 -- 01 [ JLJ ] , P50 AGO5146 -- 20 [ DRB ] , R01 AG006656 -- 16 [ SGY ] , and P01 AG015453 [ SGY ] ) , the National Institute of Neurologic Disease and Stoke ( R01 NS 047225 [ DRB ] ) , and the National Cancer Institute ( NAJ and NGC ) .
# ::alignments 120-121|0.2.1.6.0.0+0.2.1.6.0+0.2.1.6 119-120|0.2.1.6.1 118-119|0.2.1.6.1.2.0.0+0.2.1.6.1.2.0+0.2.1.6.1.2 114-117|0.2.1.6.1.1.0.2+0.2.1.6.1.1.0.1+0.2.1.6.1.1.0.0+0.2.1.6.1.1.0+0.2.1.6.1.1 112-113|0.2.1 106-107|0.2.1.6.1.0.0.2+0.2.1.6.1.0.0.1+0.2.1.6.1.0.0.0+0.2.1.6.1.0.0 104-106|0.2.1.6.1.0.1.1+0.2.1.6.1.0.1.0+0.2.1.6.1.0.1+0.2.1.6.1.0 97-103|0.2.1.5.0.5+0.2.1.5.0.4+0.2.1.5.0.3+0.2.1.5.0.2+0.2.1.5.0.1+0.2.1.5.0.0+0.2.1.5.0+0.2.1.5 88-90|0.2.0.1+0.2.0.0+0.2.0+0.2 87-88|0 82-83|0.2.1.0.1.1 79-81|0.1.0.1+0.1.0.0+0.1.0+0.1 74-75|0.2.1.0.1.2 71-73|0.0.0.1+0.0.0.0+0.0.0+0.0 63-65|0.2.1.0.0.0.0.0.1+0.2.1.0.0.0.0.0.0+0.2.1.0.0.0.0.0+0.2.1.0.0.0.0 58-62|0.2.1.4.0.3+0.2.1.4.0.2+0.2.1.4.0.1+0.2.1.4.0.0+0.2.1.4.0+0.2.1.4 48-52|0.2.1.3.0.3+0.2.1.3.0.2+0.2.1.3.0.1+0.2.1.3.0.0+0.2.1.3.0+0.2.1.3 46-48|0.2.1.3.1.1+0.2.1.3.1.0.0+0.2.1.3.1.0+0.2.1.3.1 38-41|0.2.1.2.0.2+0.2.1.2.0.1+0.2.1.2.0.0+0.2.1.2.0+0.2.1.2 31-32|0.2.1.0.1 30-31|0.2.1.0.1.0 20-28|0.2.1.1.0.7+0.2.1.1.0.6+0.2.1.1.0.5+0.2.1.1.0.4+0.2.1.1.0.3+0.2.1.1.0.2+0.2.1.1.0.1+0.2.1.1.0.0+0.2.1.1.0+0.2.1.1 16-17|0.2.1.0.0.0.1.0.0+0.2.1.0.0.0.1.0+0.2.1.0.0.0.1 12-15|0.2.1.0.2.0.2+0.2.1.0.2.0.1+0.2.1.0.2.0.0+0.2.1.0.2.0+0.2.1.0.2 10-12|0.2.1.0.2.1.2+0.2.1.0.2.1.1.0+0.2.1.0.2.1.1+0.2.1.0.2.1 8-10|0.2.1.0.2.1.0.1+0.2.1.0.2.1.0.0.1+0.2.1.0.2.1.0.0.0+0.2.1.0.2.1.0.0+0.2.1.0.2.1.0 5-6|0.2.1.0 3-4|0.2.1.0.0 1-2|0.2.1.0.0.0 0-1|0.2.1.0.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:24.196
(a4 / and 
      :op1 (p2 / person 
            :name (n10 / name 
                  :op1 "P50" 
                  :op2 "AGO5146")) 
      :op2 (t3 / thing 
            :name (n9 / name 
                  :op1 (r2 / R01) 
                  :op2 (a5 / AG006656))) 
      :op3 (p / person 
            :name (n8 / name 
                  :op1 "P01" 
                  :op2 "AG015453") 
            :op5-of (a2 / and 
                  :ARG0-of (g / grant-01 
                        :ARG0-of (s2 / support-01 
                              :ARG1 (w / work-01 
                                    :ARG0 (c / country 
                                          :name (n11 / name 
                                                :op1 "K01" 
                                                :op2 "AG26144")) 
                                    :ARG3 (o9 / organization 
                                          :name (n17 / name 
                                                :op1 "JLJ")) 
                                    :mod (t4 / this))) 
                        :ARG1 (a6 / award-01 
                              :ARG1 (i2 / investigator) 
                              :op1-of 16 
                              :op1-of 20) 
                        :ARG2 (o10 / organization 
                              :name (n18 / name 
                                    :op1 "Disease" 
                                    :op2 "Research" 
                                    :op3 "Center") 
                              :poss (d4 / disease 
                                    :mod (f / facility 
                                          :name (n20 / name 
                                                :op1 "Johns" 
                                                :op2 "Hopkins") 
                                          :wiki "Johns_Hopkins_Hospital") 
                                    :name (n19 / name 
                                          :op1 "Alzheimer's") 
                                    :wiki "Alzheimer's_disease"))) 
                  :op1 (o8 / organization 
                        :name (n16 / name 
                              :op1 "National" 
                              :op2 "Alliance" 
                              :op3 "for" 
                              :op4 "Research" 
                              :op5 "on" 
                              :op6 "Schizophrenia" 
                              :op7 "and" 
                              :op8 "Depression")) 
                  :op2 (o7 / organization 
                        :name (n15 / name 
                              :op1 "Rose" 
                              :op2 "Hills" 
                              :op3 "Foundation")) 
                  :op3 (o6 / organization 
                        :name (n13 / name 
                              :op1 "Association" 
                              :op2 "(" 
                              :op3 "Zenith" 
                              :op4 "Award") 
                        :poss (d3 / disease 
                              :name (n14 / name 
                                    :op1 "Alzheimer's") 
                              :wiki "Alzheimer's_disease")) 
                  :op4 (o5 / organization 
                        :name (n12 / name 
                              :op1 "National" 
                              :op2 "Institute" 
                              :op3 "of" 
                              :op4 "Aging")) 
                  :op6 (t2 / thing 
                        :name (n6 / name 
                              :op1 (i / Institute) 
                              :op2 (o4 / of) 
                              :op3 (n7 / Neurologic) 
                              :op4 (d2 / Disease) 
                              :op5 (a3 / and) 
                              :op6 (s / Stoke))) 
                  :op7 (o / organization 
                        :name (n / name 
                              :op1 "NGC") 
                        :op4-of (a / and 
                              :op1 (t / thing 
                                    :mod-of (d / date-entity 
                                          :day 25 
                                          :month 72 
                                          :year 04) 
                                    :name (n4 / name 
                                          :op1 (r / R01) 
                                          :op2 (n5 / NS))) 
                              :op2 (o3 / organization 
                                    :name (n3 / name 
                                          :op1 "National" 
                                          :op2 "Cancer" 
                                          :op3 "Institute")) 
                              :op3 (o2 / organization 
                                    :name (n2 / name 
                                          :op1 "NAJ")))))))

# ::snt The funding agencies generously provided for research supplies , animal care , and salary support ; the funders of this work had no role in study design , data collection and analysis , decision to publish , or preparation of the manuscript .
# ::tok The funding agencies generously provided for research supplies , animal care , and salary support ; the funders of this work had no role in study design , data collection and analysis , decision to publish , or preparation of the manuscript .
# ::alignments 41-42|0.1.0.0 38-39|0.1.0 37-38|0.1 35-36|0.4.0 33-34|0.4 31-32|0.3 30-31|0 29-30|0.2 28-29|0.2.0 26-27|0.0 25-26|0.0.0 23-24|0.0.1 22-23|0.4.0.0 20-21|0.3.0.0.0 19-20|0.3.0.0.0.0 17-18|0.3.0.0+0.3.0 15-16|0.3.0.1 14-15|0.3.0.0.0.1.2 13-14|0.3.0.0.0.1.2.0 12-13|0.3.0.0.0.1 10-11|0.3.0.0.0.1.1 9-10|0.3.0.0.0.1.1.0 7-8|0.3.0.0.0.1.0.1 6-7|0.3.0.0.0.1.0.1.0 4-5|0.3.0.0.0.1.0 3-4|0.3.0.0.0.1.0.2 2-3|0.3.0.0.0.1.0.0 1-2|0.3.0.0.0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:24.844
(a2 / and 
      :op1 (d3 / design-01 
            :ARG1 (s / study-01) 
            :ARG2 (r / role)) 
      :op1-of (o / or 
            :op2 (p / prepare-02 
                  :ARG1 (m / manuscript))) 
      :op2 (c / collect-01 
            :ARG1 (d2 / data)) 
      :op3 (a / analyze-01 
            :ARG0 (p3 / person 
                  :ARG0-of (f / fund-01 
                        :ARG1 (w / work-01 
                              :mod (t / this) 
                              :op3-of (a4 / and 
                                    :ARG1-of (p4 / provide-01 
                                          :ARG0 (a6 / agency 
                                                :ARG1-of (f2 / fund-01)) 
                                          :ARG2 (s4 / supply-01 
                                                :ARG1 (r2 / research-01)) 
                                          :manner (g / generosity)) 
                                    :op1 (c2 / care-03 
                                          :ARG1 (a5 / animal)) 
                                    :op2 (s2 / support-01 
                                          :ARG1 (s3 / salary))))) 
                  :op1-of (a3 / and))) 
      :op4 (d / decide-01 
            :ARG1 (p2 / publish-01 
                  :ARG1 -)))

# ::snt AD - Alzheimer disease .
# ::tok AD - Alzheimer disease .
# ::alignments 3-4|0 2-3|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:24.853
(d / disease 
      :mod (a / alzheim 
            :mod "AD"))

# ::snt APLP - amyloid precursor -- like protein .
# ::tok APLP - amyloid precursor -- like protein .
# ::alignments 6-7|0.0.0.0 5-6|0.0.0 3-4|0 2-3|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:24.868
(p2 / precursor 
      :mod (a / amyloid 
            :ARG1-of (r / resemble-01 
                  :ARG2 (p / protein))))

# ::snt APP - amyloid precursor protein .
# ::tok APP - amyloid precursor protein .
# ::alignments 4-5|0 3-4|0.0 2-3|0.1 0-1|0.1.0.0.0+0.1.0.0+0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:24.889
(p / protein 
      :mod (p2 / precursor) 
      :mod (a / amyloid 
            :degree (o / organization 
                  :name (n / name 
                        :op1 "APP"))))

# ::snt CaMKII - calcium-calmodulin kinase II .
# ::tok CaMKII - calcium-calmodulin kinase II .
# ::alignments 3-5|0.0.0.1+0.0.0.0+0.0.0+0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:24.904
(c / CaMKII 
      :mod-of (t / thing 
            :name (n / name 
                  :op1 (k / kinase) 
                  :op2 (i / II))))

# ::snt FA - formic acid .
# ::tok FA - formic acid .
# ::alignments 3-4|0 2-3|0.0 0-1|0.1.1+0.1.0.0+0.1.0+0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:24.918
(a / acid 
      :mod (f / formic) 
      :poss (l / league 
            :name (n / name 
                  :op1 "FA") 
            :wiki "The_Football_Association"))

# ::snt GFAP - glial fibrillary acidic protein .
# ::tok GFAP - glial fibrillary acidic protein .
# ::alignments 5-6|0 4-5|0.0 2-3|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:24.930
(p / protein 
      :mod (a / acidic) 
      :mod (g / glial 
            :degree (g2 / GFAP)))

# ::snt mo/huAPP695 - mouse APP with a humanized A domain .
# ::tok mo/huAPP695 - mouse APP with a humanized A domain .
# ::alignments 8-9|0.0 6-7|0 3-4|0.0.0.1.0+0.0.0.1+0.0.0 2-3|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:24.951
(h / humanize-01 
      :ARG1 (d / domain 
            :prep-with-of (o / organization 
                  :mod (m / mouse) 
                  :name (n / name 
                        :op1 "APP"))))

# ::snt PBS - phosphate-buffered saline .
# ::tok PBS - phosphate-buffered saline .
# ::alignments 3-4|0.0 2-3|0.0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:24.965
(p2 / pb 
      :poss-of (s / saline 
            :mod (p / phosphate-buffer)))

# ::snt SDS - sodium dodecyl sulfate .
# ::tok SDS - sodium dodecyl sulfate .
# ::alignments 4-5|0 2-3|0.0 0-1|0.0.0.0.0+0.0.0.0+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:24.981
(s / sulfate 
      :mod (s2 / sodium 
            :degree (o / organization 
                  :name (n / name 
                        :op1 "SDS"))))

# ::snt tTA - tetracycline transactivator .
# ::tok tTA - tetracycline transactivator .
# ::alignments 2-3|0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:24.987
(t2 / tTA 
      :mod-of (t / tetracycline))

# ::snt Control of Transgenic APP Expression by Dox .
# ::tok Control of Transgenic APP Expression by Dox .
# ::alignments 6-7|0.0.0.0+0.0.0+0.0 2-5|0.1.0.2+0.1.0.1+0.1.0.0+0.1.0+0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:25.010
(c / control-01 
      :ARG0 (o / organization 
            :name (n / name 
                  :op1 "Dox")) 
      :ARG1 (o2 / organization 
            :name (n2 / name 
                  :op1 "Transgenic" 
                  :op2 "APP" 
                  :op3 "Expression")))

# ::snt ( A ) Western blotting for transgenic APP using the human-specific 6E10 antibody shows expression of full-length protein in forebrain tissue from young predeposit double transgenic animals ( line 107 ) and its suppression following dox treatment .
# ::tok ( A ) Western blotting for transgenic APP using the human-specific 6E10 antibody shows expression of full-length protein in forebrain tissue from young predeposit double transgenic animals ( line 107 ) and its suppression following dox treatment .
# ::alignments 36-37|0.0.1.1.0 35-36|0.0.1.1.0.1 34-35|0.0.1.1 33-34|0.0.1 31-32|0.0 29-30|0.0.1.1.0.0 28-29|0.0.1.0 26-27|0.0.0 24-25|0.0.0.1 22-23|0.0.0.0 20-21|0.1.2 19-20|0.1.2.0 17-18|0.1.1 16-17|0.1.1.0 14-15|0.1 13-14|0 12-13|0.1.0.0.0.0 8-9|0.1.0.0.0 7-8|0.1.0.0.1.0+0.1.0.0.1+0.1.0.0 4-5|0.1.0 3-4|0.1.0.1.1+0.1.0.1.0.0+0.1.0.1.0+0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:26.210
(s2 / show-01 
      :ARG0 (a / and 
            :op1 (a2 / animal 
                  :mod (y / young) 
                  :mod (d2 / double)) 
            :op2 (s / suppress-01 
                  :ARG0 (l / line) 
                  :ARG1-of (f / follow-01 
                        :ARG2 (t / treat-03 
                              :ARG1 107 
                              :ARG2 (d / dox))))) 
      :ARG1 (e / express-01 
            :ARG0 (b / blot-01 
                  :ARG1 (o / organization 
                        :ARG0-of (u / use-01 
                              :ARG1 (a3 / antibody)) 
                        :name (n / name 
                              :op1 "APP")) 
                  :mod (w / world-region 
                        :name (n2 / name 
                              :op1 "West") 
                        :wiki "Western_world")) 
            :ARG1 (p / protein 
                  :mod (f3 / full-length)) 
            :prep-in (t2 / tissue 
                  :mod (f2 / forebrain))))

# ::snt Untreated animals show high levels of transgene expression ; protein levels drop dramatically in animals acutely treated with dox for 2 wk .
# ::tok Untreated animals show high levels of transgene expression ; protein levels drop dramatically in animals acutely treated with dox for 2 wk .
# ::alignments 20-21|0.1.1.1 16-17|0.2.0.2.0 15-16|0.2.0.2.0.0 14-15|0.2.0.2 12-13|0.2.0.1 11-12|0.2.0 10-11|0.2.0.0 9-10|0.2.0.0.0 8-9|0.2 7-8|0.1.1 6-7|0.1.1.0 4-5|0.1 3-4|0.1.0 2-3|0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:26.401
(s / show-01 
      :ARG0 (a4 / animal 
            :mod (u / untreat)) 
      :ARG1 (l2 / level 
            :ARG1-of (h / high-02) 
            :mod (e / express-01 
                  :ARG0 (t2 / transgene) 
                  :ARG1 2)) 
      :op1-of (a3 / and 
            :op2 (d2 / drop-01 
                  :ARG1 (l / level 
                        :mod (p / protein)) 
                  :ARG2 (d / dramatic) 
                  :manner (a2 / animal 
                        :ARG1-of (t / treat-01 
                              :ARG2 (a / acute))))))

# ::snt A faint , but detectable band of full-length protein remains in acutely treated animals that can be eliminated in mice born and raised on dox .
# ::tok A faint , but detectable band of full-length protein remains in acutely treated animals that can be eliminated in mice born and raised on dox .
# ::alignments 24-25|0.1.2.1.0.1.0 22-23|0.1.2.1.0.1 21-22|0.1.2.1.0 20-21|0.1.2.1.0.1.1.0 19-20|0.1.2.1.0.1.1 17-18|0.1.2.1 15-16|0.1.2.1.0.0 13-14|0.1.2 12-13|0.1.2.0 11-12|0.1.2.0.0 9-10|0.1 8-9|0.1.0 7-8|0.1.0.0 5-6|0.1.1 4-5|0.1.1.0 3-4|0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:26.672
(c / contrast-01 
      :ARG1 (f2 / faint-01) 
      :ARG2 (r2 / remain-01 
            :ARG0 (p2 / protein 
                  :mod (f / full-length)) 
            :ARG1 (b2 / band 
                  :mod (d2 / detectable)) 
            :ARG2 (a2 / animal 
                  :ARG1-of (t / treat-01 
                        :degree (a3 / acute)) 
                  :ARG1-of (e / eliminate-01 
                        :op2-of (a / and 
                              :op1 (p / possible-01) 
                              :op3 (r / raise-01 
                                    :ARG1 (d / dox) 
                                    :location (m / mouse 
                                          :ARG1-of (b / bear-02))))))))

# ::snt ( B ) Immunoblotting with the N-terminal antibody 22C11 to detect both transgenic and endogenous protein shows that dox treatment reduces APP/APLP to levels found in nontransgenic mice .
# ::tok ( B ) Immunoblotting with the N-terminal antibody 22C11 to detect both transgenic and endogenous protein shows that dox treatment reduces APP/APLP to levels found in nontransgenic mice .
# ::alignments 27-28|0.1.2.0.0 24-25|0.1.2.0 23-24|0.1.2 20-21|0.1 19-20|0.1.1 18-19|0.1.0 16-17|0 15-16|0.1.3.2 14-15|0.1.3.1 13-14|0.1.3 11-12|0.1.1.0 10-11|0.1.3.0 7-8|0.1.3.0.0 6-7|0.1.3.0.0.0.0.0+0.1.3.0.0.0.0+0.1.3.0.0.0 3-4|0.0 1-2|0.1.1.1.1+0.1.1.1.0.0+0.1.1.1.0+0.1.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:27.565
(s / show-01 
      :ARG0 (i / immunoblott) 
      :ARG1 (r / reduce-01 
            :ARG0 (d / dox) 
            :ARG1 (t / treat-03 
                  :ARG0 (b / both) 
                  :ARG1 (l2 / location 
                        :name (n2 / name 
                              :op1 "B") 
                        :wiki -)) 
            :ARG4 (l / level 
                  :ARG0-of (f / find-01 
                        :location (m / mouse))) 
            :op3-of (a / and 
                  :ARG1-of (d2 / detect-01 
                        :ARG0 (a2 / antibody 
                              :mod (c / country 
                                    :name (n / name 
                                          :op1 "N-terminal")))) 
                  :op1 (e / endogenou) 
                  :op2 (p / protein))))

# ::snt ( C ) Measurement of signal intensity from the Western blot in ( A ) shows transgenic APP levels are decreased more than 95 % by dox in both acutely and chronically treated animals ( 97.2 % for 4 wk + 2 wk dox , 98.0 % for reared on dox versus 4 wk untreated ; ANOVA effect of treatment group F4 ,15 = 85.55 , p < 0.001 ) .
# ::tok ( C ) Measurement of signal intensity from the Western blot in ( A ) shows transgenic APP levels are decreased more than 95 % by dox in both acutely and chronically treated animals ( 97.2 % for 4 wk + 2 wk dox , 98.0 % for reared on dox versus 4 wk untreated ; ANOVA effect of treatment group F4 ,15 = 85.55 , p < 0.001 ) .
# ::alignments 66-67|0.2.4.1.1.0.1.0.0.0.1.0 61-62|0.2.4.1.1.0.1.0.1+0.2.4.1.1.0.1.0+0.2.4.1.1.0.1 60-61|0.2.4.1.1.0.1.0.0 59-60|0.2.4.1.1.0.1.0.0.0 57-58|0.2.4.1.1.0 56-57|0.2.4.1.1 55-56|0.2.4.1 54-55|0.2.4.1.0 52-53|0.2.4.1.1.0.1.0.0.0.1.2 51-52|0.2.4.1.1.0.1.0.0.0.1.1 48-49|0.2.4.1.1.0.1.0.0.0.1 46-47|0.1.1.2 41-42|0.1.2 38-39|0.2.4.1.1.0.1.0.0.0.0 36-37|0.2.4.1.1.0.0 33-34|0.2.1 32-33|0.2 31-32|0.2.3 30-31|0.2.4 29-30|0.2.4.0.0 28-29|0.2.4.0 26-27|0.1.0 24-25|0.1.1.0 23-24|0.1.1.0.0 21-22|0.1.0.0 20-21|0.1 18-19|0.1.1 17-18|0.1.1.1.0.0+0.1.1.1.0+0.1.1.1 15-16|0 10-11|0.2.2 9-10|0.2.2.0.1+0.2.2.0.0.0+0.2.2.0.0+0.2.2.0 6-7|0.0 5-6|0.0.0 3-4|0.0.1 1-2|0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:29.497
(s / show-01 
      :ARG0 (i / intensity 
            :mod (s2 / signal) 
            :mod-of (m2 / measurement)) 
      :ARG1 (d2 / decrease-01 
            :ARG0 (d / dox 
                  :quant (m / more)) 
            :ARG1 (l / level 
                  :domain-of (p4 / percentage-entity 
                        :value 95) 
                  :mod (o2 / organization 
                        :name (n2 / name 
                              :op1 "APP")) 
                  :mod (p2 / percentage-entity)) 
            :ARG2 2) 
      :ARG2 (t2 / treat-01 
            :ARG0 (c2 / C) 
            :ARG1 (a3 / animal) 
            :ARG2-of (b2 / blot-01 
                  :mod (w / world-region 
                        :name (n3 / name 
                              :op1 "West") 
                        :wiki "Western_world")) 
            :degree (c / chronic) 
            :op2-of (a4 / and 
                  :op1 (b / both 
                        :mod (a5 / acute)) 
                  :op1-of (a2 / and 
                        :op2 (u / untreat) 
                        :op3 (a / anova 
                              :mod-of (e / effect-03 
                                    :ARG0 (p3 / percentage-entity) 
                                    :ARG1 (o / organization 
                                          :name (n / name 
                                                :name-of (g / group 
                                                      :mod (t / treat-03 
                                                            :ARG0 4 
                                                            :purpose-of (r / rear-01 
                                                                  :ARG0 (p / p) 
                                                                  :ARG1 (v / versu) 
                                                                  :time 4))) 
                                                :op1 "F4"))))))))

# ::snt APP levels in 4 wk + 2 wk dox , reared on dox , and nontransgenic ( NTg ) were not significantly different ( p > 0.9 , Tukey post-hoc test ) .
# ::tok APP levels in 4 wk + 2 wk dox , reared on dox , and nontransgenic ( NTg ) were not significantly different ( p > 0.9 , Tukey post-hoc test ) .
# ::alignments 30-31|0.3.0 28-29|0.3.1.0+0.3.1+0.3 24-25|0.1.0 22-23|0.2 21-22|0.2.1 20-21|0.2.2 15-16|0.2.0 14-15|0 10-11|0.1 8-9|0.0 6-7|0.0.0 3-4|0.2.1.0 1-2|0.1.1 0-1|0.1.1.0.0.0+0.1.1.0.0+0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:30.031
(a / and 
      :op1 (d2 / dox 
            :quant 2) 
      :op2 (r / rear-01 
            :ARG0 (p2 / p) 
            :ARG1 (l / level 
                  :mod (o / organization 
                        :name (n3 / name 
                              :op1 "APP")))) 
      :op3 (d / differ-02 
            :ARG1 (n2 / nontransgenic) 
            :ARG1-of (s / significant-02 
                  :ARG0 4) 
            :polarity -) 
      :op4 (p / person 
            :ARG0-of (t / test-01) 
            :name (n / name 
                  :op1 "Tukey")))

# ::snt ( D ) Measurement of signal intensity from the Western blot in ( B ) shows total APP/APLP levels in dox-treated tTA/APP mice are significantly lower than in 4-wk-old untreated mice ( ANOVA effect of treatment group F4 ,15 = 84.41 , p < 0.001 ) and indistinguishable from those of nontransgenic animals ( p > 0.9 , Tukey post-hoc test ) .
# ::tok ( D ) Measurement of signal intensity from the Western blot in ( B ) shows total APP/APLP levels in dox-treated tTA/APP mice are significantly lower than in 4-wk-old untreated mice ( ANOVA effect of treatment group F4 ,15 = 84.41 , p < 0.001 ) and indistinguishable from those of nontransgenic animals ( p > 0.9 , Tukey post-hoc test ) .
# ::alignments 60-61|0.2.3.1.0.0 52-53|0.2.0 47-48|0.2.4.0 46-47|0.2.4 42-43|0.2.3.2.0 37-38|0.2.3.1.1.0+0.2.3.1.1+0.2.3.1 36-37|0.2.3.1.0.1 35-36|0.2.3.1.0 33-34|0.2.3 32-33|0.2.3.3 30-31|0.2.3.1.0.0.0 29-30|0.2.3.1.0.0.0.0 25-26|0.2 24-25|0.2.2 22-23|0.2.3.0.0 20-21|0.2.3.0 18-19|0.2.1 16-17|0.2.1.0 15-16|0 13-14|0.0.1+0.0.0.0+0.0.0+0.0 10-11|0.2.3.2 9-10|0.2.3.2.1.1+0.2.3.2.1.0.0+0.2.3.2.1.0+0.2.3.2.1 6-7|0.1 5-6|0.1.0 3-4|0.1.1 1-2|0.2.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:31.164
(s2 / show-01 
      :ARG0 (l3 / location 
            :name (n2 / name 
                  :op1 "B") 
            :wiki -) 
      :ARG1 (i2 / intensity 
            :mod (s3 / signal) 
            :mod-of (m3 / measurement)) 
      :ARG2 (l / low-04 
            :ARG0 (a / animal) 
            :ARG1 (l2 / level 
                  :ARG1-of (t3 / total-01)) 
            :ARG1-of (s / significant-02 
                  :ARG0 (d2 / D)) 
            :compared-to (e / effect-03 
                  :ARG0 (d / dox-treat 
                        :mod-of (m2 / mouse)) 
                  :ARG1 (o / organization 
                        :ARG1-of (t2 / treat-03 
                              :ARG1-of (t / test-01 
                                    :ARG0 (m / mouse 
                                          :mod (u / untreat))) 
                              :mod-of (g / group)) 
                        :name (n / name 
                              :op1 "F4")) 
                  :ARG1-of (b / blot-01 
                        :ARG0 (p / p) 
                        :mod (w / world-region 
                              :name (n3 / name 
                                    :op1 "West") 
                              :wiki "Western_world")) 
                  :mod (a3 / anova)) 
            :op1-of (a2 / and 
                  :op2 (i / indistinguishable))))

# ::snt * , p < 0.001 versus untreated 4-wk-old mice , Tukey post-hoc test applied to significant effect of group ANOVA .
# ::tok * , p < 0.001 versus untreated 4-wk-old mice , Tukey post-hoc test applied to significant effect of group ANOVA .
# ::alignments 19-20|0.0.0.0.0.1+0.0.0.0.0+0.0.0.0 18-19|0.0.0.0.0.0 16-17|0.0.0 15-16|0.0 13-14|0.0.0.1 12-13|0.0.0.1.0 10-11|0.0.0.1.0.0.0.0+0.0.0.1.0.0.0+0.0.0.1.0.0 8-9|0.0.0.1.0.1 6-7|0 5-6|0.0.0.1.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:31.351
(u / untreat 
      :ARG0-of (s / significant-02 
            :ARG1 (e / effect-03 
                  :ARG0 (o / organization 
                        :name (n / name 
                              :name-of (g / group) 
                              :op1 "ANOVA")) 
                  :ARG2-of (a / apply-01 
                        :ARG0 (t / test-01 
                              :ARG0 (p / person 
                                    :name (n2 / name 
                                          :op1 "Tukey")) 
                              :ARG1 (m / mouse 
                                    :op1-of (v / versu)))))))

# ::snt A Levels Are Dramatically Reduced by Transgene Suppression .
# ::tok A Levels Are Dramatically Reduced by Transgene Suppression .
# ::alignments 6-8|0.1.0.0.1+0.1.0.0.0+0.1.0.0+0.1.0 4-5|0.1 3-4|0.1.1 2-3|0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:31.413
(b / be-01 
      :ARG0 (l / level-01) 
      :ARG1 (r / reduce-01 
            :ARG0 (o / organization 
                  :name (n / name 
                        :op1 "Transgene" 
                        :op2 "Suppression")) 
            :ARG1 (d / dramatically)))

# ::snt Cortical homogenates from young , predeposit tTA/APP mice used for Western blot in Figure 1 ( line 107 ) were fractionated by sequential multi-step extraction with PBS , 2 % SDS , and 70 % FA followed by human-specific A ELISA to measure transgene-derived peptide in each fraction .
# ::tok Cortical homogenates from young , predeposit tTA/APP mice used for Western blot in Figure 1 ( line 107 ) were fractionated by sequential multi-step extraction with PBS , 2 % SDS , and 70 % FA followed by human-specific A ELISA to measure transgene-derived peptide in each fraction .
# ::alignments 47-48|0.2.1.0.1 46-47|0.2.1.0.1.0 44-45|0.2.1.0.0 43-44|0.2.1.0.0.0 42-43|0.2.1.0 40-41|0.2.0 36-37|0.2 35-36|0.2.1.3+0.2.1.2.0+0.2.1.2+0.2.1 34-35|0.2.1.1 33-34|0.2.1.1.0 32-33|0 30-31|0.1.1.0+0.1.1+0.1 29-30|0.1.0 28-29|0.1.0.0 26-27|0.2.3.1 24-25|0.2.3 22-23|0.2.3.2 17-18|0.0.1.0 16-17|0.2.3.0 14-15|0.2.2 13-14|0.0.2 11-12|0.0.1 10-11|0.0.1.1.1+0.0.1.1.0.0+0.0.1.1.0+0.0.1.1 8-9|0.0 7-8|0.0.0 3-4|0.0.0.0 1-2|0.0.0.1 0-1|0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:34.729
(a / and 
      :op1 (u / use-01 
            :ARG1 (m2 / mouse 
                  :mod (y / young) 
                  :source-of (h / homogenat 
                        :mod (c / cortical))) 
            :ARG2 (b / blot-01 
                  :ARG1 107 
                  :mod (w / world-region 
                        :name (n3 / name 
                              :op1 "West") 
                        :wiki "Western_world")) 
            :time (f3 / figure)) 
      :op2 (o / organization 
            :mod (p3 / percentage-entity 
                  :value 2) 
            :name (n2 / name 
                  :op1 "SDS")) 
      :op3 (f2 / follow-01 
            :ARG0 (e2 / elisa) 
            :ARG1 (l / league 
                  :ARG0-of (m / measure-01 
                        :ARG1 (p / peptide 
                              :mod (t / transgene-deriv)) 
                        :location (f / fraction 
                              :mod (e / each))) 
                  :mod (p2 / percentage-entity 
                        :value 70) 
                  :name (n / name 
                        :op1 "FA") 
                  :wiki "The_Football_Association") 
            :ARG2 1 
            :ARG3 (e3 / extract-01 
                  :ARG0 (l2 / line) 
                  :ARG1 (p4 / pb) 
                  :mod (s / sequential))))

# ::snt A40 is shown in white , A42 in black .
# ::tok A40 is shown in white , A42 in black .
# ::alignments 8-9|0.1 6-7|0.0.0.0+0.0.0+0.0 4-5|0.1.0 2-3|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:34.746
(s / show-01 
      :ARG0 (p / person 
            :name (n / name 
                  :op1 "A42")) 
      :ARG1 (b / black-04 
            :ARG1 (w / white)))

# ::snt ( A ) PBS-soluble A levels are substantially reduced by both acute and chronic dox treatment ( ANOVA , effect of treatment group F4 ,24 = 137.10 and 386.01 , p < 0.001 , for A40 and A42 , respectively ) .
# ::tok ( A ) PBS-soluble A levels are substantially reduced by both acute and chronic dox treatment ( ANOVA , effect of treatment group F4 ,24 = 137.10 and 386.01 , p < 0.001 , for A40 and A42 , respectively ) .
# ::alignments 39-40|0.3.0 36-37|0.2 27-28|0.3 23-24|0.5.1.0.1.0+0.5.1.0.1+0.5.1.0 22-23|0.5.1.1 21-22|0.5.1 19-20|0.5.1.0.0 17-18|0.5.0 15-16|0.5 14-15|0.5.2 13-14|0.5.3 12-13|0 11-12|0.4 10-11|0.0 8-9|0.1 7-8|0.1.1 5-6|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:34.986
(a4 / and 
      :mod (b / both) 
      :op1 (r2 / reduce-01 
            :ARG1 (l / level) 
            :manner (s / substantial)) 
      :op1-of (a / and) 
      :op1-of (a2 / and 
            :mod (r / respective)) 
      :op2 (a5 / acute) 
      :op3 (t2 / treat-03 
            :ARG0 (a3 / anova) 
            :ARG1 (t / treat-03 
                  :ARG1 (o / organization 
                        :ARG1-of (e / effect-03) 
                        :name (n / name 
                              :op1 "F4")) 
                  :mod-of (g / group)) 
            :ARG2 (d / dox) 
            :mod (c / chronic)))

# ::snt A levels in treated animals are indistinguishable from nontransgenic ( NTg ) animals ( p > 0.3 , Tukey post-hoc test ) .
# ::tok A levels in treated animals are indistinguishable from nontransgenic ( NTg ) animals ( p > 0.3 , Tukey post-hoc test ) .
# ::alignments 20-21|0.0.0.0 18-19|0.0.0.1.0+0.0.0.1+0.0.0 14-15|0 12-13|0.0.1 6-7|0.0.0.0.0 4-5|0.0.2 3-4|0.0 1-2|0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:35.116
(p2 / p 
      :ARG0-of (t2 / treat-01 
            :ARG1 (p / person 
                  :ARG1-of (t / test-01 
                        :ARG0 (i / indistinguishable)) 
                  :name (n / name 
                        :op1 "Tukey")) 
            :ARG2 (a / animal) 
            :mod-of (a2 / animal 
                  :mod-of (l / level))))

# ::snt ( B ) In the young animals tested here prior to the formation of visible amyloid deposits , most A is extracted into the SDS fraction ( 84 % and 76 % of all transgene-derived A40 and A42 , respectively ) .
# ::tok ( B ) In the young animals tested here prior to the formation of visible amyloid deposits , most A is extracted into the SDS fraction ( 84 % and 76 % of all transgene-derived A40 and A42 , respectively ) .
# ::alignments 39-40|0.0 37-38|0.2.0.0+0.2.0+0.2 36-37|0 35-36|0.1.1.0+0.1.1+0.1 34-35|0.1.0 33-34|0.4 31-32|0.3 30-31|0.1.2.0.2.0.0.0+0.1.2.0.2.0.0 29-30|0.1.2 28-29|0.1.2.2 27-28|0.1.2.2.0 25-26|0.1.2.0.0 24-25|0.1.2.0.0.0.1.0+0.1.2.0.0.0.1+0.1.2.0.0.0 21-22|0.1.2.0 18-19|0.1.2.0.0.0.0 16-17|0.1.2.0.1.2.1 15-16|0.1.2.0.1.0 14-15|0.1.2.0.1.1 12-13|0.1.2.0.1.2 9-10|0.1.2.0.1.3 8-9|0.1.2.1 7-8|0.1.2.0.1 6-7|0.1.2.0.2 5-6|0.1.2.0.2.0 1-2|0.1.2.0.1.2.0.1+0.1.2.0.1.2.0.0.0+0.1.2.0.1.2.0.0+0.1.2.0.1.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:36.133
(a / and 
      :mod (r / respective) 
      :op1 (t / thing 
            :mod (t2 / transgene-deriv) 
            :name (n2 / name 
                  :op1 "A40") 
            :op3-of (a3 / and 
                  :ARG1-of (e / extract-01 
                        :ARG2 (f / fraction 
                              :mod (o / organization 
                                    :compared-to-of (m / most) 
                                    :name (n3 / name 
                                          :op1 "SDS"))) 
                        :manner (t3 / test-01 
                              :ARG1 (a4 / amyloid) 
                              :ARG2 (v / visible) 
                              :ARG4 (f2 / form-01 
                                    :ARG0 (l / location 
                                          :name (n4 / name 
                                                :op1 "B") 
                                          :wiki -) 
                                    :ARG1 (d / deposit)) 
                              :op1-of (p5 / prior)) 
                        :time (a5 / animal 
                              :mod (y / young 
                                    :mod-of (p3 / person 
                                          :quant 76)))) 
                  :op1 (h / here) 
                  :op2 (p4 / percentage-entity 
                        :value 84))) 
      :op2 (p / person 
            :name (n / name 
                  :op1 "A42")) 
      :poss-of (p2 / percentage-entity) 
      :quant (a2 / all))

# ::snt As in the PBS-soluble fraction , A levels in the SDS fraction are significantly lowered by dox treatment compared to untreated animals ( ANOVA effect of group F4 ,24 = 197.57 and 163.48 , p < 0.001 , for A40 and A42 , respectively ) .
# ::tok As in the PBS-soluble fraction , A levels in the SDS fraction are significantly lowered by dox treatment compared to untreated animals ( ANOVA effect of group F4 ,24 = 197.57 and 163.48 , p < 0.001 , for A40 and A42 , respectively ) .
# ::alignments 43-44|0.0.0.1.0.0.1 40-41|0.0 31-32|0 27-28|0.0.0.0.0.1+0.0.0.0.0+0.0.0.0 26-27|0.0.0.0.0.0 24-25|0.0.0 23-24|0.0.0.2 21-22|0.0.0.1.0.0.2.0 20-21|0.0.0.1.0.0.2.0.0 18-19|0.0.0.1.0.0.2 17-18|0.0.0.1.0.0 16-17|0.0.0.1.0.0.3 14-15|0.0.0.1.0 13-14|0.0.0.1 11-12|0.0.0.1.0.0.0 10-11|0.0.0.1.0.0.0.0.0.0+0.0.0.1.0.0.0.0.0+0.0.0.1.0.0.0.0 7-8|0.0.0.1.0.1 4-5|0.0.0.1.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:36.770
(a2 / and 
      :op1-of (a / and 
            :ARG1-of (e / effect-03 
                  :ARG0 (o / organization 
                        :name (n / name 
                              :name-of (g / group) 
                              :op1 "F4")) 
                  :ARG1-of (s / significant-02 
                        :ARG2-of (l / lower-05 
                              :ARG0 (t / treat-03 
                                    :ARG0 (f / fraction 
                                          :mod (o2 / organization 
                                                :name (n2 / name 
                                                      :op1 "SDS")) 
                                          :op1 (f2 / fraction)) 
                                    :ARG1 (r / respective) 
                                    :ARG1-of (c / compare-01 
                                          :ARG2 (a4 / animal 
                                                :mod (u / untreat))) 
                                    :ARG2 (d / dox)) 
                              :ARG1 (l2 / level))) 
                  :mod (a3 / anova))))

# ::snt Acutely treated animals retained a small ( although significant ) amount of residual peptide ( p < 0.001 compared to nontransgeinc , Tukey post-hoc test ) , whereas A levels in mice born and raised on dox were reduced to levels indistinguishable from nontransgenic ( p > 0.8 , Tukey post-hoc test ) .
# ::tok Acutely treated animals retained a small ( although significant ) amount of residual peptide ( p < 0.001 compared to nontransgeinc , Tukey post-hoc test ) , whereas A levels in mice born and raised on dox were reduced to levels indistinguishable from nontransgenic ( p > 0.8 , Tukey post-hoc test ) .
# ::alignments 51-52|0.2.0.1 47-48|0.0.0.0.0 43-44|0.2.0.2 41-42|0.1.0 40-41|0.2.0.3 38-39|0.2.0 36-37|0.0.2 34-35|0.1 33-34|0 32-33|0.0 31-32|0.0.1 29-30|0.2 27-28|0.2.0.4 24-25|0.0.0.0 22-23|0.0.0.1.0+0.0.0.1+0.0.0 20-21|0.0.0.0.1.0 18-19|0.0.0.0.1 13-14|0.2.0.0.0.0.1 12-13|0.2.0.0.0.0.1.0 10-11|0.2.0.0.0.0 8-9|0.2.0.0.0.1 5-6|0.2.0.0.0.0.0 3-4|0.2.0.0.0 2-3|0.2.0.0 1-2|0.2.0.0.0.2 0-1|0.2.0.0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:38.259
(a / and 
      :op1 (b / bear-02 
            :ARG0 (p / person 
                  :ARG0-of (t2 / test-01 
                        :ARG1 0.8 
                        :ARG1-of (c / compare-01 
                              :ARG2 (n3 / nontransgeinc))) 
                  :name (n2 / name 
                        :op1 "Tukey")) 
            :ARG1 (m / mouse) 
            :location (d / dox)) 
      :op2 (r2 / raise-01 
            :ARG1 (i / indistinguishable)) 
      :topic-of (l2 / level 
            :ARG1-of (r / reduce-01 
                  :ARG0 (a3 / animal 
                        :ARG0-of (r4 / retain-01 
                              :ARG1 (a2 / amount 
                                    :mod (s2 / small) 
                                    :quant-of (p2 / peptide 
                                          :mod (r3 / residual))) 
                              :ARG1-of (s / significant-02) 
                              :ARG1-of (t3 / treat-01 
                                    :ARG0 (a4 / acutely)))) 
                  :ARG1-of (t / test-01) 
                  :ARG2 (n / nontransgenic) 
                  :ARG4 (l / level) 
                  :op1-of (w / whereas))))

# ::snt ( C ) The FA-soluble fraction already contains a small but significant pool of aggregated A42 in untreated animals by 4 wk of age ( p < 0.05 versus nontransgenic ; Tukey post-hoc test applied to significant effect of group ANOVA F4 ,24 = 17.11 , p < 0.001 ) .
# ::tok ( C ) The FA-soluble fraction already contains a small but significant pool of aggregated A42 in untreated animals by 4 wk of age ( p < 0.05 versus nontransgenic ; Tukey post-hoc test applied to significant effect of group ANOVA F4 ,24 = 17.11 , p < 0.001 ) .
# ::alignments 40-42|0.4.0.1.1.0.0.1.0.1+0.4.0.1.1.0.0.1.0.0+0.4.0.1.1.0.0.1.0+0.4.0.1.1.0.0.1 39-40|0.4.0.1.1.0.0.0 37-38|0.4.0.1.1.0.0 36-37|0.4.0.1.1.0 34-35|0.4.0.1.1.0.0.2 33-34|0.4.0.1.1 31-32|0.4.0.0.0+0.4.0.0+0.4.0 30-31|0.4.0.1 28-29|0.4.0.1.1.2 25-26|0.1.0.0 23-24|0.4 20-21|0.4.0.1.1.1 18-19|0.4.0.1.1.0.0.2.0 17-18|0.4.0.1.1.0.0.2.0.0 15-16|0.1.1.1.0+0.1.1.1+0.1.1 14-15|0.1.1.0 12-13|0.1 11-12|0.1.0 10-11|0.4.0.1.0 9-10|0.4.0.1.0.0 7-8|0 6-7|0.3 5-6|0.2 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:40.620
(c2 / contain-01 
      :ARG0 (c3 / C) 
      :ARG1 (p4 / pool 
            :ARG1-of (s2 / significant-02 
                  :ARG0 (p2 / p)) 
            :consist-of (p3 / person 
                  :ARG1-of (a5 / aggregate-01) 
                  :name (n3 / name 
                        :op1 "A42"))) 
      :ARG3 (f / fraction) 
      :time (a6 / already) 
      :time (a3 / age-01 
            :ARG1 (p / person 
                  :name (n2 / name 
                        :op1 "Tukey") 
                  :op1-of (a2 / and 
                        :ARG2-of (c / contrast-01 
                              :ARG1 (s3 / small)) 
                        :op2 (t / test-01 
                              :ARG0-of (s / significant-02 
                                    :ARG1 (e / effect-03 
                                          :ARG0 (g / group) 
                                          :ARG1 (o / organization 
                                                :name (n / name 
                                                      :op1 "ANOVA" 
                                                      :op2 "F4")) 
                                          :ARG2-of (a / apply-01 
                                                :ARG1 (a4 / animal 
                                                      :mod (u / untreat))))) 
                              :ARG1 4 
                              :op1-of (v / versu))))))

# ::snt By 6 wk of age , the amount of A in the FA fraction is increased significantly preceding the appearance of visible deposits 2 wk later .
# ::tok By 6 wk of age , the amount of A in the FA fraction is increased significantly preceding the appearance of visible deposits 2 wk later .
# ::alignments 25-26|0.2 23-24|0.1.0 22-23|0.0.1.1 21-22|0.0.0.0.0 19-20|0.0.1 17-18|0.0 16-17|0.1 15-16|0 13-14|0.0.1.0 12-13|0.0.1.0.0.1+0.0.1.0.0.0.0+0.0.1.0.0.0+0.0.1.0.0 7-8|0.0.0 4-5|0.0.0.0 1-2|0.0.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:40.863
(i / increase-01 
      :ARG1 (p / precede-01 
            :ARG1 (a2 / amount 
                  :ARG1-of (a3 / age-01 
                        :ARG0 (v / visible))) 
            :ARG2 (a / appear-01 
                  :ARG0 (f / fraction 
                        :mod (l2 / league 
                              :name (n / name 
                                    :op1 "FA") 
                              :wiki "The_Football_Association")) 
                  :ARG1 (d / deposit) 
                  :ARG2 6)) 
      :ARG2 (s / significant-02 
            :ARG1 2) 
      :time (l / late))

# ::snt The FA pool is the only peptide fraction not lowered by acute dox treatment ( 4 wk untreated = 4 wk + 2 wk dox , p > 0.9 , Tukey post-hoc test ) , consistent with poor turnover of aggregated A species .
# ::tok The FA pool is the only peptide fraction not lowered by acute dox treatment ( 4 wk untreated = 4 wk + 2 wk dox , p > 0.9 , Tukey post-hoc test ) , consistent with poor turnover of aggregated A species .
# ::alignments 42-43|0.1 40-41|0.1.0 38-39|0 37-38|0.2 35-36|0.0 32-33|0.1.0.0.2.0 30-31|0.1.0.0.2.1.0+0.1.0.0.2.1+0.1.0.0.2 26-27|0.1.0.1 22-23|0.0.1 19-20|0.0.0 15-16|0.1.0.2 13-14|0.1.0.0 12-13|0.1.0.0.3 11-12|0.1.0.0.2.0.0 9-10|0.1.0.0.1 8-9|0.1.0.0.1.1 7-8|0.1.0.0.1.0 6-7|0.1.0.0.1.0.0 5-6|0.1.0.0.1.0.1 2-3|0.1.0.0.0.0 1-2|0.1.0.0.0.2+0.1.0.0.0.1.0+0.1.0.0.0.1+0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:42.200
(t / turnover 
      :ARG2-of (c / consistent-01 
            :ARG0 4 
            :ARG1 2) 
      :mod (s / species 
            :ARG1-of (a / aggregate-01 
                  :ARG2 (t3 / treat-03 
                        :ARG0 (l2 / league 
                              :mod-of (p5 / pool) 
                              :name (n2 / name 
                                    :op1 "FA") 
                              :wiki "The_Football_Association") 
                        :ARG0-of (l / lower-05 
                              :ARG1 (f / fraction 
                                    :mod (p4 / peptide) 
                                    :mod (o / only)) 
                              :polarity -) 
                        :ARG1 (p2 / person 
                              :ARG1-of (t2 / test-01 
                                    :ARG0 (a2 / acute)) 
                              :name (n / name 
                                    :op1 "Tukey")) 
                        :ARG2 (d / dox)) 
                  :op1-of (p3 / p) 
                  :op1-of 4)) 
      :mod (p / poor))

# ::snt ( D ) Measurements of total A , including both endogenous and transgene-derived peptides , show that animals born and raised on dox harbor A levels identical to nontransgenic animals ( p > 0.9 , Tukey post-hoc test , effect of group ANOVA F4 ,24 = 39.13 and 35.29 , p < 0.001 , for A40 and A42 , respectively ) .
# ::tok ( D ) Measurements of total A , including both endogenous and transgene-derived peptides , show that animals born and raised on dox harbor A levels identical to nontransgenic animals ( p > 0.9 , Tukey post-hoc test , effect of group ANOVA F4 ,24 = 39.13 and 35.29 , p < 0.001 , for A40 and A42 , respectively ) .
# ::alignments 59-60|0.1.1.0 56-57|0.3.3.2 47-48|0.1.1.2 42-44|0.3.3.2.0.0.0.2+0.3.3.2.0.0.0.1+0.3.3.2.0.0.0+0.3.3.2.0.0 41-42|0.3.3.2.0.0.0.0 39-40|0.3.3.2.0 37-38|0.3.3.0 35-36|0.3.3.1.0+0.3.3.1+0.3.3 31-32|0.1.0 29-30|0.2.2.0 26-27|0.2.2 25-26|0.2.1 23-24|0.2 22-23|0.1.1.1.1 20-21|0.1 19-20|0.1.1 18-19|0.1.1.1 17-18|0.1.1.1.0 15-16|0 13-14|0.3.2 12-13|0.3.2.0 11-12|0.3 10-11|0.3.1 9-10|0.3.0 5-6|0.2.2.1 3-4|0.2.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:45.361
(s / show-01 
      :ARG0 (d2 / D) 
      :ARG0-of (r2 / raise-01 
            :ARG1 (p2 / p) 
            :op2-of (a4 / and 
                  :mod (r / respective) 
                  :op1 (b / bear-02 
                        :ARG1 (a5 / animal) 
                        :location (d / dox)) 
                  :op1-of (a2 / and))) 
      :ARG1 (h / harbor-01 
            :ARG0 (m / measurement) 
            :ARG1 (l / level) 
            :ARG2 (i / identical-01 
                  :ARG1 (a3 / animal) 
                  :ARG1-of (t3 / total-01))) 
      :op3-of (a6 / and 
            :mod (b2 / both) 
            :op1 (e2 / endogenou) 
            :op2 (p3 / peptid 
                  :mod (t2 / transgene-deriv)) 
            :op4 (p / person 
                  :ARG1-of (t / test-01) 
                  :name (n2 / name 
                        :op1 "Tukey") 
                  :op1-of (a / and 
                        :ARG0-of (e / effect-03 
                              :ARG1 (o / organization 
                                    :name (n / name 
                                          :name-of (g / group) 
                                          :op1 "ANOVA" 
                                          :op2 "F4")))))))

# ::snt Whereas chronic transgene suppression fully prevents synthesis of both peptides , acute dox treatment fully suppresses A40 levels ( p > 0.8 , Tukey post-hoc test ) , but leaves a small amount of nonsuppressed A42 .
# ::tok Whereas chronic transgene suppression fully prevents synthesis of both peptides , acute dox treatment fully suppresses A40 levels ( p > 0.8 , Tukey post-hoc test ) , but leaves a small amount of nonsuppressed A42 .
# ::alignments 35-36|0.0.1.1.0+0.0.1.1+0.0.1 34-35|0.0.1.0 32-33|0.0 31-32|0.0.0 29-30|0.1 28-29|0 25-26|0.1.0.1.0 23-24|0.1.0.1.1.0+0.1.0.1.1+0.1.0.1 21-22|0.1.0.0.2.0.0 19-20|0.1.0.0.0 17-18|0.1.1 15-16|0.1.0.0 14-15|0.1.0.0.1 13-14|0.1.0 12-13|0.1.0.2 11-12|0.1.0.0.2.0.1 9-10|0.1.0.0.2.1.0 8-9|0.1.0.0.2.1.0.0 6-7|0.1.0.0.2.1 5-6|0.1.0.0.2 4-5|0.1.0.0.2.2 3-4|0.1.0.0.2.0 2-3|0.1.0.0.2.0.3 1-2|0.1.0.0.2.0.2 0-1|0.1.0.0.2.3 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:46.671
(c / contrast-01 
      :ARG1 (a / amount 
            :mod (s / small) 
            :quant-of (p / person 
                  :mod (n2 / nonsuppress) 
                  :name (n / name 
                        :op1 "A42"))) 
      :ARG2 (l / leave-13 
            :ARG0 (t2 / treat-03 
                  :ARG0-of (s2 / suppress-01 
                        :ARG1 (p3 / p) 
                        :degree (f / full) 
                        :purpose (p5 / prevent-01 
                              :ARG0 (s4 / suppress-01 
                                    :ARG0 0.8 
                                    :ARG1 (a2 / acute) 
                                    :mod (c2 / chronic) 
                                    :mod (t3 / transgene)) 
                              :ARG1 (s3 / synthesi 
                                    :poss (p4 / peptid 
                                          :mod (b / both))) 
                              :degree (f2 / full) 
                              :op1-of (w / wherea))) 
                  :ARG1 (p2 / person 
                        :ARG1-of (t / test-01) 
                        :name (n3 / name 
                              :op1 "Tukey")) 
                  :ARG2 (d / dox)) 
            :ARG1 (l2 / level)))

# ::snt The residual A42 observed in acutely treated young animals derives from uncleared aggregates extracted in the SDS and FA fractions .
# ::tok The residual A42 observed in acutely treated young animals derives from uncleared aggregates extracted in the SDS and FA fractions .
# ::alignments 19-20|0.4 18-19|0.3.1+0.3.0.0+0.3.0+0.3 17-18|0 16-17|0.2.0.0+0.2.0+0.2 13-14|0.0.0 12-13|0.0 11-12|0.0.2 9-10|0.0.1 8-9|0.0.1.0 7-8|0.0.1.0.0 6-7|0.1.0.0 5-6|0.1.0.0.0 3-4|0.1 2-3|0.1.0.2.0+0.1.0.2+0.1.0 1-2|0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:47.069
(a / and 
      :ARG0-of (a2 / aggregate-01 
            :ARG1-of (e / extract-01) 
            :ARG2-of (d / derive-01 
                  :ARG0 (a3 / animal 
                        :mod (y / young))) 
            :mod (u / unclear)) 
      :ARG1-of (o2 / observe-01 
            :ARG0 (p / person 
                  :ARG1-of (t / treat-01 
                        :ARG0 (a4 / acute)) 
                  :mod (r / residual) 
                  :name (n3 / name 
                        :op1 "A42"))) 
      :op1 (o / organization 
            :name (n2 / name 
                  :op1 "SDS")) 
      :op2 (l / league 
            :name (n / name 
                  :op1 "FA") 
            :wiki "The_Football_Association") 
      :op3 (f / fraction-01))

# ::snt * , p < 0.05 ; ** , p < 0.005 ; *** , p < 0.001 versus 4-wk-old untreated mice , Tukey post-hoc applied to significant effect of group ANOVA .
# ::tok * , p < 0.05 ; ** , p < 0.005 ; *** , p < 0.001 versus 4-wk-old untreated mice , Tukey post-hoc applied to significant effect of group ANOVA .
# ::alignments 30-31|0.0.0.0.0.1+0.0.0.0.0+0.0.0.0 29-30|0.0.0.0.0.0 27-28|0.0.0 26-27|0.0 24-25|0.0.0.2 22-24|0.0.0.2.0.0.1+0.0.0.2.0.0.0+0.0.0.2.0.0+0.0.0.2.0 20-21|0.0.0.1 19-20|0.0.0.1.0 17-18|0.0.0.1.1 5-6|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:47.339
(a2 / and 
      :ARG0-of (s / significant-02 
            :ARG1 (e / effect-03 
                  :ARG0 (o / organization 
                        :name (n / name 
                              :name-of (g / group) 
                              :op1 "ANOVA")) 
                  :ARG1 (m / mouse 
                        :mod (u / untreat) 
                        :op1-of (v / versu)) 
                  :ARG2-of (a / apply-01 
                        :ARG0 (t / thing 
                              :name (n2 / name 
                                    :op1 (t2 / Tukey) 
                                    :op2 (p / post-hoc)))))))

# ::snt Robust Transgene Suppression in Older Mice with Preexisting Amyloid Pathology .
# ::tok Robust Transgene Suppression in Older Mice with Preexisting Amyloid Pathology .
# ::alignments 7-10|0.0.0.1.0.2+0.0.0.1.0.1+0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 5-6|0.0.0 4-5|0.0.0.0 1-3|0.0.1.1+0.0.1.0+0.0.1+0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:47.368
(r / robust 
      :domain (o3 / organization 
            :location (m / mouse 
                  :mod (o2 / old) 
                  :prep-with (o / organization 
                        :name (n / name 
                              :op1 "Preexisting" 
                              :op2 "Amyloid" 
                              :op3 "Pathology"))) 
            :name (n2 / name 
                  :op1 "Transgene" 
                  :op2 "Suppression")))

# ::snt ( A ) Cortical homogenates from 6 - to 12-mo-old animals used for pathology studies described below ( line 107 ) were immunoblotted with human-specific antibody 6E10 to examine transgene suppression following 3 or 6 mo of dox treatment .
# ::tok ( A ) Cortical homogenates from 6 - to 12-mo-old animals used for pathology studies described below ( line 107 ) were immunoblotted with human-specific antibody 6E10 to examine transgene suppression following 3 or 6 mo of dox treatment .
# ::alignments 38-39|0.0.1.1.1.0 37-38|0.0.1.1.1.0.2 35-36|0.0.1.1.1 34-35|0.1 33-34|0 32-33|0.0.1.1.1.0.1.0.0.0 31-32|0.0.1.1 30-31|0.0 29-30|0.0.3 28-29|0.0.1 26-27|0.0.2 25-26|0.0.2.0 19-20|0.0.1.1.0 18-19|0.0.1.1.1.0.0 16-17|0.0.1.1.1.0.1.1 15-16|0.0.1.1.1.0.1 14-15|0.0.1.1.1.0.1.0 13-14|0.0.1.1.1.0.1.0.1 11-12|0.0.1.1.1.0.1.0.0 10-11|0.0.1.1.1.0.1.0.0.1 6-7|0.0.0 3-5|0.0.1.0.0.1+0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:49.010
(o / or 
      :op1 (s / suppress-01 
            :ARG0 6 
            :ARG1-of (e / examine-01 
                  :ARG0 (t3 / thing 
                        :name (n / name 
                              :op1 (c / Cortical) 
                              :op2 (h / homogenates))) 
                  :ARG1-of (f / follow-01 
                        :ARG0 107 
                        :ARG2 (m / mo 
                              :poss (t / treat-03 
                                    :ARG0 (l / line) 
                                    :ARG1 (d2 / describe-01 
                                          :ARG1 (s2 / study-01 
                                                :ARG2-of (u / use-01 
                                                      :ARG0 3 
                                                      :ARG1 (a2 / animal)) 
                                                :mod (p / pathology)) 
                                          :manner (b / below)) 
                                    :ARG2 (d / dox))))) 
            :ARG2 (62 / 6E10 
                  :mod (a / antibody)) 
            :mod (t2 / transgene)) 
      :op2 6)

# ::snt The blot was co-immunostained for endogenous superoxide dismutase 1 ( SOD1 ) as a control for loading .
# ::tok The blot was co-immunostained for endogenous superoxide dismutase 1 ( SOD1 ) as a control for loading .
# ::alignments 16-17|0.0.0.0.1 14-15|0.0.0.0 8-9|0.0.0.0.1.0 7-8|0.0.0 6-7|0.0.0.0.0.0 5-6|0.0.0.0.0 3-4|0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:49.128
(c2 / co-immunostain 
      :domain (b / blot-01 
            :ARG1 (d / dismutase 
                  :ARG1-of (c / control-01 
                        :ARG0 (e / endogenou 
                              :mod-of (s / superoxide)) 
                        :purpose (l / load-01 
                              :ARG1 1)))))

# ::snt ( B ) Quantitation of signal intensity from the Western blot shown in ( A ) .
# ::tok ( B ) Quantitation of signal intensity from the Western blot shown in ( A ) .
# ::alignments 11-12|0 10-11|0.1 9-10|0.1.1.1+0.1.1.0.0+0.1.1.0+0.1.1 6-7|0.0 5-6|0.0.0 1-2|0.1.0.1+0.1.0.0.0+0.1.0.0+0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:49.264
(s / show-01 
      :ARG0 (i / intensity 
            :mod (s2 / signal)) 
      :ARG1 (b / blot-01 
            :ARG1 (l / location 
                  :name (n2 / name 
                        :op1 "B") 
                  :wiki -) 
            :mod (w / world-region 
                  :name (n / name 
                        :op1 "West") 
                  :wiki "Western_world")))

# ::snt Transgenic APP levels are significantly suppressed following 3 or 6 mo of dox treatment ( 96.9 % and 97.6 % , respectively ) .
# ::tok Transgenic APP levels are significantly suppressed following 3 or 6 mo of dox treatment ( 96.9 % and 97.6 % , respectively ) .
# ::alignments 21-22|0.0.1.0.2.0 19-20|0.0.1.0.2.2.0 17-18|0 16-17|0.1 13-14|0.0 12-13|0.0.0 10-11|0.0.1 9-10|0.0.1.0.1.0 8-9|0.0.1.0.1 7-8|0.0.1.0.0 6-7|0.0.1.0 5-6|0.0.1.0.2 4-5|0.0.1.0.2.2 2-3|0.0.1.0.2.1 0-2|0.0.1.0.2.1.0.0.1+0.0.1.0.2.1.0.0.0+0.0.1.0.2.1.0.0+0.0.1.0.2.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:49.530
(a / and 
      :ARG1-of (t / treat-03 
            :ARG2 (d / dox) 
            :poss-of (m / mo 
                  :ARG2-of (f / follow-01 
                        :ARG1 3 
                        :op1-of (o / or 
                              :op2 6) 
                        :time-of (s / suppress-01 
                              :ARG0 (r / respective) 
                              :ARG1 (l / level 
                                    :mod (o2 / organization 
                                          :name (n / name 
                                                :op1 "Transgenic" 
                                                :op2 "APP"))) 
                              :ARG1-of (s2 / significant-02 
                                    :ARG0 (p / percentage-entity)))))) 
      :op1 (p2 / percentage-entity))

# ::snt * , p < 0.001 compared to 6-mo-old untreated animals , Tukey post-hoc test applied to significant effect of group ANOVA F3 ,12 = 107.22 , p < 0.001 .
# ::tok * , p < 0.001 compared to 6-mo-old untreated animals , Tukey post-hoc test applied to significant effect of group ANOVA F3 ,12 = 107.22 , p < 0.001 .
# ::alignments 20-22|0.0.0.0.0.0.0.2+0.0.0.0.0.0.0.1+0.0.0.0.0.0.0+0.0.0.0.0.0 19-20|0.0.0.0.0.0.0.0 17-18|0.0.0.0.0 16-17|0.0.0.0 14-15|0.0.0.0.0.1 13-14|0.0.0.0.0.1.0 11-12|0.0.0.0.0.1.0.0.0.0+0.0.0.0.0.1.0.0.0+0.0.0.0.0.1.0.0 9-10|0.0 8-9|0 5-6|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:49.693
(u / untreat 
      :mod-of (a3 / animal 
            :ARG2-of (c / compare-01 
                  :purpose (s / significant-02 
                        :ARG1 (e / effect-03 
                              :ARG0 (t / thing 
                                    :name (n / name 
                                          :name-of (g / group) 
                                          :op1 (a / ANOVA) 
                                          :op2 (f / F3))) 
                              :ARG2-of (a2 / apply-01 
                                    :ARG1 (t2 / test-01 
                                          :ARG1 (p / person 
                                                :name (n2 / name 
                                                      :op1 "Tukey")))))))))

# ::snt These data demonstrate that strong transgene suppression is attained both before and after the onset of amyloid pathology ( see Figure 1 for predeposit experiments ) .
# ::tok These data demonstrate that strong transgene suppression is attained both before and after the onset of amyloid pathology ( see Figure 1 for predeposit experiments ) .
# ::alignments 24-25|0.0.0.0 23-24|0.0.0.0.1 21-22|0.0.0.1.0 20-21|0.0.0.0.2.0 19-20|0.0.0.0.2 17-18|0.2.0.0 16-17|0.2.0.0.0 14-15|0.2.0 12-13|0.2 11-12|0 10-11|0.1 9-10|0.0.0.0.0 8-9|0.0 6-7|0.0.0 5-6|0.0.0.2 4-5|0.0.0.1 2-3|0.0.1 1-2|0.0.1.0 0-1|0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:50.148
(a3 / and 
      :ARG0-of (a4 / attain-01 
            :ARG1 (s2 / suppress-01 
                  :ARG1 (e / experiment-01 
                        :ARG0 (b2 / both) 
                        :ARG1 (p / predeposit) 
                        :purpose-of (s / see-01 
                              :ARG1 (f / figure))) 
                  :ARG1-of (s3 / strong-02 
                        :ARG0 1) 
                  :mod (t / transgene)) 
            :ARG1-of (d / demonstrate-01 
                  :ARG0 (d2 / data 
                        :mod (t2 / this)))) 
      :op1 (b / before) 
      :op2 (a2 / after 
            :op1 (o / onset 
                  :mod (p2 / pathology 
                        :mod (a / amyloid)))))

# ::snt ( C ) Experimental design .
# ::tok ( C ) Experimental design .
# ::alignments 4-5|0 3-4|0.1 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:50.156
(d / design-01 
      :ARG0 (c / C) 
      :mod (e / experimental))

# ::snt To examine the effects of chronic A suppression on amyloid pathology after the onset of deposition , we compared untreated controls harvested at 6 and 9 mo of age to animals placed on dox at 6 mo of age and harvested after 3 or 6 mo of treatment .
# ::tok To examine the effects of chronic A suppression on amyloid pathology after the onset of deposition , we compared untreated controls harvested at 6 and 9 mo of age to animals placed on dox at 6 mo of age and harvested after 3 or 6 mo of treatment .
# ::alignments 47-48|0.1.1.2.0 44-45|0.1.0.0 43-44|0.1.0 42-43|0.1.1.0.1.0 41-42|0.1.1.2 40-41|0.1 39-40|0.1.1 38-39|0 35-36|0.1.1.0.1.1.0 33-34|0.1.1.1.2 31-32|0.1.1.1 30-31|0.1.1.1.1 28-29|0.1.1.1.1.0 26-27|0.1.1.1.0 25-26|0.0 24-25|0.1.1.0.1.1.1 23-24|0.1.1.2.0.0 21-22|0.1.1.0.1.1 20-21|0.1.1.0.1 19-20|0.1.1.0.1.2 18-19|0.1.1.0 17-18|0.1.1.0.0 15-16|0.1.1.0.0.0.1.1 13-14|0.1.1.0.0.0.1.0 11-12|0.1.1.0.0.0.1 10-11|0.1.1.0.0.0.0.0.0 9-10|0.1.1.0.0.0.0.0.0.0 7-8|0.1.1.0.0.0.0.0 5-6|0.1.1.0.0.0.0.0.1 3-4|0.1.1.0.0.0.0 1-2|0.1.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:50.865
(a3 / age-01 
      :ARG1 9 
      :ARG1-of (h / harvest-01 
            :op1-of (o / or 
                  :op2 6) 
            :op3-of (a2 / and 
                  :op1 (c2 / compare-01 
                        :ARG0 (w / we 
                              :ARG0-of (e2 / examine-01 
                                    :ARG1 (e / effect 
                                          :part-of (s / suppress-01 
                                                :ARG1 (p2 / pathology 
                                                      :mod (a8 / amyloid)) 
                                                :mod (c3 / chronic))) 
                                    :time (a7 / after 
                                          :op1 (o2 / onset) 
                                          :op2 (d2 / deposition)))) 
                        :ARG1 (c / control-01 
                              :ARG1 3 
                              :ARG1-of (h2 / harvest-01 
                                    :ARG0 6 
                                    :op1-of (a6 / and)) 
                              :mod (u / untreat))) 
                  :op2 (p / place-01 
                        :ARG0 (m / mo) 
                        :ARG1 (a4 / animal 
                              :ARG1-of (a5 / age-01)) 
                        :ARG2 (d / dox)) 
                  :time (a / after 
                        :op1 (t / treat-03 
                              :ARG1 6)))))

# ::snt ( D ) Dox treatment leads to rapid transgene suppression even in 6-mo-old tTA/APP mice .
# ::tok ( D ) Dox treatment leads to rapid transgene suppression even in 6-mo-old tTA/APP mice .
# ::alignments 14-15|0.0.1.0 10-11|0.0.1 9-10|0.0.0 8-9|0.0.0.1 7-8|0.0.0.0 5-6|0 4-5|0.0 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:50.922
(l / lead-03 
      :ARG0 (t2 / treat-03 
            :ARG0-of (s / suppress-01 
                  :manner (r / rapid) 
                  :mod (t / transgene)) 
            :ARG1 (e / even 
                  :mod-of (m / mouse))) 
      :ARG1 (d / D))

# ::snt Immunostaining with 6E10 shows APPswe/ind levels are dramatically reduced in 6-mo-old mice treated for 1 wk with dox ( upper panel ) .
# ::tok Immunostaining with 6E10 shows APPswe/ind levels are dramatically reduced in 6-mo-old mice treated for 1 wk with dox ( upper panel ) .
# ::alignments 20-21|0.1.0 19-20|0.1.0.0 17-18|0.2 14-15|0.0 12-13|0.1.2.0 11-12|0.1.2 8-9|0.1 7-8|0.1.3 5-6|0.1.1 3-4|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:51.045
(s / show-01 
      :ARG0 1 
      :ARG1 (r / reduce-01 
            :ARG0 (p / panel 
                  :mod (u / upper)) 
            :ARG1 (l / level) 
            :ARG2 (m / mouse 
                  :ARG1-of (t / treat-01)) 
            :manner (d2 / dramatic)) 
      :op1-of (d / dox))

# ::snt A separate blot was immunostained for APP C-terminal fragments with CT15 antibody to show that the precursors to A cleavage are decreased in parallel with the full-length protein ( middle panel ) .
# ::tok A separate blot was immunostained for APP C-terminal fragments with CT15 antibody to show that the precursors to A cleavage are decreased in parallel with the full-length protein ( middle panel ) .
# ::alignments 30-31|0.1.1.0.0.0 29-30|0.1.1.2.1 27-28|0.1.2 26-27|0.1.2.0 23-24|0 21-22|0.1 19-20|0.0 16-17|0.1.0 13-14|0.1.1 11-12|0.1.1.1 10-11|0.1.1.1.0 8-9|0.1.1.2 6-7|0.1.1.2.0.0.0+0.1.1.2.0.0+0.1.1.2.0 2-3|0.1.1.0 1-2|0.1.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:51.448
(p3 / parallel-01 
      :ARG1 (c / cleavage) 
      :ARG2-of (d / decrease-01 
            :ARG1 (p4 / precursor) 
            :ARG1-of (s / show-01 
                  :ARG0 (b / blot-01 
                        :ARG1-of (s2 / separate-02 
                              :ARG0 (p / panel))) 
                  :purpose-of (a / antibody 
                        :mod (c2 / CT15)) 
                  :purpose-of (f2 / fragment-01 
                        :ARG0 (o / organization 
                              :name (n / name 
                                    :op1 "APP")) 
                        :ARG1 (m / middle))) 
            :prep-in (p2 / protein 
                  :mod (f / full-length))))

# ::snt Costaining for superoxide dismutase 1 was used as an internal control for loading ( lower panel , taken from bottom half of 6E10 blot ) .
# ::tok Costaining for superoxide dismutase 1 was used as an internal control for loading ( lower panel , taken from bottom half of 6E10 blot ) .
# ::alignments 23-24|0.0.2 20-21|0.0.1 19-20|0.0.1.0 17-18|0.0 15-16|0 14-15|0.1 12-13|0.0.3 10-11|0.0.3.0 9-10|0.0.3.0.0 6-7|0.0.3.0.1 4-5|0.0.0 3-4|0.0.2.0.0 2-3|0.0.2.0 0-1|0.0.3.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:51.688
(p / panel 
      :ARG1-of (t / take-01 
            :ARG0 1 
            :ARG3 (h / half 
                  :mod (b2 / bottom)) 
            :manner (b / blot-01 
                  :ARG1 (s / superoxide 
                        :mod-of (d / dismutase))) 
            :time (l2 / load-01 
                  :ARG1-of (c / control-01 
                        :ARG1-of (i / internal-02) 
                        :ARG2-of (u / use-01 
                              :ARG1 (c2 / costain))))) 
      :ARG1-of (l / low-04))

# ::snt Suppression of Transgenic APP Arrests Progression of Amyloid Pathology .
# ::tok Suppression of Transgenic APP Arrests Progression of Amyloid Pathology .
# ::alignments 7-9|0.1.0.1+0.1.0.0+0.1.0+0.1 2-6|0.2.0.3+0.2.0.2+0.2.0.1+0.2.0.0+0.2.0+0.2 0-1|0.0.0+0.0+0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:51.718
(o3 / organization 
      :name (n3 / name 
            :op1 "Suppression") 
      :part-of (o / organization 
            :name (n / name 
                  :op1 "Amyloid" 
                  :op2 "Pathology")) 
      :part-of (o2 / organization 
            :name (n2 / name 
                  :op1 "Transgenic" 
                  :op2 "APP" 
                  :op3 "Arrests" 
                  :op4 "Progression")))

# ::snt ( A ) Aggregated A was quantified in cortical tissue from dox-treated and control tTA/APP mice ( line 107 ) using a filter trap assay .
# ::tok ( A ) Aggregated A was quantified in cortical tissue from dox-treated and control tTA/APP mice ( line 107 ) using a filter trap assay .
# ::alignments 24-25|0.4.1 23-24|0.4.1.0.0 22-23|0.4.1.0 20-21|0.4 18-19|0.4.0 17-18|0.3 15-16|0.2 13-14|0.2.0 12-13|0 11-12|0.1 9-10|0.0.1 8-9|0.0.1.0 6-7|0.0 3-5|0.0.0.0.1+0.0.0.0.0+0.0.0.0+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:51.977
(a2 / and 
      :op1 (q / quantify-01 
            :ARG1 (t3 / thing 
                  :name (n / name 
                        :op1 (a3 / Aggregated) 
                        :op2 (a4 / A))) 
            :ARG2 (t2 / tissue 
                  :mod (c2 / cortical))) 
      :op2 (d / dox-treat) 
      :op3 (m / mouse 
            :ARG2-of (c / control-01)) 
      :op4 (l / line) 
      :op5 (u / use-01 
            :ARG0 107 
            :ARG1 (a / assay 
                  :ARG1-of (f / filter-02 
                        :ARG1-of (t / trap-01)))))

# ::snt Serial dilutions of protein homogenate were passed through a cellulose acetate filter ; protein aggregates larger than the pore size were trapped and immunostained for A .
# ::tok Serial dilutions of protein homogenate were passed through a cellulose acetate filter ; protein aggregates larger than the pore size were trapped and immunostained for A .
# ::alignments 22-23|0.0.0.0 21-22|0.0.0 19-20|0.0.1.0.0 18-19|0.0.1.0 15-16|0.0.1 14-15|0.0 13-14|0 12-13|0.0.0.0.0 11-12|0.0.0.0.0.0.1 10-11|0.0.0.0.0.0.1.0 9-10|0.0.0.0.0.0.1.0.0 6-7|0.0.0.0.0.0 4-5|0.0.0.0.0.0.0.1 3-4|0.0.0.0.0.0.0.1.0 1-2|0.0.0.0.0.0.0 0-1|0.0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:52.256
(p2 / protein 
      :ARG1-of (a2 / aggregate-01 
            :ARG1-of (t / trap-01 
                  :ARG0 (a / and 
                        :op2-of (a3 / and 
                              :op1 (p3 / pass-01 
                                    :ARG1 (d / dilution 
                                          :mod (s2 / serial) 
                                          :mod (h / homogenate 
                                                :mod (p4 / protein))) 
                                    :manner (f / filter-02 
                                          :ARG1 (a4 / acetate 
                                                :mod (c / cellulose))))))) 
            :mod (l / large 
                  :op1 (p / pore-01 
                        :ARG1 (s / size)))))

# ::snt ( B ) Quantitation of signal intensity in the linear range of each filter trap dilution series ( arrow in [ A ] ) was used to compare aggregate load across treatment groups .
# ::tok ( B ) Quantitation of signal intensity in the linear range of each filter trap dilution series ( arrow in [ A ] ) was used to compare aggregate load across treatment groups .
# ::alignments 32-33|0.0.0 31-32|0.0 30-31|0.0.0.0 29-30|0.0.0.0.0.0 28-29|0.0.0.0.0.0.0 27-28|0.0.0.0.0 25-26|0.0.0.0.0.1 18-19|0 16-17|0.0.0.0.0.1.0.0.0.1 15-16|0.0.0.0.0.1.0.0.0.1.2 14-15|0.0.0.0.0.1.0.0 13-14|0.0.0.0.0.1.0.0.0 12-13|0.0.0.0.0.1.0.0.0.1.1 10-11|0.0.0.0.0.1.0.0.0.1.0 9-10|0.0.0.0.0.1.0.0.0.1.0.0 6-7|0.0.0.0.0.1.0 5-6|0.0.0.0.0.1.0.1 1-2|0.0.0.0.0.1.0.0.0.0.1+0.0.0.0.0.1.0.0.0.0.0.0+0.0.0.0.0.1.0.0.0.0.0+0.0.0.0.0.1.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:52.579
(a3 / arrow 
      :ARG1-of (t / treat-03 
            :mod-of (g / group 
                  :op1-of (a / across 
                        :location-of (c / compare-01 
                              :ARG1 (l / load 
                                    :mod (a2 / aggregate)) 
                              :ARG2-of (u / use-01 
                                    :ARG1 (i / intensity 
                                          :ARG0-of (t2 / trap-01 
                                                :ARG1 (f / filter-02 
                                                      :ARG0 (l3 / location 
                                                            :name (n / name 
                                                                  :op1 "B") 
                                                            :wiki -) 
                                                      :ARG1 (s / series 
                                                            :ARG1-of (r / range-01 
                                                                  :mod (l2 / linear)) 
                                                            :mod (e / each) 
                                                            :mod (d / dilution)))) 
                                          :mod (s2 / signal))))))))

# ::snt Aggregated A increased significantly between 6 and 9 mo of age in untreated mice ( significant effect of group ANOVA F3 ,18 = 7.85 , p < 0.002 ) .
# ::tok Aggregated A increased significantly between 6 and 9 mo of age in untreated mice ( significant effect of group ANOVA F3 ,18 = 7.85 , p < 0.002 ) .
# ::alignments 25-26|0.2.0 19-21|0.2.1.1.1.0.2+0.2.1.1.1.0.1+0.2.1.1.1.0+0.2.1.1.1 18-19|0.2.1.1.1.0.0 16-17|0.2.1.1 15-16|0.2.1 13-14|0.4 12-13|0.4.1 10-11|0.4.0 8-9|0.1 7-8|0.2.1.0 6-7|0.3 5-6|0.2.1.1.0 3-4|0.2 2-3|0 0-2|0.0.0.1+0.0.0.0+0.0.0+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:53.597
(i / increase-01 
      :ARG0 (t2 / thing 
            :name (n2 / name 
                  :op1 (a4 / Aggregated) 
                  :op2 (a5 / A))) 
      :ARG1 (m2 / mo) 
      :ARG2 (s2 / significant-02 
            :ARG0 (p / p) 
            :ARG1 (s / significant-02 
                  :ARG0 9 
                  :ARG1 (e / effect-03 
                        :ARG0 6 
                        :ARG1 (t / thing 
                              :name (n / name 
                                    :name-of (g / group) 
                                    :op1 (a / ANOVA) 
                                    :op2 (f / F3)))))) 
      :manner (a3 / and) 
      :time (m / mouse 
            :ARG1-of (a2 / age-01) 
            :mod (u / untreat)))

# ::snt This progression of pathology was completely prevented by transgene suppression .
# ::tok This progression of pathology was completely prevented by transgene suppression .
# ::alignments 9-10|0.0 8-9|0.0.0 6-7|0 5-6|0.2 3-4|0.1 1-2|0.1.0 0-1|0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:53.627
(p / prevent-01 
      :ARG0 (s / suppress-01 
            :ARG1 (t / transgene)) 
      :ARG1 (p2 / pathology 
            :ARG1-of (p3 / progress-01 
                  :mod (t2 / this))) 
      :ARG1-of (c / complete-02))

# ::snt The amount of aggregated A was identical in untreated mice at 6 mo of age to that in 9 - or 12-mo-old animals treated with dox ( p > 0.9 , Tukey post-hoc test ) .
# ::tok The amount of aggregated A was identical in untreated mice at 6 mo of age to that in 9 - or 12-mo-old animals treated with dox ( p > 0.9 , Tukey post-hoc test ) .
# ::alignments 33-34|0.0.0.2.2 31-32|0.0.0.2.2.1.0.0+0.0.0.2.2.1.0+0.0.0.2.2.1 27-28|0.0.0.2.3.0.0.0 25-26|0.0.0.1 23-24|0.0.0 22-23|0.0.0.0 20-21|0 18-19|0.0 16-17|0.0.0.2.1 14-15|0.0.0.2.4.0 12-13|0.0.0.2.4 11-12|0.0.0.2.2.0 9-10|0.0.0.2.3 8-9|0.0.0.2.3.0 6-7|0.0.0.2 3-4|0.0.0.2.3.0.0 1-2|0.0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:54.102
(o / or 
      :op1 (9 / 9 
            :ARG1-of (t2 / treat-01 
                  :ARG0 (a / animal) 
                  :ARG2 (d / dox) 
                  :manner-of (i / identical-01 
                        :ARG0 (a4 / amount) 
                        :ARG1 (t3 / that) 
                        :ARG2-of (t / test-01 
                              :ARG0 6 
                              :ARG1 (p / person 
                                    :name (n / name 
                                          :op1 "Tukey"))) 
                        :beneficiary (m2 / mouse 
                              :mod (u / untreat 
                                    :ARG1-of (a3 / aggregate-01 
                                          :ARG0 (p2 / p)))) 
                        :time (m / mo 
                              :time (a2 / age-01))))))

# ::snt Single transgenic tTA samples were included as negative controls and showed no signal above background .
# ::tok Single transgenic tTA samples were included as negative controls and showed no signal above background .
# ::alignments 14-15|0.1.2.0 13-14|0.1.2 12-13|0.1.1 11-12|0.1.3 10-11|0.1 9-10|0 8-9|0.0.0 7-8|0.0.0.0 5-6|0.0 3-4|0.1.0.0+0.1.0 2-3|0.1.0.0.0 0-1|0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:54.818
(a2 / and 
      :op1 (i / include-01 
            :ARG1 (c / control-01 
                  :mod (n / negative))) 
      :op2 (s2 / show-01 
            :ARG0 (t / thing 
                  :ARG1-of (s3 / sample-01 
                        :ARG0 (t2 / tTA)) 
                  :ARG1-of (s4 / single-02)) 
            :ARG1 (s / signal) 
            :manner (a / above 
                  :op1 (b / background)) 
            :polarity -))

# ::snt * , p < 0.01 ; ** , p < 0.005 versus 9-mo-old untreated mice , Tukey post-hoc test ; *** , p < 0.001 versus 9-mo-old untreated mice , Student 's t-test .
# ::tok * , p < 0.01 ; ** , p < 0.005 versus 9-mo-old untreated mice , Tukey post-hoc test ; *** , p < 0.001 versus 9-mo-old untreated mice , Student 's t-test .
# ::alignments 32-33|0.1.1 30-31|0.1.0+0.1 28-29|0.0.0.0 18-19|0.0.0 16-17|0.0.1.0+0.0.1+0.0 14-15|0.0.0.1.0 13-14|0.0.0.1.0.0 11-12|0.0.0.1 5-6|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:54.956
(a / and 
      :op1 (p2 / person 
            :ARG0-of (t2 / test-01 
                  :ARG1 (m / mouse) 
                  :op2-of (v / versu 
                        :op1 (m2 / mouse 
                              :mod (u / untreat)))) 
            :name (n / name 
                  :op1 "Tukey")) 
      :op2 (p / person 
            :ARG0-of (s / study-01) 
            :poss-of (t / t-t)))

# ::snt ( C ) Amyloid pathology in the hippocampus of representative mice from each treatment group : Hirano silver stain ( top row ) , thioflavin-S ( middle row ) , and A immunohistochemistry ( bottom row ) .
# ::tok ( C ) Amyloid pathology in the hippocampus of representative mice from each treatment group : Hirano silver stain ( top row ) , thioflavin-S ( middle row ) , and A immunohistochemistry ( bottom row ) .
# ::alignments 35-36|0.0.3.0 34-35|0.0.3 32-33|0.0.2.1.2 30-31|0.0.2.1 27-28|0 26-27|0.0.2.1.0.0 24-25|0.0.2.1.1 21-22|0.0.1.2.0.0.0 20-21|0.0.1.2.0.0 18-19|0.0.2.1.0 17-18|0.0.2.1.0.1 16-17|0.0.2.0.0+0.0.2.0+0.0.2 14-15|0.0.1 13-14|0.0 12-13|0.0.1.0 10-11|0.0.1.2 9-10|0.0.1.2.0 7-8|0.0.1.2.1 4-5|0.0.1.1 3-4|0.0.1.1.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:55.527
(r2 / row 
      :op1 (t3 / treat-03 
            :ARG0 (c / C) 
            :ARG1 (g / group 
                  :mod (e / each) 
                  :mod (p2 / pathology 
                        :mod (a2 / amyloid)) 
                  :source-of (m2 / mouse 
                        :ARG0-of (r4 / represent-01 
                              :ARG1 (t2 / top 
                                    :mod-of (r3 / row))) 
                        :mod-of (h / hippocampu))) 
            :ARG2 (p / person 
                  :name (n / name 
                        :op1 "Hirano") 
                  :op1-of (a / and 
                        :op2 (s / stain-01 
                              :ARG1 (m / middle) 
                              :mod (s2 / silver)) 
                        :op3 (t / thioflavin-) 
                        :op4 (i / immunohistochemistry))) 
            :op1-of (b / bottom 
                  :mod-of (r / row))))

# ::snt Amyloid burden increases dramatically between 6 and 9 mo of age in untreated animals , but remains stable in transgene-suppressed mice over the same period ( 6 mo + 3 mo dox and 6 mo + 6 mo dox ) .
# ::tok Amyloid burden increases dramatically between 6 and 9 mo of age in untreated animals , but remains stable in transgene-suppressed mice over the same period ( 6 mo + 3 mo dox and 6 mo + 6 mo dox ) .
# ::alignments 36-37|0.0 33-34|0.2.0 32-33|0.1.1.0 31-32|0.1.1.0.1 29-30|0.3.1.0 26-27|0.1.0.0 24-25|0.1.1.0.0 23-24|0.1.1.0.0.0 20-21|0.2.1 19-20|0.2.1.0 17-18|0.3.1 16-17|0.3 15-16|0 13-14|0.1.3 12-13|0.1.3.0 10-11|0.2 8-9|0.3.0 7-8|0.3.1.1 6-7|0.1.1 5-6|0.1.1.0.0.0.0 3-4|0.1.2 2-3|0.1 1-2|0.1.0 0-1|0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:56.896
(c / contrast-01 
      :ARG0 6 
      :ARG1 (i / increase-01 
            :ARG0 (b / burden-01 
                  :ARG1 6 
                  :mod (a5 / amyloid)) 
            :ARG1 (a4 / and 
                  :op1 (a / and 
                        :op1 (p / period 
                              :ARG1-of (s / same-01 
                                    :ARG0 6)) 
                        :op2 (d / dox))) 
            :manner (d2 / dramatic) 
            :time (a2 / animal 
                  :mod (u / untreat))) 
      :ARG1-of (a3 / age-01 
            :ARG0 6 
            :op1-of (m / mouse 
                  :mod (t / transgene-suppress))) 
      :ARG2 (r / remain-01 
            :ARG1 (m2 / mo) 
            :ARG3 (s2 / stable-03 
                  :ARG0 3 
                  :ARG1 9)))

# ::snt Single transgenic animals ( tTA only shown here ) show no sign of amyloid pathology at any age tested .
# ::tok Single transgenic animals ( tTA only shown here ) show no sign of amyloid pathology at any age tested .
# ::alignments 18-19|0.1.3.0 17-18|0.1.3 16-17|0.1.3.1 14-15|0.1.1 13-14|0.1.1.0 11-12|0.1 10-11|0.1.2 9-10|0 7-8|0.0.0.0 6-7|0.0.0 5-6|0.0.0.1 4-5|0.0 2-3|0.1.0 0-1|0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:57.171
(s2 / show-01 
      :ARG0 (t2 / tTA 
            :ARG1-of (s3 / show-01 
                  :location (h / here) 
                  :mod (o / only))) 
      :ARG1 (s / sign-02 
            :ARG0 (a4 / animal 
                  :mod (s4 / single-02)) 
            :ARG1 (p / pathology 
                  :mod (a3 / amyloid)) 
            :polarity - 
            :time (a / age-01 
                  :ARG1 (t / test-01) 
                  :mod (a2 / any))))

# ::snt A ELISA Confirms Arrest of Progression without Clearance of Peptide in Mice with Preexisting Aggregates .
# ::tok A ELISA Confirms Arrest of Progression without Clearance of Peptide in Mice with Preexisting Aggregates .
# ::alignments 13-15|0.1.0.0.1+0.1.0.0.0+0.1.0.0+0.1.0 11-12|0.1 9-10|0.2.0 7-8|0.2 5-6|0.0.0.0 3-4|0.0.0 2-3|0 1-2|0.0.1.0+0.0.1+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:57.267
(c2 / confirm-01 
      :ARG0 (o2 / organization 
            :ARG0-of (a / arrest-01 
                  :ARG1 (p2 / progression)) 
            :name (n2 / name 
                  :op1 "ELISA")) 
      :ARG1 (m / mouse 
            :prep-with (o / organization 
                  :name (n / name 
                        :op1 "Preexisting" 
                        :op2 "Aggregates"))) 
      :manner (c / clearance 
            :mod (p / peptide)))

# ::snt A levels in untreated 6 - and 9-mo-old tTA/APP line 107 mice ( shown in Figure 4 ) were compared to those in 9 - and 12-mo-old animals treated with dox from the age of 6 mo. .
# ::tok A levels in untreated 6 - and 9-mo-old tTA/APP line 107 mice ( shown in Figure 4 ) were compared to those in 9 - and 12-mo-old animals treated with dox from the age of 6 mo. .
# ::alignments 35-36|0.1.0.0 33-34|0.1.2.2 30-31|0.1.2.1 28-29|0.1.2 27-28|0.1.2.0 25-26|0.1 23-24|0.1.2.2.0 19-20|0.1.0 16-17|0.1.2.2.3 15-16|0.0 13-14|0 11-12|0.1.2.2.2 10-11|0.1.2.2.5 9-10|0.1.2.2.1 6-7|0.1.1 4-5|0.1.2.2.4 3-4|0.1.2.3 1-2|0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:57.610
(s / show-01 
      :ARG0 (f / figure) 
      :ARG1 (a3 / and 
            :op1 (c / compare-01 
                  :ARG0 6 
                  :ARG1 (l2 / level)) 
            :op1-of (a4 / and) 
            :op2 (t / treat-01 
                  :ARG0 (a2 / animal) 
                  :ARG1 (d / dox) 
                  :ARG2 (a / age-01 
                        :ARG1 9 
                        :op1-of (l / line) 
                        :op1-of (m / mouse) 
                        :op1-of 4 
                        :op1-of 6 
                        :op1-of 107) 
                  :op1-of (u / untreat))))

# ::snt Single transgenic APP samples were included as negative controls .
# ::tok Single transgenic APP samples were included as negative controls .
# ::alignments 8-9|0.0 7-8|0.0.0 5-6|0 3-4|0.1.0+0.1 2-3|0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 0-1|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:57.901
(i / include-01 
      :ARG1 (c / control-01 
            :mod (n / negative)) 
      :ARG2 (t / thing 
            :ARG1-of (s / sample-01 
                  :ARG0 (o / organization 
                        :name (n2 / name 
                              :op1 "APP"))) 
            :ARG1-of (s2 / single-02)))

# ::snt Cortical homogenates were fractionated by sequential multi-step extraction with PBS , 2 % SDS , and 70 % FA followed by human-specific A ELISA to measure transgene-derived peptide in each fraction .
# ::tok Cortical homogenates were fractionated by sequential multi-step extraction with PBS , 2 % SDS , and 70 % FA followed by human-specific A ELISA to measure transgene-derived peptide in each fraction .
# ::alignments 30-31|0.0.2 29-30|0.0.2.0 27-28|0 26-27|0.1 25-26|0.0 22-24|0.0.3.1.0.1+0.0.3.1.0.0+0.0.3.1.0+0.0.3.1 19-20|0.0.3 18-19|0.0.3.2.1+0.0.3.2.0.0+0.0.3.2.0+0.0.3.2 17-18|0.0.3.0 16-17|0.0.3.0.0 15-16|0.0.0 13-14|0.0.0.1.1.0+0.0.0.1.1+0.0.0.1 12-13|0.0.0.1.0 11-12|0.0.0.1.0.0 9-10|0.0.0.0.1.0+0.0.0.0.1+0.0.0.0 7-8|0.0.0.0.0 5-6|0.0.0.0.0.0 1-2|0.0.1 0-1|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:58.662
(p / peptide 
      :ARG1-of (m / measure-01 
            :ARG0 (a2 / and 
                  :op1 (t3 / thing 
                        :ARG1-of (e3 / extract-01 
                              :mod (s / sequential)) 
                        :name (n4 / name 
                              :op1 "PBS")) 
                  :op2 (o / organization 
                        :mod (p3 / percentage-entity 
                              :value 2) 
                        :name (n3 / name 
                              :op1 "SDS"))) 
            :ARG2 (h / homogenat 
                  :mod (c / cortical)) 
            :location (f / fraction 
                  :mod (e / each)) 
            :purpose-of (f2 / follow-01 
                  :ARG0 (p2 / percentage-entity 
                        :value 70) 
                  :ARG1 (t2 / thing 
                        :name (n / name 
                              :op1 (a / A) 
                              :op2 (e2 / ELISA))) 
                  :mod (l / league 
                        :name (n2 / name 
                              :op1 "FA") 
                        :wiki "The_Football_Association"))) 
      :mod (t / transgene-deriv))

# ::snt A40 is shown in white , A42 in black .
# ::tok A40 is shown in white , A42 in black .
# ::alignments 8-9|0.2 6-7|0.0.0.0+0.0.0+0.0 4-5|0.2.0 2-3|0 0-1|0.1.0.0+0.1.0+0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:58.717
(s / show-01 
      :ARG0 (p / person 
            :name (n / name 
                  :op1 "A42")) 
      :ARG1 (t / thing 
            :name (n2 / name 
                  :op1 "A40")) 
      :ARG2 (b / black-04 
            :ARG1 (w / white)))

# ::snt ( A and B ) Most A in the brains of plaque-bearing mice is extracted into the FA and SDS fractions .
# ::tok ( A and B ) Most A in the brains of plaque-bearing mice is extracted into the FA and SDS fractions .
# ::alignments 20-21|0.3.0 19-20|0.3.0.0.0.0+0.3.0.0.0+0.3.0.0 18-19|0.3 17-18|0.2.1+0.2.0.0+0.2.0+0.2 14-15|0 12-13|0.0 11-12|0.0.0 9-10|0.0.1 5-7|0.1.0.1+0.1.0.0+0.1.0+0.1 3-4|0.1.1.0.1+0.1.1.0.0.0+0.1.1.0.0+0.1.1.0 2-3|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:25:59.170
(e / extract-01 
      :ARG0 (m / mouse 
            :mod (p / plaque-bear) 
            :part (b / brain)) 
      :ARG1 (t / thing 
            :name (n3 / name 
                  :op1 (m2 / Most) 
                  :op2 (a2 / A)) 
            :op2-of (a3 / and 
                  :op1 (l2 / location 
                        :name (n4 / name 
                              :op1 "B") 
                        :wiki -))) 
      :ARG2 (l / league 
            :name (n2 / name 
                  :op1 "FA") 
            :wiki "The_Football_Association") 
      :destination (a / and 
            :ARG1-of (f / fraction-01 
                  :ARG0 (o / organization 
                        :name (n / name 
                              :op1 "SDS")))))

# ::snt Consistent with amyloid burden ( Figures 4 and Figure S3 ) , SDS - and FA-extracted A levels in untreated 9-mo-old mice were significantly higher than in untreated 6-mo-old mice ( Tukey post-hoc test applied to significant effect of group ANOVA for SDS and FA fractions F3 ,18 = 4.72 -- 12.92 , p < 0.02 ) .
# ::tok Consistent with amyloid burden ( Figures 4 and Figure S3 ) , SDS - and FA-extracted A levels in untreated 9-mo-old mice were significantly higher than in untreated 6-mo-old mice ( Tukey post-hoc test applied to significant effect of group ANOVA for SDS and FA fractions F3 ,18 = 4.72 -- 12.92 , p < 0.02 ) .
# ::alignments 53-54|0.3.0.0.0.2.0 45-46|0.3.0.0.0 44-45|0.3.0.0.0.1.0.1+0.3.0.0.0.1.0.0.0+0.3.0.0.0.1.0.0+0.3.0.0.0.1.0 43-44|0.3.0.0.0.1 40-41|0.3.0.0.1.1+0.3.0.0.1+0.3.0.0 39-40|0.3.0.0.1.0 37-38|0.3.0.1.1 36-37|0.3.0.1.1.0 34-35|0.3.0.1 33-34|0.3.0 31-32|0.3.1.0+0.3.1+0.3 29-30|0.3.0.1.2 24-25|0.3.0.0.0.2 23-24|0.3.0.0.0.2.2 21-22|0.3.0.0.0.0 19-20|0.3.0.1.0 17-18|0.3.0.0.0.2.1 15-16|0.3.0.1.1.0.0 14-15|0.0.0.0 8-10|0.2.0.1+0.2.0.0+0.2.0+0.2 7-8|0 6-7|0.3.0.0.0.2.2.0 5-6|0.1 3-4|0.0 2-3|0.0.1 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:00.875
(a4 / and 
      :ARG2-of (b / burden-01 
            :ARG0 (c / consistent 
                  :op1-of (a3 / and)) 
            :mod (a5 / amyloid)) 
      :op1 (f4 / figure) 
      :op2 (t2 / thing 
            :name (n4 / name 
                  :op1 (f3 / Figure) 
                  :op2 (s3 / S3))) 
      :op3 (p2 / person 
            :ARG0-of (t / test-01 
                  :ARG1 (o / organization 
                        :manner-of (f / fraction-01 
                              :ARG0 (m2 / mouse) 
                              :ARG1 (a / and 
                                    :op1 (l / league 
                                          :name (n / name 
                                                :op1 "FA") 
                                          :wiki "The_Football_Association")) 
                              :ARG2-of (h / high-02 
                                    :ARG0 (p / p) 
                                    :ARG1 (l2 / level) 
                                    :ARG1-of (s2 / significant-02 
                                          :ARG0 4))) 
                        :name (n2 / name 
                              :name-of (g / group) 
                              :op1 "ANOVA")) 
                  :ARG1-of (a2 / apply-01 
                        :ARG0 (u / untreat) 
                        :ARG2 (e / effect-03 
                              :ARG1-of (s / significant-02 
                                    :ARG0 (f2 / fa-extract))) 
                        :time (m / mouse))) 
            :name (n3 / name 
                  :op1 "Tukey")))

# ::snt In contrast , 3 or 6 mo of transgene suppression held A at levels equivalent to those harbored when treatment was started ( p > 0.2 compared to 6 mo untreated mice , Tukey post-hoc test ) .
# ::tok In contrast , 3 or 6 mo of transgene suppression held A at levels equivalent to those harbored when treatment was started ( p > 0.2 compared to 6 mo untreated mice , Tukey post-hoc test ) .
# ::alignments 35-36|0.2.1.0.0 33-34|0.2.1.0.1.0+0.2.1.0.1+0.2.1.0 31-32|0.1.2 30-31|0.1.2.0 28-29|0.2.0.0 26-27|0.1 25-26|0.1.1 21-22|0.2 19-20|0.2.1 17-18|0.2.0 14-15|0.2.1.0.0.0 13-14|0.0.2 10-11|0.0 9-10|0.0.0 8-9|0.0.0.0 6-7|0.0.1 5-6|0.2.1.0.2.0 4-5|0.2.1.0.2 3-4|0.1.0 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:01.533
(c2 / contrast-01 
      :ARG1 (h2 / hold-04 
            :ARG0 (s2 / suppress-01 
                  :mod (t3 / transgene)) 
            :ARG1 (m2 / mo) 
            :location (l / level)) 
      :ARG2 (c / compare-01 
            :ARG0 3 
            :ARG1 0.2 
            :ARG2 (m / mouse 
                  :mod (u / untreat))) 
      :manner-of (s / start-01 
            :ARG0-of (h / harbor-01 
                  :ARG1 6) 
            :ARG1 (t2 / treat-03 
                  :ARG1 (p / person 
                        :ARG0-of (t / test-01 
                              :ARG1 (e / equivalent)) 
                        :name (n / name 
                              :op1 "Tukey") 
                        :op2-of (o / or 
                              :op1 6)))))

# ::snt * , p < 0.05 ; ** , p < 0.005 ; *** , p < 0.001 versus 9-mo-old untreated mice , Tukey post-hoc test .
# ::tok * , p < 0.05 ; ** , p < 0.005 ; *** , p < 0.001 versus 9-mo-old untreated mice , Tukey post-hoc test .
# ::alignments 24-25|0.0.0 22-23|0.0.1.0+0.0.1+0.0 20-21|0.0.0.0.0 19-20|0.0.0.0.0.0 17-18|0.0.0.0 5-6|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:01.578
(a / and 
      :op1 (p / person 
            :ARG0-of (t / test-01 
                  :ARG1 (v / versu 
                        :op1 (m / mouse 
                              :mod (u / untreat)))) 
            :name (n / name 
                  :op1 "Tukey")))

# ::snt Significance for APP versus 9-mo-old untreated mice is based on Student 's t-test .
# ::tok Significance for APP versus 9-mo-old untreated mice is based on Student 's t-test .
# ::alignments 12-13|0.2 10-11|0.2.0.0+0.2.0 8-9|0 6-7|0.2.0.0.0 5-6|0.2.0.0.0.0 3-4|0.0 2-3|0.1.0.0.0+0.1.0.0+0.1.0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:01.744
(b / base-02 
      :ARG0 (v / versu) 
      :ARG1 (s2 / significance 
            :beneficiary (o / organization 
                  :name (n / name 
                        :op1 "APP"))) 
      :ARG2 (t / t-t 
            :poss (p / person 
                  :ARG0-of (s / study-01 
                        :ARG1 (m / mouse 
                              :mod (u / untreat))))))

# ::snt ( C ) The PBS fraction represents less than 0.1 % of total A ( note the change in y-axis from [ A ] and [ B ] ) , but only here do A levels in the dox-treated mice differ from those in younger untreated mice .
# ::tok ( C ) The PBS fraction represents less than 0.1 % of total A ( note the change in y-axis from [ A ] and [ B ] ) , but only here do A levels in the dox-treated mice differ from those in younger untreated mice .
# ::alignments 46-47|0.0.0.0.1.1.1 45-46|0.0.0.0.1.1.1.0 44-45|0.0.0.0.1.0 40-41|0.0.0.0.1.1 39-40|0.0.0.0.1.1.0 38-39|0.0.0.0.1.1.0.0 35-36|0.0.0.0.1.2 32-33|0.0.0.0.1.3.0 31-32|0.0.0.0.1.3.0.0 30-31|0.0.0.0.1 26-27|0.1.0.1+0.1.0.0.0+0.1.0.0+0.1.0 24-25|0.1 19-20|0.0.1 17-18|0.0 15-16|0 12-13|0.0.0.0.1.3 10-11|0.0.0.0.1.3.1.0 9-10|0.0.0.0.1.3.1.0.0 7-8|0.0.0.0.1.3.1 6-7|0.0.0.0 5-6|0.0.0 4-5|0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 1-2|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:02.733
(n2 / note-01 
      :ARG1 (c2 / change-01 
            :ARG0 (f / fraction 
                  :ARG0-of (r / represent-01 
                        :ARG1 (c3 / C) 
                        :ARG1-of (c / contrast-01 
                              :ARG0 (y / young) 
                              :ARG1-of (d / differ-02 
                                    :ARG0 (m2 / mouse 
                                          :mod (d2 / dox-treat)) 
                                    :ARG2 (m / mouse 
                                          :mod (u / untreat))) 
                              :ARG2 (l / level) 
                              :purpose-of (t / total-01 
                                    :ARG0 (h / here 
                                          :mod (o / only)) 
                                    :ARG1 (l3 / less 
                                          :op1 (p / percentage-entity 
                                                :value 0.1))))) 
                  :mod (t2 / thing 
                        :name (n3 / name 
                              :op1 "PBS"))) 
            :ARG1 (y2 / y-axi)) 
      :op1-of (a / and 
            :op2 (l2 / location 
                  :name (n / name 
                        :op1 "B") 
                  :wiki -)))

# ::snt Although both peptides appear elevated in the treated groups compared to the untreated 6-mo-old mice , only A40 reaches statistical significance ( p < 0.05 , Tukey post-hoc test applied to significant effect of group ANOVA for A40 F3 ,18 = 4.60 , p < 0.02 ) .
# ::tok Although both peptides appear elevated in the treated groups compared to the untreated 6-mo-old mice , only A40 reaches statistical significance ( p < 0.05 , Tukey post-hoc test applied to significant effect of group ANOVA for A40 F3 ,18 = 4.60 , p < 0.02 ) .
# ::alignments 37-39|0.0.1+0+0.0+0.0.0 35-36|0.0.0.0.0.0.1+0.0.0.0.0.0+0.0.0.0.0 34-35|0.0.0.0.0.0.0 32-33|0.0.0.0 31-32|0.0.0.0.1 29-30|0.0.0.0.2 28-29|0.0.0.0.2.1 20-21|0.0.0.0.2.0.1.1.0.0 19-20|0.0.0.0.2.0.1.1.0.0.1 18-19|0.0.0.0.2.0.1.1.0 17-18|0.0.0.0.2.0.1.1.2.0+0.0.0.0.2.0.1.1.2+0.0.0.0.2.0.1.1 16-17|0.0.0.0.2.0.1.1.1 14-15|0.0.0.0.2.0.1.3.0 12-13|0.0.0.0.2.0.1.1.0.0.0 9-10|0.0.0.0.2.0.1.3 8-9|0.0.0.0.2.0 7-8|0.0.0.0.2.0.0 4-5|0.0.0.0.2.0.1 3-4|0.0.0.0.2.0.1.2 2-3|0.0.0.0.2.0.1.0 1-2|0.0.0.0.2.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:04.375
(a / A40 
      :op1-of (n / name 
            :name-of (t / thing 
                  :ARG2-of (e / effect-03 
                        :ARG0 (o / organization 
                              :name (n2 / name 
                                    :name-of (g / group) 
                                    :op1 "ANOVA")) 
                        :ARG1-of (s / significant-02) 
                        :ARG2-of (a2 / apply-01 
                              :ARG0 (g2 / group 
                                    :ARG1-of (t4 / treat-01) 
                                    :prep-in-of (e2 / elevate-01 
                                          :ARG0 (p / peptid 
                                                :mod (b / both)) 
                                          :ARG1 (t3 / thing 
                                                :ARG0-of (r / reach-01 
                                                      :ARG1 (s2 / significant-02 
                                                            :ARG1 (u / untreat) 
                                                            :mod (s3 / statistic))) 
                                                :mod (o2 / only) 
                                                :name (n3 / name 
                                                      :op1 "A40")) 
                                          :ARG1-of (a3 / appear-02) 
                                          :ARG1-of (c / compare-01 
                                                :ARG2 (m / mouse)))) 
                              :ARG1 (t2 / test-01)))) 
            :op2 (f / F3)))

# ::snt A similar trend was seen for A42 , where ANOVA yielded a significant effect of group for PBS-soluble A42 ( F3 ,18 = 3.75 , p < 0.03 ) , however this was due only to differences between the untreated 6 - and 9-mo-old groups .
# ::tok A similar trend was seen for A42 , where ANOVA yielded a significant effect of group for PBS-soluble A42 ( F3 ,18 = 3.75 , p < 0.03 ) , however this was due only to differences between the untreated 6 - and 9-mo-old groups .
# ::alignments 44-45|0.0.2.1 42-43|0.0.2 40-41|0.0.0.0.0 39-40|0.1.0 36-37|0.0.2.0.1 34-35|0.0.2.0 31-32|0.0.2.0.0 17-19|0.0.0.1.0.1+0.0.0.1.0.0+0.0.0.1.0+0.0.0.1 15-16|0.0.0.0 13-14|0.0.0 12-13|0.0.0.2 10-11|0.0.0.3 9-10|0.0.0.3.0.0.0+0.0.0.3.0.0+0.0.0.3.0 6-7|0.0.1.0+0.0.1+0.0 4-5|0 2-3|0.1 1-2|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:05.756
(s2 / see-01 
      :ARG0 (p2 / person 
            :ARG2-of (e / effect-03 
                  :ARG0 (g2 / group 
                        :mod 6) 
                  :ARG1 (p / person 
                        :name (n / name 
                              :op1 "PBS-soluble" 
                              :op2 "A42")) 
                  :ARG1-of (s / significant-02) 
                  :ARG1-of (y / yield-01 
                        :ARG0 (o2 / organization 
                              :name (n2 / name 
                                    :op1 "ANOVA")))) 
            :name (n3 / name 
                  :op1 "A42") 
            :op1-of (a / and 
                  :op2 (o / only 
                        :domain (t / this) 
                        :prep-to (d / differ-01)) 
                  :op3 (g / group))) 
      :ARG1 (t2 / trend-01 
            :ARG1 (u / untreat) 
            :ARG1-of (r / resemble-01)))

# ::snt  , p < 0.05 versus 6-mo-old untreated mice , Tukey post-hoc test ;    , p < 0.001 versus 6-mo-old untreated mice , Student 's t-test .
# ::tok  , p < 0.05 versus 6-mo-old untreated mice , Tukey post-hoc test ;    , p < 0.001 versus 6-mo-old untreated mice , Student 's t-test .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:05.758
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt Neuritic and Glial Pathology Are Unchanged following Transgene Suppression .
# ::tok Neuritic and Glial Pathology Are Unchanged following Transgene Suppression .
# ::alignments 7-9|0.0.0.0.0.1+0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 6-7|0.0.0 2-6|0.1.0.3+0.1.0.2+0.1.0.1+0.1.0.0+0.1.0+0.1 1-2|0 0-1|0.0.1.0+0.0.1+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:05.811
(a / and 
      :op1 (t / thing 
            :ARG1-of (f / follow-01 
                  :ARG2 (o / organization 
                        :name (n / name 
                              :op1 "Transgene" 
                              :op2 "Suppression"))) 
            :name (n3 / name 
                  :op1 "Neuritic")) 
      :op2 (o2 / organization 
            :name (n2 / name 
                  :op1 "Glial" 
                  :op2 "Pathology" 
                  :op3 "Are" 
                  :op4 "Unchanged")))

# ::snt Dystrophic neurites and activated astrocytes surround most compact plaques in tet-off APP mice ( line 107 ) .
# ::tok Dystrophic neurites and activated astrocytes surround most compact plaques in tet-off APP mice ( line 107 ) .
# ::alignments 15-16|0.0.0.0 14-15|0.2.0.0 12-13|0.3 11-12|0.3.0.0.0+0.3.0.0+0.3.0 8-9|0.2 7-8|0.2.0 6-7|0.2.0.1 5-6|0 4-5|0.0.0.1 3-4|0.0.0 2-3|0.0 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:06.096
(s / surround-01 
      :ARG0 (a3 / and 
            :op1 (a2 / activate-01 
                  :ARG0 107 
                  :ARG1 (a / astrocyt))) 
      :ARG1 (n2 / neurit) 
      :ARG2 (p / plaqu 
            :ARG1-of (c / compact-01 
                  :ARG2 (l / line) 
                  :degree (m2 / most))) 
      :location (m / mouse 
            :mod (o / organization 
                  :name (n / name 
                        :op1 "APP"))))

# ::snt Dark-stained , ubiquitin-filled neurites and reactive astrocytes form a halo around cored , fibrillar deposits by 6 mo of age that worsens with time in untreated mice .
# ::tok Dark-stained , ubiquitin-filled neurites and reactive astrocytes form a halo around cored , fibrillar deposits by 6 mo of age that worsens with time in untreated mice .
# ::alignments 26-27|0.3.0.0.0.0 25-26|0.3.0.0.0 23-24|0.3.0.1.0.0 21-22|0.3.0.1.0 19-20|0.3.0 17-18|0.3.0.1 16-17|0.3.0.0.1 14-15|0.0.0.0.0 11-12|0.3.0.0 10-11|0.0.0.0 9-10|0.0.0 7-8|0.0 6-7|0.4 5-6|0.3 4-5|0 3-4|0.2 2-3|0.4.0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:06.451
(a4 / and 
      :domain-of (f / form 
            :op1 (h / halo 
                  :location (a2 / around 
                        :op1 (d / deposit)))) 
      :op1 (d2 / dark-stain) 
      :op2 (n / neurit) 
      :op3 (r / reactive 
            :ARG0-of (a / age-01 
                  :ARG1 (c / core-01 
                        :ARG0 (u / untreat 
                              :mod-of (m / mouse)) 
                        :ARG1 6) 
                  :time-of (m2 / mo 
                        :ARG0-of (w / worsen-01 
                              :ARG1 (t / time))))) 
      :op4 (a3 / astrocyt 
            :mod (u2 / ubiquitin-fill)))

# ::snt Both plaque-associated pathologies are arrested , although not reversed , by transgene suppression .
# ::tok Both plaque-associated pathologies are arrested , although not reversed , by transgene suppression .
# ::alignments 12-13|0.0 11-12|0.0.0 8-9|0.2 7-8|0.2.1 4-5|0 2-3|0.1 1-2|0.1.0 0-1|0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:06.488
(a / arrest-01 
      :ARG0 (s / suppress-01 
            :ARG1 (t / transgene)) 
      :ARG1 (p / pathologi 
            :mod (p2 / plaque-associat)) 
      :time (r / reverse-01 
            :ARG1 (b / both) 
            :degree -))

# ::snt Hirano silver stain ( top row ) ; GFAP immunohistochemistry ( middle row ) ; ubiquitin immunohistochemistry ( bottom row ) .
# ::tok Hirano silver stain ( top row ) ; GFAP immunohistochemistry ( middle row ) ; ubiquitin immunohistochemistry ( bottom row ) .
# ::alignments 19-20|0.0.0.0 18-19|0.0.0.0.0 16-17|0.2 15-16|0.2.0 12-13|0.0.0.1 11-12|0.0.0.1.0 9-10|0.1 7-8|0 5-6|0.0.0.0.0.0.0 4-5|0.0.0.0.0.0 2-3|0.0 1-2|0.0.1 0-1|0.0.0.2.0+0.0.0.2+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:06.691
(a / and 
      :op1 (s / stain-01 
            :ARG0 (p / person 
                  :mod-of (r / row 
                        :mod (b / bottom 
                              :mod (t / top 
                                    :mod-of (r3 / row)))) 
                  :mod-of (r2 / row 
                        :mod (m / middle)) 
                  :name (n / name 
                        :op1 "Hirano")) 
            :mod (s2 / silver)) 
      :op2 (i2 / immunohistochemistry) 
      :op3 (i / immunohistochemistry 
            :mod (u / ubiquitin)))

# ::snt Transgene Suppression Attenuates Hyperactivity in tTA/APP Mice .
# ::tok Transgene Suppression Attenuates Hyperactivity in tTA/APP Mice .
# ::alignments 6-7|0.0 0-4|0.1.3+0.1.2+0.1.1+0.1.0+0.1+0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:06.708
(o / organization 
      :mod (m / mouse) 
      :name (n / name 
            :op1 "Transgene" 
            :op2 "Suppression" 
            :op3 "Attenuates" 
            :op4 "Hyperactivity"))

# ::snt ( A ) A 48-h measure of ambulation records extreme hyperactivity in untreated double transgenic mice compared to single transgenic and nontransgenic controls ( line 107 ) .
# ::tok ( A ) A 48-h measure of ambulation records extreme hyperactivity in untreated double transgenic mice compared to single transgenic and nontransgenic controls ( line 107 ) .
# ::alignments 25-26|0.0.0.0.0.0 24-25|0.1 22-23|0.0 20-21|0 18-19|0.0.1 16-17|0.0.0 15-16|0.0.1.0 13-14|0.0.1.0.0 12-13|0.0.1.1 10-11|0.0.0.1 9-10|0.0.0.1.0 8-9|0.0.0.0.0.1 7-8|0.0.0.0 5-6|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:06.846
(a / and 
      :op1 (c / control-01 
            :ARG2-of (c2 / compare-01 
                  :ARG0 (a2 / ambulation 
                        :ARG1-of (m2 / measure-01 
                              :ARG0 107 
                              :domain-of (r / record))) 
                  :ARG1 (h / hyperactivity 
                        :mod (e / extreme))) 
            :mod (s / single-02 
                  :ARG0 (m / mouse 
                        :mod (d / double)) 
                  :ARG1 (u / untreat))) 
      :op2 (l / line))

# ::snt This phenotype is completely eliminated by rearing the double transgenic mice on dox .
# ::tok This phenotype is completely eliminated by rearing the double transgenic mice on dox .
# ::alignments 12-13|0.0.2 10-11|0.0.0 8-9|0.0.0.0 6-7|0.0 4-5|0.0.1 3-4|0.0.1.0 1-2|0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:06.933
(p / phenotype 
      :ARG0-of (r / rear-01 
            :ARG1 (m / mouse 
                  :mod (d2 / double)) 
            :ARG1-of (e / eliminate-01 
                  :ARG1-of (c / complete-02)) 
            :prep-on (d / dox)) 
      :mod (t / this))

# ::snt ( B ) The same data shown in ( A ) are replotted to magnify data from untreated control and dox-treated groups .
# ::tok ( B ) The same data shown in ( A ) are replotted to magnify data from untreated control and dox-treated groups .
# ::alignments 21-22|0.1 20-21|0.1.0 19-20|0 18-19|0.0 17-18|0.0.0 15-16|0.0.1 14-15|0.0.1.0 6-7|0.0.1.0.0.0 5-6|0.0.1.0.0.0.0 4-5|0.0.1.0.0.0.0.0 1-2|0.0.1.0.0.2+0.0.1.0.0.1.0+0.0.1.0.0.1+0.0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:07.120
(a / and 
      :op1 (c / control-01 
            :ARG0 (u / untreat) 
            :ARG1 (d2 / data 
                  :ARG1-of (m / magnify-01 
                        :ARG0 (l / location 
                              :ARG1-of (s / show-01 
                                    :ARG0 (d3 / data 
                                          :ARG1-of (s2 / same-01))) 
                              :name (n / name 
                                    :op1 "B") 
                              :wiki -)))) 
      :op2 (g / group 
            :mod (d / dox-treat)))

# ::snt ( C and D ) Activity levels in the combined control groups of ( A ) and ( B ) are here separated by genotype .
# ::tok ( C and D ) Activity levels in the combined control groups of ( A ) and ( B ) are here separated by genotype .
# ::alignments 24-25|0.0.0 22-23|0.0 21-22|0.0.2 18-19|0.2.1.1+0.2.1.0.0+0.2.1.0+0.2.1 16-17|0.2 11-12|0.2.0.0 10-11|0.2.0 9-10|0.2.0.0.0 6-7|0.0.1 5-6|0.0.1.0 3-4|0.3 2-3|0 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:07.230
(a3 / and 
      :ARG2-of (s / separate-01 
            :ARG0 (g / genotype) 
            :ARG1 (l2 / level 
                  :mod (a2 / activity)) 
            :location (h / here)) 
      :op1 (c3 / C) 
      :op1-of (a / and 
            :ARG1-of (c / control-01 
                  :ARG0 (g2 / group 
                        :ARG1-of (c2 / combine-01))) 
            :op2 (l / location 
                  :name (n / name 
                        :op1 "B") 
                  :wiki -)) 
      :op2 (d / D))

# ::snt None of the single transgenic or nontransgenic control groups display the hyperactivity present in untreated tTA/APP animals .
# ::tok None of the single transgenic or nontransgenic control groups display the hyperactivity present in untreated tTA/APP animals .
# ::alignments 16-17|0.0.2 14-15|0.0.2.0 12-13|0.0.1 11-12|0.0.1.0 9-10|0.0 8-9|0.1 7-8|0.1.0 5-6|0 3-4|0.1.1 0-1|0.0.0.0+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:07.709
(o / or 
      :manner-of (d / display-01 
            :ARG0 (p2 / person 
                  :quant (n / none)) 
            :ARG1 (p / present 
                  :mod (h / hyperactivity)) 
            :ARG2 (a / animal 
                  :mod (u / untreat))) 
      :op1 (g / group 
            :ARG0-of (c / control-01) 
            :ARG1-of (s / single-02)))

# ::snt Again , note the y-axes have been enlarged for detail compared to ( A ) .
# ::tok Again , note the y-axes have been enlarged for detail compared to ( A ) .
# ::alignments 10-11|0.1.1 9-10|0.1.2 7-8|0.1 4-5|0.1.0 2-3|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:07.755
(n / note-01 
      :ARG0 (a / again) 
      :ARG1 (e / enlarge-01 
            :ARG1 (y / y-ax) 
            :ARG1-of (c / compare-01) 
            :purpose (d / detail-01)))

# ::snt Citation : Jankowsky JL , Slunt HH , Gonzales V , Savonenko AV , Wen JC , et al. ( 2005 ) Persistent amyloidosis following suppression of A production in a transgenic model of Alzheimer disease .
# ::tok Citation : Jankowsky JL , Slunt HH , Gonzales V , Savonenko AV , Wen JC , et al. ( 2005 ) Persistent amyloidosis following suppression of A production in a transgenic model of Alzheimer disease .
# ::alignments 35-36|0.0.0.0.0.1.1.0 34-35|0.0.0.0.0.1.1.0.0 32-33|0.0.0.0.0.1.1 28-29|0.0.0.0.0.1 25-26|0.0.0.0.0 24-25|0.0.0.0 22-23|0.0.0.0.0.1.0 20-21|0.0.0.0.0.1.0.0.0+0.0.0.0.0.1.0.0 17-19|0.0.0.0.0.2.0.1+0.0.0.0.0.2.0.0+0.0.0.0.0.2.0+0.0.0.0.0.2 14-16|0.0.0.0.0.1.4.0.1+0.0.0.0.0.1.4.0.0+0.0.0.0.0.1.4.0+0.0.0.0.0.1.4 11-13|0.0.0.0.0.1.3.0.1+0.0.0.0.0.1.3.0.0+0.0.0.0.0.1.3.0+0.0.0.0.0.1.3 8-10|0.0.0.0.0.1.2.0.1+0.0.0.0.0.1.2.0.0+0.0.0.0.0.1.2.0+0.0.0.0.0.1.2 5-7|0.0.1+0+0.0+0.0.0 2-4|0.0.0.0.0.0.0.1+0.0.0.0.0.0.0.0+0.0.0.0.0.0.0+0.0.0.0.0.0 0-1|0.0.0.0.0.1.5 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:08.428
(s2 / Slunt 
      :op1-of (n5 / name 
            :name-of (t2 / thing 
                  :ARG1-of (f / follow-01 
                        :ARG2 (s / suppress-01 
                              :ARG0 (o / organization 
                                    :name (n6 / name 
                                          :op1 "Jankowsky" 
                                          :op2 "JL")) 
                              :ARG1 (p / produce-01 
                                    :ARG0 (p2 / persistent 
                                          :li (d2 / date-entity 
                                                :year 2005)) 
                                    :ARG1 (m / model 
                                          :poss (d / disease 
                                                :mod (a / alzheim))) 
                                    :location (c2 / country 
                                          :name (n4 / name 
                                                :op1 "Gonzales" 
                                                :op2 "V")) 
                                    :location (c / country 
                                          :name (n3 / name 
                                                :op1 "Savonenko" 
                                                :op2 "AV")) 
                                    :op1-of (p3 / person 
                                          :name (n2 / name 
                                                :op1 "Wen" 
                                                :op2 "JC")) 
                                    :op1-of (c3 / citation)) 
                              :ARG2 (t / thing 
                                    :name (n / name 
                                          :op1 (e / et) 
                                          :op2 (a2 / al.)))))) 
            :op2 (h / HH)))

# ::snt PLoS Med 2 ( 12 ) : e355 .
# ::tok PLoS Med 2 ( 12 ) : e355 .
# ::alignments 7-8|0 4-5|0.0.0.1 2-3|0.0 0-2|0.0.0.0.1+0.0.0.0.0+0.0.0.0+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:26:08.446
(e / e355 
      :quant (2 / 2 
            :mod-of (o / organization 
                  :name (n / name 
                        :op1 "PLoS" 
                        :op2 "Med") 
                  :op1 12)))

